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Abstract 
Introduction: Pneumonia contributes significantly to the morbidity and mortality in stroke 
patients, especially those fed via nasogastric tubes.  
 
Methods: This project was conducted in two steps; 
1. A randomised controlled trial: The efficacy of prokinetic agent metoclopramide was 
tested in a double-blind randomised controlled trial. Acute stroke patients with no 
pneumonia needing nasogastric feeds were randomized to 10 mg metoclopramide or 
placebo three times daily via the nasogastric tube for 21 days or until feeds 
discontinued. Participants were examined daily for clinical evidence of pneumonia.  
2. A secondary analysis of data collected for the diagnosis of pneumonia. This was 
performed to identify early diagnostic markers of post-stroke pneumonia. 
 
Results:  
1) For the MAPS study 60 patients (mean age 78 years, mean NIHSS 19) were randomized, 30 
in each group. Pneumonia was diagnosed in 26/30 and 08/30 in placebo and treatment group 
respectively (p <0.001).  
2) Signs and symptoms of 47 radiologically confirmed pneumonia revealed that hypoxia, 
tachypnoea and inspiratory crackles were the most consistent signs in early pneumonia and 
pyrexia, cough, and purulent sputum were less commonly observed. CRP of 40 mg/l had the 
best predictive value for early diagnosis of post-stroke pneumonia. 
 
Conclusion: Treatment with metoclopramide treatment was associated with a significant 
reduction of aspiration and pneumonia. However, the incidence of pneumonia in the control 
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gourp was very high and may have led to a false positive result. The findings of this study 
should therefore be confirmed in a larger study. A raised CRP of 40 mg/l or above was a 
senditive and specific diagnostic marker for post-stoke pneumonia.  
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Chapter 1 Introduction 
 
1.1 Project background 
Stroke is the third leading cause of mortality in England and Wales1;2. The severity of the 
initial cerebral injury and intra-cranial complications such as cerebral oedema due to large 
cerebral infarction, and the effects of haemorrhage are responsible for mortality within the 
first few days. After the first few days medical complications such as aspiration 
pneumonia, pulmonary embolism, urinary tract infection, and urosepsis contribute 
significantly to mortality and morbidity3. Amongst these pneumonia is the leading cause of 
post-stroke morbidity and mortality and is directly related to post-stroke dysphagia4-6. 
 
There are three stages of swallowing, oral, pharyngeal and oesophageal, and these are all 
affected by stroke7. A high incidence of dysphagia following acute stroke has been 
demonstrated in numerous studies, with an incidence of 25 to 70% depending on the study 
population and the criteria used8;9. Several studies have shown that aspiration and 
pneumonia are common complications in dysphagic patients following acute stroke and 
contribute significantly to morbidity, length of stay, poor stroke outcome and mortality10;11. 
Patients with severe dysphagia or patients too drowsy to assess are maintained nil by mouth 
to prevent aspiration and nasogastric tube remains the main method of feeding in these 
patients. However, aspiration and pneumonia remains a common complication even when 
the patients are maintained nil by mouth and fed via nasogastric tubes12-14. This is partly 
due to continuing oropharyngeal dysfunction and aspiration in the presence of the 
nasogastric tube15-18 and partly due to dysfunction of the lower oesophageal sphincter and 
the stomach following severe stroke resulting in gastroparesis, increased gastric volume, 
and regurgitation19-21. Presence of a nasogastric tube in the already dysfunctional lower 
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oesophageal sphincter increases regurgitation. Neutralisation of gastric acid by nasogastric 
feeds, migration of Gram negative bacteria from the oropharynx and biofilm formation on 
the nasogastric tube result in colonisation of the gastric contents by pathogenic bacteria22-24. 
Micro-aspiration of regurgitated infected gastric contents contributes to the development of 
pneumonia17;25. 
 
Several studies26-29 have been done to assess the efficacy of different agents in reducing the 
incidence of pneumonia in post-stroke patients with varying success. Though some studies 
have been performed to assess prevention of pneumonia in patients fed via nasogastric 
tubes, limited information is available in stroke patients fed via nasogastric tubes. 
Metoclopramide is a dopamine 2 receptor antagonist of the upper gastrointestinal tract and 
is a commonly used prokinetic agent30. It increases lower oesophageal sphincter tone, 
improves gastric contractions, and forward peristalsis of the stomach which should in 
theory reduce reflux, micro-aspiration, and pneumonia30.  
 
The aim of this chapter is to provide a comprehensive background to stroke and the 
concomitant relationship with dysphagia, aspiration, and pneumonia, and the effect of a 
nasogastric tube on lower oesophageal sphincter and aspiration. In addition, methods 
currently available to prevent pneumonia in critically ill patients and patients fed via 
nasogastric tubes will be reviewed. Finally, actions of metoclopramide and mechanisms of 
how regular treatment with metoclopramide would reduce the incidence of pneumonia in 
acute stroke patients fed via nasogastric tubes will be explored.  
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1.2. Stroke  
1.2.1. Definition and aetiology  
  
The World Health Organisation defines stroke as a neurological deficit of sudden onset 
resulting in focal rather than global dysfunction, with symptoms lasting 24 hours or more 
or result in death within 24 hours and after adequate investigations the symptoms are 
secondary to a non traumatic vascular lesion31. If neurological symptoms resolve 
completely within 24 hours of onset clinical presentation is defined as a transient ischaemic 
attack (TIA)32. Crescendo TIAs are TIAs which occur with increasing frequency and 
duration or several episodes occurring within few days33. 
 
Cerebral infarction and primary intra-cerebral haemorrhage are the two most common 
causes of stroke34. Cerebral infarction occurs when an area of the brain is deprived of its 
blood supply due to an occlusion of its arterial blood supply leading to death of neurones 
secondary to lack of oxygen. Atheromatous carotid or vertebral artery occlusion, 
atheromatous arterial thrombosis within cerebral vessels or an arterial embolus from a 
distal site can lead to this vessel occlusion resulting in cerebral ischaemia and infarction34. 
Intracranial perforating striate small vessel disease, mainly secondary to hypertension, can 
lead to lacunar infarcts deep in the brain especially in the basal ganglia, internal capsule or 
pons. These lacunar infarcts are small (less than 1.5cm in diameter) and can be multiple. 
Slow accumulation of such infarcts can give rise to vascular dementia34. Rare causes of 
ischaemic stroke include hyper-coagulable status, autoimmune vasculitis, bacterial 
endocarditis and anti-cardiolipin antibody syndrome34. 
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 Primary intracranial haemorrhage accounts for 8% of strokes35. Cerebral haemorrhage is 
caused by rupture of micro-aneurysms and degeneration of walls of small blood vessels of 
small deep penetrating arteries. In older normotensive patients weakening of cerebral blood 
vessels due to cerebral amyloid angiopathy can give rise to cerebral bleeds 34. Less 
common causes are bleeding into a cerebral tumour or bleeding from an arterio-venous 
malformation. Rupture of a berry aneurysm usually produces a subarachnoid 
haemorrhage35. 
 
1.2.2. Symptoms and classification 
 Common presenting symptoms of stroke are unilateral weakness with or without sensory 
impairment, speech disturbances or visual defects. Due to the sudden nature of the 
symptoms, either the patient or an observer can usually give an exact time of the disease 
onset. Sometimes the patient first notes symptoms of a stroke on waking in the morning 
(wakeup stroke) or stroke signs will be evident on examination of a patient who is brought 
into the hospital due to symptoms such as acute confusion, fall or collapse in the 
community36. 
 
Depending on the signs and symptoms stroke can be classified clinically into four distinct 
syndromes as defined by the Oxfordshire Community Stroke Project,37 e.g. Total Anterior 
Circulation Syndrome (TACS), Partial Anterior Circulation Syndrome (PACS), Lacunar 
Syndrome (LACS), and Posterior Circulation Syndrome (PoCS). The classification 
provides a good estimate of the affected territory, prognostic factors such as survival, 
residual disability and risk of recurrence. TACS strokes, account for 15% of all strokes, and 
have a mortality of 50% within the first month, and 50% of survivors are dependent at 12 
months following stroke. PACS strokes account for 35% of all strokes. Lacunar strokes and 
posterior circulation strokes are associated with 10% to 15% mortality within the first 
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month of stroke and 20% to 40% of the survivors will be dependent after 6 months37. These 
stroke types are explained in more detail in appendix 1. 
 
1.2.3. Impact of stroke on the individual and society  
Each year 110,000 people in England and Wales have their first stroke and 30,000 people 
go on to have further strokes38. As people live longer, stroke is the most common cause of 
disability in the world and is the third largest cause of death in the United Kingdom1;2. 
Stroke is also the leading cause of major disability in England and Wales accounting for 
around 53,000 deaths each year with over 450,000 people who are disabled due to 
stroke39;40. Stroke patients occupy up to 20% of all acute hospital beds, 25% of the long 
stay beds and about 40% of nursing home beds41. In Staffordshire, a district of around 
500,000 people, there are approximately 1000 new cases of stroke per year. Eighty percent 
of stroke patients are admitted to hospital with an average stay of four weeks42. 
 
Strokes are not only devastating to the individual involved but also to their families, carers 
and society. In the United Kingdom there are about 110,000 new strokes each year which 
are responsible for about 5% of the total National Health Services budget43. In the United 
States almost 800,000 people experience a new or recurrent stroke each year which 
accounts for 5.5% of all deaths and a cost of $73 billion42. Compared with other medical 
and psychological problems, stroke is associated with the highest odds of incurring a wide 
range of disabilities which costs around £8.9 billion to the National Health Service and 
society every year in lost productivity and in formal care44;45. The extent of recovery from 
stroke is not only determined by the extent of neurological defects at stroke onset, but also 
by post-stroke complications such as hypoxia, infections, thrombosis and malnutrition4. 
This makes post-stroke care such as reducing infections, early mobilisation, and improving 
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nutrition as important as hyper acute stroke care such as thrombolysis and other 
interventional procedures. 
 
1.3. Dysphagia  
 1.3.1. Neurological control of swallowing 
Dysphagia is a disruption to normal swallowing. Central control of swallowing is organised 
at two levels involving both the cerebral cortex and the brainstem. The primary brain-stem 
swallowing mechanism is thought to originate from the medulla as a pre-programmed 
reflex. The swallowing sequence can be activated even after the removal of cortical and sub 
cortical areas above the brain stem46. The swallowing centre acts as a “Central pattern 
generator” and is localised in the medulla, with two levels of interoperation, namely the 
Nucleus Tractus Solitarius and the Nucleus Ambiguous with its surrounding reticular 
formation. Both have sensory inputs from cerebral and peripheral pathways with delivery 
of the final swallowing sequence by efferent cranial nerves47. These impulses reach the 
muscles of mastication via the mandibular branch of the trigeminal nerve and the facial 
nerve, tongue movements via hypoglossal and first two cranial roots and muscles of the 
palate, pharynx and larynx by the vagus nerve48. Sensory feedbacks are carried along in the 
9th, 10th and trigeminal cranial nerves and terminate in the spinal nucleus of the trigeminal 
nerve and the dorsal region of the brain stem swallowing centre49. They also receive 
sensory input from the higher cortical areas. The Nucleus Tractus Solitarius is involved in 
the initiation of swallowing and the organization of the swallowing sequences. The 
reticular formation surrounding the Nucleus Ambiguous serves primarily as a connecting 
pathway to various motor neurons coordinating the swallowing sequelae. These two 
regions are bilaterally represented in the brainstem and are interconnected extensively. This 
allows either side of the brain the ability to coordinate the pharyngeal and laryngeal phases 
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of swallowing. Afferent fibres from the peripheral areas enter into the afferent receptor 
portals of this swallowing centre and synapse on “premotor neurons”. This information can 
initiate or modify ongoing motor activity of the swallowing process 50,51. 
 
 While reflexive swallowing depends on the swallowing centres in the brainstem, voluntary 
initiation of swallowing involves corresponding motor areas of the cerebral cortex. Cortical 
sensory and motor areas of swallowing regulation influence mastication and swallowing 
via cortico-bulbar pathways. They receive afferents from the receptors of the gastro-
intestinal tract52. In addition reflexive swallowing also show bilateral activity concentrated 
to the primary motor-sensory regions in the cortex. Centres involved in voluntary 
swallowing are located in multiple areas of the brain which include the right orbital frontal 
cortex, bilateral sensory motor cortices, bilateral tempero-polar cortices, left mesial pre-
motor cortex and cingulate, supplementary motor area, pre-cuneus, cuneus, bilateral insular 
cortices, putamen, thalamus, globus pallidus, left cerebellum and dorsal brain stem52. Of 
these most important areas are located in the sensory motor cortex, anterior cingulate 
cortex, adjacent supplementary motor areas, insula, operculum and precuneus53. This 
indicates swallowing involves the recruitment of a neural network with areas outside the 
primary motor cortex and the medullary brainstem. Within the motor cortex, the 
representation of swallowing muscles are somatotrophic, with oral muscles more lateral 
and pharyngeal muscles being more medial.  
 
Cortical control of swallowing is bilaterally represented and is multifocal with some 
potential for spatial facilitation between the responses from each hemisphere54. However, 
there is asymmetrical somatotrophic representation of the midline swallowing muscles in 
the motor cortex, which is suggestive of a functionally dominant swallowing hemisphere55. 
The dominant hemisphere for swallowing is probably independent of handedness and the 
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speech centre56. This may partly explain the difficulties in the correlation of the extent, side 
and location of the ischaemic brain injury with the severity of gastrointestinal dysfunction 
following an acute stroke. Damage to the hemisphere with overall dominant swallowing 
function can lead to significant dysphagia. Some studies have shown swallowing related 
activities are lateralised to the left hemisphere both for involuntary swallowing (of saliva) 
and for voluntary swallowing57-59.  
 
1.3.2. Swallowing dysfunction after Stroke 
Dysphagia due to cortical lesions is secondary to involvement of various neural 
connections from the precentral gyrus and the internal capsule60. They can affect the 
voluntary actions of the pharyngeal and laryngeal musculature of the contralateral side with 
peristaltic dysfunction and spasticity. Lesions of the lower inferior precentral gyrus and 
posterior portion of the inferior frontal gyrus in either hemisphere can cause a delay in the 
initiation of the pharyngeal response due to interference of pharyngeal feedback. A lesion 
in the insular region which has multiple close functional connections to several areas of the 
brain coordinating swallowing which include the lateral and mesial premotor cortex, the 
primary and secondary somotosensary cortex and the frontal, parietal and temporal 
opercula can increase the swallowing threshold and a delay in the pharyngeal phase of 
swallowing60;61. 
 
A brainstem stroke can affect the serial activation of the cranial nerve motor neurones 
(bulbar swallowing cortex) by the central patterns generator which is located in nucleus of 
Tractus Solitarius and Nucleus Ambiguus and motor neurones in the Nucleus of Tractus 
Solitarius and the dorsal motor nucleus of the Vagus which innervate the muscles of 
deglutition. Bulbar swallowing centre is also partly responsible for the initiation of the 
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voluntary triggering of the swallowing reflex in addition to spontaneous reflexes due to 
facilitatory fibres from the cortex. Thus there will also be a delay in the initiation of 
swallowing due to the affection of these corticobulbar fibres following an acute stroke. 
Less commonly, in more severe corticobulbar disease, the voluntary oropharyngeal 
swallowing reflex cannot be initiated at all though the reflex swallowing can still be 
initiated by the bulbar swallowing centre acting alone without the cortical input62. There is 
also a pyramidal inhibitor of the swallowing reflex which is relayed on the bulbar centre 
via corticobulbar pathways. Thus, corticobulbar involvement not only alters the excitatory 
influences but also affects the neuronal network which has an inhibitory control. This is 
supported by some stroke patients who have increased mandibular and palatopharyngeal 
reflexes and patients with amyotrophic lateral sclerosis who have suprabulbar palsy with 
increased brainstem reflexes63, 64 65. Patients with combined cortical and brainstem strokes 
associated with bilateral lower cranial nerve dysfunction are at greatest risk of dysphagia 
and aspiration. In addition patients with bilateral supratentorial, bilateral hemispheric 
strokes are associated with a higher incidence of severe and prolonged dysphagia rather 
than a patient with unilateral hemispheric stroke due to the damage to the swallowing 
dominant hemisphere and the absence of contralateral cortex to reorganize and take over 
the control of the swallowing process66. 
1.3.3. Oesophageal sphincter and gastric dysfunction following acute stroke 
Dysphagia is only one aspect of gastro-intestinal dysfunction following stroke. After acute 
stroke, patients display a spectrum of gastro-intestinal dysfunctions such as gastro-
intestinal haemorrhage secondary to stress ulcers, delayed gastric emptying, gastro-
oesophageal sphincter dysfunction and colorectal dysfunction67. This may be due to 
disruption of several centres in the brain responsible for gastro-intestinal motility and is not 
fully understood. It is thought to involve cortical and medullary centres, in a multifocal and 
bilateral pattern with a dominant hemisphere which is independent of the patients’ 
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handedness67. As lower oesophageal and gastric dysfunction following stroke has a direct 
relevance to the work done in this thesis, these changes are discussed in more detail in this 
section. 
Ischaemic brainstem strokes can affect the Nucleus of Tractus Solitarius and the Nucleus 
Ambiguous and are associated with decreased tone of the lower oesophageal sphincter and 
variable tone (which may also be increased) of the upper oesophageal sphincter. These 
neurones are usually tonically active and inhibited first and later forcefully activated again 
during the swallowing process68.  Motor neurones to the smooth muscles of the oesophagus 
including the lower oesophageal sphincter are located in two sub regions of the dorsal 
motor nucleus of the Vagus in the medulla. Its rostal region contains neurones that mediate 
excitation and the caudal region mediates the inhibition of the oesophagus69. A study on the 
effects of an ischaemic stroke on oesophageal peristaltic function demonstrated significant 
peristaltic dysfunction during early phase of stroke including higher number of non-
peristaltic oesophageal contractions in patients with unilateral hemispheric stroke 
irrespective of the presence of dysphagia70;71.   
 
To ensure the swallowed food bolus effectively enters the stomach, a potent proximal 
gastric relaxation is triggered by the vagal afferent mechano-sensors in the lower 
oesophagus. It causes a reduction in the intra-gastric pressure an increase in the gastric 
volume. These neurones of Nucleus of Tractus Solitarius which are activated by 
oesophageal distension project heavily to the dorsal motor nucleus of the Vagus and offer 
the primary source of pre-ganglionic autonomic control of the stomach72. Vagal control 
over gastric tone and motility is affected by the activity of two antagonistic vagal efferent 
projections. Activation of pre-ganglionic cholinergic neurones in the gastric mucosa results 
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in vagal mediated increasing gastric tone and motility. Rapid gastro inhibition can occur by 
inhibition of these neurones. 
 
It has been demonstrated that there is a delay in gastric emptying and drug absorption by 
the stomach following acute stroke73. Intolerance to enteral nutrients and increased 
incidence of Helicobacter pylori colonisation as a result of delayed gastric emptying also 
have been demonstrated following stroke73. Similarly in patients with ischaemic stroke, 
colorectal dysfunction occurs due to a combination of lesions of the central and peripheral 
nervous system, immobility, dehydration and altered dietary habits. The colonic transit 
time is prolonged, especially in the right side of the colon. Intestinal pseudo-obstruction 
either due to defective enteric neurons, smooth muscles or both is not uncommon. All these 
can result in abdominal distension and increased intra-abdominal pressure which would 
lead to further dysfunction of the stomach and gastro-oesophageal reflux74. 
 
1.3.4. Dysphagia following stroke 
Dysphagia after stroke is common and impairment of the swallowing mechanism has been 
shown in 25 – 70 % of patients with a stroke 75. This wide range is due to the variations in 
study designs and methods used for the diagnosis of dysphagia5. About 50% of stroke 
patients are diagnosed as having dysphagia by clinical criteria and over 64% by video-
fluoroscopy 8. In the context of stroke, oropharyngeal dysphagia can be defined as a 
disruption of the passage of the bolus through the mouth and pharynx. Abnormal lip 
closure, lingual in-coordination and a delayed or absent swallowing reflex may lead to 
disturbances in the oral and pharyngeal stages of swallowing. Consequences of these 
include incomplete oral clearance, pharyngeal pooling, regurgitation and aspiration76. Early 
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identification is important in the management of stroke patients as many studies have 
demonstrated the association between impaired swallow and aspiration following 
stroke8;10;77. 
 
Various types of abnormalities of all three stages of the swallowing process can be seen in 
patients following an acute stroke. Larger hemispheric strokes and brain stem strokes are 
associated with significant and persistent swallowing difficulties61. Damage to the motor 
cortex or internal capsule in a hemispheric stroke can affect the musculature of the pharynx 
and the larynx in addition to the contralateral hemiparesis61. Total laryngeal paralysis is not 
seen after a hemispheric stroke due to bilateral supra-nuclear vagal innervations61. 
However, a brain stem stroke can affect the glossopharyngeal, vagal and hypoglossal nuclei 
which can give rise to dysfunction of the pharynx, palate and the larynx61. Smithard et al 
found an association between the side of the stroke and aspiration at one month after an 
acute stroke but this association was not seen in when assessed within the first week78.  
 
Following stroke, there may be dyspraxia and food pocketing in the lateral sulcus between 
cheeks and gum margins in the oral phase of swallow. This is due to the reduced tone of the 
buccinator muscle, which is innervated by the lower half of the facial nerve79. Also poor 
coordination of swallowing and talking can lead to the bolus entering the pharynx when the 
airway is not protected78. Tongue movements are reduced which affects the bolus size, 
chewing and movements of the bolus inside the mouth80. There is also a reduction in the 
resting salivary flow80. All these factors contribute to a delay in the oral phase81. Reduced 
tongue movements also lead to food collecting along the palatal vault and impairment of 
formation of a cohesive bolus79. This and reduced oral sensation can result in premature 
entry of the food bolus in to the pharynx which can potentially enter the airway79. In frontal 
lobe damage the “tongue thrust” pattern of swallowing may occur, with anterior movement 
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of the tongue rather than coordinated posterior movements, leading to rejection of food 
from the mouth which often perceived as patient is spitting his food out79. 
 
The cough reflex is frequently weak or absent following a stroke and there is also a delay 
or loss of triggering of the swallowing reflex 61;79. Both these impairments can lead to 
penetration or aspiration of the food bolus which depends on the patient’s posture and size 
and consistency of the food bolus7. Paralysis or changes in the soft palatal movement can 
lead to nasal regurgitation. Impairment of pharyngeal and laryngeal sensation can further 
increase the risk of aspiration82. There is also impairment of the laryngeal ascent, laryngeal 
adductor reflex and impaired vocal fold mobility which also can increase the risk of 
aspiration, especially if there is reduced sensation of the pharyngo-laryngeal region83. 
There is a reduction of pharyngeal peristalsis following a stroke which can lead to 
incomplete pharyngeal clearance, collection of food particles in the valleculae and the 
pyriform sinus, impaired relaxation of the crico-pharyngeal muscles and delay in transit of 
the bolus, all of which can lead to possible overflow of food material in to the airways 
during the swallow82. Impaired upper oesophageal sphincter relaxation can lead to an 
increased post swallow residue with increased risk of aspiration84. 
  
Research into changes of oesophageal function and peristalsis following an acute stroke is 
limited. It has been shown that there is a reduction in the oesophageal peristalsis and failure 
of relaxation of the lower oesophageal sphincter following an acute stroke79. Further 
studies have demonstrated that resting lower oesophageal sphincter tone is reduced 
following stroke predisposing to reflux and aspiration, especially if there is increased 
residual gastric volume due to gastroparesis79;85;86.  
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Association of dysphagia with lesions affecting the brainstem as it interferes with 
glossopharyngeal and vagus nuclei, which control the pharyngeal muscles and bilateral 
hemispheric lesions due to its affection of bilateral cortico-bulbar fibres, have been known 
for a long time35. However, the association of dysphagia with unilateral hemispheric 
strokes was not well established until mid 1980s. One of the first studies of dysphagia after 
acute stroke was done in the late 1980s by Gordon et al who investigated one hundred 
patients who had an acute stroke and dysphagia within the first 48 hours after admission 
and demonstrated that 45% of these patients had problems of swallowing76. Contrary to the 
then common belief that dysphagia is mainly seen in brainstem strokes or in bilateral 
hemispheric strokes, the majority of patients in this study had unilateral hemispheric 
strokes and these dysphagic patients had a higher incidence of chest infection, dehydration 
and death. One can argue that this study overlooked patients with bilateral cortico-bulbar 
lesions secondary to bilateral lacunar infarcts in the basal ganglia, presenting with 
symptoms of bilateral cortical lesions. However, in this study dysphagia wasn’t restricted 
to patients who had other risk factors such as previous cerebrovascular disease, 
hypertension or diabetes, leading to an increased risk of bilateral lacunar infarcts affecting 
cortico-bulbar tracts in both hemispheres. A larger study on 357 unilateral hemispheric 
stroke patients confirmed that 30% had dysphagia within the first 48 hours of admission 
but only 6% had persistent dysphagia after one month 87. Similarly another study 
demonstrated that 39% of 124 patients with acute non-haemorrhagic stroke failed the initial 
swallowing screening and 19% of patients needed enteral nutrition during their acute 
care11. 
  
All these studies confirm that dysphagia is common after a hemispheric stroke. 
Identification of dysphagia in stroke is important as this predisposes a patient to 
aspiration88. About one third of acute stroke patients with swallowing difficulties will 
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develop aspiration pneumonia11. Lower respiratory tract infections were more common in 
aspirators (68%) than in the non-aspirators (6%)8. Keeping the patient nil by mouth did not 
prevent the occurrence of chest infections in these patients who were shown to aspirate 
suggest that they continue to aspirate their oropharyngeal secretions silently, which were 
colonised by pathogenic organisms89. A literature review demonstrated that there was an 
increased risk of pneumonia in patients with dysphagia and this was even greater in 
patients with aspiration75. Aspiration pneumonia is a major cause of morbidity and 
mortality in stroke patients and is one of the major causes of post-stroke hypoxia11. 
 
In patients with acute hemispheric stroke, studies using videofluoroscopy have shown that 
dysphagia and aspiration were more common than shown in studies which used only 
clinical testing for the diagnosis of dysphagia90;91. A study using videofluoroscopy to 
diagnose dysphagia demonstrated that aspiration was seen up to 50% of patients with an 
acute stroke92. In a similar study Kidd et al using videofluoroscopy reported that aspiration 
was seen in 42% of patients when tested within 72 hours and was related to the presence of 
dysphagia89. A literature review of 107 relevant articles from 1966 to 2005 demonstrated 
that dysphagia is common problem following acute stroke and the reported incidence 
varied with the method used, lowest was using cursory screening methods (37% to 45%), 
higher using clinical testing (50% to 55%) and highest using instrumental testing (64% to 
78%)75. The literature review also demonstrated that stroke patients with dysphagia had 
three fold risk of developing pneumonia than patients without dysphagia and even higher, 
an 11 fold risk of developing pneumonia if dysphagia was associated with aspiration.  
 
Many patients with dysphagia following unilateral hemispheric strokes show some 
recovery within the first few weeks of the acute event. A study using transcranial magnetic 
stimulation demonstrated that non dysphagic and persistently dysphagic patients showed 
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little change in the cortical representation of the pharynx over time, where as dysphagic 
patients who recovered showed increased representation of muscles of swallowing in the 
unaffected hemisphere without change in the affected hemisphere93. This often preceded 
the actual recovery of swallowing. This suggests recovery of swallowing may follow 
remodelling and reorganization of cerebral functions in the undamaged previously non-
dominant (swallowing) hemisphere to take over the control of the swallowing process. 
Patients who remained dysphagic did not show this reorganisation of the non dominant 
hemisphere. This reorganization is often independent of the recovery of any associated 
hemiparesis55. This recovery of the swallowing process takes place over the next days to 
weeks.  
 
Studies have reviewed the duration of dysphagia following stroke as it is important in the 
specialist management of these patients. Dysphagia and aspiration is most severe within the 
first two weeks following stroke8;76;89. It has been demonstrated that a significant number 
of patients regained their swallow within 14 days and most of the chest infections occurred 
within the first seven days following stroke76. Using bedside swallowing testing, Smithard 
et al demonstrated that though 51% of acute stroke patients had dysphagia and were at risk 
of aspiration, most the swallowing problems resolved within the first three days following 
stroke. However, 27% of patients were still at risk of aspiration at the end of the first week 
and 15 % at the end of one month9. Dysphagia persisting for more than three months 
following stroke was associated with a less favourable outcomes11. Further studies have 
confirmed that dysphagic symptoms resolved within a month in most patients though may 
persist beyond six months in a small percentage of patients and dysphagia persisting for 
more than three weeks was associated with less favourable outcome10;94. A study using 
videofluoroscopy have confirmed that dysphagia was most severe during the first two 
weeks, with the risk of aspiration at its highest, resolved in most patients by the end of two 
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weeks, and only 8% of patients continued to aspirate after three months8. In addition, the 
study also demonstrated that patients with right hemispheric lesions were more likely to 
aspirate than patients with left hemispheric lesions8. 
 
Studies have been done to assess the long term impact of post-stroke dysphagia. A study by 
Mann et al on 128 patients with their first stroke, assessed swallowing function clinically 
and videofluoroscopically over six month to assess the impact on dysphagia, recovery and 
the long term prognosis. At presentation, swallowing abnormality was detected in 51% of 
patients clinically and 64% patients using videofluoroscopy. At six months after the stroke, 
87% of 112 survivors had return to their pre-stroke diet. However, clinical evidence of 
swallowing abnormalities was present in 50% of these patients. Videofluoroscopy 
performed at 6 months in 67 patients who had a swallowing abnormality at baseline 
showed penetration occurred in 34% patients and aspiration in another 17 patients. The 
single independent baseline predictor of chest infection during six month follow-up was 
delayed or absent swallow reflex (detected by videofluoroscopy) and the single 
independent predictor of failure to return to normal diet was delayed oral transit time. 
Independent predictors of the combined outcome events of swallow impairment, chest 
infection or aspiration at six months were delayed oral transit seen in videofluoroscopy, 
penetration, age over 70 and male sex10. 
 
In conclusion, dysphagia is a common problem following acute stroke and seen in both 
hemispheric and brain stem lesions, though the detection of dysphagia varies depending on 
the inclusion criteria and the methods used for the diagnosis. As detailed before, 
videofluoroscopy is only used in clinical situations where the bedside swallowing tests are 
inconclusive or if there is a strong suspicion of silent aspiration though it provides better 
results. It is possible that the true incidence of dysphagia and aspiration is higher than 
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reported above since those studies were performed in patients who could comply with 
formal swallowing testing and video-fluoroscopic procedures. This excludes a significant 
proportion of acute stroke patients with large strokes who are unconscious or too drowsy to 
be assessed by procedures which are commonly used to test dysphagia. Therefore the true 
incidence of dysphagia may be much higher than shown in many clinical studies. 
Dysphagia is most severe during the first few weeks following stroke and therefore 
increased vigilance for early identification and treatment of complications are required at 
this stage. In addition to the increased vigilance to detect complications, interventions to 
prevent aspiration and pneumonia should also be carried out at least during these early 
weeks following stroke. 
 
1.4. Aspiration 
As described above, dysphagia due to abnormal lip closure, lingual coordination and 
delayed or absent swallowing reflex is an important complication following acute stroke 
and these result in incomplete oral clearance, pharyngeal pooling, regurgitation and 
aspiration60.The entry of food or fluid in to the laryngeal vestibule is defined as penetration 
and the entry of food below the vocal cords is defined as aspiration.  
 
1.4.1. Silent aspiration 
Following stroke, though some patients have symptoms of aspiration, in a significant 
proportion of patients it may not be noticed. If aspiration initiates a cough reflex this is 
called overt aspiration. Aspiration which occurs without eliciting a cough reflex is called 
silent aspiration95. Aspiration carries a significant risk of pneumonia as the aspirate carries 
bacteria from the oropharynx in to the lungs88. In patients with stroke, the risk of 
development of pneumonia is seven times greater in patients who aspirate and studies have 
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shown that incidence of pneumonia in patients who have silent aspiration is six times 
greater than in patients who could cough on aspiration96;97. Videofluoroscopy gives more 
accurate results than clinical testing in relation to the incidence of silent aspiration 
following acute stroke. A study by Daniel et al in patients with acute stroke demonstrated 
that 33% had dysphagia when clinically tested, but up to two third (65%) of patients had 
evidence of silent aspiration which could only be demonstrated by using videofluoroscopy 
88
. However, aspiration pneumonia due to silent aspiration is not only confined to patients 
with acute stroke88;95. Patients with various neurological conditions such as Parkinson’s 
disease and motor neurone disease with dysphagia often aspirate silently, and pneumonia is 
the fourth most frequent cause of death in elderly patients with co-existing neurological 
diseases98. This is due to the weakness and poor coordination of pharyngeal musculature, 
poor initiation of swallowing and impaired vocal cord motion. 
 
Silent aspiration may result from reduced pharyngeal sensation and from weakness or in-
coordination of the pharyngeal musculature99. A study using videofluoroscopy 
demonstrated that patients who have a latency greater than 5 seconds in the swallowing 
response and in cough on instillation of a citric acid aerosol to the pharynx had a higher 
incidence of aspiration pneumonia100. Prolonged tracheal intubation or tracheostomy are 
known to desensitize the oropharynx and are associated with a higher incidence of silent 
aspiration and pneumonia100. Repeated exposure of the pharynx to gastric acid due to 
gastro-oesophageal reflux disease can also reduce pharyngeal sensation, predisposing to 
silent aspiration88.  
 
Presence of a weak cough reflex is a predictor of silent aspiration. There are two types of 
reflex cough79. The primary cough reflex, which is also described as the laryngeal cough 
reflex, occurs at the level of the larynx and is mostly responsible in clearing the upper 
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airway. The less productive delayed deeper cough is called tracheo-bronchial cough. 
Various local and central neurological disorders affecting the pharynx can interfere with 
both cough reflexes and predispose a patient to aspiration101. It has been shown that there is 
a progressive loss of protective swallowing and cough reflexes with age102. However, many 
older people continue to lead active lives without recurrent bouts of pneumonia. This 
indicates that disease and degenerative changes affecting the central nervous system and 
neuro-muscular coordination rather than the changes due to age itself predispose an older 
individual to aspiration and pneumonia79. A scintiographic study of older patients with 
pneumonia showed longer latency in swallowing response in patients with previous basal 
ganglia infarcts than those without. 
 
The relationship between dysphagia and silent aspiration is incompletely understood. Some 
patients have severely disordered swallowing, but transport of saliva and food to the 
stomach proceeds safely, but others who appear to have a safe swallow and no indicators 
for aspiration at bedside testing will have silent aspiration on video-fluoroscopic 
examination95. Therefore, the possibility of silent aspiration should always be considered in 
stroke patients with unexplained recurrent pneumonia and these may require more 
specialised investigations. 
 
1.4.2. Clinical predictors of aspiration 
Identification of clinical predictors of aspiration is important to ensure proper management 
of such patients and to prevent future complications, to plan out further investigations and 
appropriate feeding methods. Using videofluoroscopy a study demonstrated that half of 
stroke patients had evidence of aspiration within 24 months following their stroke103. 
Aspiration was more commonly seen in patients with bilateral cranial nerve signs (71%) 
than in patients with unilateral cortical signs (29%)104. Dysphagia was the most common 
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clinical sign in the patients who aspirated regularly. In another study aspiration was 
commonly seen in patients with dysphonia, abnormal gag reflex and a weak cough105. Also 
the co-existence of an abnormal gag and an impaired voluntary cough were more predictive 
of aspiration than each of these symptoms in isolation. Linden and colleagues studied 249 
patients with primary neurological problems including stroke and found nine clinical 
indicators namely, dysphonia, wet phonation, decreased/absent laryngeal excursion, nursed 
in a recumbent position, wet spontaneous cough, decreased gag reflex, drooling and 
reduced ability to swallow secretions, harsh phonation and breathy phonation that were 
significantly associated with aspiration as identified by videofluoroscopy106. 
 
Only few studies have been done to assess the clinical predictors of aspiration following 
acute stroke. In a study based on videofluoroscopic examination of patients within 5 days 
of acute stroke, six clinical indicators were identified to distinguish patients who are at an 
increased risk of aspiration following acute stroke 77. Abnormal cough, abnormal gag 
reflex, dysphonia, dysarthria, voice change and cough after swallow were identified as 
independent predictors of aspiration. Presence of two or more of these signs further 
increased the risks of aspiration. The study also identified an abnormal volitional cough 
and a cough with swallowing were independent predictors of aspiration and presence of 
two of above will predict the risk of aspiration with 78% accuracy (sensitivity 69.6% and 
specificity 84.4%). These features were independent so that a patient may demonstrate one 
feature in isolation without the presence of an additional feature. Another study confirmed 
that some or all of these features are related to the risk of aspiration either in isolation or of 
any combination107. It has been reported that cough during swallowing and clinical 
estimates of presence of aspiration are the two most reliable features for predicting 
aspiration108 and impaired consciousness and weak voluntary cough were independent 
predictors of aspiration following stroke109. 
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Studies to determine specific neurological predictors of dysphagia and aspiration have not 
been very successful. Demonstration of a dominant, more important hemisphere for 
swallowing has been discussed before. Furthermore, some studies have demonstrated that 
the lesions in the two hemispheres have different swallowing problems, specifically left 
hemispheric lesions have been associated with oral stage dysfunction and the right 
hemispheric lesions with pharyngeal stage dysfunction107;110. However, not all other studies 
support these findings111;112. A retrospective study of 65 acute stroke patients failed to 
demonstrate a significant association between dysphagia and aspiration and the size of the 
lesion or its location. Though described previously, according to this study aphasia was not 
a predictor of poor swallowing outcome. However, the presence of neuro-cognitive features 
such as hemispatial neglect and apraxia predicted protracted dysphagia but prospective 
studies are needed for investigation of these relationships107. The need for further research 
was emphasised by a study in 151 consecutive acute stroke patients which showed that the 
intensity of dysphagia or aspiration was not predicted by the type of the stroke113. The 
study further demonstrated that non-dominant cortical strokes were associated with 
dysphagia though there was no association with sub-cortical non-dominant strokes. 
 
In summary, aspiration is common in dysphagic patients and carries a risk of pneumonia. 
Silent aspiration is particularly important as the patients affected have lost their ability to 
expectorate the infected material and the aspiration goes unnoticed by the attending clinical 
staff. Videofluoroscopy provides a higher yield in diagnosing aspiration, especially silent 
aspiration. Physicians should be aware of signs and symptoms predicting aspiration, and 
ensure regular dysphagia assessments are conducted and further investigations, such as 
videofluoroscopy to detect silent aspiration, are considered so that pneumonia is prevented. 
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1.4.3. Clinical consequences of dysphagia and aspiration 
The potential link between fever and stroke was recognised more than 170 years ago in a 
textbook written by Christian Wilhelm Houfeland. According to his work, one of the most 
frequent complications following stroke was fever, which occurred in 61% of acute stroke 
patients114. However, it took many years to recognise that such medical complications 
contributed significantly to the outcome after cerebral ischaemia115. It has been reported 
that up to 95% of patients have at least one relevant medical complication within first three 
months after stroke and that more than 50% of patients with severe strokes die during 
hospitalisation due to one or more medical complications4;116. 
 
Several studies have demonstrated a strong association between dysphagia and pneumonia. 
In a prospective study in 91 acute stroke patients, Gordon et al noted a higher rate of chest 
infections in dysphagic acute stroke patients than in non-dysphagic stroke patients. Many 
of these had hemispheric strokes and were classified as severe strokes76. Dysphagia has 
been reported as an independent predictor for stroke severity and was associated with a 
higher incidence of respiratory problems, longer length of stay, and higher mortality and 
morbidity87. Dysphagia results in aspiration and confirmed aspiration increases the risk of 
pneumonia by 11 fold75. The incidence of lower respiratory tract infection was as high as 
68% in stroke patients who aspirated during videofluoroscopy than in non-aspirators(6%) 
and the use of intravenous fluids without oral intake did not prevent pneumonia in the 
patients who had persistent silent aspiration8. Aspiration contributes to the high incidence 
of pneumonia in stroke patients, compared to the incidence of pneumonia in age matched 
non- stroke patients on elderly care wards, which is only 5%117.  
 
Swallowing problems also lead to dehydration and malnutrition. Malnutrition can increase 
the risk of infections, gastrointestinal haemorrhage, low albumin levels, oedema and 
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development of pressure sores. Poor hydration can lead to electrolyte disturbances, 
paralytic ileus, constipation, vomiting, poor confidence, increased length of stay, and 
institutionalisation118. Poor nutritional state has been correlated with increased mortality 
after admission with an acute stroke119.  
 
Mortality is higher in stroke patients who are also dysphagic than in non-dysphagic stroke 
patients. Dysphagia is an independent predictor of mortality, and subjects who develop 
aspiration pneumonia have a higher mortality even after adjusting for stroke severity120. 
Odderson et al have demonstrated that dysphagia on admission was an independent 
predictor of mortality and dysphagic patients had a longer length of stay, were less likely to 
be discharged home and were twice likely to be discharged to a nursing home than non-
dysphagic patients 11.  
 
1.4.4. Pulmonary complications of aspiration 
Aspiration is defined as the inhalation of oropharyngeal or gastric contents into the larynx 
and lower respiratory tract121. Several pulmonary syndromes may occur after aspiration, 
depending on the amount of aspiration, the nature of the aspirated material, the frequency 
of aspiration, host factors such as the age, immune status and underlying local or systemic 
disease processes and the host’s response to the aspirated material122.  
  
Aspiration of stomach contents into the lungs can produce a range of signs and symptoms 
which include coughing, choking, wheezing, shortness of breath, cyanosis and hypoxaemia 
and can result in four different outcomes. These are rapid clearance of the aspirated 
material, or laryngeal obstruction with asphyxia and the risk of death, chemical injury / 
aspiration pneumonitis caused by the inhalation of sterile acidic gastric contents, and 
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aspiration pneumonia123. Aspiration pneumonitis, which is also referred as Mendelson’s 
syndrome, can recover completely with a brief febrile but uncomplicated course or can 
progress to a severe respiratory distress and death or development of pneumonia with 
pyrexia, cough with purulent sputum, coarse lung crackles on auscultation and signs of 
consolidation in the chest radiograph124. This is because even small amounts of gastric acid 
can lead to chemical injury of pulmonary capillaries and cause exudation of proteinacious 
fluid which can give rise to bronchospasm, pneumonitis and hypoxia. Secondary infection 
of the damaged tissues can occur from the onset if gastric contents is colonised by bacteria 
especially in the presence of a high pH in the stomach or from the organisms aspirated 
from the oropharynx. Secondary infection is likely even following aspiration of stomach 
contents with a low pH which prevents the growth of the majority of bacteria125. The fourth 
outcome is aspiration pneumonia and is defined as an infectious process caused by the 
inhalation of oropharyngeal secretions which are colonized by pathogenic bacteria122. 
Pulmonary aspiration is an important cause of serious illness and death not only in stroke 
patients also among nursing home residents, elderly people as well as in hospitalised 
patients with other neurological disorders126 and will be discussed in detail below.  
 
Approximately 50% of all healthy adults and 70% of patients with depressed conscious 
level aspirate small amounts of oropharyngeal secretions during sleep127. The low bacterial 
burden in the normal pharyngeal secretions, presence of mainly non virulent commensal 
organisms, forceful coughing, active cilliary transport and normal immune mechanisms 
usually result in clearance of this material without serious adverse effects127. Any condition 
that increases the volume or the bacterial load of the aspirate or causes impairment of the 
defence mechanisms can lead to development of aspiration pneumonia128. These conditions 
include neurological dysphagia, reduced level of consciousness resulting in poor cough 
reflex and glottic closure, disruption of the gastro-oesophageal junction, or anatomic 
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abnormalities in the upper gastro intestinal tract129. Mechanical disruption of the glottic 
closure or upper oesophageal sphincter due to tracheostomy, endotracheal intubation, 
nasogastric feeding and upper gastrointestinal tract endoscopies are associated with an 
increased risk of aspiration. The risk is also higher in older people because of an increased 
incidence of dysphagia and poor oral care resulting in oropharyngeal colonisation with 
potential pathogens, and more frequent gastro-oesophageal reflux130. 
 
Secretions are less likely to be expectorated in patients with a stroke due to reduced level of 
consciousness, muscle paresis and poor cough. However, there is no significant reduction 
in the volume of oropharyngeal secretions and in the presence of reduced pharyngeal 
sensation and insufficient glottic closure, various quantities of this infected material can 
enter the respiratory tract131. Poor oral hygiene, high inoculation and impaired host 
defences contribute to the high bacterial content of these secretions. Such episodes of 
aspiration may be witnessed, produce only subtle signs such as a weak cough, gurgling or 
wheeze or, more commonly occur silently, which can only be demonstrated by occurrence 
of oxygen desaturation or other specialised investigations. Patients who aspirate silently 
without clinical signs of dysphagia or well recognised signs and symptoms of aspiration are 
at a greater risk of chest infection, as their feeding will not be supervised or restricted and 
may receive less oropharyngeal care or suction. 8 Even if the aspirate is sterile due to low 
pH, aspiration of gastric contents can cause acid induced damage leading to atelectasis and 
necrosis which becomes secondarily infected123;131.  
 
Knowledge of bacteriology of aspiration pneumonia is important as it determines the 
choice of antibiotics. The bacterial flora of the oropharynx of a healthy individual mainly 
consists of facultative Gram positive bacteria, commonly alpha haemolytic streptococci and 
corynebacterium species132. By occupying receptor sites on the oral mucosa they interfere 
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with the adherence of pathogenic aerobic Gram negative bacilli and by consuming 
available nutrients and producing substances toxic to them, these commensal bacteria 
inhibit colonization of the oropharynx by aerobic Gram negative bacilli. Colonisation of the 
oropharynx by aerobic Gram negative bacilli occurs within few days of hospitalisation and 
correlates with the severity of the illness.27. One study had demonstrated that 37% of 
moderately ill patients and 73% of severely ill patients carry Gram negative bacilli in their 
oropharynx133. Similar findings are seen in acute stroke patients compared with patients on 
rehabilitation units who have less colonization 134. 
 
Common organisms involved in aspiration pneumonia in the community overlap with 
community acquired pneumonia (CAP) and are predominantly Streptococcus pneumoniae 
and Haemophilus influenzae135. Gram negative organisms that colonise the oropharyngeal 
mucosa are responsible for hospital acquired pneumonia and aspiration pneumonia6. Many 
studies have demonstrated that Enterobacteriaceae, Pseudomonas, Klebsiella and 
Staphylococcus aureus are the organisms responsible for most of hospital acquired 
aspiration pneumonias136. Factors that increase the risk of colonization and the bacterial 
load of the oropharynx, and increase the volume of aspirate all raise the risk of aspiration 
pneumonia128. 
 
Studies by Moinne et al and Torres et al have suggested that up to 15% of cases of 
community acquired pneumonia are due to aspiration137;138. There is also a considerable 
overlap of aspiration pneumonitis and aspiration pneumonia in critically ill patients 
including patients with acute stroke6. Aspiration pneumonia can result when large volumes 
of gastric contents including food and oropharyngeal secretions are vomited or regurgitated 
and aspirated, though the lung pathology started as an aspiration pneumonitis6. The 
stomach contents may not have a low pH in patients who are fed via nasogastric tubes, as 
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the enteral formulae have pH values of 6.6 to7 which can buffer the gastric acid to near 
neutral level. In addition, injury to pulmonary tissue can be worse if the aspirate contains 
large concentrations of pepsin and refluxed bile and trypsin from the duodenum. Also the 
aspirate can carry potentially pathogenic organisms from the oropharynx and the stomach, 
both of which may have bacterial overgrowth due to the nasogastric feeds. In addition 
damaged lung tissue can get secondarily infected with oropharyngeal secretions, resulting 
in aspiration pneumonia. 
  
Diagnosis of aspiration pneumonia is difficult in stroke patients as an episode of witnessed 
aspiration is essential for firm diagnosis and clinically significant episodes of aspiration 
may occur silently. However, certain broncho-pulmonary segments are commonly affected 
by aspiration, and involvement of these segments has been used for the diagnosis of 
aspiration pneumonia139. Therefore pneumonia due to silent aspiration is made when a 
patient at risk of aspiration has signs of pneumonia and radiological evidence of infiltrates 
in a broncho-pulmonary segment which is commonly affected by aspiration. In patients 
who aspirate while in a supine posture, the most common sites of infiltrates will be the 
posterior segment of the upper lobes and the apical segments of the lower lobes. Infiltrates 
are commonly seen in the basal segments of the lower lobes in patients who aspirate when 
upright or in a semi-recumbent position6. Radiologically visible infiltrates often occur 
within several hours of the event and improve over the next few days with treatment. An 
increase in the shadowing indicates super-infection or retained secretions. However, these 
radiographic signs are not pathognomonic140. 
 
Aspiration may be confirmed by the use of invasive investigations such as broncho-
alveolar lavage, fibreoptic bronchoscopy, percutaneous needle aspiration and open lung 
biopsy. These methods are costly, can cause significant patient discomfort, need special 
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expertise, and can be associated with high complication rates, and are therefore not 
routinely carried out to diagnose aspiration pneumonia. Scintigraphic studies and 
continuous oesophageal pH monitoring can also be used to detect silent aspiration140. These 
tests are not done in routine practice partially due to costs and also because the general 
management and antibiotic therapy is very similar for both types of pneumonia. The usual 
course of aspiration pneumonia is comparable to that of community acquired pneumonia 
though there is a higher incidence of cavitations and abscess formation of the lung tissues if 
there is delay in the treatment132. 
 
Most studies of aspiration pneumonia do not define specific criteria for diagnosis of 
aspiration pneumonia and mention only the criteria for diagnosing any pneumonia in the 
methodology. One review article on aspiration pneumonia suggests the use of following 
signs and symptoms for the diagnosis of aspiration pneumonia, if they were to develop 
after a bout vomiting or regurgitation in a patient at risk of aspiration139.  
• Symptoms of development of a chest infection such as new onset cough, 
wheeze, hypoxaemia and tachypnoea 
• Clinical signs such as new inspiratory crackles or bronchial breathing  
• Pyrexia 
• Leucocytosis 
• New pulmonary infiltrates in the gravity dependant lung regions 
 
In summary, aspiration leads to serious pulmonary complications and unless aspiration is 
witnessed or gastric contents or enteral feeds are detected on tracheal suction, it is difficult 
to prove that an episode of pneumonia is secondary to aspiration. Specific tests to confirm 
aspiration or aspiration pneumonia are not done in routine clinical practice, and clinicians 
have to rely on chest radiographic appearances which are not pathognomonic. 
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Differentiating aspiration pneumonitis from pneumonia in the critically ill may not be 
clinically relevant as one follows the other and will be treated with appropriate antibiotics. 
Considering the high incidence of silent aspiration following stroke, it is possible that many 
episodes of post-stroke pneumonia might have originated following aspiration, though this 
is difficult to prove. This may be why many studies have chosen any pneumonia as 
opposed to aspiration pneumonia as their primary outcome. 
 
1.4.5. Aspiration in critically ill patients including acute stroke patients 
It is recognized that a critically ill patient has a higher risk of aspiration and aspiration 
pneumonia6. Ventilator associated pneumonia is the most frequent and serious intensive 
care unit acquired infection and is associated with a mortality of 20% to 30%. 
Oropharyngeal dysphagia, reduced pharyngeal sensation and poor cough play a significant 
role in the development of ventilator associated pneumonia in mechanically ventilated 
patients such as patients with brain injury, acute stroke, intracranial infection and 
unconsciousness due to various sedatives and hypnotics. Low GCS due to neurological 
disease or medications is a well known risk factor for aspiration as patients with a reduced 
level of consciousness have impaired upper airway protective mechanisms. A recent study 
has shown that aspiration was higher in patients with GCS of 9 or less or when heavy 
sedation has been used141. In addition various gastro intestinal dysfunctions leading to 
gastroesophageal reflux, inability to clear the regurgitated material due to dysphagia and 
aspiration of regurgitated stomach contents mixed with infected oropharyngeal secretions 
also contribute to the development of ventilator associated pneumonia, which will be 
described in detail later. Being nursed in a supine position and nasogastric intubation may 
also increase the gastro-oesophageal regurgitation and aspiration of these patients142.  
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Acute neurological injury leads to a cascade of local and systemic metabolic responses 
leading to a hypercatabolic, hypermetabolic and hyperglycaemic state with altered immune 
responses and altered gastrointestinal function143. Studies in mechanically ventilated, 
critically ill patients with brain injuries have shown that there is a significant gastric 
dysfunction and a delay in gastric emptying. A study in 72 critically ill patients using 
acetoaminophen absorption from the stomach demonstrated a significant delay in gastric 
emptying and was associated with enteral feed intolerance and gastric colonisation144. 
Patients who were treated with opioid analgesics and narcotics had the most severe delay in 
gastric emptying. In another study done on a similar patient population using C13 octanoic 
acid feeds and serial breath tests for C13O2 excretion, demonstrated significant delay in 
gastric emptying following acute brain injury145. Early administration of enteric nutrition 
improves clinical outcomes, reduces infection and other complications. However, 
maintaining nutrition can be a challenge as nasogastric feeding is still complicated by 
aspiration and pneumonia as described below. 
 
Various types of gastro intestinal dysmotilities ranging from delayed gastric emptying to 
gastroparesis have been described in patients who are critically ill. Gastroparesis is 
commonly seen in critically ill patients and occurs due to a combination of decreased 
gastric contractility and defective coordination of gastric contraction across the antro-
pyloric region146. This is a combined effect of increased stress hormones, adrenergic 
stimulation, vagoparesis and concurrent medication such as anaesthetics and narcotic 
analgesia147. Intra-abdominal surgery, drugs such as morphine, dopamine and propofol, 
sepsis mediated by interleukin-1 and nitric oxide, hyperglycaemia, hypokalaemia, renal 
failure and raised intracranial pressure all contribute to gastroparesis. The syndrome of 
severe gastroparesis and intestinal ileus complicating critical illness is described as 
gastrointestinal failure. Gastrointestinal failure complicates about 10% of intensive care 
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admissions and is typically seen within the first few days of a critical illness. It is an 
independent risk factor for death and is more commonly seen in patients with acute medical 
and surgical illnesses than in patients following elective surgery 148. 
  
Gastroesophageal reflux is seen in up to 30% of patients who are kept in the supine 
position149. Studies have confirmed that stress hormone adrenalin causes long lasting 
relaxant effect on the lower oesophageal sphincter favouring gastroesophageal reflux150. 
Gastroesophageal reflux occurs in critically ill patients even in the absence of nasogastric 
tubes or enteral feeds150. Poor gastric emptying and gastroparesis can lead to gastric 
distension, increase in gastric residual volume, poor closure of the lower oesophageal 
sphincter and regurgitation of gastric contents, which can lead to aspiration and 
pneumonia147. 
 
Upper digestive feeding intolerance (UDFI) is defined as gastroparesis leading to increased 
residual gastric volume above a given threshold or recurrent vomiting during enteral feeds 
and is the commonest complication encountered during of nutritional support in critically 
ill patients 151. It has been demonstrated that only 35% of critically ill patients tolerated 
enteral nutrition and 65% of critically ill patients had one or more gastrointestinal 
complications during their enteral feeds152;153. Eighty five percent of these patients had high 
gastric residual volumes and 75% of these patients had at least one episode of vomiting and 
64%of patients showed evidence of gastroesophageal regurgitation153.  
 
These gastrointestinal dysfunctions interfere with feeding and maintenance of an adequate 
nutritional input in these patients as feeds have to be interrupted due to vomiting. Most 
episodes of aspiration are small in volume and may not lead to pneumonia, but the 
likelihood of pneumonia increases with multiple episodes of aspiration154. Therefore, in 
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2002, the North American Summit on aspiration in critically ill patients issued risk factors 
for aspiration (table 1.1) and has recommended that all patients on an intensive care unit 
should be stratified according to the risk of aspiration25.  
 
Gastric residual volume is commonly measured to assess the risk of aspiration during 
enteral feeds. However, data are conflicting for what gastric residual volume represents 
intolerance155. Most clinicians use 150 to 200 ml of gastric aspirate as a significant 
indicator of gastrointestinal motility dysfunction. The common practice of aspirating the 
stomach to measure gastric residual volume has been criticised by some clinicians as being 
unreliable and lacking standardisation156. Also it fails to differentiate normal gastric 
secretions from enteral feeds and can result in unnecessary interruptions of the enteral 
feeding regime. Several more reliable, harmless and sensitive methods such as 
scintigraphy, paracetamol absorption test, breath test, ultrasound and gastric impedance 
monitoring are now available154. However, refractometry seems to be the most appropriate 
tool for the regular assessment of gastric volume of the critically ill patient. Several trials 
have been done to assess the effects of prokinetic agents such as cisapride, erythromycin 
and metoclopramide to promote gastric emptying but the effect of these medications in 
prevention of aspiration pneumonia still inconclusive154. 
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Table 1-1 Risk factors for aspiration identified but the North American Summit 
 
Risk Factors for aspiration identified by the North American Summit 
Major risk factors 
Documented previous episodes of aspiration 
Decreased level of consciousness  
Neuromuscular disease or structural abnormalities of the digestive tract 
Endotracheal intubation 
Vomiting 
Persistently high gastric residual volumes 
Supine positioning 
Additional risk factors 
Presence of a nasogastric tube 
Non-continuous or intermittent feeding 
Abdominal/thoracic surgery or trauma 
Delayed gastric emptying 
Poor oral care 
Age 
Inadequate nursing staff 
Large size or diameter of feeding tube 
Malpositioned feeding tube 
Transport 
(Adopted from McClave et al25) 
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As described before gastroesophageal reflux is an important cause of aspiration and 
nosocomial pneumonia in ventilated critically ill patients on an intensive care units. Lower 
oesophageal sphincter dysfunction has been demonstrated in patients with brain injury. It 
has been demonstrated that acute head injury causes temporary dysfunction of the lower 
oesophageal sphincter which improves with neurological recovery. Patients who had a 
GCS of less than 12 within 72 hours of head injury were assessed for lower oesophageal 
sphincter dysfunction and tests were repeated at one week. Lower oesophageal sphincter 
dysfunction was seen in all patients, and the average gastric to oesophageal pressure 
difference was lower (-0.49mm Hg, range -3.4 to 2.5mm Hg) compared to a normal value 
of greater than 20 mm Hg. This pressure difference had improved to 13.3mm Hg at the end 
of the first week and this lower oesophageal sphincter dysfunction contributed to vomiting, 
aspiration pneumonitis and problems in maintaining enteral feeding157;158. 
 
The mechanism of gastroesophageal reflux in these patients differs from healthy subjects. 
Most episodes of gastroesophageal reflux in healthy adults are associated with transient 
lower oesophageal sphincter relaxation. This phenomenon is not commonly seen in 
critically ill patients as anaesthesia and sedation inhibits the triggering of the transient 
lower oesophageal sphincter relaxation 19. Nind et al demonstrated that in critically ill 
patients the lower oesophageal sphincter pressure was very low or absent. The study was 
done using oesophageal impedance rather than pH manometry of the oesophagus to detect 
the reflux episodes. This method is thought to be superior in detecting gastric reflux in 
nasogastric tube fed patients as the pH may be artificially high due to proton pump 
inhibitors or the buffering action of the enteral feeds. The study demonstrated that reflux in 
these patients was due to low or absent basal lower oesophageal sphincter pressure rather 
than transient lower oesophageal sphincter relaxation. More than two thirds of reflux 
episodes occurred spontaneously when lower oesophageal sphincter pressure is absent in 
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these patients. Increased intra abdominal pressure due to straining and coughing induced by 
suctioning or gastric distension contributed to the rest of the reflux episodes (20-30%). 
There was also a marked reduction in the activity and peristalsis of the body of the 
oesophagus159. The study also demonstrated that acid reflux occurred in 60% of patients 
and there were prolonged periods of acid exposure, secondary to impaired clearance 
following acid reflux. This is partly due to decreased oesophageal motility, secondary to 
adrenergic stimulation, hypotension and sepsis. Also, this is due to a reduction of chemical 
neutralization of regurgitated gastric acid in the oesophagus by swallowed salivary 
bicarbonate, secondary to impaired swallowing and loss of saliva due to suctioning and 
drooling160. 
 
Studies in acute stroke patients have shown similar results. A study in 62 acute stroke 
patients using oesophageal manometry also demonstrated transient upper and lower 
oesophageal sphincter dysfunction in the first two weeks following acute stroke and 
dysfunction of both these sphincters resulted in an increased incidence of aspiration and 
pneumonia85. A similar study by Hassett et al using oesophageal manometry and 24 hour 
pH monitoring in recent onset dysphagic stroke patients demonstrated that lower 
oesophageal sphincter dysfunction was common in this group of patients and led to 
gastroesophageal reflux and aspiration and patients with minimal gastroesophageal reflux 
had a higher survival rates and less aspiration pneumonia.86. The study also demonstrated 
that reflux was significantly influenced by the patient’s posture and there were significantly 
more reflux events when patients were nursed either in the right lateral position or the 
supine position than in left lateral or sitting positions86. The observed increase in 
gastroesophageal reflux and aspiration in the supine position compared to the sitting 
position has been well documented in previous studies, but an increase in the incidence of 
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reflux when patients are nursed in the right lateral position has not been documented 
previously.  
 
Several methods have been used to diagnose the reflux of gastric contents into the pharynx 
and the lungs in critically ill patients. The glucose oxidase test consists of determination of 
the glucose concentration in the tracheal secretions after a glucose meal20. Demonstration 
of a blue dye in the tracheal secretions following a test meal has been used in the past21. 
More recently demonstration of gastric enzyme pepsin or of micro beads that were 
incorporated in a test meal in the tracheal aspirate has been used with greater safety and 
success. To detect silent aspiration of stomach contents, Clayton el al monitored tracheal 
pH using an electrode which was inserted in to the trachea through the crico-thyroid 
membrane under a local anaesthetic161.The study was done in 32 acute stroke patients, 4-19 
days after the acute stroke. These patients were considered to be safe to have oral feeds 
after their swallow was assessed by bedside assessment and videofluoroscopy. The study 
demonstrated that nine out of thirty two patients showed signs of aspiration following an 
acidic meal. Though a small study, the results were statistically significant. Also the 
requirement to use of an invasive technique to diagnose gastro-oesophageal reflux and 
silent aspiration highlights the difficulties in diagnosing reflux and silent aspiration in 
stroke patients using conventional methods.  
 
Other studies done in critically ill patients in an intensive care setting have shown that risk 
of aspiration was significantly higher soon after extubation of a patient162;163. Residual 
effects of sedative drugs, swallowing dysfunction secondary to alteration of upper air way 
sensitivity, glottic injury and dysfunction of laryngeal musculature have been given as 
some reasons for this observation163. Alterations in swallowing reflexes can occur in 
patients who have been ventilated for more than 24 hours and may persist for 48 hours. 
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Keeping such patients nil by mouth for 6 hours and restricting oral intake to a pureed diet 
for further 48 hours can reduce the risk162. Similarly a recent study demonstrated that acute 
stroke patients who were intubated for neurovascular interventions had a higher incidence 
of aspiration pneumonia than stoke patients who had the intervention under a local 
anaesthetic164. The study reviewed 136 acute ischaemic stroke patients after endovascular 
treatment, 83 patients were given a local anaesthetic without intubation and 53 patients 
were intubated. Aspiration pneumonia was diagnosed in 14% of patients who were not 
intubated and in 23% of patients who were intubated. After adjusting for age, gender and 
severity of the neurological deficit, poor outcome at discharge and in-hospital mortality 
was significantly higher among patients who were intubated (83% versus 55%) 
 
In conclusion, studies in critically ill patients with brain injury have shown that aspiration 
and pneumonia are major complications and that a reduced level of consciousness was 
significantly associated with the development of pneumonia. This may be due to an 
attenuation of pharyngeal protective reflexes, reduced sensation, worsening of the 
coordination of breathing and swallowing, and cough. In addition, significant dysfunction 
of the lower oesophageal sphincter, delayed gastric emptying, increased residual gastric 
volume and enteral feed intolerance have been demonstrated secondary to neurological, 
hormonal and biochemical changes. These mechanisms predispose critically ill patients to 
aspiration and pneumonia. It may not be possible to correct the impaired level of 
consciousness secondary to underlying neurological damage. However, good 
oropharyngeal care, removal of excessive secretions by suctioning, application of methods 
to improve lower oesophageal sphincter function and gastric motility combined with 
vigilance in the detection of feed intolerance could potentially reduce the incidence of 
pneumonia in this patient group. The next section will review in detail of lower 
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oesophageal sphincter dysfunction with nasogastric tubes and mechanisms in which 
nasogastric tubes make reflux and aspiration worse. 
 
1.4.6. Nasogastric tubes as a cause of aspiration and pneumonia  
Lower gastroesophageal sphincter  
Before the discussion of how nasogastric tubes can cause aspiration, it is important to 
understand the structure and the mechanisms of the lower gastro-oesophageal sphincter 
(LES). The lower gastroesophageal sphincter is a physiological entity represented by an 
asymmetrical muscular thickening at the gastro-oesophageal junction and manometrically 
identified as a high pressure zone. Anatomically the LES is a 3 to 5 cm long segment of 
tonically contracted smooth muscle of which 1-2 cm is situated below the diaphragm. This 
pressure is exerted during resting conditions and is generated by an inward calcium leak 
with partial depolarisation of the smooth muscles which make up the LES. This leaves the 
sphincter in a state of tonic contraction preventing reflux from the stomach to the 
oesophagus165.  
 
Reflux of gastric content occurs166:  
i) When the intrinsic LES pressure is primarily and permanently low 
ii) Though the LES pressure is normal, it is only exerted on a limited area. e.g.: 
sphincter is too small 
iii) During transient LES relaxation – Spontaneous LES openings unrelated to 
peristaltic contraction of the body of the oesophagus 
iv) During respiratory fluctuation in the LES pressure 
v) Increased gastric volume and delayed gastric emptying  
vi) Presence of a nasogastric (NG) tube 
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The LES resting pressure varies from 7-25 mm Hg in relation to intra-gastric pressure and 
is measured by stationary manometry. The LES competency results from the combined 
effect of sphincter pressure, overall length of the sphincter and the length of the LES 
exposed to the positive pressure of the abdomen167. The LES is considered defective if any 
of these mechanical parameters fails and this will lead to gastroesophageal reflux which 
can be confirmed by 24 hour pH monitoring. LES pressure can be directly affected by 
intra-abdominal pressure, gastric distension, peptides, hormones, foods and many drugs168. 
The commonest mechanical cause for regurgitation through the LES pressure is inadequate 
length of its intra abdominal segment or an abnormally short total sphincter area. This will 
contribute to reflux as a response to the variation in the intra-abdominal pressure. A rise in 
the intra-gastric pressure beyond the intra abdominal pressure due to gastric dilatation can 
produce reflux if the LES pressure is low and especially if the intra gastric segment of the 
sphincter is too short. In addition gastric dilatation reduces the length of the lower 
oesophageal sphincter are making reflux worse. 
 
The gastroesophageal junction is a specialised segment of the upper gastrointestinal tract 
designed to prevent reflux of gastric contents into the oesophagus. Two structures, namely 
the lower oesophageal sphincter and the crural diaphragm act together to generate this high 
pressure area. Swallowing reduces the lower oesophageal sphincter pressure to match the 
intra gastric pressure but the protective effect of the oncoming peristaltic wave prevents 
any reflux during this swallowing induces sphincter relaxation. Prolonged monitoring of 
the lower oesophageal sphincter pressure has shown that there are episodes of spontaneous 
sphincter relaxation which occur even in the absence of swallowing. Though this is 
commoner in patients with reflux oesophagitis, this phenomenon is also seen in normal 
healthy people. This phenomenon is called transient lower oesophageal sphincter relaxation 
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(TLESR) and occurs as a result of a balance being created between the intra-oesophageal 
and intra-gastric pressure, which is also called the common cavity phenomenon. This 
accounts for 98% of acid reflux episodes in normal subjects. This complex phenomenon is 
thought be a physiological response triggered by gastric distension. It is not clear whether 
transient lower oesophageal sphincter relaxation alone is responsible for gastro-
oesophageal reflux disease 167. 
 
Recent studies have shown that transient lower oesophageal sphincter relaxation is the 
main mechanism which is responsible for the gastro-oesophageal reflux. It involves 
prolonged relaxation of the lower oesophageal sphincter mediated by a vasovagal neural 
pathway synapsing in the brain stem. This is especially true in the presence of defective 
oesophageal peristalsis either due to various neurological disorders or prolonged exposure 
of the oesophageal mucosa to the reflux material. Acid reflux can lead to complications 
such as oesophagitis, Barrett’s oesophagitis and eventually oesophageal carcinoma. 
Presence of hiatus hernia can further contribute the transient lower oesophageal sphincter 
relaxation. Drugs such as atropine, baclofen and loxiglumide have been shown to reduce 
the rate of transient lower oesophageal sphincter relaxation and the number of reflux 
episodes168;169. 
 
The lower oesophageal sphincter pressure can also change during respiration. These 
changes are directly proportionate to the depth of the inspiration and can be abolished by a 
skeletal muscle paralysing agent. Also intra-crural fibre contraction of the diaphragm 
during inspiration has been confirmed by crural diaphragmatic EMG and has a protective 
effect on the gastro-oesophageal reflux170. Electromyographic studies have also 
demonstrated that in delayed gastric emptying, oesophageal dilatation, vomiting or 
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eructation there is a reduction in the electrical activity of the crural fibres which favours 
gastro-oesophageal reflux168;171. 
 
1.4.7. Nasogastric tube feeding and aspiration 
Nasogastric tube feeding is an effective and a safe method of providing nutrition in patients 
who have swallowing difficulties172. According to the latest Royal College of Physicians 
(RCP) guidelines, all stroke patients should have a screening test for their ability to 
swallow within four hours of admission1. The Royal College of Physicians Guidelines also 
recommend that a formal swallow assessment within the first 24 hours of admission by a 
speech and language therapist, a specially trained doctor or a nurse using standard tests and 
a nasogastric tube should be considered if they remain nil by mouth1. Patients who have 
mild to moderate dysphagia are commenced on a diet of modified texture and consistency, 
and patients with severe dysphagia or patients who are too drowsy to be assessed are kept 
nil by mouth and commenced on nasogastric feeds172.  
 
It is easy to presume that in patients who are nil by mouth, nasogastric feeds provide a safer 
method of providing nutrition without the risks of aspiration and pneumonia. In a study to 
examine the relationship between the incidence of pneumonia and oropharyngeal protective 
reflexes in 143 consecutive stroke patients over a period of two years, Nakajob et al 
showed that pneumonia was significantly lower in dysphagic stroke patients who are fed 
via nasogastric tubes rather than managed only on oral feeds100. Patients were grouped as 
oral feeding without dysphagia, oral feeding with dysphagia, nasogastric feeds with 
dysphagia and bedridden patients fed via nasogastric tubes. Further analysis of the study 
showed that reduced oropharyngeal protective reflexes were related to the incidence of 
pneumonia even in patients who were fed enteraly. Nasogastric tubes were only effective in 
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preventing pneumonia in mildly or moderately disabled stroke patients with attenuated 
protective reflexes. Bedridden severe stroke patients with severe dysphagia who were on 
enteral feeds had the highest incidence of pneumonia.  
 
Though nasogastric tubes are designed to deliver feeds in to the stomach in patients with 
risks of aspiration and pneumonia, several studies have demonstrated that patients fed via 
nasogastric tubes continue to be associated with high risk of pneumonia12;13;173. Most of the 
early studies have been done in nursing homes and in patients with dementia. In a 
retrospective cross-sectional study of key predictors of aspiration pneumonia involving 
more than ten-thousand patients in nursing homes, Longmore et al demonstrated that tube 
feeding was the third strongest predictor for aspiration pneumonia out of 18 predictors174. 
A systematic review by Finucane et al to identify whether nasogastric feeds in patients with 
advanced dementia prevents aspiration pneumonia, improves survival, reduces the risk of 
pressure sores and infections or improves function and found no evidence that nasogastric 
feeds improved any of these important outcomes175. The latter review also reported that the 
risks were substantial and concluded that the practice of tube feeding should be carefully 
reconsidered in this population175. 
 
Even in patients with no previous swallowing problems or neurological disease nasogastric 
feeds have shown to increase the risk of reflux and aspiration. It has been demonstrated that 
in post-operative patients who needed a nasogastric tube following elective abdominal 
operations had an increased incidence of post operative pyrexia, atelectasis and 
pneumonia140. A study by Manning et al in post operative lower abdominal surgical 
patients using endoscopically placed lower oesophageal manometers and pH probes to 
record the pressure and the pH of the lower oesophagus showed that patients who had 
nasogastric tubes had lower oesophageal sphincter pressures and significantly more 
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episodes of gastro-oesophageal reflux than patients who did not have nasogastric tubes (a 
mean of 137 episodes of reflux as opposed to 8 episodes). Also the reflux episodes lasted 
longer and the drop in pH was greater in patients who had nasogastric tubes157. 
  
An association between enteral feeds and aspiration pneumonia in ventilated patients has 
been demonstrated even in older studies. A study by Pingleton et al in mid 1980s suggested 
that the presence of a nasogastric tube predisposed patients to aspiration and that the size of 
the nasogastric tube, the method of delivery, and the position of the patient also affected the 
incidence of aspiration pneumonia176. In addition work by the same author showed that 
gastric microbial growth increased after enteral nutrition and that the presence of an antacid 
or a H2 receptor antagonist favoured microbial colonisation by increasing the pH of the 
gastric contents12;17. 
 
Though thought to be a safe method of providing nutrition to a dysphagic or unconscious 
acute stroke patient, there are several studies that show nasogastric tubes only provide a 
limited protection against aspiration and pneumonia. Some studies also have demonstrated 
that dysphagic patients fed via nasogastric tubes have a high incidence of aspiration and 
pneumonia varying from 13% to 21% 10;76;177. However, these incidences are low when 
compared to more recent studies which have demonstrated rates varying from 33% to 
68%178-180. The relatively lower incidences in these older studies were due to the fact that 
patients who had an impaired level of consciousness were excluded, those would be 
expected to be at high risk of aspiration and pneumonia179. A study by Dziewas et al 
demonstrated that pneumonia occurred in 44% of tube fed acute stroke patients178 and a 
prospective study by Langdon reported an incidence of pneumonia of 59% in 330 acute 
ischaemic stroke patients fed via nasogastric feeds who were followed-up for 30 days 
following stroke180. In addition, sub-analysis of data of the ‘Turn-mob’ program, a 
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physiotherapy program to reduce post-stroke pneumonia within 14 days following acute 
stroke, did not prevent pneumonia in the subgroup of patients who were enteraly fed who 
had a pneumonia incidence of 68.2%181. It has also been demonstrated that patients who are 
fed via nasogastric tubes have a high incidence of pneumonia, if there was associated 
gastro-oesophageal reflux. In a prospective study Satou et al has shown that 89% of 
enteraly fed patients developed pneumonia if there was associated reflux, as opposed to 
42% if there was no reflux13. 
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Table 1-2 Incience of Pneumonia in patients fed via nasogastric tubes 
 
Study Number of tube 
fed patients 
Ventilated / 
Intubated 
Other uses of 
nasogastric tube 
Incidence of 
pneumonia 
 
Langdon et al180 
 
74 
 
No 
 
No 
 
 
59% 
 
Cuesy et al181 
 
46 
 
No 
 
No 
 
68.2% 
 
Dziewas et al178 
 
100 
 
Yes 
Gastric drainage 
during first 24 
hours 
 
44% 
 
Hilker et al177 
  
Yes 
 
 
Unclear 
 
Dysphagic patients 
54% 
Ventilated patients 
84% 
 
Satou et al13 
 
18 
 
No 
 
No 
If associated with 
reflux- 89% 
If no reflux- 42% 
 
Student No: 940137947014 47 
1.4.8. Mechanisms in which nasogastric tubes and feeds predisposes pneumonia 
 
Continued aspiration of pharyngeal secretions 
Healthy elderly people produce an average of 0.1 to 0.3 ml/minute of saliva without 
stimulation and 1.0 to 1.5 ml/minute with stimulation182. Colonization of the oropharynx 
with Gram negative bacteria can occur within a few days of hospital admission, and the 
contaminated oral secretions can be aspirated causing pneumonia. The presence of a 
nasogastric tube does not prevent continued aspiration of infected oropharyngeal secretions 
and this is partly responsible for the high incidence of pneumonia in severely dysphagic 
patients even if they are managed nil orally and maintained on enteric feeds, especially in 
the presence of silent aspiration. A study by Dziewas et al in one hundred acute stroke 
patients fed via nasogastric tubes demonstrated that most patients who were on nasogastric 
feeds acquired pneumonia as early as the second or third day after stroke onset and was 
thought to be due to increased oropharyngeal secretions, impairment of laryngeal elevation 
and disruption of upper and lower oesophageal sphincters178.  
 
A literature review by Gomes et al confirmed that aspiration is the most common 
complication in enterally fed patients and demonstrated that the source of aspiration was 
accumulated secretions in the pharynx and reflux of gastric contents from the stomach17. 
Continuous presence of a nasogastric tube causing desensitisation of the pharynx making 
aspiration worse has been suggested16. It has been demonstrated that stroke patients in 
intensive care units who had suction of their sub-glottic space regularly had a lower 
incidence of pneumonia183;184. Also it has been demonstrated that edentulous patients 
developed less pneumonia in similar situations which may be due to the aspirated 
secretions containing fewer bacteria185.  
Student No: 940137947014 48 
Worsening reflux 
Studies have demonstrated that lower oesophageal sphincter dysfunction and reflux is made 
worse with nasogastric tubes. Scintigraphy studies have clearly demonstrated regurgitation 
of gastric contents and aspiration in patients who are fed via nasogastric tubes even without 
underlying neurological dysfunction186;187. Reduced lower gastro-oesophageal sphincter 
tone and gastric distension have been shown to be responsible for this reflux and 
aspiration187. Placement of a nasogastric tube is associated with a reduced gastro-
oesophageal sphincter tone in children and development of gastroesophageal reflux188. In 
addition, nasogastric tubes can get displaced, can cause excessive gagging, retching and 
coughing, all of which can lead to regurgitation of gastric contents, which can result in 
aspiration189. In a patient with reduced upper airway protective reflexes, pharyngeal 
stimulation by a nasogastric tube can also increase the risk of aspiration by reducing the 
lower oesophageal sphincter tone17.  
 
Studies have shown that critically ill patients who are on nasogastric feeds have clinically 
silent micro-aspiration from the stomach, more frequently than witnessed large volume 
aspiration190;191. Some studies have shown that almost 90% of patients fed via nasogastric 
tubes had at least one episode of aspiration even though most were clinically silent141;192. 
Some studies have used oesophageal manometry and 24 hour oesophageal pH monitoring 
to demonstrate lower oesophageal sphincter dysfunction in acute stroke patients who are 
receiving nasogastric feeds13;67. A study by Lucas et al using oesophageal manometry 
demonstrated that that lower oesophageal dysfunction was a significant problem in acute 
stroke patients and often precludes safe gastric feeding67. Oesophageal sphincter pressures 
were significantly reduced following stroke, with an average lower oesophageal sphincter 
pressure of 14 mm Hg (normal 29 ± 2.6 mm Hg) and an average upper oesophageal 
sphincter pressure of 24 mm Hg (normal 47 ± 5.6 mm Hg). In this study feeding 
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jejunostomies were performed in patients with significantly low lower oesophageal 
sphincter pressures and the others had feeding gastrostomies. Even with feeding 
jejunostomies the patient population with lower oesophageal sphincter pressures had a 
syndrome of increased gastric and biliary secretion with regurgitation which required 
continued nasogastric suctioning during the first two weeks. Addition of a blue dye into the 
enteric feeds confirmed that oesophageal aspirates were not regurgitated jejunal feeds but 
originated from the stomach. 
  
Not all micro-aspirations due to gastric reflux are associated with pneumonia. However, 
pneumonia occurred more in frequent aspirators, with an incidence four times higher in 
patients who aspirate gastric contents frequently when compared to the patients who 
aspirate infrequently. A study by Satou et al using 24hour oesophageal pH monitoring 
demonstrated that 63% of patients who were on nasogastric feeds after an acute MCA 
infarction had episodes of gastro-oesophageal reflux and two-third of these patients 
developed aspiration pneumonia. The incidence of aspiration pneumonia was significantly 
higher in patients who had gastro oesophageal reflux (89.9%) than patients who did not 
have gastro oesophageal reflux (42%)13. This study also showed that patients who had a left 
hemispheric lesion had significantly more episodes of gastro oesophageal reflux than 
patients with right-sided cerebral lesions though there was no difference in the pH of the 
reflux. 
 
In addition to demonstrating sphincter dysfunction and reflux, it is also important to 
demonstrate gastric contents in the lungs to confirm the gastric source of aspiration. Using 
an enteral feed formula containing microscopic beads McClave et al found that 75% of 
nasogastrically fed critically ill patients had at least one microscopic aspiration during early 
course of their illness25. Another study to detect the presence of gastric enzyme trypsin in 
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tracheal secretions found that 320 of 360 critically ill patients who were fed via nasogastric 
tubes had at least one episode of micro-aspiration. This study also demonstrated that not all 
micro-aspirations were associated with pneumonia.  
 
 It is evident that the increased incidence of aspiration in stroke patients on fed via 
nasogastric tubes is due to a combination of several inter-related factors namely, loss of 
anatomical integrity of the lower oesophageal sphincter, gastroparesis, and reflux17. 
Feeding tubes provide no protection from aspiration pneumonia via the gastro-pulmonary 
route. Presence of pre-existing gastroesophageal dysmotility and hiatus hernia may also 
increase the risk of aspiration103;193. In addition, increase in the frequency of transient lower 
oesophageal sphincter relaxation has been suggested due to chronic stimulation of the 
pharynx by the nasogastric tube but further confirmation is needed to support this theory194. 
Desensitisation of the pharyngoglottal adduction reflux due to the presence of the 
nasogastric tube and an increase in the pharyngeal secretions and changes in the laryngeal 
elevation due to the presence of a nasogastric tube have been suggested by some 
researchers but all need further confirmation by larger studies15;16. 
 
Oropharyngeal colonisation 
The bacterial composition of pharyngeal secretions is important as it is the main offending 
agent that enters the lower respiratory tract to cause aspiration pneumonia. A millilitre of 
saliva contains one hundred million to one billion bacteria when compared to clear water, 
which has only hundred to thousand bacteria per millilitre. Though saliva contains a large 
number of bacteria, most of them are not pathogenic and will not give rise to pneumonia. 
Gram negative bacteria found in hospitals and nursing homes can lead to colonisation of 
the oral cavity and pharynx in patients and that can lead to changes in the pharyngeal flora. 
Student No: 940137947014 51 
Presence of oral or dental disease, antibiotic therapy, systemic illness, reduction of salivary 
flow, and malnutrition predisposes to such colonisation17.  
 
The incidence of bacterial colonisation increases with the severity of the underlying 
disease. It has been demonstrated that colonisation with Gram negative bacteria occurred in 
6% of normal,35% of moderately ill, and 73% of severely ill patients18. Reduction of 
salivary flow is an important risk factor and was commonly seen in these patients who are 
dehydrated and not fed orally. Adherence of micro-organisms to the epithelial cells plays 
an important role in pharyngeal colonisation. This is affected by multiple host and bacterial 
factors and increased by malnutrition and severe co-morbidities195. All these risk factors are 
commonly seen in patients with severe strokes who are kept nil by mouth.  
 
The presence of a nasogastric tube itself predisposes to oropharyngeal colonisation, which 
can be made worse by accompanying poor oral care and being kept by nil by mouth196;197. 
It has also been shown that oral and dental disease, antibiotic therapy, systemic illnesses, 
malnutrition and reduction of salivary flow increase the incidence of Gram negative 
bacterial colonisation of the oral and pharyngeal mucosa in patients fed via nasogastric 
tubes17;198. Oropharyngeal mucosal cultures were more frequently positive for Gram 
negative bacilli (81%) in patients with a nasogastric tube than in patients who are fed by 
percutaneous gastrostomy (51%). The study also demonstrated that non-dysphagic orally 
fed controls only had a colonisation rate of 17.5%22. Leibovitz et al demonstrated that 
elderly patients with a nasogastric tube for at least 2 weeks develop oropharyngeal 
colonisation including adherent biofilm formation on the nasogastric tube by Pseudomonas 
organisms22. Also colonisation with Pseudomonas and other Gram negative bacilli was 
more frequent than in non-dysphagic orally fed controls. These organisms provide a 
reservoir contributing to aspiration pneumonia.  
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Gastric colonisation 
Presence of a nasogastric tube also increases the incidence of colonisation of gastric 
contents with Gram negative bacteria17;199. Gastric acid prevents growth of bacteria and the 
contents of the stomach are sterile under normal circumstances. Colonisation of gastric 
contents with potentially pathogenic organisms can occur when the pH of the stomach is 
increased by the use of antacids, histamine H2 receptor blockers and proton pump 
inhibitors200. Gastric colonisation by Gram negative bacteria can also occur in patients who 
receive enteral feeding which neutralises gastric acid, patients with gastroparesis and in 
small bowel obstruction17. Several groups have reported cases of Gram negative 
pneumonia and bacteraemia in which the organism was also isolated either in the 
nasogastric feed or from the nasogastric tubing201. Reflux of infected gastric contents adds 
to the bacterial burden of already colonized pharyngeal secretions and aspiration from this 
pharyngeal pool of secretions is responsible for the high incidence of Gram negative 
pneumonia seen in these patients.  
 
It has been reported that elderly patients on long-term NG feeds have a significantly higher 
prevalence of Gram negative bacteria in gastric juices than similar patients who are on oral 
feeds (73% Vs 13%)23. Pseudomonas aeruginosa and Klebsiella pneumoniae were the 
commonest organisms isolated. The authors also conclude that there was a reduction of 
stimulated salivary flow in patients who are on long-term NG feeds and there was a 
significant difference in the concentrations of sodium, amylase, phosphorus and 
magnesium. In addition, the concentration of uric acid, which is the main non-enzymatic 
antioxidant of saliva, was significantly lower in patients who received long-term NG feeds 
which favours bacterial colonisation23. 
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Evidence of bacterial migration 
In many instances in enterally fed patients, the bacterial contents of the pharynx and the 
stomach are the same. Though it is possible to differentiate whether the aspirate is gastric 
or pharyngeal by the assessment of the pH or by the presence of gastric enzymes, it is more 
difficult by assessing its bacterial content as in many instances the bacterial burden of the 
pharynx and the stomach are the same. In a study in ITU patients fed via nasogastric tubes, 
87% had one or more similar organisms cultured simultaneously from the upper airway and 
stomach202. This is as the nasogastric feeds increases the gastric pH, which favours Gram 
negative bacterial colonisation of gastric secretions, and bacteria from the stomach can 
migrate upwards along the tube to colonise the pharynx and vice versa203. Segal et al 
studied the bacteriology of gastric juices of 52 patients who were fed via nasogastric tubes 
to assess the bacteriological burden of the gastric juice. In addition to gastric juice drawn 
after an overnight fast, cultures were taken from the oropharynx. Out of 107 samples 
pathogenic bacteria were isolated in 74% of stomach samples and 69% of oropharyngeal 
samples24. Gram negative bacteria and Staphylococcus aureus were the commonest 
organisms. Proteous species (26%) and Escherichia coli (22%) were the most common 
isolates from the gastric juices and Proteous species (24%) and pseudomonas species 
(21%) were the commonest from the oropharynx. Similarity in the composition of the 
oropharyngeal and gastric flora were observed indicating the passage of pathogenic 
bacteria in both directions. The gastric pH was higher than normal and this was highly 
correlated with the isolation of pathogenic bacteria. This support that in addition to the 
oropharynx, the stomach of the NG fed patients constitutes a reservoir of pathogens with 
the risk of aspiration pneumonia.  
 
Bio-film formation 
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Recent studies have shown that oral colonisation of patients with NG tubes has led to 
development of bio-films on their feeding tubes204-206. Initial attachment of bacterial cells 
on to the surface of the nasogastric tube is followed by their multiplication and the 
production of an exopolysacharide which lead to biofilm formation. These biofilms are 
sessile cell communities attached to a surface and to each other, and are usually embedded 
in various polymeric substances produced by the bacteria206. Attachment of bacteria to 
biotic or abiotic surfaces as biofilms can enhance resistance to environmental stresses and 
provide protection from various disinfectants. The pH of the medium, nutrient availability 
and the nature of the abiotic surface can affect biofilm formation207. 
 
Enterobacter sakazakii is an organism that has been shown to form biofilms on latex, 
silicon, polycarbonate, glass, stainless steel, and polyvinyl chloride. This organism can 
cause bacteraemia, sepsis, meningitis and necrotizing enterocolitis208. Cronobacter 
sakazakii, salmonella serovars, and acinetobacter are other bacteria known to form bioflims 
on enteric feeding tubes. These films occur inside the lumen within 8 -24 hours of the tube 
being placed. Biofilm can inoculate subsequent feeds, clumps can get detached and be 
passed to the stomach where they can grow further and cause serious problems in 
susceptible individuals205. 
 
In summary, though nasogastric feeding is an easy and an inexpensive way of providing 
nutrition to stroke patients who are unable to swallow, the nasogastric tube itself 
predisposes these patients to aspiration and pneumonia by worsening oropharyngeal 
colonisation, worsening lower oesophageal sphincter dysfunction and reflux. In addition 
nasogastric feeds promote gastric colonisation of pathogenic bacteria by neutralising 
gastric acids, trans-migration of bacteria and bio-film formation. Reflux of infected gastric 
contents adds to the bacterial burden of already colonized pharyngeal secretions. Aspiration 
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from this infected pharyngeal pool of secretions is responsible for the high incidence of 
pneumonia observed in these patients. However, many stroke patients have to depend on 
nasogastric feeds until the swallow improves or a PEG tube is inserted. It is therefore 
important to investigate methods of reducing the risk of pneumonia in these patients. 
 
1.5. Pneumonia following acute stroke 
Following acute stroke, mortality in the first week is mainly due to the initial cerebral 
injury and the loss of several central regulatory centres. Cerebral oedema secondary to the 
acute brain injury reaches a peak within the first few days and can lead to raised 
intracranial pressure, malignant middle cerebral artery syndrome, and uncal or cerebellar 
coning which can result in a fatal outcome. In patients who survive the initial brain injury, 
the overall survival and prognosis depend on the occurrence of medical complications6. 
Davenport et al demonstrated that 59% of patients who survive acute stroke had medical 
complications which contributed up to 20% of post-stroke mortality. Nosocomial infections 
contributed to one third of these medical complications, commonest being pneumonia4;5. 
Urinary tract infection is the second commonest infection following stroke with incidences 
varying from 6% to27%. However, Urinary tract infections have been shown to have a 
lesser impact on neurological outcome and mortality than pneumonia5.  
 
The percentage of patients with an acute stroke surviving the initial neurological injury has 
improved due to the recent advances in management of hyper-acute stages of stroke and 
most stroke patients being treated in dedicated acute stroke units or neurological intensive 
care units 209. This has lead to an increased in number of critically ill stroke patients 
surviving long enough to develop major medical complications such as pneumonia and 
pulmonary embolism. As previously described pneumonia is common following stroke and 
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significantly contributes to the post-stroke morbidity, mortality, length of stay and poor 
neurological recovery and outcome5;10;89. Therefore prevention of pneumonia is important. 
In patients who develop pneumonia, early and accurate diagnosis is important, as early 
initiation of appropriate antibiotics will improve survival. However, early diagnosis of 
pneumonia can be difficult in stoke patients as signs and symptoms of pneumonia can be 
masked by neurological dysfunction, old age and stroke associated immunosuppression. 
This section (1.5) discusses The British Thoracic Society Guidelines for the diagnosis of 
pneumonia and the effects of stroke on some parameters used for the diagnosis and 
prediction of pneumonia. 
 
1.5.1. Effects of pneumonia in stroke patients 
Studies have demonstrated that post-stroke infection, especially pneumonia is 
independently associated with poor functional outcome (Modified Rankin Scale > 2) after 
an ischaemic stroke5;10;210. Post-stroke infections were reported in 15% of patients and out 
of these 88% had a poor outcome at one year. A multicenter retrospective Canadian study 
demonstrated that development of pneumonia after stroke was associated with increased 
mortality at 30 days and 1 year, a longer length of stay and dependency at discharge211. A 
study by Kwan et al assessing 439 patients found that post-stroke infections can also affect 
patients admitted with transient ischaemic attacks as well as acute strokes and was 
associated with poorer short term outcome212. 
 
A recent systemic review and a meta-analysis on post-stroke infections involving 87 
studies which included 137,817 patients showed that there was considerable heterogeneity 
between studies in infection rates and the criteria for the diagnosis of post-stroke infections. 
However, the overall pooled infection rate was 30% and rates of pneumonia and urinary 
tract infection were 10% each. The rate of pneumonia was considerably higher in patients 
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managed in intensive care units with an incidence of 45%. Studies which specifically 
evaluated rates of infection in stroke patients reported even a higher incidence of 
pneumonia, possibly due to the more rigorous methods of detection of pneumonia213. 
 
In stroke patients with pneumonia poor neurological outcomes are secondary to the 
resulting hypoxaemia that can affect the neurological recovery of the ischaemic penumbra. 
Pneumonia can impair neuronal survival within the ischaemic penumbra by causing 
hypoxia, fever and electrolyte disturbance214;215. Fever can increase the cerebral metabolic 
demands, promote acidosis and can change the permeability of the blood-brain 
barrier216;217. In addition recent studies have demonstrated that activation of the 
inflammatory cascade due to infection itself play a significant role in causing further 
damage to an already ischaemic brain218. Pro-inflammatory cytokines secondary to 
infection can up regulate adhesion molecules, recruit and activate leukocytes, promote 
leukocyte-endothelial interaction and convert local endothelium in the penumbra into a 
prothrombotic state219. Activation and adhesion of leukocytes may also cause disturbances 
to the microcirculation in the ischaemic brain tissue which can lead to enlargement of the 
necrotic zone and the ischaemic penumbra117;196;220. This activation of the inflammatory 
cascade is reflected in the peripheral circulation by increased hepatic synthesis of 
fibrinogen and C-reactive proteins (CRP). Studies assessing inflammatory markers have 
shown that increased CRP, fibrinogen and chitotriosidase levels (a very sensitive parameter 
of proliferation of activated macrophages) were significantly associated with worse 
neurological scores and poor functional outcomes. The entry of Gram negative bacteria into 
the blood stream can produce lipopolysacharide induced thrombosis through tumour 
necrosis factor release, activation of the extrinsic pathway, reduction of thrombomodulin 
and inhibition of the fibrinolytic system221-223. All these mechanisms can worsen penumbral 
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ischaemia resulting in larger infarct volumes, higher mortality and poorer functional 
outcome. 
 
Pneumonia has been shown to be the commonest cause of death in the post acute phase, 
highest contributor to the mortality and accounting for nearly one third of all deaths 
following acute stoke116;224;225. A retrospective study on over 14,000 patients demonstrated 
a threefold increased risk of death among stroke patients who develop pneumonia after 
adjustment for stroke severity226. This association was recognised as early as 1980’s and in 
a large prospective study, Wade et al found that 43% of patients with an acute stroke had 
swallowing difficulties when assessed within the first week and 35-40% of patients with an 
abnormal swallow following an acute stroke died within six months227. Also the aspirators 
were significantly more disabled than the non aspirators with worse neurological and 
functional outcomes at three months89. Inter-current pneumonia was a predictor of poor 
functional outcome following a stroke, others been a higher NIHSS score, dysphagia, 
impaired consciousness, urinary incontinence and raised body temperature on admission228. 
In addition, pneumonia remains the leading cause of death even after discharged from the 
hospital120. Though the incidence varies according to the patient population included and 
the diagnostic criteria used, aspiration and pneumonia can affect a significant proportion of 
patients who are dysphagic following acute stroke and contributes significantly to the 
mortality and morbidity following acute stroke10. 
 
Post-stroke pneumonia also significantly contributes to the economic burden of post-stroke 
management. In an American study the cost of hospitalisation of patients with post-stroke 
pneumonia was more than twenty thousand dollars, which was more than 3 times the cost 
of managing a patient without pneumonia229. Also patients who had post-stroke pneumonia 
were over 70% more likely to require further care following discharge. According to this 
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report, the annual cost of stroke associated pneumonia in the United States was more than 
459 million dollars229. 
 
1.5.2. Timing of stroke associated pneumonia (SAP) 
Pneumonia and pulmonary embolism have been identified as the leading causes of 
mortality between the second and fourth week following a stroke in the early 1990s230. 
These complications were attributed to a combination of immobility, reduced level of 
consciousness, and motor deficits231. More recent studies have shown many patients 
developed pneumonia earlier following their stroke rather than in the second week as 
shown in previous studies. A study by Hilker et al in stroke patients in a neurological 
intensive care units had shown that 21% of patients fulfilled criteria for the diagnosis of 
pneumonia and that 58% of these patients had symptoms and signs within the first 48 hours 
(range from 0 to 6 days)177. Further studies done on stroke units have demonstrated that 
pneumonia is an early complication with nearly half of the pneumonias occurring within 
two to three days of stroke onset and 70-80% of patients developed pneumonia within first 
week following stroke117;178;184;232;233. It is also possible that a significant number of these 
very early pneumonias were acquired prior to hospital admission due to aspiration at the 
onset of stroke, which is also referred as community acquired aspiration pneumonia by 
some clinicians6;234. 
 
Many studies do not provide a clear picture of the number of episodes of pneumonia in 
patients with acute stroke. This may be because they were conducted in Intensive 
Treatment Unit/Neurology Intensive Care Unit settings where the average length of stay of 
patients was 6 to 7 days177. Persistent swallowing difficulties and aspiration are common 
within the first two weeks after acute stroke and patients with persistent swallowing 
problems have a prolonged hospital stay235;236. Therefore it is possible that these patients 
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had recurrent bouts of pneumonia on another unit, which were not included in the data 
collection or analysis of the original studies.  
 
Other reasons for high incidence of pneumonia in stroke patients 
It has been reported that the frequency of infectious complications post-stroke is 23- 65%, 
significantly higher than the prevalence of hospital acquired infections in other hospital 
patients which ranges from 6-9%237. Eighty-five percent of patients who survive an acute 
stroke will have various medical complications of which infections account for 23% to 
65%, and this is also true for patients in the rehabilitation phase238. Prospective studies 
report even higher incidences of medical complications which vary from 40% to 96% of 
patients239. This suggests that stroke patients are more susceptible to infection and the 
possibility of an immuno-suppressed state induced by stroke in these patients240. 
 
There is now a growing body of evidence that in addition to impairment of bulbar reflexes, 
dysphagia, a reduced level of consciousness and aspiration, central nervous system injury 
induced immunodepression (SIDS) plays a significant role in the development of post-
stroke pneumonia241;242. Pneumonia accounts for the majority of these infections, but 
aspiration alone is not sufficient to explain the high incidence of pneumonia in stoke 
patients88. About 50% of healthy adults aspirate pharyngeal secretions during sleep without 
major consequences or pneumonia suggesting that there may be an additional immune 
dysfunction in patients following acute stroke6. Experimental and clinical observations 
have shown that central nervous system injury leads to an immune deregulation which 
increases the susceptibility to infections and this may explain bacteraemia and frequent 
pneumonia following even small volumes of oropharyngeal aspiration241. In a murine 
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model, intranasal aspiration of only 200 colony forming units of Streptococcus pneumoniae 
was sufficient to cause severe pneumonia and bacteraemia if it was preceded by transient 
middle cerebral artery (MCA) occlusion, but would have needed more than 200,000 units 
in otherwise normal animals. 
 
It is thought that stroke-induced immunosuppression is due to complex interactions in the 
hypothalamic pituitary adrenal axis and is mediated by pro-inflammatory cytokines 
produced by the damaged brain tissue241. This results in increased cortisol production, 
activation of sympathetic nervous system, adrenal medulla and the cholinergic nerve 
pathway. Cerebral ischaemia triggers a rapid stress response in the hypothalamic pituitary 
adrenal axis leading to a large increase in corticotrophin and cortisol levels in the blood 
which is seen within 12 hours of cerebral ischaemia and is initiated by stimulation of the 
paraventricular nucleus of the hypothalamus to produce a surge of corticotrophin releasing 
factor. The resulting surge of glucocorticoids from the adrenal cortex suppresses the 
production of pro-inflammatory mediators and cytokines such as Interleukin-1β, tumour 
necrosis factor (TNFα), Interleukin -8, nitric oxide, and prostaglandins. It also facilitates 
the release of anti-inflammatory mediators and cytokines such as Interleukin-4, tumour 
growth factor-β, and Interleukin -10 and causes lymphocytic apoptosis243. This leads to 
reduced lymphocytic counts, impaired T-cell and natural killer cell activity and reduced 
mitogen and cytokine production. Severe strokes with larger volumes of infarcted tissue 
can lead to higher cortisol levels and worse outcomes. Activation of the locus coeruleus 
and adrenal medulla lead to an increase in catecholamine production which results in a shift 
from proinflammatory T-1 activation to anti-inflammatory T-2 activation244. A 
catecholamine mediated defect in early lymphocytic activation is thought to be the key 
factor in the impaired antibacterial immune response after stroke242. An associated 
deficiency of interferon-γ (INFγ) and impaired transfer of T- and natural killer cells can be 
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observed within 24 hours of an ischaemic stroke. Immuno-suppression following stroke 
can last for several weeks242. It has been demonstrated that infarct size was predictive of 
post-stroke infections and inversely correlated with admission and post-stroke T-cell 
counts245. Stroke volume was the only independent predictor for lymphopenia and 
monocyte dysfunction and respiratory infections246. Aspiration pneumonia in animals after 
focal cerebral ischaemia can be prevented by β-adrenoceptor blockage suggesting that 
immunodepression by sympathetic hyperactivity is a key factor for post-stroke pneumonia. 
In animal studies, treatment with IFN-γ early after focal cerebral ischaemia has been shown 
to reduce bacterial burden significantly. In addition IFN-γ deficiency and susceptibility to 
bacterial infections can be prevented by blocking the sympathetic nervous system, but not 
the hypothalamic adrenal pituitary axis247. Administration of the β-blocker propranolol 
reduces mortality after MCA occlusion in animal models. These observations suggests that 
immunodepression by sympathetic hyperactivity is important in the development of post-
stroke pneumonia219. Targeting brain induced immune-suppression is a theoretically 
attractive strategy to prevent or minimise the incidence of post-stroke pneumonia. Further 
research is required for better understanding of the pro-inflammatory and anti-
inflammatory cascades that follow an acute stroke. Therapeutic implications remain 
unclear. Better evaluation of how they translate from animal studies to humans is needed. 
 
1.5.3. Diagnosis of pneumonia  
Studies of pneumonia from several countries have used widely diverging definitions and 
inclusion criteria for the diagnosis of pneumonia. These include a combination of signs, 
symptoms, and radiological features135;248;249. The British Thoracic Society criteria for the 
diagnosis of pneumonia vary depending on the place of diagnosis and the facilities 
available e.g. in a primary care setting or in a hospital250. For patients seen in general 
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practice, the British Thoracic Society accepts a diagnosis without the aid of investigations 
or chest radiographs and relies solely on history and clinical features250. The diagnosis of 
pneumonia in hospital has to be supported by further investigations and a chest radiograph 
in addition to the physical signs of a chest infection, as it is the gold standard for the 
diagnosis of pneumonia 
 
 1.5.3.1. The diagnosis of pneumonia in the community setting  
Studies have demonstrated that clinical signs and symptoms such as pyrexia >38°C, 
pleuritic chest pain, dyspnoea and tachypnoea in association with new and localizing 
clinical signs on physical examination of the chest such as dullness on percussion, 
bronchial breathing and inspiratory crackles provide adequate information for a reliable 
diagnosis of pneumonia251;252. In one study 39% of adults who were treated as lower 
respiratory tract infection and had new focal signs on chest examination had evidence of 
pneumonia on the chest radiograph when compared to only 2% of patients who did not 
have physical signs on chest examination252. 
  
However, another study in 71 patients demonstrated that the emphasis should be on the 
duration of symptoms and signs rather than on the combination of respiratory symptoms 
and signs alone which were of little value in differentiating patients with pneumonia 
confirmed by a positive chest radiograph from patients who did not have pneumonia253. A 
shorter duration of all these signs (less than 24 hours) had a significant positive predictive 
value for a clinical diagnosis of pneumonia. Statistical modelling of clinical signs to predict 
the presence of community acquired pneumonia in 1819 adults attending a hospital out-
patient department with acute cough as their only symptom found that only 2.6% such 
patients had radiographic signs of pneumonia251. However, the study also demonstrated that 
a combination of clinical signs e.g. acute cough, temperature over 37.8°C, raised 
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respiratory rate (over 25 breaths per minute), sputum production throughout the day, 
myalgia, night sweats, combined with the absence of rhinorrhoea or sore throat had a 
sensitivity of 91% and a specificity of 40% for a diagnosis of pneumonia251. These studies 
demonstrate that a combination of good physical examination and interpretation of physical 
signs is as reliable as a chest radiograph for diagnosing pneumonia. Having more physical 
signs and considering the duration of symptoms adds to the strength of the diagnosis of 
pneumonia. 
 
Therefore British Thoracic Society criteria for the diagnosis of community acquired 
pneumonia in the community have not included the need for a chest radiograph, though 
fulfilment of all four criteria are required for the diagnosis of pneumonia250. 
I. Symptoms of acute lower respiratory illness, such as cough and at least one other 
lower respiratory tract symptom such as tachypnoea, defined as a respiratory rate 
over 25 per minute, purulent sputum, or pleuritic chest pain  
II. New focal chest signs on examination, such as dullness on percussion, crackles, 
or bronchial breathing on auscultation 
III. At least one feature to suggest systemic infection (either the symptom complex of 
sweating, fever, shivers, aches and pains, or presence of a temperature of 38° 
Celsius or more  
IV. No other explanation for the current illness 
 
Although many patients with community acquired pneumonia can be managed in the 
community without investigations, clinical diagnosis of pneumonia without a chest 
radiograph can be inaccurate. There is no individual physical sign that is diagnostic of 
community acquired pneumonia, but the presence of normal vital signs and a normal chest 
examination make a diagnosis of pneumonia very unlikely254. This is further compounded 
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by inter-observer variability in eliciting and interpretation of physical signs199;254;255. In 
addition presence of co-morbidities such as left ventricular failure, chronic obstructive 
pulmonary disease and other chronic lung diseases can make interpretation of physical 
signs difficult. Older patients can commonly present with non-specific symptoms and will 
have minimal or absent signs of a respiratory illness256. Symptomatology can be different 
in an older person as they can present with non-specific symptoms such as confusion and 
absence of pyrexia is commoner than in a younger person135;257. Therefore a chest 
radiograph is preferred if such facilities are available. 
 
The British Thoracic Society also has issued a set of guideline for the diagnosis of 
pneumonia in places where there are facilities to have a chest X-ray250;258. These are: 
I. Symptoms and signs consistent with an acute lower respiratory tract 
infection as above (I to IV) 
II. Shadowing in the radiograph which is at least segmental and was not known 
to be previously present and there is no other explanation for that shadow 
 
1.5.4. Problems encountered with the diagnosis of pneumonia in stroke patients 
Diagnosis of pneumonia based on clinical features alone can be even more difficult in 
patients with acute stroke. Due to muscle paralysis, lack of pharyngeal sensation, and 
reduced cough reflex, well recognised clinical symptoms of a lower respiratory tract 
infection such as cough and purulent sputum are commonly not observed in patients with 
large strokes213. In clinical practice, purulent sputum is often found only by oropharyngeal 
suctioning or during chest physiotherapy. In addition, most stroke patients are older and 
older people often do not manifest recognised signs of infection such as pyrexia and 
rigors259. Also stroke-induced immunodepression may affect a patient’s ability to mount a 
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febrile reaction to infection260. Therefore relying on such symptoms alone will delay the 
diagnosis of pneumonia, especially in the early stages of acute stroke. Also a reduced level 
of consciousness, receptive dysphasia and muscle paralysis can affect the compliance 
needed for a good physical examination of the respiratory system. Poor inspiratory effort 
and the paralysis of the ipsilateral dome of the diaphragm can lead to collapse of the lower 
lobe, which can interfere with the interpretation of physical signs261. Hemiparesis can also 
involve the muscles of respiration and this leads to reduced voluntary inspiration and chest 
expansion, which will affect auscultatory signs such as bronchial breathing and inspiratory 
crackles262. Bilateral lower lobe collapse due to poor posture and reduced inspiratory effort 
can further affect the interpretation of physical signs263. Furthermore, co-existing illnesses 
such as left ventricular failure, fluid overload, chronic obstructive pulmonary disease or 
pulmonary embolism can produce chest signs that mimic pneumonia5. These problems are 
compounded by inter-observer variability in the interpretation of the signs as well as by the 
compliance and wakefulness of the patient255. 
 
Pyrexia of >38°C is a well recognised indicator of an acute infection. It is due to an 
immune response and subsequent release of proinflammatory cytokines264. However, older 
patients do not always mount a strong inflammatory response to infection and may not 
exhibit pyrexia265. A recent study assessing inflammatory responses in older persons has 
shown that patients who had microbiologically confirmed infections (pneumonia, UTI and 
cellulitis) had a mean temperature of 37.6 ± 0.9°C and patients who had probable infection 
according to International Sepsis Definition Conference (ISDC) criteria only had a mean 
temperature or 36.5 ± 0.58°C266. 
 
In stroke patients, interpretation of temperature as a parameter of infection is complex, as 
cerebral injury itself can increase the body temperature. A temperature >37.5°C is very 
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common early after stroke, occurring in up to 61% of patients267. Pontine haemorrhage is a 
well known pathology that produces hyperpyrexia268. Several studies have shown that large 
cerebral infarction are associated with increased body temperature and is a poor prognostic 
sign and a multitude of different inflammatory and biochemical mechanisms for this 
detrimental effect have been identified215;269-271. One study of 390 patients with acute stroke 
demonstrated that increased body temperature within six hours of admission was 
independently related to the infarction size, initial stroke severity, mortality and the 
outcome270. For each increment of a single degree Celsius in the body temperature, the 
relative risk of a poor outcome (measured as death or a low SSS) increased by 2.2 fold. A 
similar study in 725 consecutive severe acute stroke patients (SSS <25) who had a normal 
body temperature on admission, the body temperature started to rise 4 to 6 hours after 
stroke onset and a persistent elevation of temperature for 10 to 12 hours was related to poor 
outcome269. This initial rise in body temperature was not observed in mild to moderate 
strokes and an initial body temperature less than 37.6°C was not related to stroke severity 
or stroke outcome. The aetiology of fever after stroke is not always evident and even after a 
rigorous search the cause of the fever may remain elusive, leading to the assumption of 
‘central’ or neurogenic fever in these patients272. Therefore, pyrexia is not a reliable sign 
for the diagnosis of an acute infection in acute stroke. 
 
Severely ill immobile stroke patients are more likely to have portable chest radiographs 
rather than departmental radiographs as these patients are too ill to be moved out of the 
unit273. Also many such radiographs are performed in semi-supine or recumbent position 
rather than as erect postero-anterior view due to patient drowsiness and paralysis274. Poor 
positioning and inability to take in a deep breath and hold for a good inspiratory chest 
radiograph can affect the identification of radiological signs of pneumonia in the chest 
radiograph, especially on the lower zones274. Another study demonstrated that high 
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percentage of other diagnostic tests such as chest radiographs were falsely negative due to 
poor inspiratory effort or falsely positive due to mimics such as lobar collapse and 
pulmonary infarction136.  
 
Microbiological diagnosis can be difficult as it may not be possible to obtain a proper 
sample due to poor cough and contamination from oropharyngeal secretions6. It has been 
reported that 40% of patients in an intensive care setting with pneumonia were not able to 
expectorate and that the sputum cultures frequently were sterile due to concomitant or 
previous antibiotic treatment. In addition the results may not be reliable, as sputum may be 
contaminated by oropharyngeal commensal flora.  
 
1.5.5. The role of microbiological investigations in the diagnosis of pneumonia 
According to the International Sepsis Definition Conference (ISDC) 2001, the diagnosis of 
definite infection requires fulfilment of both clinical and microbiological criteria275. 
Patients with clinical manifestations of infection and radiological evidence of infection 
without microbiological confirmation are defined as probable infection and patients with 
clinical features of infection without established microbiological or radiological 
confirmation are defined as possible infection. As for the diagnosis of pneumonia 
microbiological confirmation should include isolation of an offending organism either in 
the blood or sputum cultures or presence of a positive serology. 
 
Establishing a microbiological aetiological cause for pneumonia facilitates identification of 
resistant organisms and their antibiotic sensitivity pattern which allows narrowing down the 
spectrum of antibiotic used. This reduces the cost, the threat of antibiotic resistance and 
side effects such as antibiotic related diarrhoea. The British Thoracic Society guidelines 
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recommend blood cultures for all patients with suspected pneumonia276. Streptococcus 
pneumoniae, Haemophilus influenzae, Staphylococcus aureus and Klebsiella can be 
isolated in blood cultures. A positive culture is a highly specific indicator of 
microbiological aetiology and is a marker of the severity of the illness277. However, many 
patients with pneumonia do not have associated bacteraemia which are partly due to 
concomitant administration of antibiotics277. The sensitivity of blood cultures in 
pneumococcal pneumonia is at best only 25% 278. Interpretation of blood culture results in 
patients with devices such as a central lines or indwelling catheters should be reviewed in 
relation to the clinical context. In immuno-competent patients a positive blood culture of a 
known skin commensal such as Staphylococcus albus is not considered as an aetiological 
organism for pneumonia, and is more likely to be due to contamination. The common 
organisms responsible for pneumonia are generally same for the young and the elderly, 
except for Mycoplasma pneumoniae and legionella infections which are less frequent in the 
older population and Haemophilus influenzae which is more commonly identified279;280. In 
nursing home residents Gram negative bacilli and anaerobes has been shown to occur more 
frequently than in matched elderly patients, likely secondary to chronic aspiration281. 
 
In stroke patients, the specific pathogen is often identified in only 25% of patients, even on 
tracheal culture or bronchoalveolar lavage282. Sputum cultures are most likely to be positive 
if the sample is purulent. Purulent sputum is defined as secretions of the lungs, bronchi or 
trachea that have more than 25 neutrophils and less than 10 squamous epithelial cells per 
low power field (x 100)283. Repeated production of purulent sputum over a period of 24 
hours is more indicative of onset of infection in the lower respiratory tract rather than a 
single episode of purulent sputum or change in the colour or character of the sputum. 
Changes in the character of sputum refer to the colour, consistency, odour and the quantity 
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of the sputum. Though sputum cultures may identify the causative agent, they have a low 
sensitivity and specificity for the diagnosis of pneumonia for a number of reasons: 
• Inability of patients to produce a good specimen  
• Prior treatment with antibiotics 
• Delay in transfer and processing of samples (mainly at weekends) 
• Difficulties in interpretation secondary to contaminant upper airway respiratory 
flora which includes potential pathogens such as pneumococci and coliforms284. 
 
However, many stroke physicians do not depend on microbiological methods for the initial 
diagnosis and management of pneumonia due to poor yield and delay285. This is not 
uncommon in patients with other illnesses as prospective aetiological studies of non-stroke 
patients have demonstrated that a microbiological aetiology was not found in 45-60% of 
patients and, that the yield is even lower in hospitalized patients278;286. 
 
In many studies of post-stroke pneumonia, Staphylococcus aureus and Gram negative 
bacteria such as E coli, Klebsiella pneumoniae, enterobacter and Pseudomonas aerugenosa 
have been the most commonly identified organisms6;234;287;288. A study on post-stroke 
pneumonia on a neuro-intensive care unit demonstrated that Gram negative bacteria were 
implicated in 40% to 60% of patients and Staphylococcus aureus in 20% - 40% patients177. 
Streptococcal species, which is still the commonly isolated pathogen in community 
acquired pneumonia, is less commonly found in the sputum cultures of post-stroke patients. 
This is due to the early colonisation of oropharynx by Gram negative bacilli in these 
patients and aspiration of this endogenous material frequently being responsible for 
pneumonia. Irrespective of whether studies were performed on wards or intensive care 
units, the microbiological pattern was similar in early post-stroke pneumonia and this early 
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onset pneumonia is sometimes referred to as community acquired aspiration 
pneumonia6;232;234. 
 
In summary, the yields of cultures are not very high in post-stroke pneumonia and often no 
causative organism is isolated. This is partly due to the difficulties of obtaining a good 
sputum sample secondary to the neurological deficit, poor cough and lowered level of 
consciousness. Infections caused by anaerobic bacteria require special culture techniques 
for isolation which are not often carried out by laboratories. Local administrative problems 
such as delays in the specimen transportation to the laboratories and not processing sputum 
culture samples during a weekend can affect this yield even further. In addition, culture 
results which only state the presence of upper respiratory tract flora without identification 
of the predominant organism do not help establish the diagnosis. Also, some of the 
suspected pneumonia may have a different aetiology such as lobar collapse or a non 
infective aspiration pneumonitis due to regurgitated gastric contents which have not yet 
been infected by pathogenic organisms. 
 
1.5.6. The role biochemical markers for the diagnosis of pneumonia 
White blood count, C-reactive proteins, erythrocyte sedimentation rate, and procalcitonin 
are biochemical markers which are used for the diagnosis of any acute infection including 
pneumonia. Of these, white blood count and C-reactive proteins are commonly used to 
diagnose post-stroke pneumonia and will be described in more detail in this section. 
 
White Blood Count 
 
In the general population, including patients with acute stroke, a leucocytosis, white blood 
count (WBC) of more than 12 x 106/ml or leucopenia, a WBC of less than 4 x 106/ml, is 
highly suggestive of a bacterial infection. In a patient with a chest infection a WBC of more 
Student No: 940137947014 72 
than 15 x 106/ml strongly suggests a bacterial infection, but a lower count does not exclude 
this289. A WBC of more than 20 x 106/ml is an indicator of the severity of the pneumonia. 
  
Changes in the WBC count have been shown in patients with ischaemic strokes with no 
infection. An increment in the neutrophil count can occur as early as day one following 
stroke and is related to the infarct volume, which is more pronounced with large infarcts246. 
The rise is smaller in strokes with low infarct volumes and the neutrophil count reaches the 
baseline by the fourth day following stroke. Lymphocytopenia is observed in strokes with 
large infarct volumes and is the basis of stroke-induced immuno-depression, which is 
discussed in detail in section 1.5.10. 
 
In addition urea, electrolytes and liver function tests can be used to assess the severity of 
the pneumonia. For an example, a concentration of urea over 7 mmol/l is used as an 
indication of a severe pneumonia in combination with other symptoms and signs of 
pneumonia (Confusion, high Urea, Respiratory rate, Blood pressure and Age <65 = 
CURB65 score)249. However, the reliability of these scoring systems have not been 
assessed acute stroke patients and may be unreliable as indicators such as confusion may 
directly be related to stroke and high urea secondary to the reduced oral intake due to 
dysphagia. 
 
C-reactive protein 
C-reactive protein (CRP) is an acute phase protein, produced in the liver and has a normal 
plasma level concentration of less than 10 mg/l. Bacterial infection can rapidly increase 
CRP levels several-fold within a few hours and the levels may remain elevated until 
resolution of the active inflammation290. However, it is not very specific, as other illnesses 
such as pulmonary embolism, deep vein thrombosis, myocardial infarction, malignancies, 
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autoimmune diseases, vasculitidies, trauma and rheumatoid arthritis are associated with an 
elevated CRP. The main mediator stimulating CRP production is interleukin 6 (IL-6), but 
other proinflammatory cytokines such as tumour necrosis factors (TNF) and interleukin-1 
(IL-1) have been also shown to be responsible. 
 
Increased concentration of the CRP in the plasma is useful for the diagnosis of infection 
and determining the course of an infection259. Studies have demonstrated that high CRP 
levels within 24 hours of admission are predictive of a bacterial infection and that a fall in 
the CRP level is usually associated with resolution of the disease291. Assay of CRP is fast, 
readily available and inexpensive. However, the majority of studies of CRP have been done 
in young patients and in intensive care units. However, sub-analysis of data on various 
illnesses have shown that mean CRP levels were much higher in elderly patients with 
septicaemia than previously believed292;293. Earlier studies have suggested that CRP 
response to invasive bacterial infections may be delayed in frail elderly patients294;295. It has 
been suggested that a delayed IL-6 response, the main stimulator for CRP production, and 
impaired production of pro-inflammatory cytokines are responsible for this poor response 
of CRP264;295. However, more recent studies have shown the usefulness of CRP for the 
diagnosis of acute infections in an older patient266;296-298. A study done in 232 older patients 
with confirmed infection (pneumonia including aspiration pneumonia 34%, urinary tract 
infection 21%, cellulitis 27% and exacerbation of chronic obstructive pulmonary disease 
7%) demonstrated that a significant elevation of CRP within 24 hours of hospitalisation 
was predictive of a bacterial infection and a CRP level of 60 mg/l had the best combination 
of sensitivity, specificity and predictive value though this concentration was lower than 
previously published291;297. Large prospective studies have demonstrated that a high CRP 
reading within 24 hours of admission to the hospital in older people was highly predictive 
of an acute infection266;291.  
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CRP levels have an important role in the monitoring of patients with pneumonia299. The 
median time for a 50% reduction of CRP level was 3.3 days following treatment and CRP 
levels which do not fall by 50% within 4 days of initiation of treatment suggest failure of 
treatment or development of complications such as empyema or antibiotic associated 
diarrhoea299. CRP may also provide a clue to the aetiology of the pneumonia as 
pneumococcal pneumonia is associated with a higher CRP level than viral or mycoplasma 
pneumonias 300;301. An arbitrary cut-off of 100 mg/l has been used as a marker to help 
distinguish pneumonia from an exacerbation of chronic obstructive pulmonary disease299. 
 
It has been demonstrated that a raised CRP level on admission is a more sensitive marker 
for the presence of pneumonia than a raised WBC count or an increased temperature and 
that the majority of patients with pneumonia on admission had a CRP over 50 mg/l300. 
Further analysis demonstrated that 75% of patients with pneumonia had a CRP of over 100 
mg/l and that CRP levels were higher in patients who did not receive antibiotics prior to 
admission300. Some studies have demonstrated that a cut-off value of 40 mg/l was sufficient 
in older patients with bacterial infections and a CRP level of 60 mg/l provided the optimal 
combination of sensitivity, specificity, and predictability for an underlying infection rather 
than a non-infective aetiology264;266. Another study demonstrated that a cut-off value for 
sepsis should be 80 mg/l irrespective of the age of the patient302.  
 
There is emerging evidence on the peripheral inflammatory response following stroke. In a 
prospective study in 36 patients with acute ischaemic stroke Emsley et al showed that the 
CRP levels were elevated on admission (4 mg/l), relative to age matched controls (2 mg/l) 
(p = 0.01)220. The greatest elevation was observed at 5-7 days from stroke onset (18 mg/l) 
(p <0.001). Similar results have been demonstrated in other studies and high CRP levels 
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within first week have shown to be associated with unfavourable outcomes, recurrence of 
stroke and other cardiovascular events303;304. This very early increase in the inflammatory 
markers may either be induced by stroke itself, or may indicate a pre-existing inflammatory 
condition which may have contributed to the development of stroke. A prospective study in 
51 acute stroke patients demonstrated that an increased level of CRP on the day of 
admission was associated with an ongoing infection and resulted in poor neurological 
outcomes218. However, the study concluded that the infection was acquired prior to stroke 
onset and the resulting inflammatory process predisposed these patients to have a stroke 
rather than infection was acquired following stroke. 
 
1.5.7. The role of the chest radiograph in the diagnosis of pneumonia 
New infiltrates detected in the chest x-ray concomitant with signs and symptoms of a chest 
infection have been the key requirement for the diagnosis of hospital acquired pneumonia. 
Many studies of pneumonia use chest radiograph as a prerequisite for diagnosis of 
pneumonia. However, there have been questions about the reliability of the chest 
radiographs if done too early in suspected pneumonia cases. Studies have demonstrated that 
the initial chest x-ray lacked sensitivity and in suspected community acquired pneumonia 
chest radiograph may not demonstrate any parenchymal change in up to 21% of 
patients273;305. In addition more than half of the patients who had a negative chest 
radiograph on admission went on to develop radiographic infiltrates within 48 hours273. 
Another study demonstrated that a chest radiograph was not always necessary for the 
diagnosis of pneumonia as combined cough, purulent sputum, fever, tachycardia, 
tachypnoea and abnormal chest signs had a sensitivity of 95% and specificity of 56% of 
predicting pneumonia306. The study also suggested that chest radiographs were unnecessary 
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in patients with acute respiratory symptoms, if their vital signs and physical examination 
finding are within normal limits.  
 
Even in hospitalised patients, chest radiographs done too early lack sensitivity in 
diagnosing pneumonia as a review of chest radiographs on hospitalised patients with final 
clinical diagnosis of pneumonia found that in one third of patients the initial radiograph had 
no evidence of pneumonia305. In this study, though many clinical characteristics were 
similar between patients who were radiologically asymptomatic, those with symptomatic 
chest radiographs on admission were older (73 years versus 68 years) and had greater 
pneumonia specific severity illness scores. Both groups had similar rates of positive sputum 
and blood cultures. However, microbiology was different as streptococcus pneumonia was 
more common in patients with chest x-ray confirmed pneumonia than in the patients who 
had normal chest radiographs, in whom other streptococcus species and Gram negative 
bacilli were more frequent. In-hospital mortality was similar in both groups. This study 
concluded that patients who were admitted with signs and symptoms of pneumonia with no 
confirmation in the chest radiographs had serious lower respiratory tract infections with 
substantial rates of bacteraemia and mortality. It has been suggested that absence of 
radiographic findings should not supersede clinical judgement and empirical treatment305. 
 
Though the lower lobes are affected commonly regardless of the aetiology, there are no 
characteristic radiographic features to predict the likely pathogen258. However, certain 
radiographic appearances are more likely to be associated with particular organisms such as 
pneumonia caused by Staphylococcus aureus is more likely to present with multi-lobar 
shadowing, cavitation, pneumatoceles and spontaneous pneumothorax. Also Klebsiella 
pneumonia commonly affects the upper lobes (especially on the right), and may be 
associated with a bulging interlobar fissure and abscess formation with cavitation307;308. 
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Homogenous shadowing is less commonly seen in mycoplasma pneumonia. Multifocal 
involvement and pleural effusion at presentation are more likely due to bacteraemic 
pneumococcal pneumonia than with non bacteraemic pneumococcal pneumonia. 
 
Hospital acquired pneumonia is defined as pneumonia which occurs after 48 hours of 
hospitalisation. Criteria for diagnosis of hospital acquired pneumonia may vary according 
to the healthcare system and country. The United States Centre for Disease Control criteria 
for hospital acquired pneumonia requires the presence of radiological changes in two or 
more serial chest radiographs with at least one of new or progressive and persistent 
infiltrate, consolidation, cavitation or pneumatocele. In patients without underlying 
pulmonary or cardiac diseases such as chronic obstructive pulmonary disease, respiratory 
distress syndrome, broncho-pulmonary dysplasia and pulmonary oedema, one definite 
chest radiograph is acceptable if the clinical and microbiological criteria for the diagnosis 
of pneumonia are fulfilled309. 
 
In patients with pre-existing pulmonary or cardiac disease non-infective conditions such as 
pulmonary oedema, pulmonary embolism and congestive cardiac failure may simulate 
signs of pneumonia. In the presence of such medical conditions, serial chest radiographs 
are required to distinguish these non-infective conditions from an infective pathology. It 
has been suggested that a comparison of radiographs at diagnosis, three days before 
diagnosis and days two and seven after diagnosis of pneumonia should be done if available. 
Clinical features of pneumonia have a rapid onset and progression but radiological findings 
do resolve more slowly and may persist for several weeks. In addition a rapid radiological 
improvement suggests a non-infective process such as atelectasis or congestive cardiac 
failure rather than pneumonia309.  
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There are many radiological terms describing the radiographic changes of pneumonia such 
as “air space disease”,” patchy areas of increased density”, and “focal opacification”. In 
addition some radiological reports do not use the term pneumonia. However, in the 
appropriate clinical setting such descriptive terms are considered as positive radiological 
findings for the diagnosis of pneumonia309. 
 
In critically ill patients with extended hospital stay there may be multiple episodes of 
hospital acquired pneumonia. For the diagnosis of recurrent hospital acquired pneumonia, 
evidence of the initial infection, a combination of new signs and symptoms and new 
radiological evidence are required. Identification of a new pathogen or a change in the 
pathogen alone is not adequate for diagnosis of a new episode of pneumonia309. 
 
 Radiological resolution frequently lags behind clinical improvement, especially following 
bacteraemic pneumococcal pneumonia and legionella pneumonia. It has been demonstrated 
that complete resolution of chest radiographic changes was seen at 2 weeks in 51% of 
cases, by 4 weeks in 64%, and in 73% in 6 weeks. Radiological resolution is slower in 
older persons, in patients with multi-lobar involvement, in smokers, and in hospitalised 
patients rather than patients in the community258.Radiological deterioration following 
admission to a hospital is more common in older patients and in staphylococcal 
pneumonia307. Radiological changes of pneumonia caused by atypical pathogens improve 
faster than when the pneumonia is caused by other bacterial organisms310. A multivariate 
analysis showed only age and multi-lobular involvements were independently related to the 
rate of radiological resolution258. 
  
Studies of the role of CT chest scans for the diagnosis of pneumonia are limited. One study 
has shown CT scans improve the accuracy of the diagnosis of community-acquired 
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pneumonia when compared with chest x-ray alone311. Also CT scans are more sensitive and 
can be used in subjects where the diagnosis is in doubt312. However, in usual hospital 
practice CT scanning has a limited role as an investigative tool due to the cost, availability, 
time required and use of radiation. 
 
1.5.8. Risk factors and clinical predictors of pneumonia 
In view of the high morbidity and mortality associated with aspiration and pneumonia, 
physicians need to identify stroke patients who are at risk of pneumonia and provide 
intensive preventative interventions to such patients. Until recently most of the studies of 
risk factors for pneumonia were performed in patients managed on intensive care units, in 
which stroke patients only formed a small proportion of the patient population.  
 
Risk factors for post-stroke pneumonia 
A depressed level of consciousness, tube feeding, immobility, endotracheal intubation, 
mechanical ventilation, stroke location, reduced pharyngeal sensation, and abnormal 
voluntary cough were all positively correlated with risk of aspiration in videofluoroscopic 
studies77;313;313. However, there have been only few studies prior to the last two decades 
that reviewed the association of these variables with the development of pneumonia. A 
study on 103 patients with head injury demonstrated that the incidence of microbiologically 
proven pneumonia was 21% and the risk factors for the development of pneumonia were 
presence of a nasogastric tube, continuous enteral feeds, mechanical ventilation more than 
a day, use of H2 receptor blockers, use of intense sedation, muscle relaxants, use of 
barbiturates and corticosteroids, intubation, craniotomy, and positive end expiratory 
pressure ventilation314. However, the mean age of these patients was 41 years and 
considering other patient criteria and the therapeutic interventions received, these patients 
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were significantly different to patients managed on stroke units who will have a different 
risk factor profile. 
 
Studies new and old have identified that poor oral health and the presence of oral pathogens 
as risk factors for pneumonia following acute stroke 76;232 315;316. In a retrospective study in 
378 consecutive stroke patients, Langmore et al has suggested a stage model for predicting 
aspiration pneumonia, which included dependence of oral care, reduction in salivary flow 
(due to reduced production and medication), altered oral flora, increased concentration of 
bacteria in saliva and aspiration317. The study also demonstrated that patients who had a 
history of chronic obstructive airway disease had a higher risk of post-stroke pneumonia 
and patients with diabetes and hypertension developed pneumonia early in their post-stroke 
period317. 
  
Table 1.3 shows various clinical predictors for post-stroke pneumonia which have been 
identified by some recent studies. Many have identified stroke severity (clinical and/or 
radiological assessment), dysphagia, unsafe water swallowing test, old age, a reduced level 
of consciousness, and mechanical ventilation as highly predictive of pneumonia. In a 
landmark study on stroke patients managed in a neuro-intensive care unit, Hilker et al 
demonstrated that a reduced GCS on admission (<8/15), a large neurological deficit, 
presence of dysphagia endotracheal intubation, and mechanical ventilation were significant 
risk factors for stroke associated pneumonia177. The risk of pneumonia was highest in the 
acute stage and in patients with non lacunar strokes in the middle cerebral artery territory. 
The study also demonstrated that posterior circulation strokes and multifocal infarctions in 
various vascular territories also had a higher incidence of pneumonia due to a cumulative 
effect on swallowing reflex, bulbar palsy and aspiration.  
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Predictors of post-stroke pneumonia 
Pre-existing abnormalities in the chest radiograph was also a predictor of stroke associated 
pneumonia as it was demonstrated in an earlier study318. These may be an indicator of 
silent aspiration, increased susceptibility of the lung to infection or of early 
pneumonia177;318. A more recent prospective study in 236 acute stroke patients on a 
neurological intensive care unit demonstrated more detailed independent predictors for 
stroke associated pneumonia which included dysphagia, a NIHSS score 10 or more, non-
lacunar basal ganglia infarction, and any other infection present on admission. These risk 
factors could predict stroke associated pneumonia with 76% sensitivity and 88% 
specificity. In addition, the study also demonstrated that patients with lacunar infarctions 
had significantly lower risk of developing pneumonia and patients with a reduced level of 
consciousness and vomiting did not respond well to the initial course of antibiotics233.  
 
In one of the first studies of predictors for post-stroke pneumonia conducted on a stroke 
unit, Dziewas et al demonstrated that a decreased level of consciousness and the presence 
of severe facial palsy were independent predictors for post-stroke pneumonia178. A high 
NIHSS score on admission was an independent predictor of a poor outcome according to 
this study. A decreased level of consciousness has also been identified as a risk factor for 
aspiration and pneumonia in patients with other non-stroke neurological disorders as it is 
associated with a reduction of protective reflexes and impairment of the coordination 
between breathing and swallowing127. In contrast, the association of severe facial palsy and 
aspiration is stroke specific and may reflect the effects of co-existing weakness and 
incordination of the tongue and the oropharyngeal musculature.  
 
A prospective trial of predictors of pneumonia in acute stroke patients which included 412 
patients with ischaemic and haemorrhagic strokes demonstrated that age over 65 years, an 
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abbreviated mental test (AMT) score of less than 8, dysarthria or dysphonia, a modified 
Rankin scale score of four or more and failure of the water swallow test were major 
predictors of post-stroke pneumonia. The presence of two or more of these risk factors 
predicted pneumonia with 91% sensitivity and 76% specificity319. However, the study did 
not demonstrate the presence of chronic obstructive pulmonary disease, reduced salivary 
flow or multiple medications as predictors for development of pneumonia, which is in 
contrary to common consensus319. This study has been criticised as abbreviated mental test 
is not performed routinely in stroke patients and may be unreliable soon after a stroke.  
 
Scoring systems for prediction of stroke associated pneumonia 
Several scoring systems have been introduced to formally predict the risk of pneumonia in 
stroke patients. In a retrospective study, Chumbler et al reviewed data of 1363 stroke 
patients admitted to several regional hospitals between 1998 and 2003 to formulate and 
validate a scoring system for predicting stroke associated pneumonia320. Points were 
assigned scored for an abnormal swallow test and a history of pneumonia (4 points), the 
NIHSS score (3 points), patients being found face down at the time of stroke onset (3 
points), and age over 70 years (2 points). A 3-level classification system was created 
denoting a low, median and a high risk of pneumonia. The rate of pneumonia was 2% for 
the low risk group, 4% for the medium risk group and 23% for the high risk group320. 
Recently, a simpler 10 point scoring system was introduced to predict the risk of post-
stroke pneumonia. After reviewing data on 15,335 patients and using multivariable 
regression analysis, independent predictors of pneumonia were translated into a point 
scoring system, the A(2)DS(2) score. The points are scored as: Age over 75 year = 1, Atrial 
fibrillation = 1, dysphagia = 2, male Sex = 1, stroke severity, NIHSS 0-4 = 0, 5-15 = 3, 
above 16 = 5. The risk of pneumonia varied between 0.3% in patients with a score of 0 and 
39.4% in patients with a score of 10321. Prediction and calibration properties were 
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reproduced in the validation cohort consisting of over 45000 patients with ischaemic 
strokes. 
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Table 1-3 Clinical Predictors of Pneumonia in stroke patients 
Author Clinical predictors 
Langmore et al 1998317 • comorbidities such as hypertension and diabetes  
• chronic obstructive airway disease  
• multiple cerebral infarctions  
• aspiration on videofluoroscopic studies 
 Hilker et al 2003 177 • a reduced GCS on admission (<8/15)  
• a large neurological deficit  
• endotracheal intubation 
• mechanical ventilation  
• presence of dysphagia  
• non lacunar strokes in the middle cerebral artery 
territory  
• posterior circulation strokes 
• multifocal infarctions in various vascular 
territories 
Dziewas et al 2004178 • a decreased level of consciousness  
• a high NIHSS score  
• presence of severe facial palsy 
Sellars et al 2007319 • age >65 years  
• a low abbreviated mental test score <8  
• dysarthria or dysphonia  
• a modified Rankin scale score of four or more  
• failure of the swallow test  
• stroke severity (total anterior circulation stroke)  
• initial NIHSS score more than 6  
• a lower serum albumin level 
Walter et al 2007233 • age >73 years  
• impaired vigilance  
• dysphagia, NIHSS >10  
• non-lacunar basal ganglia infarction  
• any other infection present on admission  
• combined brain stem and cerebellar infarctions 
• infarctions affecting >66% of the middle cerebral 
artery territory  
• hemispheric infarctions exceeding middle 
cerebral artery territory  
• mechanical ventilation  
• cardio-embolic strokes 
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1.5.9. Methods used in clinical trials to establish the diagnosis of pneumonia in stroke 
patients 
 
Criteria for any patient group 
There are several standard criteria for the diagnosis of pneumonia relevant to any patient 
group. The BTS guidelines for the diagnosis of pneumonia were discussed earlier. The 
criteria of the US Centre for Disease Control and Prevention (CDC) for the diagnosis of 
pneumonia are another standard criteria which has been commonly used322. According to 
these guidelines at least one of the first (A) and one from the latter (B) criteria should be 
fulfilled in addition to new onset pulmonary infiltrates on the chest radiograph to make a 
definite diagnosis of pneumonia is made. 
A) Abnormal respiratory examination- new onset crackles, signs of consolidation 
B) Investigations to suggest an ongoing infection- positive microbiological cultures 
from the blood or lower respiratory tract, leucocytosis and elevation of 
inflammatory markers 
 
Criteria used in stroke research 
Owing to the complexity of the signs and symptoms of pneumonia in stroke patients and to 
problems related to biochemical and microbiological investigations, different studies have 
included various combinations of signs, symptoms and laboratory reports for the diagnosis 
of pneumonia. After reviewing the literature on stroke associated pneumonia from 1985 to 
2010, it was apparent that many studies did not adhere to standard criteria for the diagnosis 
of pneumonia and that the diagnostic methods differed between studies. Also most of the 
studies of stroke associated pneumonia were undertaken in patients in an intensive care 
setting and a significant proportion of patients were intubated and ventilated. However, 
Student No: 940137947014 86 
most studies included new development of inflammatory shadowing on the chest 
radiograph as an essential criterion for the diagnosis. 
 
Few stroke studies have used criteria of the US Centre for Disease Control and Prevention 
(CDC) with some modifications for the diagnosis of pneumonia. Some studies have used 
another set of standardized criteria, commonly referred as MANN’S criteria for the 
diagnosis of pneumonia. These require three or more of the following characteristics to be 
fulfilled: temperature over 38°C, productive cough with purulent sputum, abnormal 
respiratory examination, abnormal chest radiographs findings, arterial hypoxia, and 
isolation of a relevant pathogen on the Gram stain or by culture10. Patients who do not fulfil 
these criteria, but where a clinical diagnosis was made by the attending physician, these 
patients were considered to have a suspected pneumonia319 10. 
 
Table 1.4 lists details of various diagnostic criteria used by various authors for the 
diagnosis of stroke associated pneumonia. Many studies have considered varying 
combinations of tachypnoea (respiratory rate >22/min), tachycardia, inspiratory crackles 
and bronchial breathing as abnormal respiratory examination. Hypoxia has been defined as 
pO2 <70 mm Hg or oxygen saturation <94% by many authors. The temperature 
requirement was higher in older studies (38°C) though more recent studies only required 
temperatures of 37.5 – 37.8°C. Many studies had a total WBC >11 x 106/ml or <4 x 106/ml 
as abnormal though some required higher a value as 12 x 106/ml. Presence of leucocytosis 
or a microbiological diagnosis was not always required and CRP as an inflammatory 
marker was used only in few studies. A positive chest radiograph was a requirement in 
many studies. 
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However, in some studies the diagnosis of pneumonia was vague and non-standardised and 
some had not defined or described pneumonia and the clinical diagnosis of the attending 
clinicians were taken from case notes retrospectively27;319;323. Even in a landmark study on 
oral selective decontamination by Gosney et al, the diagnosis of pneumonia was made by 
the clinical-care team, usually when patients were commenced on antibiotics. 
 
Diagnosis of aspiration pneumonia 
Development of pneumonia following a witnessed aspiration was considered as aspiration 
pneumonia in many studies. Some studies diagnosed aspiration if enteral formula was 
suctioned from oropharyngeal secretions. Most studies described above had broader 
diagnoses such as stroke associated pneumonia or ventilator associated pneumonia rather 
than trying to identify aspiration pneumonia as a separate entity. It may be that in stroke 
patients and patients in an ITU on whom most of the studies were done, silent aspiration is 
commoner than witnessed aspiration. Radiological evidence of infiltrates in a characteristic 
broncho-pulmonary segment which is known to be affected by aspiration could have been 
used for the diagnosis of aspiration. However, no study had done the necessary radiographs 
to view these segments or reviewed the existing radiographs in such detail. Also the 
reported frequency of aspiration in enterally fed patients depended on how aspiration was 
clinically defined (either silent or symptomatic) and the method of diagnosis of aspiration 
(Pepsin Analysis, radionuclide tagged feeds).  
 
In summary, studies had varying diagnostic criteria and did not have a gold standard for the 
diagnosis of pneumonia. A positive chest radiograph was a requirement in many studies 
and the validity of some components such as purulent sputum, cough and fever were 
doubtful.  
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Table 1-4 Criteria for the Diagnosis of Pneumonia 
Author Diagnostic criteria 
US Centres for Disease 
Control and Prevention 
(CDC) 2004322 
At least one of:  
• abnormal respiratory examination  
• pulmonary infiltrates on the chest radiograph 
And, at least one of:  
• productive cough with purulent sputum 
• positive microbiological cultures from the lower 
respiratory tract  
• leucocytosis  
• increased CRP levels 
 
“Mann” criteria 
Mann and Hankey 
199910 
Three of the following criteria 
• fever >38°C  
• productive cough  
• abnormal respiratory examination [respiratory rate >22 
per minute/crackles or bronchial breathing/arterial 
hypoxia (pO2 <70 mm Hg or oxygen saturation <94% 
or PaO2 <9.3kPa)],  
• tachycardia  
• abnormal chest radiograph  
• culture of a relevant pathogen 
 
Kammersgaard et al 
2001324 
At least 2 of:  
• fever >37.5°C  
• total leucocytes >9000 /ml 
• positive chest radiograph  
• positive results from microbiological analysis 
 
Kwan and Hand et al 
2007212 
• presence of relevant clinical symptoms and/or signs 
(example purulent cough, unilateral inspiratory 
crackles, bronchial breath sounds)  
with at least one of:  
• fever >37.5°C  
• leucocytosis  
• a positive chest radiograph 
 
Vogelgesang et al 
2008325 
• Presence of clinical signs  
• CRP >50 mg/l  
• procalcitonin >0.5 ng/ml 
Chamorro et al 2005 
Urra et al 2009241;245 
• temperature >37.5°C in two determinations  
• temperature >37.8°C on one occasion in patients with 
suggestive symptoms (example: cough, dyspnoea, 
pleuritic pain)  
• total white cell count 11,000 /ml or <4,000 /ml  
• pulmonary infiltrates on the chest radiograph  
• positive results from microbiological analysis 
Schwarz et al 200829 • new infiltrates in chest radiographs  
plus at least one of:  
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• fever >38°C  
• total white cell >12,000 /ml or <3,000 /ml  
• purulent tracheal secretions 
 
Tanzi et al 2011326 • clinical signs or symptoms (fever and/or productive 
cough and consolidation on chest radiograph)  
• positive Gram stain/culture 
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1.6. Prevention of pneumonia in stroke patients 
Prevention of pneumonia is important for the general wellbeing of an older person and 
even more following stroke as it will reduce mortality, morbidity and length of hospital 
stay. As an individual becomes older, the incidence of pneumonia increases and this is 
associated with a rise in mortality327. Changes in host defences such as reduced IgG and 
lymphopenia, co-existing illnesses, concurrent medication that can affect swallowing and 
respiratory secretions, changes in the oral bacterial flora secondary to the use of dentures 
and poor oral care, and age related changes to the swallowing mechanism have been shown 
to be responsible for the high incidence328;329. In this section, the methods to prevent post-
stroke pneumonia have been discussed under two headings. Initial general review of non-
phramacological measures of pneumonia prevention is followed by a more detailed review 
on drug therapies which have been used to prevent pneumonia following stroke. As my 
research project is on metoclopramide a detailed review of literature, following steps which 
would be undertaken for a systematic review, was conducted on drug therapies which have 
been used to prevent post-stoke pneumonia.  
 
1.6.1. General measures 
1.6.1.1. Vaccination  
Vaccination against Influenza given once a year has been shown to reduce influenza, viral 
pneumonia and secondary bacterial pneumonia in people over the age of 65 years330. It has 
been shown to reduce the number of febrile days and all other respiratory conditions 
associated with influenza331. There is also evidence that polyvalent pneumococcal vaccine 
reduces the incidence of pneumococcal pneumonia in older people and in patients who 
have other risk factors such as COPD332. This vaccination is now recommended for all 
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adults over the age of 70 years333. While there is no specific evidence of its effect in 
patients with stroke, in vaccination of a wide range of older people will reduce pneumonia 
risk in vaccinated patients who subsequently develop a stroke. 
 
1.6.1.2. Oral hygiene 
Aspiration of colonised oropharyngeal secretions is an important risk factor for 
development of aspiration pneumonia in an older person334. Studies have shown that older 
patients receiving good oral care had a lower incidence of pneumonia than patients who did 
not have oral care and reduced oropharyngeal colonisation and inflammation 335. In 
addition, poor denture care has been shown to promote bacterial growth in oropharyngeal 
secretions with an increased incidence of aspiration pneumonia, and nursing home 
residents who received intensive oral care had a lower incidence of pneumonia than 
residents who had usual oral care185;336;337. The importance of good oral care is not limited 
to nursing home residents; a study in patients on intensive care units which included all 
ages demonstrated that regular dental plaque decontamination reduced dental plaque 
growth and incidence of pneumonia when compared to standard care338. Therefore, good 
regular oral care and denture care is important to reduce the incidence of pneumonia. 
 
1.6.1.3. General clinical care  
The gastro-intestinal tract is a potential source of Gram negative bacteria which can give 
rise to pneumonia339. Inappropriate use of antibiotics or antibiotic prophylaxis can promote 
colonization with drug resistant organisms or select a resistant strain in the oropharynx 
which can be aspirated 339. In addition, antibiotic induced vomiting may increase the risk of 
aspiration. Elevation of gastric pH due to antacids and proton pump inhibitors increases the 
risk of bacterial overgrowth in the stomach176;202;340. Thus, having strict antibiotic policies, 
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avoidance of unjustified antibiotic treatment and of proton pump inhibitors could 
potentially reduce the risk of pneumonia. 
 
Though there is a progressive reduction of the swallowing reflex and pharyngeal sensation 
with age341;342 it is not associated with an increased risk of aspiration as there is no 
significant impairment in laryngeal protective mechanisms or in the cough reflex with 
age343. However, the use of sedatives and narcotics has been shown to depress the cough 
reflex in older people, especially during sleep127. Thus, avoidance of such medications or 
limitation of their use will reduce the risk of aspiration during sleep127. 
 
Regular hand washing and use of barrier techniques to prevent cross-infection have been 
recognised as important methods in the prevention of nosocomial infections344;345. 
Appropriate handling of mechanical feeding devices, respiratory devices, suction apparatus 
and maintenance of a safe distance between patients’ beds also reduces cross infection in 
hospital patients including those with a stroke346. 
 
1.6.1.4. Assessment of swallowing and risks of aspiration  
The importance of a formal dysphagia screening protocol in the reduction of pneumonia 
was demonstrated in a study on 2532 acute stroke patients316. The study concluded that the 
risk of pneumonia was significantly higher at sites with no formal dysphagia screening and 
that a formal dysphagia protocol should be offered to all stroke patients regardless of stroke 
severity316. There are several ways of diagnosing dysphagia and the risk of aspiration 
which include bedside swallow assessment, assessment of oxygen saturation while 
swallowing and more specialised tests such as videofluoroscopy and fibreoptic endoscopic 
evaluation of swallowing, 347.  
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The bedside swallowing assessment is the commonly used swallow test following stroke as 
this test will provide adequate information regarding the presence and the severity of 
swallowing disturbances and the way the nutrition should be managed. Routine assessment 
is started with oropharyngeal examination. Patients are observed for presence and severity 
of facial asymmetry, facial weakness, extent of drooling, and pooling of saliva. This is 
followed by observing the type of speech and non speech movements of the mandible, lips, 
tongue, palate and the pharynx. The ability to produce a volitional cough is assessed and 
the nature of the voice and the severity of the dysphonia are noted. Assessments of 
dysarthria also include evaluation of articulatory precision, fluency and intelligibility. It has 
been reported that a weak voluntary cough, wet voice, cough on swallow, a prolonged 
swallow or a combination of these are highly predictive of aspiration347.  
 
Several forms of bedside swallowing assessment tests have been used to evaluate patients 
with an acute stroke. A common method of predicting aspiration is by the assessment of the 
difficulties in drinking measured small volumes of water as the bedside assessment of 
dysphagia76;87;348. Smithard et al used 5 ml aliquots followed by a larger volume (60 ml), 
observing for dribbling, cough, dysphonia, laryngeal elevation, and the time to finish the 
drink109.A combination of all these signs were significantly predictive of aspiration and 
logistic regression identified that a reduced conscious level and a weak voluntary cough 
were significant independent predictors of aspiration. A study compared 302 swallowing 
assessments with aspiration on videofluoroscopy demonstrated that patients who coughed 
after swallowing or developed a hoarse voice or a wet voice had the highest risk of 
aspiration349. In the above mentioned study, the time and the number of swallows required 
to drink 150 ml of water, cough, delayed swallow, and dysphonia also indicated a problem 
with swallowing and risk of aspiration. Elicitation of the gag reflex is not routinely 
performed in clinical practice as it has been demonstrated that up to 30% young adults and 
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44% of healthy older adults have unilateral or bilateral absent gag reflexes350. While 
impairment of the gag reflex and reduced laryngo-pharyngeal sensation are associated with 
swallowing difficulties, some studies have shown that they are less predictive of aspiration 
than the presence of a weak cough or dysphonia95;109. In addition elicitation of the ‘gag’ 
reflex causes significant discomfort to the patient.  
 
Videofluoroscopy (modified barium swallow) is the gold standard of swallowing 
assessment and risks of aspiration in patients with dysphagia and most studies have been 
correlated with detection of aspiration on videofluoroscopy351. Videofluoroscopy consists 
of video recording of a patient’s swallowing mechanism during swallowing a given volume 
of barium paste starting with 3 ml and increased in volume if no adverse effects such as 
aspiration are noted. The patient stands or sits at 45 to 90 degrees while consuming barium 
impregnated liquids of different consistencies and the swallowing is imaged in lateral and 
antero-posterior projections. It is a dynamic study where the therapists can examine the 
anatomical structures and function of the oral and pharyngeal phases of swallowing and test 
potential compensatory techniques351;352.  
 
Royal College of Physicians of London Guidelines of stroke care recommend bedside 
swallow assessment within first 24 hours of acute stroke1. However, the most valid 
protocol is yet to be determined and may be irrelevant as different centres already have 
established screening tools316. A commonly used method is the ability to swallow different 
volumes of water as described in Smithard’s study. This is due to the test being safe, easily 
repeated and straightforward to perform. Any doubt about a patient’s ability to swallow 
safely will usually result in nil by mouth and referred to a speech and language therapist353. 
Asymptomatic patients will be placed on normal diet and fluids but will be observed during 
mealtimes and respiratory status monitored79;88. 
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1.6.1.5. Control of gastroesophageal reflux  
Gastric reflux is not uncommon in older people354. It has been estimated that more than one 
third of the older population have symptoms of gastroesophageal reflux, at least 
intermittently355. Aspiration of large volumes of acidic gastric contents gives rise to lung 
damage and aspiration pneumonitis (Mendelson’s syndrome)356. Even aspiration of small 
amounts of gastric fluid can damage the tracheo-bronchial mucosa and lung epithelium 
though it may not clinically manifest as aspiration pneumonitis or pneumonia357. This 
damage is worse when the aspirate is acidic, but epithelial damage can also be due to the 
pepsin content and the low osmolality of the aspirate. Damaged lung tissue can get 
secondarily infected causing pneumonia202;340. Gastric reflux occurring over longer periods 
can result in interstitial pulmonary fibrosis358. Thus treatment of gastro-oesophageal reflux 
disease should reduce the incidence of pneumonia. Elevation of the head end of the bed and 
use of prokinetic medications such as cisapride and metoclopramide can reduce gastro 
oesophageal reflux 359. Surgical procedures such as fundoplication have been performed 
with varying success rates in patients with intractable gastro-oesophageal reflux disease not 
responding to medical treatment but are not recommended in first few weeks after 
stroke360. 
 
1.6.1.6. Turn-mob program 
This was a study which examined the effect of passive mobilisation in bed following acute 
stroke181. It was a randomised control trial to assess the efficacy of regular turning and 
passive mobilisation of acute stroke patients, carried out by a relative who received specific 
training in the technique from a physiotherapist compared to routine patient care181. There 
were 223 participants within 48 hours of acute stroke, predominantly partial anterior 
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circulation strokes (88%), with a mean NIHSS score of 12-14 (52%). Patients with 
haemorrhagic strokes and who were ventilated were excluded. The mobilisation program 
was carried out every 6 hours for 3 consecutive days. The program consisted of passive 
mobilisation of the 4 limbs through each segments’ entire range of motion, sustaining for 
10 seconds, every 6 hours. In addition to the passive movements those patients were turned 
to left and right lateral recumbent position every two hours. Follow-up was for 14 days 
post-discharge and signs and symptoms of pneumonia were the primary endpoint. The 
study had firmly defined criteria for the diagnosis of pneumonia which included a chest 
radiograph. The study demonstrated that there was a 61% of reduction in the episode of 
pneumonia in patients who were treated with turn-mob passive exercises as opposed to 
patients only receiving standard care (Control group 26.8% vs. turn-mob group 12.6%). 
However, the predominant stroke type was PACS (89%), 30% had a NIHSS of 2 to 7 and 
41% had a NIHSS of 8 to 13, which shows the majority of patients who were recruited 
were either mild or moderate strokes. Only 20% of patients had an impaired swallow 
(which was assessed by the gag reflex) and enterally fed patients only formed 20% of the 
patient population. The program did not prevent pneumonia in nasogastrically fed group as 
68.2% of these patients developed pneumonia. 
 
1.6.1.7. Secondary prevention of cerebrovascular disease 
Dementia and atherosclerotic cerebrovascular disease have been shown to be more closely 
associated with aspiration pneumonia than with any other neurological disorder in old 
age361. Patients with multiple lacunar infarcts have been shown to have a significant delay 
in the swallowing response and a reduction in the frequency of swallowing during sleep362. 
The risk of aspiration is highest during sleep as both the cough reflex and spontaneous 
cough are reduced during sleep in these patients with chronic cerebrovascular disease363. 
Silent cerebral infarcts are commoner than expected with incidences ranging from 23% to 
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51%364;365. Patients with silent cerebral infarctions, i.e. patients with radiologically 
demonstrable infarcts without any neurological impairment have a higher incidence of 
pneumonia than patients with no silent infarctions366. The incidence is higher in patients 
with cerebral infarctions deep in the brain, especially in basal ganglia region than in the 
cortex361;366. Therefore, primary and secondary stroke prevention by appropriate use of 
anti-platelet agents, statins and anticoagulant therapy not only prevent further strokes but 
also reduce the risks of aspiration and pneumonia following stroke. 
 
1.6.2. Review of literature on drug therapies to reduce pneumonia in 
acute stroke patients 
Introduction 
 
Background review of literature done for this thesis showed that there was a paucity of 
research into prevention of pneumonia following acute stroke other than assessment and 
management of dysphagia. In addition, there was only limited evidence on drug treatment 
for prevention of pneumonia following stroke. As this could be a sample error, it was 
decided to conduct a detailed literature review on the interventions that are available to 
prevent post-stroke pneumonia following guidelines of a formal systematic review. The 
aim was to establish what evidence was available on this topic as a systematic review is 
considered as the strongest evidence available for a particular clinical question.  
 
Systematic reviews are reviews of primary studies that have an explicit statement of aims 
and objectives of the review with methods that are pre-planned367. Such reviews which 
have a strict design and include a comprehensive, reproducible search of all available 
evidence which can be critically appraised to provide a critical summary of all available 
evidence addressing a particular issue. In addition, completion of such a review was 
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thought to be important to address the perceived lack of research in this field, and to 
support the work in this thesis. 
 
1.6.2.1. Methods 
The literature review as in any systematic review began with the identification of a clinical 
problem368. The clinical question at the heart of this review was ‘Drug therapies that are 
used to prevent pneumonia in patients following acute stroke’. A review protocol was then 
designed, studies were searched and the relevant studies were selected and appraised for 
quality. Data were collected from these selected studies, findings were synthesised and 
were summarised and a final report was written. Khan et al had produced a framework to 
perform a systematic review and the literature review for this thesis was conducted 
according to this step-by-step staged framework 368.  
Step 1- framing the question 
Step 2- identifying relevant work 
Step 3- assessing the quality of studies 
Step 4- summarizing the evidence 
Step 5- interpreting the findings 
A systematic review requires two reviewers to be involved in the process of review of 
articles to minimise selection bias. The review of literature for the thesis was carried out 
only by one reviewer (the researcher) due to unavailability of a second review and due to 
time pressures. However, every effort was taken to minimise bias and to include all 
relevant articles in the literature review and not to overlook relevant articles.  
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1.6.2.2. Identification of the clinical question 
The clinical question that needed a literature review for this thesis was ‘are there any drug 
therapies that can be used to prevent pneumonia in patients following acute stroke’. To be 
included in the review, trials had to meet the following inclusion and exclusion criteria. 
 
1.6.2.3. Inclusion criteria 
Selection of papers 
 
• Published clinical trials 
• Tested a drug therapy for prevention of post-stroke pneumonia 
 
Selection of studies 
• Studies which included participants aged 18 years or over 
• Participants with a diagnosis of stroke 
• Describe a pharmacological intervention 
• Describe and define the intervention clearly 
• Describe pneumonia clearly 
 
1.6.2.4. Exclusion criteria 
• Studies that reviewed the effect of diagnosis and management of post-stroke 
pneumonia 
• Interventions which included non-drug interventions such as electrical or magnetic 
stimulation 
• Animal studies 
• Publications prior to 1980 
Student No: 940137947014 100 
• Interventions which used medications which are not listed in BNF 
• Studies which included less than 10 participants 
No paper was excluded on the basis of language or the community it came from. Review 
papers and editorials were excluded from search results.  
 
1.6.2.5. Identifying relevant work 
Search strategies and selection of relevant studies  
Embase and Medline databases were searched using Medical Subject Headings (MeSH) 
terms stroke, pneumonia and prevention with the logical operator ‘AND’, covering the 
period from January 1980 to January 2013. The search was not restricted to the type of 
article to capture as many as relevant publications during the initial search. However, the 
search was restricted to adults (over the age of 18 years) and to human studies. Duplicates 
were excluded from the results after combining both databases. Also to capture as many 
relevant publications as possible, a general search of the internet was performed using 
Google and Google Scholar Search Engines and a hand searching of various medical 
journals was performed. Following completion of the searches, preliminary screening of 
retrieved articles was carried out to exclude irrelevant studies. Titles from all electronic hits 
were reviewed online and potentially relevant titles were downloaded and saved in a 
separate folder. These included editorials, review articles, guidelines, letters and case 
reports.  
 
In addition to the literature search, relevant articles obtained via the internet (Google) 
search were included. The first stage of screening was completed based on the study titles 
and by immediately excluding those outside the topic and the ones which did not fulfil the 
inclusion criteria or had exclusion criteria. Publications which were considered not to be 
relevant were also excluded. Examples of irrelevant papers included pneumonia in 
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coronary heart disease, prevention in pneumonia in older people, pneumonia as a 
complication of dysphagia and general preventive strategies of stroke. All abstracts of the 
titles pertaining to stroke and pneumonia were considered as potentially relevant and were 
downloaded and saved in another folder for the second stage of review.  
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Figure 1-1 - Study Eligibility Flow Chart 
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Figure 1-2 - Search History 
Search History:  
1. MEDLINE; pneumonia.ti,ab; 74087 results.  
2. MEDLINE; exp PNEUMONIA/; 69708 results.  
3. MEDLINE; stroke.ti,ab; 128486 results.  
4. MEDLINE; exp STROKE/; 75162 results.  
5. MEDLINE; prevent*.ti,ab; 865677 results.  
6. MEDLINE; exp PREVENTION/; 1394 results.  
7. MEDLINE; 1 OR 2; 106929 results.  
8. MEDLINE; 3 OR 4; 154922 results.  
9. MEDLINE; 5 OR 6; 866021 results.  
10. MEDLINE; 7 AND 8 AND 9; 181 results.  
11. EMBASE; pneumonia.ti,ab; 93123 results.  
12. EMBASE; exp PNEUMONIA/; 171982 results.  
13. EMBASE; stroke.ti,ab; 178238 results.  
14. EMBASE; exp STROKE/; 49175 results.  
15. EMBASE; prevent*.ti,ab; 1052773 results.  
16. EMBASE; exp PREVENTION/; 13120 results.  
17. EMBASE; 11 OR 12; 194724 results.  
18. EMBASE; 13 OR 14; 197779 results.  
19. EMBASE; 15 OR 16; 1056409 results.  
20. EMBASE; 17 AND 18 AND 19; 455 results.  
21. EMBASE; 20 [Limit to: (Human Age Groups Adult 18 to 64 years or Aged 65+ 
years)]; 204 results.  
22. MEDLINE; 10 [Limit to: (Human Age Groups All Adult 19 plus years)]; 123 
results.  
23. EMBASE,MEDLINE; Duplicate filtered:  
 [20 [Limit to: (Human Age Groups Adult 18 to 64 years or Aged 65+ years)]],  
 [10 [Limit to: (Human Age Groups All Adult 19 plus years)]]; 327 results.  
257 unique results (70 duplicates) 
Student No: 940137947014 104 
The second stage of the review was based on study abstracts of these publications saved to 
identify further articles which were not relevant, and these were also excluded. Articles on 
predictors or risks of post-stroke pneumonia and secondary effects of pneumonia in stroke 
patients were excluded. Also studies of prevention of pneumonia by assessment and 
management of dysphagia and studies of post-stroke medical complications which 
included pneumonia were excluded. Any study based upon low patient numbers (<10) was 
excluded to prevent inclusion of case studies or reports as they may contain untested 
opinions. Also, studies using non-specified medications or drugs which were not included 
British National Formulary were excluded. After the second stage of sifting was complete, 
full texts of all relevant papers were downloaded, printed and reviewed by the researcher.  
 
Assessing study quality 
Assessment of quality of studies is an important component of a systematic review. The 
strength of evidence assessed is mainly to measure the appropriateness of the study design 
to answer the specific research question368. The randomised controlled trial design is 
normally the most appropriate source of evidence for judging the effectiveness of 
individual or group interventions369. Multiple quality checklists and numerical scales from 
4- 55 have been identified to assess the quality of a study370. However, The Cochrane 
Handbook for Systematic Reviews of Interventions highlights that methodological 
assessment using a scoring system can be fraught with difficulty371. Therefore 
methodological quality assessment of studies were conducted using guidelines 
recommended by ‘Methods for development of NICE public health guidance, March 
2006)369. The data collection form, ‘Methodology checklist for RCT’ (appendix 2), as 
recommended by NICE was used to enter study details and every effort was done to be 
unbiased with the quality assessment as there was no second reviewer. The following 
indicators were recorded in the review of overall quality of the trials. 
Student No: 940137947014 105 
• method of randomisation 
• concealment 
• blinding of participants 
• blinding of care providers to the intervention group 
• blinding of outcome assessor 
• reliability and validity of outcome measures used 
• potential confounding factors 
• statistical analysis 
 
Randomisation allows fair and equal allocation of participants to each treatment group. It 
also seeks to ensure statistical comparability of treatment groups372. The process of 
concealment ensures that participants and the researcher have no knowledge of impending 
allocation and correct randomisation relies upon appropriate concealment373. Without 
concealment there is a risk of the process of randomisation being inappropriately 
influenced. Unblinded studies are prone to bias, which would either exaggerate or 
underestimate the ‘true’ effect of an intervention. In addition, if participants are not 
blinded, the knowledge of their group allocation may impact upon their assessment of 
outcome of any intervention they receive. Assessment of confounding factors is important 
as these can influence the effect of the intervention. In a randomised study, confounding 
factors are expected to be roughly equally distributed between groups368. 
 
Final quality assessment of the studies were conducted using guidelines recommended by 
‘Methods for development of NICE public health guidance, March 2006369. Each study was 
categorised by study type (type 1-4) and quality graded using a code, ‘++’, ‘+’ or ‘-’, based 
on the extent to which the potential source of bias has been minimised (Appendix 3)369. 
Later the scores of study design and quality were combined. 
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Assessment of heterogeneity in systematic review 
Variability of the studies which were pooled together in a systematic review is defined as 
heterogeneity. Variability of the outcomes utilised, interventions explored and participants 
included is defined as clinical heterogeneity and variability in study design or quality is 
defined as methodological heterogeneity371. Variability in the evaluation of treatment 
effects of the studies is defined as statistical heterogeneity. For the purpose of the 
systematic review performed for this thesis, clinical heterogeneity was based upon the 
characteristics of populations, interventions and outcomes. Methodological heterogeneity 
was based upon study design and quality. There was no intention to exclude any study from 
the review based upon a poor review of methodological quality. Also a sub-group analysis 
and a meta-analysis of the studies were not planned as a part of the systematic review for 
the thesis. 
 
1.6.2.6. Data extraction and evidence tables  
Prior to beginning data extraction, each article was reviewed for the type of study, country 
of origin, year of publication, number of patients, primary and secondary outcomes, type 
and the duration of the intervention and the incidence of pneumonia, as given in the table 
1.5.  
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Table 1-5 - Information extracted from selected studies on interventions 
 
Year of publication Type of study 
Primary outcomes Secondary outcomes 
Number of patients Intervention used 
Duration of intervention Complications 
Inclusion criteria Nasogastric feeds 
 
 
Data extraction was conducted using data extraction sheets as recommended by ‘Methods 
for development of NICE public health guidance, March 2006369. As there was no second 
reviewer, data extraction was done by the researcher and every effort was made to be 
unbiased during this process. Completed methodology check lists (Appendix 2) and data 
extraction sheets (Appendix 4) were used to produce evidence tables. This was to identify 
similarities and differences between selected studies including study population, 
intervention used and outcome measures. After the data extraction, the publications were 
reviewed to find out different types of drug therapies used and group them according the 
class of drug therapy. 
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1.6.3. Results 
The first search used the terms stroke, pneumonia and prevention produced 123 results in 
Medline and 204 results in Embase from 1980 to 2013 (table 1.6).  
 
Table 1-6 - Databases, Search Terms and Hits Used for the Review 
 
Database Search Terms Results 
Pneumonia  106929 
Prevention 866021 
Stroke  154922 
Pneumonia + Prevention + Stroke 181 
MEDLINE 
Pneumonia + Prevention + Stroke (limited to 
humans, Adult over18) 
123 
   
Pneumonia 194724 
Prevention 1056409 
Stroke 197779 
Pneumonia + Prevention + Stroke 455 
EMBASE 
Pneumonia + Prevention + Stroke (limited to 
humans, Adult over18) 
204 
   
 Total results 327 
 Unique results (after duplicates filtered out) 257 
 
 
Of these 70 were duplicate results, therefore there were 257 unique hits. All titles of these 
articles were reviewed by the researcher and 202 were excluded as they were not relevant 
to the search e.g. studies related to pneumonia in other medical conditions as they did not 
review any aspect of prevention of pneumonia in stroke patients. This left 55 papers in total 
for the second stage of review (abstracts), which reviewed various aspects of stroke-related 
pneumonia. Of these 16 were excluded as they reviewed the impact of formal assessment 
of dysphagia in prevention of stroke-associated pneumonia. Five more studies were 
excluded as they were on predictors of risk factors for pneumonia. Twelve studies were 
excluded as they reviewed post-stroke complications and pneumonia was one of those 
complications. Studied which reviewed the effect of pneumonia on stroke patients were 
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also excluded (n = 6). There were also two studies on prevention of pneumonia in post-
stroke patients using traditional Chinese medications and they were excluded as review 
only considered medications listed in the BNF. Two studies were excluded as they had less 
than 10 patients in the studies. Two were excluded as they were letters to the editors 
discussing individual opinions. Though the study showed a significant reduction in post-
stroke pneumonia, the physiotherapy study ‘turn-mob program’ was excluded as it did not 
use any medication. The remaining 9 studies could be divided into three major subgroups 
of drug therapies used to prevent post-stroke pneumonia as use of ACE inhibitors, use of 
prophylactic antibiotics, and the rest grouped as miscellaneous. Though they did not appear 
in the original search, three additional papers, one on oral decontamination in post-stroke 
patients27, one on Cochrane collaboration meta-analysis on preventative antibiotics374 and 
another meta-analysis on ACE inhibitors375 were included in the review, making a total of 
12 articles. These three additional articles were identified by the researcher from the 
Google search. Though all articles on ACE inhibitors were in chronic stroke rather than 
acute stroke, they were retained in view of their clinical significance. 
 
Full articles of all 12 abstracts were obtained and were critically reviewed. The systematic 
review identified two studies of ACE inhibitors and one meta-analysis on ACE inhibitors. 
The two articles on ACE inhibitors were excluded as they also appeared in the meta-
analysis. The extra article on ACE inhibitors which did not appear in the original search but 
which was added later was excluded, partly as it included patients other than stroke and the 
subset of trials which were in stroke patients were included in the meta-analysis on ACE 
inhibitors which appeared in the original search. The Cochrane collaboration on meta-
analysis of preventative antibiotic therapy was excluded as four of the total of five studies 
which were included in the meta-analysis had already appeared in my literature search and 
the other article by De Falco376 did not specify the age of its participants, which was a pre-
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requisite to be included in the literature search. One study was excluded as it reviewed the 
effect of prior treatment with statin on the incidence of pneumonia. One article was 
excluded as it was a review article. Of the four articles on preventative antibiotics, one 
article reviewed the effect of preventative antibiotics on the neurological recovery and did 
not state the infection rates. However, this study was not excluded from the review as it 
was felt that the effect of antibiotics on the rate of infections would have affected the 
neurological recovery of the participants and the authors were to be contacted regarding the 
rates of pneumonia of that study. This gave a total of 6 articles for the literature review 
(figure 1.3) 
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Figure 1-3- Process of Literature Review Results   
Literature Review results 
n= 257 (n= number of publications) 
n=55.  
n=39 
n=34 
n=22 
n=16 
n=14 
n=9  
n=12 – Full article reviewed 
n=6 - For the literature review 
Excluded  
• 1- Included non-strokes 
• 3 - Already in meta-
analysis  
• 1- Prior use of statins 
• 1- Review article 
Excluded 5 –Examined risk 
factors for pneumonia 
Excluded 16 – Assessed effect 
of dysphagia assessment on 
pneumonia prevention 
Excluded 12 – Described as 
one of stroke complications 
Excluded 6 – Described of 
pneumonia on stroke outcome 
Excluded 2 – Treated with 
Chinese herbal medications 
Excluded 4 - <10 patients  
Excluded 1 - physiotherapy 
studies 
Excluded 202 (pneumonia in 
other conditions) 
Added 3 extra relevant 
articles  
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Table 1-7 Summary of Assessment of Methodological Quality 
 
Name of the study  MISS 
 
PANTHERIS 
 
ESPIAS 
 
Minocycline 
treatment in 
acute stroke 
Selective oral 
decontamination 
study 
Agents used Mezlocillin + 
sulbactam 
Moxifloxacin Levofloxacin Minocycline Polymyxin E, 
Colistin, 
Amphotericin  
Power calculation Not done Performed Performed Performed Under powered 
Randomisation 
method 
Computer 
generated 
number sheet  
Computer 
generated 
adaptive 
randomisation 
Computer 
generated 
number sheet 
Randomisation 
according to the 
patient’s 
hospital identity 
number 
Computer 
generated 
Concealment Numbered 
sealed 
envelope 
Clear 
concealment  
Opening a 
sealed 
envelope 
Unclear  Yes 
Blinding of patients Treatment 
team not 
blinded 
Yes Yes No Yes 
Blinding of 
interventional 
procedures 
Un-blinded  Yes Yes No Yes 
Blinding of 
outcome assessors 
Yes Yes Yes Yes Yes 
Follow-up and 
exclusions 
Maximum 10 
days. Well 
defined 
exclusion at 
the start of the 
trial 
6 months 
follow-up for 
survival and 
neurological 
recovery 
3 months 
follow-up for 
survival and 
neurological 
recovery 
3 months 
follow-up for 
survival and 
neurological 
recovery 
Follow-up 3 
weeks  
 
Exclusion after 
randomisation 
No Yes No No No 
Selective reporting 
and other survey of 
bias 
None noted ICH excluded, 
exclusion of 
patients with 
poor prognosis 
following 
randomisation. 
PP analysis 
instead of ITT 
used to assess 
the pneumonia  
None noted None noted None noted 
Reliability of 
outcome measures 
used 
Well defined 
outcome 
measures  
Well defined 
outcome 
measures 
Well defined 
outcome 
measures 
Well defined 
outcome 
measures 
Well defined 
outcome 
measures 
Statistical analysis 
performed 
Standard 
statistical 
methods used. 
(Chi-square, 
Mann-
Whitney Rank 
test) 
Standard 
statistical 
methods used. 
ITT and PP 
analysis  
Standard 
statistical 
methods used. 
ITT and 
ANCOVA 
adjusted 
baseline for 
CRP & WBC 
Standard 
statistical 
methods used. 
ITT and PP 
analysis 
Standard 
statistical 
methods used. 
 
ESPIAS - Early Systemic Prophylaxis of Infection After Stroke study, PANTHERIS - Preventive ANtibacterial 
THERapy in acute Ischemic Stroke, MISS - The Mannheim Infection in Stroke Study ICH – inter-cerebral 
haemorrhage, PP – per-protocol, ITT – Intention-to-treat, ANCOVA – analysis-of-covariance, CRP, C-reactive 
protein, WBC white cell count, 
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1.6.3.1. Assessment of methodological quality 
Of the six articles included in the systematic review, five articles (four articles on 
preventative antibiotics and one article on selective oral decontamination) and one meta-
analysis on the use of ACE-inhibitors were assessed for their methodological quality. The 
assessment revealed a few methodological weaknesses in the literature reviewed which are 
described below and are summarised in table 1.7.  
 
Power calculation 
Only three studies included details of power calculation to determine an appropriate sample 
size28;377;378. 
  
Method of randomisation 
All five studies were randomised controlled studies and four used computer-generated 
randomisation methods. One study used the patients’ hospital identity number to generate a 
randomisation sequence378. 
 
Concealment 
Apart from one study378, the rest reported concealment via a codes sealed in envelops. 
 
Blinding 
Three studies were double-blind controlled studies27;28;377 and the other two only had 
outcome assessors blinded29;378. 
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Selective reporting and other sources of bias 
Apart from the PANTHERIS study using per-protocol (PP) analysis to demonstrate a 
significant reduction in the incidence of pneumonia no other source of bias was identified. 
As all the studies were randomised controlled studies, confounding factors were expected 
to be roughly equally distributed between the two groups. This was confirmed by assessing 
participants’ baseline criteria in all five studies. 
 
Statistical tests employed 
All five studies used standard parametric and non-parametric methods, when appropriate, 
during data analysis. 
 
Homogeneity 
There was no homogeneity in respect of interventions, participants, and outcome measures 
which made pooling of data were impossible. However, the next sections will discuss each 
category individually, highlighting their clinical messages and limitations.  
The necessary assessment of the type of evidence and the quality appraisal has been shown 
in table 1.8. 
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Table 1-8 Summary Table for Type and Quality of Evidence for Studies 
 
Post-stroke pneumonia prevention by 
angiotensin-converting enzymes inhibitors: 
results of a meta-analysis (included 5 
studies) 
 
1++ 
MISS - The Mannheim infection in stroke 
study 
 
1+ 
PANTHERIS - Preventive antibacterial 
therapy in acute ischemic stroke 
 
1- 
ESPIAS - Early systemic prophylaxis of 
infection after stroke study 
 
1+ 
Minocycline treatment in acute stroke  
1+ 
Selective oral decontamination study  
1+ 
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1.6.3.2. Data extraction and evidence tables 
The articles were divided into three categories of primary treatment choice as  
• use of ACE inhibitors 
•  use of prophylactic antibiotics 
•  use of selective oral decontamination 
Relevant data from data extraction sheets were entered into evidence tables for each of the 
primary treatment choice categories, as difficulties in combining the interventions and the 
outcomes of each category into one table.  
 
1.6.4. Preventative antibiotics 
Four studies were identified which evaluated preventative antibiotics in patients following 
acute stroke28;29;377;378. All four trials were randomised controlled studies and two had a 
double blind design. Allocation concealment was insufficient in the study which used 
minocycline378. Three of the studies described ineligibility withdrawals after the 
randomisation in accordance with trial criteria or due to inability to complete the treatment 
protocol. One study did not describe the withdrawals29. In this study, patients with a life 
expectancy of less than 90 days were excluded, therefore the overall mortality rate was 0%. 
Lampl’s study excluded patients with dysphagia and other three studies did not report on 
the incidence of dysphagic patients. 
 
Of four studies involving 426 patients in total, two studies were double blind and both used 
fluoroquinolones (levofloxacin, moxifloxacin)28;377, the third study used minocycline378 and 
the fourth used a combination of a beta-lactam antibiotic with a beta-lactamase inhibitor29. 
More details are given in the table 1.9. In all studies antibiotic therapies were started within 
24 hours of stroke onset and Lampl et al’s study required the presence of symptoms for at 
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least 6 hours. The duration of antibiotic treatment varied between 3 to 5 days. Most patients 
(93%) had ischaemic strokes as only the ESPIAS study included cerebral haemorrhages. 
Stroke severity was based on the NIHSS in 3 studies and varied from greater than 4 to 
greater than 11. Lampl et al’s study used the modified Rankin Scale to assess the disability 
associated with stroke.  
 
The primary outcome was infection rate in two studies28;377 and the proportion of patients 
with fever in one study29 though the rate of infection was measured as a secondary 
outcome. The fourth study (n = 151), which used minocycline measured NIHSS and 
modified Rankin Scale as the primary outcome and did not measure the rate of infection378. 
Of three studies which reported infection rate, two studies specified the type of infection 
and Chamorro’s study did not specify the type of infection. The definition of an infection 
varied significantly between studies. One study used the official criteria of the US centre 
for Disease Control and Prevention, however, with significant modifications28. Secondary 
outcomes were scores of modified Rankin Scale, NIHSS and Barthel Index and survival. 
The infections that were observed were mostly pneumonia (n = 61) and urinary tract 
infections (n = 21). The infection rate in the placebo group was 38.1% (53 of 139 patients) 
and 23.5% (32 of 136 patients) in the patients who received an antibiotic. The studies 
which recorded infection rates (n = 275) demonstrated that in adults with acute stroke 
preventative antibiotics reduced the incidence of infection. The number needed to treat to 
prevent infection was 7 and to prevent death was 83. Mortality varied from 0% to 7%, and 
there was no significant reduction in the mortality in the patients who had antibiotics. 
Nearly 5% of patients (10 out of 210) who had antibiotics died compared to 6% (13 out of 
216) of patients who had a placebo. However, when comparing the incidence of pneumonia 
there appeared to be no benefit, as in three studies the pneumonia rates were not given29;378 
and in the other (Harms et al) the reduction was not statistically significant. No major side-
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effects or harm were observed other than that one patient who was treated with mezlocillin 
plus sulbactam developed exanthema and another patient developed elevated liver 
enzymes29. 
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Table 1-9 - Studies of Preventative Antibiotics 
 
Study (reference) Antibiotic Year of 
publication 
Number of patients 
(Antibiotic/Placebo) 
Type of 
study 
Chamorrow et al 
(ESPIAS)377 
 
Levofloxacin/ 
Placebo 
2005 67/69 RCT 
Lampl et al378 
 
 
Minocycline/ 
Control 
2007 74/77 RCT 
Harms et al 
(PANTHERIS) 
28
 
 
Moxifloxacin 
/Placebo 
2008 39/40 RCT 
Schwarts et al 
(MISS)29 
 
 
Mezlocillin plus 
Sulbactam/ 
 control 
2008 30/30 RCT 
(A – antibiotics, P – placebo, RCT – Randomised controlled trial, ESPIAS - Early Systemic Prophylaxis of 
Infection After Stroke study, PANTHERIS - Preventive ANtibacterial THERapy in acute Ischemic Stroke, 
MISS - The Mannheim Infection in Stroke Study) 
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Table 1-10 Studies of Preventative Antibiotics Outcome 
 
Study (reference) 10 outcome 
 
20 outcome Duration of 
intervention  
Infection 
rate A vs P 
n/N (%) 
Pneumoni
a A vs P 
n/N (%) 
Chamorrow et al 
(ESPIAS)377 
 
 
 
Rate of infection 
at one week 
post-stroke 
Neurological 
outcome and 
mortality at 
day 90 
3 days 12/66 (18) 
vs. 11/64 
(17) p=0.7 
Not stated 
Lampl et al378 
 
 
 
 
NIHSS, MRS 
and Barthel 
score at 90 days 
 5 days Not stated Not stated 
Harms et al 
(PANTHERIS) 
28
 
 
 
Infection within 
11 days 
Neurological 
outcome, 
mortality  
5 days 6/39(15) 
vs. 
13/40(33) 
p=0.1 
3/39 (7.7) 
vs. 8/40 
(20) 
P=0.2 
Schwarts et al 
(MISS)29 
 
 
Changes in body 
temperature 
Rate of 
infection at 
day 10 
4 days 15/30(50) 
vs. 27/30 
 (90) p= 
0.002 
Not stated 
(NIHSS – National Institute of Health stroke scale, MRS – modified Rankin scale, ESPIAS - Early Systemic 
Prophylaxis of Infection After Stroke study, PANTHERIS - Preventive ANtibacterial THERapy in acute 
Ischemic Stroke, MISS - The Mannheim Infection in Stroke Study, A – Antibiotic group, P – placebo group) 
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1.6.5. ACE inhibitors 
Details of the meta-analysis on post-stroke pneumonia prevention by ACE inhibitors were 
reviewed379. Details on the studies which were included in the meta-analysis are given in 
the table 1.11. There were a total of 8,693 patients from three RCTs and two cohort studies, 
4940 were Asians and 3753 were non Asians (Europeans and Australians). There were total 
of 473 episodes of pneumonia in the total group. The sample size varied from 394 to 6105 
post-stroke patients. The control group had other antihypertensives, such as angiotensin 
receptor blockers, beta-blockers, calcium channel blockers, and in the study by Ohkubo et 
al a placebo. Two studies were retrospective380;381 and others were prospective26;382;383. 
 
The incidence of pneumonia in the control groups ranged from 4.7 to 17.9%. All studies 
showed a preventative effect of ACE inhibitors compared with the control groups. The 
overall combined relative risk following administration of ACE inhibitors compared to 
control was 0.61 (95%CI 0.51-0.75, P <0.001). When the analysis was restricted to the 
Asian population (after excluding 3753 Caucasian patients from Ohkubo’s study), the 
relative risk was estimated at 0.42 (95%CI 0.32-0.56, P <0.001). Apart from Ohkubo’s 
study, other four studies only were on Japanese patients. Review of these four studies 
showed that the preventative effect of ACE inhibitors were greater in the Japanese patients 
than the other Asian patients, with a relative risk of 0.38 (95%CI 0.27-0.54, p 
<0.001)26;380;381;383. The estimated number needed to treat (NNT) for all five studies was 
34.3 (95%CI 25.9-50.6) range (9.3-113.6) and was 20.4 (95%CI 16.3-27.4) where only 
data from the Asian patients were analysed.  
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Table 1-11 - Studies of ACE Inhibitors 
 
Study (year 
of 
publication) 
(reference) 
Patients Number 
of 
patients 
Patient 
number 
(ACEI/ 
Placebo) 
Type of 
study 
Duration 
of 
interventio
n (years) 
Elderly 
(>65 
years) 
Rate of 
pneumo
nia 
(ACEI) 
Event / 
Total 
n/N (%) 
 
Rate of 
pneumonia 
(control) 
Event/total 
n/N (%) 
Sekizawa et 
al 
(1998)383 
 
 
HT and 
history 
of stroke 
440 127/313 RCT 2 yes 9/127 
(7%) 
56/313 
(18%) 
Arai et al 
(2000)381 
 
 
 
HT and 
history 
of stroke 
394 208/186 Retrospe
ctive 
cohort 
study 
4 yes 8/208 
(4%) 
15/186 
(8%) 
Arai et al 
(2001)380 
 
 
 
HT and 
history 
of stroke 
404 209/195 Retrospe
ctive 
cohort 
study 
2 yes 10/209 
(5%) 
23/195 
(12%) 
Ohkubo et 
al (2004)382 
 
 
 
 
HT and 
history 
of stroke 
or TIA 
6,105 
(all) 
2,352 
(Asian) 
3.051/ 
3,054 
(all) 
1,176/ 
1,176 
(Asian) 
RCT 3.9 no All 
117/3,05
1 
(4%) 
Asian 
26/1,176 
(2%) 
All 
144/3,054 
(5%) 
Asian 
48/1,176 
(4%) 
Arai et al 
(2005)26 
 
 
HT and 
history 
of stroke 
1,350 430/920 RCT 3 yes 12/430 
(3%) 
79/920 
(9%) 
 
(ACEI- Angiotensin Converting Enzyme Inhibitors, HT- Hypertension, RCT- Randomised Control Trial)  
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1.6.6. Selective oral decontamination 
One study was identified which assessed the effect of selective oropharyngeal 
decontamination (SDD) in acute stroke patients27. The aim of the study was to determine 
the levels of colonisation of pathogenic aerobic Gram-negative bacteria (AGNB) in acute 
stroke patients and the effect of SDD on oral flora and its effect on post-stroke pneumonia 
and mortality. It was a prospective single blinded randomised controlled trial and the 
patients (n = 203) were randomised to receive either SDD with oralbase gel containing a 
combination of antibiotics (colistin, polymyxin and amphotericin) or placebo applied 
topically to the oral mucous membranes four times a day. The study included patients with 
both safe and unsafe swallow and the treatment continued for two weeks for patients with a 
safe swallow and three weeks for patients with unsafe swallowing. Twenty patients died 
and 19 withdrew, therefore full follow-up was obtained in 164 patients. The primary 
endpoint of the trial was the rate of AGNB carriage and the study demonstrated that SDD 
significantly reduced the AGNB carriage following acute stroke (p = 0.03). The incidence 
of pneumonia was a secondary outcome and the treatment group had significantly less 
number of pneumonia, eight in total and seven (87%) in the placebo group and one in the 
treatment group (13%) which was statistically significant (p = 0.03).  
 
1.6.7. Discussion 
Introduction 
This literature review demonstrated that there is only limited evidence on the use of 
medical treatments for the prevention of pneumonia in patients following acute stroke. Out 
of what initially appeared to be a large number of citations only six research articles 
(including one meta-analysis of five trials) fit the required criteria. The level of 
heterogeneity was such that pooling of data was impossible and separate descriptions of 
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each group were provided instead. The systematic review did not identify any clear 
evidence for medications that can reduce pneumonia in acute stroke patients who are fed 
via nasogastric tubes.  
 
ACE inhibitors 
Substance P is a neurotransmitter that plays a pivotal role in the swallowing reflex and acts 
via neurokinin receptors384. An extensive plexus of nerves which contain substance P has 
been demonstrated in the upper airway epithelium which synapses with glossopharyngeal 
and vagal endings385. A reduction in substance P levels by capsaicin desensitization or by 
blockage of neurokinin receptors has been shown to reduce cough and swallowing reflexes 
induced by various stimuli 386;387. In addition, inhibition of substance P centrally with direct 
antagonists or dopamine antagonists interrupts swallow388. It has been demonstrated that 
patients with aspiration pneumonia have lower levels of substance P in their respiratory 
epithelium384. Thus, medication that increases substance P levels in the upper airway 
should stimulate the cough reflex by its stimulatory action on the glossopharyngeal and 
vagus nerves387. Substance P is degradated by the enzyme angiotensin converting 
enzyme388. It has been demonstrated that the use of an ACE inhibitor increases substance P 
levels in the upper respiratory tract and increases the sensitivity of the cough reflex and is 
thought to be responsible for dry cough, which is a common side effect of ACE inhibitor 
treatment389;390.  
 
Though large numbers of studies have demonstrated that the use of ACE inhibitors reduced 
the incidence of pneumonia in older patients, patients with cardiac illness and in diabetes, 
the systematic review identified only few studies that assessed the effect of ACE inhibitors 
in patients following stroke. Even these studies were conducted on chronic stroke patients 
rather than acute stroke patients, with the follow-up periods up-to 4 years. The beneficial 
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effect of ACE inhibitors in reducing pneumonia following stroke was more significant in 
the Asian population than European Caucasian population26;382. These findings are similar 
to the findings of the meta-analysis by Caldeira et al in patients with various diseases such 
as congestive cardiac failure, diabetes and stroke which demonstrated that though ACE 
inhibitors significantly reduced the risk of pneumonia in all patients the odds reduction was 
significantly higher in Asian patients (57% vs. 12%, p <0.001)375. Studies of the effect of 
ACE inhibitors on pneumonia in non-stroke Asian population have demonstrated 
conflicting results as a study by Arai et al on 576 patients with no previous strokes did 
demonstrate a reduction in pneumonia with ACE inhibitors391, a study by Terammoto et al 
on a similar patient group failed to demonstrate a similar beneficial effect392. However, in 
patients with a history of stroke, all studies have demonstrated that ACE inhibitors 
significantly reduced the incidence of pneumonia in the Asian population. This was further 
confirmed by the sub-analysis of the PROGRESS trial data which demonstrated that ACE 
inhibitors (perindopril) significantly reduced the risk of pneumonia of Asian ethnicity with 
no significant effect on non-Asian participants382. The mechanism by which ACE inhibitors 
reduce incidence of pneumonia has been discussed in the previous section. Genetic 
differences in ACE polymorphism between non-Asian and Asian population have been 
suggested as a possible explanation for this difference in protective effect observed in the 
Asian population393. Polymorphism I/I and I/D, which are more prevalent in Asian 
population was responsible for the protective effect seen in the post-hoc analysis in 
PROGRESS trial, where as the D/D polymorphism particularly common in white 
population was less protective. Though the genetic evidence is equivocal, the reduced 
protective effect may explain the increased levels of serum ACE inhibitors were still 
associated with high levels of kinin catabolism in patients with the D/D polymorphism394. 
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Even in Asian population the best effects of ACE inhibitors were seen in patients with a 
stroke, which can be explained the mechanism of action of ACE inhibitors. ACE inhibitors 
through the inactivation of substance P and increasing kinins levels in the upper airways 
improve upper airway reflexes such as swallowing and cough395. However, when consider 
the in swallowing mechanism in an older individual, it is clear that older people have their 
cough and swallow reflexes intact unless complicated by other concurrent illnesses396;397. 
Addition of an ACE inhibitor to a such person will not have any obvious beneficial effect 
on the incidence of pneumonia as they still have intact upper airway protective mechanisms 
despite the other changes associated with old age. However, following stroke even patients 
with a normal cough reflex aspirate small volumes of saliva, especially during sleep, 
increasing the risk of aspiration pneumonia ten-fold391. Therefore when an older person 
suffers a stroke, treatment with ACE inhibitors improve or restore these defences by 
inactivating substance P, thereby exerting a protective effect on risk of aspiration and 
pneumonia.  
 
Preventative antibiotics 
Though the collective data demonstrated that preventative antibiotics did reduce the 
incidence of post-stroke infections, individual review of each paper showed widely 
differing outcomes. Though all studies did not report on the incidence of pneumonia, sub-
analysis of the available data did not demonstrate that the use of antibiotics prevented post-
stroke pneumonia. One study (ESPIAS) was terminated prematurely as the rate of infection 
was similar in patients in both groups. Selection bias was implicated, as some studies 
included patients with less severe strokes and some studies excluded patients with an 
estimated life expectancy of less than 90 days following recruitment. This selected patients 
with less severe strokes, as reflected in low mortality rates, and this might have 
overestimated the effects of the antibiotics. Also withdrawal of some patients after 
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randomization on the grounds of ineligibility may have been influenced by the knowledge 
of outcome, which would again favour the antibiotic regimen. This selection of patients 
would have been responsible for the low mortality seen in these trials, ranging from 0% – 
7%, far less than the average mortality following acute stroke. Though in the per-protocol 
analysis (which was highlighted in the results of the trial) showed a significant reduction in 
pneumonia in the PANTHERIS study, but the intention to treat analysis did not show such 
reduction. Also, the antibiotics used in two studies (ESPIAS and PANTHERIS) are not 
commonly used on stroke wards now, as the use of quinolones has been associated with a 
high incidence of Clostridium difficile infection398. In addition the problem of inducing 
drug resistance should be considered in use of prophylactic antibiotic treatment. 
 
One trial used minocycline for its potential neuroprotective effects as it has several anti-
inflammatory effects, reduces microglial activation, inhibits apoptotic cell death and has a 
favourable effect on experimental animal stroke studies399. However, it has inadequate 
microbiological cover for the predominant organisms responsible for post-stroke 
pneumonia. Of other antibiotics ceftriaxone appears to be more promising as a prophylactic 
antibiotic in view of its neuroprotective effects400. This beta-lactum antibiotic reduced 
mortality and neurological deficits in rat models, as it improves neuronal survival within 
the penumbra and has shown to up-regulate of neurotrophics in the peri-infarct zone401. It 
also has a broader antibacterial spectrum which is effective against many organisms 
responsible for post-stroke pneumonia398. These observed effect warrant further evaluation 
of preventative antibiotics. However, to study these effects the trials should have 
standardised definition of pneumonia and review clinical and functional outcomes such as 
Modified Rankin Scale (mRS) and length of stay. 
 
Student No: 940137947014 128 
Miscellaneous group 
The principle of the oral selective decontamination is that colonisation of oropharynx with 
aerobic Gram-negative bacteria- AGNB is common following acute stroke and reduction in 
the colonisation will result in a reduction of pneumonias caused by aspiration of infective 
oropharyngeal secretions6;283. Though in the study on SDD, pneumonia was not the primary 
outcome, it demonstrated that SDD significantly reduced the incidence of pneumonia in 
post-stroke patients. However, the incidence of pneumonia was significantly lower in both 
groups than in many previous studies (5%). Also, there were no formal criteria for the 
diagnosis of the pneumonia which was obtained by examining the case notes for evidence 
of probable pneumonia. The three antibiotics which were used as SDD are no longer 
available in the NHS.  
 
1.6.8. Conclusion 
In spite of a high incidence of pneumonia following stroke and its contribution towards 
post-stroke mortality and morbidity, my reading of the evidence is that there is a significant 
lack of research into medical interventions to prevent stroke related pneumonia. It may be 
partly due to stroke patients being included into the same trials on prevention of pneumonia 
with mixed participants such as older people, nursing home residents and patients with 
other common medical conditions such as diabetes and chronic heart disease. Historically, 
not recognising stroke as a specific disease entity and branding stroke along with elderly 
care research or chronic central nervous system diseases may be partly responsible in the 
lack of research into acute stroke. 
 
There is emerging evidence from one recent meta-analysis including five clinical studies 
that ACE inhibitors significantly reduce pneumonia, but this evidence is restricted to 
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patients with chronic stroke. Results from antibiotic studies are conflicting. A much larger 
study (Stroke INF, n = 1200) is still recruiting and may resolve this issue402. More research 
is also needed in relation to safety of prophylactic antibiotics and to establish whether 
pneumonia is delayed rather than prevented, and to determine if broader spectrum 
antibiotics are more effective in treatment. The potential risk of development of bacterial 
resistance is a major disadvantage of preventative antibiotics. Potential benefits of the use 
of antibiotics should be weighed with the problems such as selecting out resistant strains, 
antibiotic related side effects such as Clostridium difficile infection and general induction 
of resistant microbial strains403.  
 
More research is needed on antibiotics with neuro-protective effects and methods to 
prevent antibiotic resistance when used regularly on a stroke ward. Most importantly, none 
of the studies have specifically targeted patients fed via nasogastric tubes, in whom the 
incidence of pneumonia is several-fold higher than in other stroke patients. Further research 
is needed into prevention of pneumonia in stroke patients, especially in severe strokes and 
in patients fed via nasogastric tubes. Although promising, at least in theory, there is no 
study of the use of antiemetic agents in the prevention of post-stroke pneumonia.   
 
1.7. Interventions to reduce pneumonia in patients fed via nasogastric 
tubes 
Aspiration pneumonia has always been a significant clinical problem in critically ill 
dysphagic patients and is associated with increased use of antibiotics, longer time on 
mechanical ventilation, increased length of hospital stay and high mortality. Pneumonia 
continues to occur even if oral feeding is not attempted and the patients are fed via 
nasogastric tubes due to aspiration of oropharyngeal secretions and regurgitated gastric 
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contents. In addition to the approaches to prevention of pneumonia which was described in 
the previous section, these patients who are fed via nasogastric tubes require further 
preventative measures to reduce pneumonia related to the nasogastric tube. Various 
methods including changes in body posture, selective oropharyngeal decontamination, post 
pyloric feeding, and subglottic suctioning have been tried with varying success. As the 
thesis focuses on the prevention of aspiration and pneumonia in stroke patients who are fed 
via nasogastric tubes, interventions to reduce the incidence of aspiration and pneumonia in 
patients receiving nasogastric feeds will be discussed in detail in this section.  
 
1.7.1. Body posture 
Studies have shown that risk factors for pneumonia, such as gastro-oesophageal reflux and 
aspiration in the critical ill intensive care patients who are fed via nasogastric tubes, can be 
reduced by managing them in a semi-recumbent position (elevation of the head end of the 
bed by 30°-45°). In ventilated patients who are receiving nasogastric feeds, supine posture 
has been shown to increase the risk of gastric aspiration and pneumonia when compared to 
patients who are nursed in the semi-recumbent position and the risk was dependent on the 
length of time the patient was kept in the supine posture404;405. In a prospective study 
involving 86 critically ill intensive-care patients, microbiologically confirmed aspiration 
pneumonia occurred in 23% of patients who were managed in supine position while 
receiving nasogastric feeds when compared to only 5% of patients who were managed in a 
semi-recumbent position 406. 
 
Some studies have shown that the benefit of a semi-recumbent posture was not always 
observed in the presence of nasogastric feeds. These studies have concluded that 
nasogastric tube was an independent risk factor for gastro-oesophageal reflux irrespective 
of body posture404;407. However, semi-recumbent posture was still beneficial as there were 
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fewer episodes of reflux, aspiration and pneumonia though it was not statistically 
significant. In a large, prospective study involving critically ill ventilated patients using 
radioactive technetium (Tc99) labelled feeds, it was demonstrated that irrespective of the 
body posture radioactivity was detected in the oropharyngeal contents within first five 
hours of commencement of nasogastric feeds. This indicates the continued occurrence of 
gastro-oesophageal reflux even when patients were maintained in the semi-recumbent 
posture. However, the radioactivity of the endobronchial secretions was more in patients 
who were managed in the supine position407. 
  
This available evidence led to the clinical acceptance that elevation of the head end to 45 
degrees or more is a simple and a safe method of reducing aspiration pneumonia with no 
extra cost. Aspiration still can occur when transferring patients between units or while 
having investigations, as during these procedures patients are usually placed in a recumbent 
position. This may be at least partly responsible for the findings of a study by Rowat et al, 
which demonstrated that stroke patients were most likely to be hypoxic in the scanners or 
during ward to ward transfers408.  
1.7.2. Nasogastric feeding regime  
Nasogastric feeds are administered either continuously over 10 to 12 hours or as 
intermittent bolus feeds every 2 to 3 hours, with the volume of each bolus being about 250 
ml. Most studies of nasogastric feeding regime were done in critically ill intensive-care 
patients and it has been shown that high volumes of feed per session in intermittent feeding 
can lead to larger residual gastric volumes, gastric distension, enteral feeding intolerance, 
and increased gastro-oesophageal reflux409;410. These studies also demonstrated that more 
patients developed aspiration pneumonia when fed using intermittent bolus feeds than on 
continuous feeds. In studies involving enterally fed elderly patients, intermittent large bolus 
feeds were less well tolerated and were associated with diarrhoea411;412. In addition, patients 
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on continuous feeds achieved their nutritional goals faster and had fewer episodes of chest 
infection irrespective of age and the severity of stroke 411.  
 
Continuous feeds have their own limitations such as patients being attached to feeding 
tubes longer, which interferes with patients’ mobilisation and therapy input and the 
tendency to raise the gastric pH facilitating gastric colonization of Gram negative bacteria, 
which increase the risk of pneumonia413. However, the study also demonstrated that though 
the gastric pH was lower in patients receiving intermittent feeds, the rate of ventilator 
associated pneumonia was similar in both groups413.  
 
It has been recommended that nasogastric feeds should be started at a slower rate usually 
25 ml/hour and gradually build-up to the required rate (usually 100 ml/hour) over a period 
of 48 to 72 hours414;415. Studies done in intensive care patients recommend that the volume 
of the residual gastric content should be monitored and evidence of abdominal distension 
(by regular measurement of abdominal girth) should be observed over the first few days of 
commencing nasogastric feeds. If the residual gastric content is more than 200 ml or if the 
patient has significant abdominal distension, the rate of the feed should be reduced and the 
build up of the rate should be done at a slower rate414;415. Some frail older patients may not 
tolerate a rate of 100 ml/hour, thus such patients should have a lower rate of 75 ml/hour 
and may need longer feeding sessions to achieve the prescribed feeding regime415. Feeding 
should preferentially be done during morning and afternoons rather than overnight as a 
semi-recumbent posture may be difficult and uncomfortable to maintain and observations 
for complications such as regurgitation and vomiting are missed in a darkened ward415. 
Intermittent bolus feeds should be started at a 200 ml bolus administered over an hour and 
advancing the volume to reach the target feed volume with a limited number of feeds, 
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which is usually 3 to 4 times a day415. Thus initially there may be 5 to 8 bolus feeds to 
achieve the required nutritional intake.  
 
On the assumption that liquid feeds support gastro-oesophageal reflux, trials have been 
done to assess the effect of semi-solidification of nutrients. A study involving 14 stroke 
patients who were on PEG feeds, twenty four hour oesophageal multichannel intra-luminal 
impedance and pH was measured during and after feeding with semi-solidified and liquid 
feeds respectively. Though a small study, it demonstrated that semi-solidification of 
nutrients did not appear to be effective in preventing gastro-oesophageal reflux caused by 
liquid PEG feeds416.  
 
Studies in adults comparing continuous versus bolus feeds as a means to reduce the 
incidence of pneumonia have been mainly conducted on intensive care units though the 
recommendations may be applicable to patients with acute stroke. The evidence available 
so far suggest that continuous feeds are better tolerated by patients and associated with a 
lower incidence of pneumonia than bolus feeds. As opposed to intubated, ventilated 
intensive care patients, patients on stroke units will be mobilised early following stroke will 
have more inter-departmental transfers and practical difficulties of maintaining semi-
recumbent position throughout the time period of continuous nasogastric feeds. In addition, 
bolus feeds are more physiological as they stimulate more distal colonic motor suppression 
and promote water resorption415. Therefore more studies are needed on nasogastric feeding 
regimes and body posture during enteral feeds in patients managed on stroke units.  
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1.7.3. Size of nasogastric tube 
As nasogastric tubes interfere with the function of the lower oesophageal sphincter, it can 
be assumed that nasogastric tubes with a larger diameter can induce sphincter dysfunction 
and reflux more than a fine bore tube. Several studies have been conducted to assess this 
possibility. However, the results contradict each other as described below. A randomised 
controlled trial in mechanically ventilated, critically ill patients demonstrated that there was 
no increased incidence of gastro oesophageal reflux or aspiration pneumonia in patients 
who were fed using fine bore 8F nasogastric tubes when compared to a similar group of 
patients who did not have nasogastric feeds. However, patients who had their feeds through 
16F nasogastric tubes had significantly higher incidence of reflux and pneumonia than 
patients who were fed using fine bore nasogastric tubes417. A study done in children with 
continuous oesophageal pH monitoring to detect lower oesophageal sphincter dysfunction 
and reflux concluded that the size of the NG tube was a significant risk factor predisposing 
the child to gastro oesophageal reflux and that nasogastric tubes with a larger diameter 
increased the gastro oesophageal reflux and interfered with clearance of the acid from the 
oesophagus418. However, a study in adult intubated and ventilated patients with head injury 
failed to demonstrate that small-bore (2.85mm diameter) nasogastric tubes were associated 
with less gastro-oesophageal reflux and micro aspiration following a radio-active 
technetium colloid meal, when compared to patients with medium–bore nasogastric tubes 
(6mm)419. Another study in ventilated adults showed similar results and demonstrated that 
there was any significant difference in the episodes of reflux in patients who were fed using 
small bore (8F) tubes than large bore (14F) tubes420. In a large study Metheny et al 
demonstrated that monitoring of the residual volume to evaluate gastric emptying, 
prevention of mal-position of the feeding tube and avoidance of supine posture during 
feeding were more important than the size and site of the tube placement421 Therefore in 
clinical practice nasogastric tubes of medium size are used (8-10F) as smaller tubes are 
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easily obstructed by feeds and medication and larger tubes can cause undue discomfort to 
patients and can lead to nasal and oesophageal ulceration420. The main indications for the 
use of large-bore tube are the need for repeated gastric aspiration or need for administration 
of highly viscus drugs or feeds via the nasogastric tube415. 
 
1.7.4. Gastric pH management 
As higher gastric pH is associated with gastric colonisation and an increased incidence of 
pneumonia, studies have been performed to assess the effect of alteration of gastric pH and 
bacterial colonization. A multi-centre, double blind randomized study in ventilated patients 
who were given either nasogastric feeds of a pH of 6.5 or an acidic nasogastric feed with a 
pH of 3.5 (achieved by adding hydrochloric acid) demonstrated that there was a significant 
reduction of gastric colonization in the group who received acidic feeds and a non 
significant reduction in the incidence of the pneumonia422. However, patients who were on 
an acidic formula had a higher residual gastric volume, more interruption to their feeds and 
higher mortality when compared to the control group. This was secondary to acidaemia and 
upper gastrointestinal haemorrhage which obscured any potential benefit from a reduction 
in the incidence of pneumonia. In addition there was no difference in the duration of 
mechanical ventilation, length of the ITU stay or usage of antibiotics422.  
 
Studies have also assessed the association of agents which increase gastric pH to prevent 
gastric ulceration, with gastric colonization and ventilator associated pneumonia in patients 
fed via nasogastric tubes. A multi-centre randomized placebo controlled trial including 
1200 patients showed that there was no significant difference in ventilator associated 
pneumonia, upper gastrointestinal haemorrhage, length of ITU stay or mortality between 
two groups of patients who were treated with either sucralfate, a gastro protective agent 
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that does not alter the gastric pH, or intravenous ranitidine423. However, a meta-analysis of 
eight randomized trials comparing ranitidine and sucralfate has shown that there is a 
significant increase in the incidence of ventilator related pneumonia in patients who are 
treated with ranitidine424. 
 
The use of proton pump inhibitors also increase the gastric pH and has been linked to an 
increased risk of community acquired pneumonia425-427. An association between the use of 
proton pump inhibitors and an increased risk of pneumonia has been demonstrated in 
critically ill ventilated patients428;429. Studies comparing the incidence of pneumonia in 
enterally fed patients treated with either H-2 receptor blockers or proton pump inhibitors 
have been inconclusive. A study in 887 patients who had cardiothoracic surgery and had 
either ranitidine or a proton pump inhibitor (pantoprazole) as stress ulcer prophylaxis 
demonstrated that the use of pantoprazole was associated with a higher incidence of 
ventilator associated pneumonia than ranitidine425. However, another large study, in a 
similar patient group failed to show such association. 
 
The available evidence suggests that increasing the gastric pH is associated with an 
increase in the incidence of pneumonia as it promotes gastric colonisation of Gram 
negative bacteria. Avoiding unnecessary medications for gastric acid suppression has been 
agreed as a part of various guidelines and care bundles in the prevention of pneumonia in 
ventilated and enterally fed patients429;430. However, reducing the gastric pH by 
acidification of feeds though reduced the incidence of pneumonia was associated with 
harmful side effects and increased mortality. 
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1.7.5. Control of subglottic secretions 
Aspiration of pooled oropharyngeal and sub-glottic secretions which are colonized by 
bacteria is a major cause for aspiration pneumonia in dysphagic patients6. Aspiration of 
colonised tracheal secretions above an inflated endotracheal tube cuff which is also referred 
as the “pool of death” by some authors is a common cause pneumonia151. Usual clinical 
practice is suctioning of pooled secretions as required, usually performed following clinical 
examinations by medical and physiotherapy staff. Few studies have been conducted to 
compare the incidence of pneumonia in critically ill patients with continuous subglottic 
suctioning as opposed to intermittent suctioning of oropharynx when required. A 
randomised controlled study in 155 patients compared continuous aspiration using a 
specialized endotracheal tube to standard care demonstrated a significant reduction in the 
number of Gram positive cocci and Haemophilus influenza organisms in their sputum184. In 
addition there was a significant delay in the onset of pneumonia, which was 12 days in 
patients with continuous suction compared to 5 -9 days in patients who only had standard 
care184. However, there was no difference in the number of ITU days or in mortality. Two 
further studies confirmed that there was a lower incidence of ventilator associated 
pneumonia in patients who received continuous sub-glottic suction431;432. A recent meta-
analysis has shown that continuous subglottic suction reduces ventilator associated 
pneumonia in high risk patients and is cost effective. However, there was no significant 
benefit on the duration of ventilation, length of hospital stay or on mortality433. Though a 
promising concept in stroke patients with severe dysphagia, no studies have been to assess 
its efficacy following acute stroke. 
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1.7.6. Avoidance of sedatives 
A depressed level of consciousness worsens a patient’s swallowing problems127. In addition 
to this narcotics also delay gastric emptying and increase the risk of gastroesophageal 
reflux and aspiration. Meissner et al demonstrated that intragastric naloxone (which 
antagonises antiperistaltic effects while preserving analgesia) in patients who are on 
continuous fentanyl infusion improved gastric emptying and reduced the incidence of 
pneumonia434. Therefore it is important to use sedatives sparingly or not at all whenever 
possible in patients who are critically ill. Daily sedation interruption and assessment for 
readiness to wean are strategies carried out to reduce pneumonia in critically ill ventilated 
patients who are fed via nasogastric tubes435. 
 
1.7.7. Site of delivery of feeds 
It can be argued that as lower oesophageal sphincter dysfunction, reflux and gastric stasis 
cause significant problems when feeds are delivered to the stomach, a more distal site for 
tube placement should reduce the incidence of these complications and pneumonia. 
However, several randomized studies have demonstrated that the incidence of aspiration 
pneumonia is similar in patients who have a nasogastric tube and patients with tubes placed 
in the duodenum (post pyloric tubes) and in the small bowel25;422 187. Three meta-analyses 
of these studies of gastric feeds versus small bowel feeds have come to conflicting 
results436;437. The first meta-analysis demonstrated that there was a significant reduction in 
pneumonia with small bowel feeds when compared to gastric feeds, though there was no 
reduction in mortality. The study recommended that patients with a history of reflux and 
aspiration or a medical condition resulting in delayed gastric emptying should have their 
feeds delivered to the jejunum rather than to the stomach436. However, another meta-
analysis by Marik et al failed to show such an advantage437. It is unclear why post pyloric 
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feeds do not show a clear advantage over gastric feeds, but may be related to technical 
differences between the studies, such as definition of pneumonia, location of feeding tube 
port and the use of concurrent gastric decompression. Also enteral feeding directly into the 
small bowel may paradoxically inhibit gastric emptying through a feedback mechanism 
called the “ileal break” and causes an increase in the incidence of reflux and aspiration438. 
To counteract this ileal break some centres routinely use concurrent gastric decompression 
in patients who are receiving post pyloric feeds.  
 
It has been suggested that small bowel feeding should be considered when patients are 
intolerant of gastric feeding, especially when aspiration is detected439 and enteral feeds 
should be commenced using small bowel tubes if there is a high risk of gastric 
intolerance440. However, this procedure is not widely feasible as it requires personnel with 
special training440. The North American Summit recommends post pyloric feeds in patients 
who have two or more risk factors for aspiration and the American Society for Parenteral 
and Enteral Nutrition (ASPEN) recommends jejunal feeding tubes for patients at high risk 
of aspiration151.  
 
Although the PEG tube is a more effective way of feeding, better tolerated by the patient, 
and has a lower incidence of displacement, there is no difference in the incidence of 
aspiration pneumonia when compared to nasogastric tubes236. A study which reviewed 69 
patients with gastrostomies and 86 patients with jejunostomies found no difference in the 
rate of pulmonary aspiration or other pulmonary complications149. Another study by 
Metheny et al to assess the effects of site of the feeding tube on aspiration failed to 
demonstrate any preferred feeding site154. Therefore, the site of the enteral feeding tube 
does not alter the incidence of pneumonia. 
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1.7.8. Oral and selective digestive bacterial decontamination 
As the bacterial content of oropharyngeal secretions significantly contributes to aspiration 
pneumonia, several studies have assessed the efficacy of oral and selective digestive 
bacterial decontamination (SDD) for the reduction of pneumonia and mortality in 
ventilated patients who are fed nasogastric tubes27;441;442. The full form of SDD has four 
components, an oral gel containing a combination of antimicrobial drugs applied to the oral 
cavity four times a day, a liquid suspension containing the same antimicrobial administered 
via a nasogastric tube, a three day course of intravenous antibiotics and, fourthly, strict 
infection control measures441. The intention is eradication of Gram negative bacilli from the 
oropharynx while preserving the normal bacterial flora. 
 
Studies have looked at various combinations such as oral and gastrointestinal 
decontamination with or without intravenous antibiotics, oral decontamination alone and 
gastrointestinal decontamination alone. Most of the studies were done in critically ill 
patients in intensive care units. The antibiotic used, criteria for diagnosis of pneumonia and 
the type of patient population varied but selective digestive decontamination significantly 
reduced the incidence of pneumonia and was independent of the choice of antibiotics 442;442. 
The majority of studies which used oral decontamination alone also showed a significant 
reduction in the incidence of pneumonia though there was no reduction in mortality, 
duration of the mechanical ventilation or length of stay in the intensive care units. In the 
trials which also used intravenous antibiotics, development of bacterial resistance was a 
significant concern414. 
  
Not many studies have assessed the efficacy of oral decontamination on stroke patients. In 
a randomised controlled double blind trial, Gosney et al studied the effect of SDD using a 
gel containing 2% colistin, 2% polymyxin and 2% amphotericin B, applied three times a 
Student No: 940137947014 141 
day for 3 weeks in stroke patients with poor swallow and for 2 weeks in patients with a 
normal swallow27. This is the first study using the SDD in acute stroke patients. The 
primary outcome was the level of oral colonization and isolation of Gram negative bacteria 
(AGNB) and secondary outcomes were effects of selective digestive decontamination on 
the incidence of pneumonia, mortality and morbidity. It had already been shown that the 
AGNB colonize the oropharynx of a stroke patient soon after hospital admission and one 
study has demonstrated that the change of oral flora occurred as early as 24 hours following 
hospitalisation27. Colonisation correlates with the severity of the illness, with an incidence 
of 37% in moderately ill and 79% in seriously ill patients with similar incidence in acute 
stroke patients133;287. Mostly these AGNB are Echserichia coli and enterobacter 287. 
Gosney’s study demonstrated a similar pathogenic spectrum as shown in previous studies 
and the sputum cultures confirmed that these bacteria were implicated in the documented 
episodes of aspiration pneumonia. The study also showed a high level of carriage and 
colonisation in patients within the first three weeks following their stroke, which was in 
keeping with previous studies287. The study confirmed that SDD can eradicate AGNB from 
the oral cavity of acute stroke patients. Oral decontamination also reduced documented 
episodes of pneumonia, though this result may not be reliable as there were no clear 
guidelines for the diagnosis of pneumonia. Also the incidence of pneumonia was much 
lower than many other studies conducted in post-stroke patients. In addition the mortality 
remained unchanged and re-colonisation of the oropharynx occurred after discontinuation 
of SDD treatment. The Royal College of Physicians Stroke Guidelines now recommend 
routine application of antibacterial oral gel in stroke patients who are fed via nasogastric 
tubes1. 
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1.7.9. Avoiding malpositioned nasogastric tubes 
Any nasogastric tube where the distal end is not in the stomach is called a malpositioned 
tube. Malpositioned nasogastric tubes can occur due to faulty insertion or tube migration 
back into the oesophagus following a bout of retching or vomiting or due to restlessness or 
agitation of the patient. A malpositioned nasogastric tube can have its distal end in the 
trachea or in either bronchus, but more commonly in the right bronchus due to its 
alignment with the trachea.  
 
 Feeding through misplaced tubes can occur if its position is not checked prior to each feed. 
The position of the distal end of the tube should be confirmed before commencement of 
each feed as the tube can migrate proximally or distally in the gastrointestinal tract either 
due to being regurgitated back to the oesophagus or being carried into the duodenum by 
gastric peristalsis. A tube may be pulled out by a confused patient or may be accidently 
dislodged during patient care or movements. A recent study in 201 critically ill patients, 25 
episodes of proximal displacement of nasogastric tubes were reported over three days and 
patients with displacement had a higher incidence of aspiration and pneumonia443.  
 
Observing the external length of the nasogastric tube can provide some indication of such 
displacement but this is not a reliable indicator as the distal tip can spontaneously enter the 
oesophagus and remain coiled in the oesophagus without altering its external length. 
Previously an auscultatory method was used to confirm the position of the nasogastric tube, 
with the assumption that gurgling sounds when air is insufflated through the nasogastric 
tube confirmed that the distal end of the nasogastric tube was within the stomach (Woosh 
test). This test is no longer carried out as concerns have been raised over it safety and 
reliability. Measuring and confirming an acidic pH of the aspirate is reliable. However, use 
of neutral enteral feeds and proton pump inhibitors can result in higher pH values of the 
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aspirate thus limiting its value. Also it may be difficult to obtain an aspirate in some 
patients. In these difficult clinical situations a chest radiograph becomes the only reliable 
method of confirming the position of the nasogastric tube444. Reliance on chest x-ray or 
assessment of the pH of the nasogastric aspirate to confirm the tube position has reduced 
the incidence of pneumonia due to administration of enteral formula into the lungs via 
malpositioned tubes. Radiography remains the gold standard for confirming tube 
placement, and in many institutions it is mandatory before a nasogastric tube is used for 
feeding especially when the tube requires stylets for insertion445. Recently there have been 
several safety guidelines regarding the confirmation of the position of the nasogastric tube 
to avoid aspiration and pneumonia secondary to malposition446. 
 
1.7.10. Reduction of Bronchorrhea 
Stroke-induced excessive bronchial secretions can occur, particularly in brain stem 
strokes447. Methods to reduce bronchorrhea have described and a few recent studies report 
the effect on the incidence of pneumonia. In a study of 19 patients with bronchorrhea 
showed that all had brain stem strokes with 55% affecting the dorsal lateral medulla. 
Increased bronchial secretions were mediated via the parasympathetic nervous system, and 
copious amounts of secretions developed within three days after stroke onset and persisted 
for up to two months448. Use of anti-cholinergic medications reduced the volume of 
secretions and patient discomfort, the need for regular expectoration or oropharyngeal 
suctioning, episodes of aspiration pneumonia and the number of courses of antibiotics448. A 
case report on two patients showed that trans-dermal scopolamine reduced increased 
salivation and possibly aspiration after an acute stroke. However, treatment with 
scopalamine was associated with significant side effects449. 
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1.7.11. Regular measurements of gastric residual volumes 
Measurement of gastric residual volumes (GRV) has been used to assess the risk of 
aspiration in enterally fed patients. A large GRV indicates intolerance to feeds, as well as 
symptoms such as vomiting and aspiration, which should prompt either a reduction in the 
infusion rate or cessation of feeding. However, threshold GRV values that mark increased 
risk of enteral feed intolerance are not universally agreed and therefore vary widely among 
hospitals. An excessively low threshold will lead to frequent and unnecessary 
discontinuation of feeds which will interfere with provision of the necessary nutrition. 
Chang et al defined enteral feed intolerance as a GRV of greater than 150 ml on two 
consecutive measurements done every 4 hours or a single GRV of greater than 500 ml. In 
this study 46% of the patients had enteral feed intolerance with an increased incidence of 
pneumonia and mortality. However, a study done by McClave et al found no difference in 
aspiration with a GRV of 200 ml compared to a GRV of 400 ml, as a threshold above 
which nasogastric feeding should be withheld. The study also demonstrated that an 
increased GRV had a low sensitivity for diagnosing the risk of aspiration25. This 
demonstrates inconsistency between studies of the importance of the GRV as a predictor of 
risk of aspiration. 
 
Gastric residual volume measurement also has several technical issues that interfere with 
its accuracy. A small diameter feeding tube may collapse with suction, and withdrawal of 
gastric contents with a syringe may not empty the stomach completely. Aspiration also 
varies with the location of the ports of the tube, location of the distal end in the stomach 
and the position of the patient. In addition the volume of the aspirate may not only be 
gastric secretions but also could contain nasogastric feeds. Thus, it has been recommended 
that GRV measurements should be combined with clinical assessment of enteral feed 
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intolerance such as auscultation of bowel sounds and assessment of abdominal 
distension450. As mentioned in a previous section, several guidelines exist on how to 
diagnose GRV. The North American Summit recommended feeds to be withheld if the 
GRV is greater than 500 ml and careful bedside evaluation to be carried out if GRV is 
between 200 to 500 ml. The American Society for Parenteral and Enteral Nutrition 
(ASPEN) guidelines state that feeding should be withheld if residual volumes exceed 200 
ml in two successive assessments25. 
 
1.7.12. Cranial and pharyngeal electrical stimulation  
Because brainstem swallowing centres have bilateral cortical innervation, measures that use 
electrical stimulation to enhance cortical input of the unaffected sensori-motor cortex could 
potentially expedite the takeover of the swallowing centre of the unaffected hemisphere, 
which might in turn enhance the recovery of dysphagia. Kumar et al studied the effect of 
non invasive brain stimulation on improvement of stroke related dysphagia. In this pilot 
study 14 patients with subacute unilateral hemispheric infarctions were randomised to have 
anodal transcranial direct current stimulation (tDCS) or to sham stimulation of the sensori-
motor cortical representation of swallowing on the unaffected hemisphere over five 
consecutive days. Severity of the dysphagia was measured using a validated swallowing 
scale, the Dysphagia Outcome and Severity Scale. Patients who received anodal tDCS 
gained 2-6 points of improvement on the Dysphagia Outcome and Severity Scale compared 
to the control group who only had a 1.25 point improvement. Recent studies have 
examined the role of pharyngeal electrical stimulation in expediting the recovery of 
swallow after acute stroke451-453. The hypothesis is that electrical stimulation of the pharynx 
will generate sensory impulses reaching both dominant and non-dominant swallowing 
centres in motor cortices which will enhance the takeover of the swallowing function by 
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the undamaged non-dominant swallowing centre454. Initial studies were done in healthy 
subjects who had 1Hz repetitive transcranial magnetic stimulation to induce a unilateral 
virtual lesion in the pharyngeal motor cortex followed by active or control (sham) 
pharyngeal electrical stimulation. Motor evoked potentials and swallow accuracy were 
recorded before and after the virtual lesions to assess the response to the pharyngeal 
electrical stimulation. Following this study, fifty acute stroke patients with dysphagia 
underwent pharyngeal electrical stimulation to assess its efficacy on swallow. The primary 
end point was the reduction of aspiration two weeks post intervention. The study showed 
that pharyngeal electrical stimulation for 3 days improved airway protection, reduced 
aspiration, improved feeding status and shortened hospital stay455. Both these types of 
electrical stimulation studies need further investigation in a larger number of patients prior 
to be used as routine treatment for dysphagia456.  
 
Paced glottic closure with a subcutaneously implanted stimulator linked to the ipsilateral 
recurrent laryngeal nerve using perineural electrodes has been tried to reduce aspiration on 
persistent aspirators following acute stroke. In a small study including five patients, 
Broniatowski et al showed that paced vocal cord adduction significantly reduced the 
incidence of aspiration and pneumonia. Again though promising, these new interventions 
need further research on larger number of patients457. 
 
In summary, though a number of interventions have been tried to reduce the incidence of 
pneumonia in enterally fed patients though only a few measures have shown consistent 
positive results. However, most were conducted in patients who were on intensive care 
units, in which acute stroke patients only form a small percentage. Only few studies 
included stroke patients managed on stroke units. Though some of the recommendations of 
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these ITU studies may be applicable to stroke patients as both stroke patients on stroke 
units and ITU patients share dysphagia, reduced protective reflexes, nasogastric feeding, 
and gastro oesophageal sphincter dysfunction. However, they also differ in several ways as 
ITU patients tend to be younger, have more comorbidities and have various contributory 
factors that would favour gastroparesis and reflux than patients managed on stroke units. 
They are almost invariably intubated and ventilated; both would increase the gastro-
oesophageal reflux and aspiration. Disease profiles of ITU patients also differ as the 
majority of these patients are post-operative, have several major illnesses, and many have 
multi-organ failure. In addition these patients receive various medications such as 
anaesthesia, dopamine, narcotics and neuromuscular blocking agents, which affect the 
motility of the gastro-intestinal tract, gastric perfusion, residual gastric volume and gastro-
oesophageal reflux. This is worsened by the autonomic response and increased stress 
hormones associated with stress and pain. Also these patients are intensely observed and 
commonly receive one-to-one nursing care. In contrast to ventilated paralysed patients in 
an ITU, patients with an acute stroke are older, have stroke as the main illness and are less 
intensely monitored. They can be restless and agitated, are able to use the non-paralysed 
arm to pull out the nasogastric tube, sometimes several times a day, especially during the 
first few days of their illness. Passing a nasogastric tube through an already colonised 
oropharynx several times can introduce bacteria into the stomach along the nasogastric 
tube. Furthermore, vomiting induced by pharyngeal irritation, restlessness and agitation 
favours aspiration, especially if the patients are not observed intensely. 
 
Maintaining appropriate position during feeds, ACE inhibitors and selective oral 
decontamination have shown to reduce the incidence of pneumonia following stroke. 
Maintaining the body posture at 30 degrees or more is now standard practice during 
nasogastric feeds. The Royal College of Physicians (RCP) stroke guidelines recommend an 
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ACE inhibitor as one of the first line antihypertensive in stroke patients unless 
contraindicated. These also enhance cough and reduce pneumonia as an additional effect. 
Liquid preparations are available for patients who have dysphagia or fed via nasogastric 
tubes. The most recent RCP guidelines also recommend chlorhexidine oral gel as standard 
practice for all stroke patients who remain nil by mouth. Data on prophylactic antibiotics 
are inconclusive and this treatment should not be used unless new studies provide strong 
evidence. A considerable amount of safety precautions are now being carried out to 
confirm the position of nasogastric tube to prevent feeding using a nasogastric tubes which 
is wrongly positioned. However, aspiration and pneumonia still remains a significant cause 
of mortality and morbidity in stroke patients who are fed via nasogastric tubes suggesting 
that further research and new interventions are necessary to prevent this serious medical 
complication in stroke patient, who depend on enteral feeds for their nutrition.  
 
1.7.13. Prokinetic Agents 
Prokinetic agents are drugs that improve gastric emptying by promoting forward gastric 
peristalsis. They also reduce the residual gastric volume and gastric stasis and this leads to 
a reduction of gastro-oesophageal regurgitation458. Prokinetic agents have been extensively 
researched in diabetic gastroparesis and reflux oesophagitis and have shown to reduce 
symptoms by promoting gastric emptying459. It has been demonstrated that prokinetic 
agents also improve gastric emptying in enterally fed patients and the North American 
Summit recommends the use of prokinetic agents in patients on enteral feeds, who have 
more than two major risk factors for aspiration25. Prokinetic agents which have been 
researched include cisapride, erythromycin, domperidone and metoclopramide460. Studies 
of the efficacy of prokinetic agents mainly relate to critically ill ITU patients, and patient 
numbers are small461;462. The effects of each individual agent on the gastrointestinal tract 
are described below.  
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Cisapride 
Cisapride is a prokinetic agent which improves upper gastric motility by direct action on 
gastric serotonin 5HT4 receptors and indirectly as a parasympathomimetic. Stimulation of 
serotonin receptors leads to a release of acetylcholine in the autonomic nervous system in 
the upper gastrointestinal tract. It also increases the muscle tone in the lower oesophageal 
sphincter and improves gastric motility. However, cisapride has now been withdrawn due 
to life threatening side effects such prolongation of the QT interval and predisposition to 
cardiac arrhythmias463. 
 
Erythromycin 
Erythromycin increases gastric motility by acting on the motilin receptors of the upper 
gastrointestinal tract which stimulates contraction of the gut and gall bladder and triggers a 
phase of migrating myoelectric complexes464. It also increases lower oesophageal sphincter 
tone and oesophageal peristalsis. Erythromycin improves gastric motility in diabetic 
gastroparesis, in patients following partial gastrectomy, after vagotomy and in chronic 
intestinal pseudo-obstruction465. Side effects of erythromycin are nausea, vomiting, 
stomach cramps and the development of antibiotic resistance, which could be a major 
problem in patients who are prone to recurrent pneumonia398. Erythromycin also associated 
with an increased risk of sudden cardiac death especially when given with medications that 
inhibit the effect of the cytochrome p-450 3A enzyme466. 
 
Several studies of erythromycin in enterally fed critically ill patients demonstrated that they 
improve gastric emptying though the effect lasts only for a short period464;467. In a study of 
40 critically ill enterally fed ventilated patients Reignier et al showed that erythromycin 
250 mg 6 hourly for 5 days improved gastric emptying, which was measured by regular 
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aspiration of the residual gastric volume, led to a higher return rate to successful enteral 
nutrition468. This improvement in emptying was only seen in the first few days and no 
significant difference in residual gastric volumes on the 4th and 5th days. A smaller study in 
critically ill mechanically ventilated patients intolerant to nasogastric feeds (indicated by a 
residual volume >250 ml when feeding was administered at a rate of 40 ml/hour) also 
showed a transient improvement of the residual gastric volume one hour after infusion of 
200 mg erythromycin 469. A study in critically ill enterally fed ventilated patients with head 
injuries and gastric feed intolerance (defined as a residual volume >150 ml) demonstrated a 
more sustained improvement in gastric motility and that also enhanced early nutritional 
intake with erythromycin470. Therefore the evidence suggests that erythromycin transiently 
improves gastric motility in enterally fed critically ill patients and may therefore reduce the 
risk of gastro oesophageal reflux and aspiration.  
 
Metoclopramide  
Metoclopramide is one of the most commonly used anti-emetics in clinical practice. It is 
cheap and has relatively few side effects. Metoclopramide has similar prokinetic actions as 
erythromycin, but carries no risk of antibiotic associated complications. It has a better 
safety profile than the agents discussed before and was therefore selected as the prokinetic 
agent for the MAPS study. Mechanism of action, pharmacokinetics and adverse effects of 
metoclopramide are discussed in section 1.8.  
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1.8. Metoclopramide  
 
 
Figure 1-4 Metoclopramide molecular structure 
 
 
Metoclopramide is a commonly used antiemetic in clinical practice. It has a central action 
on the chemoreceptor trigger zone and a peripheral action on the upper gastro-intestinal 
tract. It improves gastric motility by blocking gastro-inhibitory dopaminergic D2 receptors 
in the upper gastrointestinal tract30. It is also a mixed 5-HT3 receptor antagonist and a 5-
HT4 receptor agonist. Its central mechanism of action closely resembles the antiemetic 
effect of phenothiazines by its direct antagonist effect on the D2 receptors in the 
chemoreceptor trigger zone in the brain stem. The chemoreceptor trigger zone is located 
close to the area postrema on the floor of the fourth ventricle in the medulla. It receives 
input from blood borne hormones and drugs and is connected to the vomiting centre where 
it initiates vomiting. The chemoreceptor trigger zone is situated outside the blood brain 
barrier, and this is reason why drugs such as dopamine which do not enter the central 
nervous system produce nausea. At higher doses 5-HT3 antagonist activity also contribute 
to the anti-emetic effect of metoclopramide. 
  
However, the main action of metoclopramide as a prokinetic agent is due to its dopamine 
D2 receptor blocking effect on the gastro intestinal tract. Dopamine acting via D2 receptors 
has a direct relaxant effect on the upper gastro-intestinal tract, mainly the lower 
oesophageal sphincter, fundus and the antrum. Dopamine also inhibits the release of 
prokinetic acetylcholine from the cholinergic neurones of the myenteric plexus by 
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activating pre-junctional D2 receptors which indirectly inhibit upper gastro-intestinal 
muscle activity471. Metoclopramide by antagonising the inhibitory effects of dopamine on 
pre-synaptic and post-synaptic D2 receptors, increases the lower oesophageal sphincter 
pressure, gastric tone and gastric antral contractility. It also improves antro-duodenal 
coordination and peristalsis of the stomach and duodenum30. In addition metoclopramide 
sensitises the gut to the stimulatory effects of acetylcholine and increases pre-synaptic 
excitatory 5- HT4 receptor activity, both of which improves forward peristalsis30. It 
therefore accelerates gastric emptying, reduce gastric stasis and decrease post-prandial 
fundal relaxation via its multiple actions. Metoclopramide also reduces gastro oesophageal 
reflux due to increased LES tone30. Prokinetic properties of metoclopramide are limited to 
the proximal gastro-intestinal tract. 
 
1.8.1. Pharmacokinetics and metabolism 
Metoclopramide undergoes first pass hepatic metabolism and is partially metabolised by 
the cytochrome P450 (CYP) system which exhibits significant individual variation 472. Oral 
bioavailability ranges from 30% to 100% and 20% to 30% of the drug is excreted 
unchanged in the urine. Impaired clearance of metoclopramide is seen in patients with renal 
insufficiency and cirrhosis. Individual variations in the genotypes and phenotypes of the 
CYP system affect the drug level and may increase the risk of complications such as 
tardive dyskinaesia in low metabolisors. Metoclopramide is also a competitive inhibitor of 
the P450 enzyme similar to neuroleptic agents such as haloperidol, chlorpromazine and 
risperidone. Concomitant use of metoclopramide with neuroleptic agents may increase the 
bioavailability of each drug which increases the risk of side effects. Metoclopramide is 
available as tablets, as a liquid preparation, and an orally absorbed sublingual preparation. 
An intranasal formulation is also available and has the advantage of rapid onset of action 
and circumvention of the first pass hepatic metabolism. Subcutaneous and intravenous 
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injections have been shown to improve symptoms in patients with more refractory 
symptoms. 
 
Metoclopramide is effective as a short-term treatment of gastroparesis, but a meta-analysis 
of long-term metoclopramide therapy showed no consistent benefit on gastric motility after 
one month473. However, this was mainly based on small and uncontrolled open label 
studies. Another study demonstrated that gastric emptying transiently improved with 
metoclopramide and returned to baseline in spite of continued treatment after one month474. 
Nevertheless, symptomatic improvement of gastroparesis continued beyond this suggesting 
this may not only be due to the pro-motility effect, but also due to its antiemetic effect and 
normalization of gastric slow wave dysrhythmia475. 
 
Metoclopramide is widely used as a treatment of gastroparesis, especially in diabetes458. 
Currently it is the only drug which is approved by the Unites States Food and Drug 
Administration (US FDA) for the treatment of gastroparesis25. The use of metoclopramide 
in critically ill patients in ITU who have gastroparesis has been investigated. A double-
blind study in 40 patients, who were enterally fed after coronary artery bypass surgery 
using paracetamol absorption test, showed that a single dose of intravenous 
metoclopramide effectively improved gastric emptying476. Another the study has 
demonstrated that although metoclopramide had a prokinetic effect on stomach it did not 
have any effect on the gall bladder477. 
 
As both cisapride and metoclopramide promote gastric emptying in critically ill patients, 
studies have been done to compare cisapride and metoclopramide for facilitating gastric 
emptying and improving tolerance to nasogastric feeding using gastric residual volumes 
and gastric emptying times478. Studies concluded that though both cisapride and 
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metoclopramide enhanced gastric emptying and improved tolerance to enteral feeds, 
metoclopramide provided a quicker onset of action and reduced gastric residual volume to 
a greater extent than cisapride478;479. 
  
1.8.2. Adverse effects 
Most of the side-effects from metoclopramide result from its ability to cross the blood-
brain barrier480. The British National Formulary cites extrapyramidal effects especially 
acute dystonic reactions as the most frequent side-effect398. Dystonic reactions can occur in 
0.2-6% of patients and increases with higher doses481. These can be spasmodic and 
sustained involuntary muscle contractions resulting in twisting, repetitive movements or 
abnormal postures. It can present as torticollis, facial spasm, oculogyric crisis, trismus, and 
opisthotonis. These adverse effects are seen mainly in children and young females, though 
it has been reported in older females. Dystonic reactions usually occur within first 24 – 48 
hours after initiation of therapy and are fully reversible within 24 hours following 
discontinuation of the metoclopramide with no long lasting effects482. 
  
Other extrapyramidal reactions include akathisia, a subjective feeling of inner restlessness 
and objective findings of motor restlessness483. This is mainly seen with intravenous 
administration, especially with rapid administration484. Prolonged therapy can result in 
Parkinsonian-like symptoms including tremor, rigidity and bradykinesia482. These 
symptoms resolve within 2-3 months of discontinuation of metoclopramide. Occasionally 
tardive dyskinesia, characterised by involuntary movements of the face, tongue or 
extremities, can be a side effect of use of long-term use of metoclopramide482. The 
incidence can vary from 1 to 15% after usage of metoclopramide for more than three 
months and may not reverse even after discontinuation of the medication. 
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In addition drowsiness, lethargy and fatigue are reported by 10% of patients and 
metoclopramide can worsen underlying depression. Blockade of central D2 receptors can 
also cause hyperprolactinaemia485. Other side-effects include restlessness, diarrhoea, 
neuroleptic malignant syndrome, rashes, pruritus, oedema, and rarely 
methaemoglobinaemia. Most of these side-effects are fully reversible with discontinuation 
of metclopramide. 
 
1.8.3. Trials done to assess the efficacy of metoclopramide in the prevention of 
aspiration and pneumonia in patients who are fed via nasogastric tubes. 
While there are good reasons to hypothesize that metoclopramide could reduce aspiration 
and pneumonia in acute stroke patients who are fed via nasogastric tubes, an extensive 
literature search in databases such as Medline, Mednet, Cochrane library and CINAHL did 
not reveal any clinical trials to support the use of metoclopramide in this patient group. The 
search reviewed articles from 1960 to 2010 and the key word which were used are stroke, 
aspiration, pneumonia, nasogastric feeds, enteral feeds, gastro oesophageal reflux and 
metoclopramide. There were studies using metoclopramide to reduce the intolerance of 
enteral nutrition therapy in critically ill traumatic brain injury patients and patients in 
intensive care units. However, the studies reviewed only the actions of metoclopramide on 
residual gastric volumes and improvement on achieving nasogastric feed targets rather than 
its effect on aspiration and pneumonia155;486;487.  
 The closest was a study by Yavagal et al to assess the effect of metoclopramide in the 
prevention of pneumonia in critically ill patients receiving nasogastric feeds in an intensive 
care unit (ICU)488. It was a randomised controlled trial of 305 consecutive patients admitted 
to the ICU who required nasogastric feeding within 24 hours of admission to the unit. 
Metoclopramide was administered via the nasogastric tube, at a dose of 10 mg every eight 
hourly. A total of 174 patients received the placebo and 131 patients received 
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metoclopramide. The patient population was predominantly post-operative, many 
following intra-abdominal surgery and the average age was 35. The majority had 
endotracheal intubation, tracheostomy and mechanical ventilation. The study showed that 
metoclopramide did not decrease the rate of pneumonia nor had any effect on the mortality. 
However, there was a statistically significant (p = 0.006) delay of 1.5 days in the 
development of pneumonia in the treatment group. The study population of this study was 
significantly different to an average patient on a stroke unit as these patients were younger, 
had more co-morbidity and have various contributory factors that would favour 
gastroparesis and reflux such as intubation and mechanical ventilation. Therefore it is 
possible that patients managed on a stroke ward may have different outcomes when treated 
with metoclopramide. Also the study did not encounter any major side-effects of 
metoclopramide. Therefore a study to test the effect of metoclopramide on the incidence of 
aspiration and pneumonia in acute stroke patients fed via nasogastric tubes can be justified. 
 
1.9. Summary of the evidence  
Stroke is the third leading cause of mortality in England and Wales. In patients who survive 
the initial cerebral injury medical complications, such as aspiration pneumonia, pulmonary 
embolism, and urinary tract infections are the most likely causes of death. Amongst these 
pneumonia is the most common and the leading cause of increased length of stay, poor 
neurological outcome, morbidity and mortality. Pneumonia also affects the nutritional state, 
as recurrent aspiration can result in interruption of feeds, which further compromises 
recovery. Therefore, an intervention that reduces aspiration and pneumonia would be 
expected to improve recovery, mortality and long term clinical outcome in patients with 
acute stroke. 
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Dysphagia following acute stroke is common with an incidence up to 70%. Aspiration and 
pneumonia are common complications of dysphagia with incidence ranging of 25% to 
55%. Aspiration can cause pneumonia either by aspiration of oropharyngeal secretions 
colonized by pathogenic bacteria. Severely dysphagic patients or patients who are too 
drowsy are kept nil by mouth and fed via nasogastric tubes to avoid aspiration. However, 
nasogastric feeding itself is still associated with a significant risk of aspiration and high 
incidence of pneumonia. Several studies have demonstrated that nasogastric feeds increases 
the risk of pneumonia by more than six fold.  
 
Oropharyngeal pooling, re-colonisation of oropharyngeal mucosa by pathogenic Gram 
negative bacteria and micro aspiration of oropharyngeal secretions are recognised 
contributors towards the development of post-stroke pneumonia and will continue in spite 
of presence of a nasogastric tube. In addition, there is a significant reduction in lower 
oesophageal sphincter tone and gastric motility following stroke. This is partly due to the 
initial neurological injury and partly secondary to circulating stress hormones following 
acute stroke. These result in reduced peristalsis of the stomach, gastroparesis, increased 
gastric volumes, gastro-oesophageal sphincter dysfunction and gastro-oesophageal reflux. 
Regurgitation of stomach contents to an already dysfunctional pharynx and micro-
aspiration of this material also significantly contribute to the development of post-stroke 
pneumonia. In addition, the presence of a nasogastric tube through the lower oesophageal 
sphincter has been shown to further impair sphincter function and worsen regurgitation.  
 
Regurgitated gastric contents are a significant cause of pneumonia in patients fed via 
nasogastric tubes. It can be argued that this micro-aspiration should not cause pneumonia 
as the gastric acid usually prevents growth of bacteria. However, acidic gastric aspirates 
can damage the lung tissue which is then at risk of being secondarily infected. More 
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commonly, patients who are fed via nasogastric tubes have a higher gastric pH due to the 
neutralisation of gastric acid by the feeds. This promotes colonisation of the gastric 
contents with potentially pathogenic organisms such as Gram negative bacteria and 
Staphylococcus aureus. Analysis of the bacterial composition of the oropharynx and the 
gastric contents in patients who are fed via nasogastric tubes indicates passage of 
pathogenic bacteria in both directions. Biofilm formation on the nasogastric tube has also 
been suggested as a factor.  
 
Several interventions to reduce aspiration and pneumonia in stroke patients have been 
tested. These include maintaining appropriate posture during feeds, acidification of 
stomach contents, selective gastro-intestinal decontamination, intermittent versus bolus 
feeds and preventative antibiotics. Apart from the maintenance of body posture at 30 
degrees and selective oropharyngeal decontamination, none have demonstrated a reduction 
in the incidence of pneumonia in post-stroke patients fed via nasogastric tubes. 
 
After reviewing the mechanisms responsible for gastro- oesophageal dysfunction and 
aspiration following stroke, it can be postulated that an agent that improves forward gastric 
peristalsis, and increases gastro-oesophageal sphincter tone could reduce reflux and 
aspiration. Metoclopramide is a commonly used prokinetic agent which acts on the 
dopamine D2 receptors in the upper gastrointestinal tract and antagonises the inhibitory 
effects of dopamine on the upper gastrointestinal tract. Therefore metoclopramide can 
increase the lower oesophageal sphincter pressure, gastric tone and gastric antral 
contractility. All these mechanisms accelerate gastric emptying, reduce gastric stasis, 
increase lower oesophageal sphincter tone and reduce gastro-oesophageal reflux. The 
rationale behind the MAPS trial is that metoclopramide would reduce reflux and aspiration 
of stomach contents into the respiratory tract and therefore would reduce the incidence of 
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pneumonia in acute stroke patients. The only study that tested the effect of metoclopramide 
in patients receiving nasogastric feeds was done on an ITU and demonstrated that 
metoclopramide significantly delayed the onset of pneumonia. As there was some 
beneficial effect, it is justified to test the effect of metoclopramide in patients with acute 
strokes who are fed via nasogastric tubes. In addition, as stroke patients are older it is 
possible that many of these already have gastro-oesophageal reflux which would be made 
worse by the stroke and a nasogastric tube. Also as they did not encounter any significant 
side effects when used in the recommended doses, it gives the reassurance of the safety of 
metoclopramide when used in this patient population. Therefore MAPS study was designed 
to test the efficacy of metoclopramide in reducing aspiration and pneumonia in acute stroke 
patients who are fed via nasogastric tubes. 
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Chapter 2 Aims and Structure of the thesis  
 
Aims of this study:  
• To test whether metoclopramide can reduce aspiration and pneumonia in acute 
stroke patients who are fed via nasogastric tubes in a randomised control trial 
•  To conduct a secondary analysis of data collected for the diagnosis of pneumonia 
as part of the study above, to identify early predictors of post-stroke pneumonia 
 
Hypotheses to be tested: 
• Regular treatment with the prokinetic agent metoclopramide prevents aspiration, 
pneumonia and hypoxia in stroke patients fed via nasogastric tubes 
• An increased respiratory rate and a drop in oxygen saturations are good predictors 
of pneumonia in acute stroke patients  
• A raised CRP level can be used as a biochemical marker for early diagnosis of 
pneumonia in acute stroke patients  
 
Chapter structure  
• The effect of metoclopramide on the incidence of pneumonia in stroke patients who 
are fed via nasogastric tubes: the MAPS study (chapter 3) 
• Secondary analysis of data from the MAPS study relating to signs and symptoms of 
pneumonia for the early diagnosis of  post-stroke pneumonia (chapter 4) 
• A general discussion and conclusion (chapter 5) 
 
These studies will add to the limited body of knowledge on prevention of pneumonia in 
stroke patients fed via nasogastric tubes and early predictors of post-stroke pneumonia. 
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Chapter 3  MAPS study 
 
Abstract - Does Metoclopramide reduce Pneumonia in acute Stroke 
Patients fed via nasogastric tubes? (MAPS study) 
 
Introduction: Aspiration and pneumonia is a common problem in dysphagic patients fed 
via nasogastric tubes. This is partly due to continued aspiration of infected oropharyngeal 
secretion and partly due to aspiration of refluxed gastric contents, secondary to lower 
oesophageal sphincter dysfunction, gastroparesis, and regurgitation which follows acute 
stroke. Metoclopramide, a dopamine-2 receptor antagonist of the upper gastrointestinal 
tract increases lower oesophageal sphincter tone, improves gastric contractions, and 
forward peristalsis of the stomach. In theory it should reduce reflux, therefore aspiration 
and pneumonia in this patient population. The aims of the study were to assess whether 
regular treatment with metoclopramide reduces the incidence of pneumonia in acute stroke 
patients fed via nasogastric tubes.  
 
Methods: This is a double-blind randomised controlled trial. Patients within 7 days of 
admission with an acute stroke who needed nasogastric feeds and did not have signs of 
pneumonia were randomized to 10 mg metoclopramide or placebo three times daily via the 
nasogastric tube for 21 days or until nasogastric feeds were discontinued. Participants were 
examined daily for clinical evidence of pneumonia. A diagnosis of pneumonia was made 
when a patient had clinical signs of pneumonia, high inflammatory markers, and new 
radiological features of chest infection using radiography. 
 
Results: Sixty patients (mean age 78 years, 22 males, mean NIHSS 19) were randomized 
(metoclopramide n = 30, placebo n = 30). Pneumonia was diagnosed in 26/30 and 08/30 in 
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placebo group and treatment group respectively (p <0.001). The rate of aspiration, lowest 
oxygen saturation, highest C-reactive protein, highest white blood cell count, and NIHSS 
score were also significantly lower in the metoclopramide group. The study could not show 
any statistical difference in mortality between the two groups. 
 
Conclusion: This study has shown metoclopramide to improve clinical outcomes in 
patients fed via NGT. The findings of this study should be confirmed in a larger study. 
. 
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3.1. Introduction 
As already described, pneumonia is common in acute stroke patients who are fed via 
nasogastric tubes and any intervention that can prevent pneumonia will contribute to better 
patient recovery and survival. In this chapter, the design and the results of the effect of 
metoclopramide on the incidence of pneumonia in acute stroke patients who have rely on 
nasogastric feeds for their survival will be reported. 
 
3.2. Methodology 
3.2.1. Study design and setting 
This was a randomized, double-blind placebo-controlled clinical trial which was conducted 
in the Acute Stroke Unit of University Hospital of North Staffordshire, Stoke-on-Trent. 
This is a 32 bed unit which has 16 male and 16 female beds. Patients are admitted to the 
unit via the Accident and Emergency Department, the Emergency Assessment Unit, the 
Medical Receiving Area and via other wards. About 900-1000 acute stroke patients are 
admitted per annum to the University Hospital of North Staffordshire Hospital, and of these 
admissions over 90% are admitted directly to the stroke unit.  
 
3.2.2. Recruitment 
All acute stroke patients admitted to the Acute Stroke Unit were eligible for recruitment. 
All these patients initially presented to the Accident and Emergency Department with 
sudden onset of focal neurology which was suggestive of an acute stroke. The majority of 
these patients were identified in the community by the paramedics and brought to the 
Accident and Emergency Department as a medical emergency. All patients with a 
suspected stroke were assessed by an experienced doctor to establish a clinical diagnosis of 
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a stroke. Patients with clinical signs and symptoms of acute stroke underwent an urgent CT 
scan of the brain within four hours of presenting. A combination of signs and symptoms 
and CT scan findings was used to formally diagnose acute strokes and the aetiology. All 
patients whose clinical features confirmed by neuro-imaging were transferred to the Stroke 
Unit. Non-stroke diagnoses such as subdural haemorrhages and cerebral tumours which 
would have presented with similar neurological signs were identified after the review of CT 
images and were referred to appropriate specialities. 
 
Bedside swallowing assessment according to unit policies was performed in all patients. 
Patients who fail the swallowing test or remained too drowsy to be tested were kept nil by 
mouth and nasogastric feeds were considered, unless the patient was moribund and feeding 
was not considered appropriate. Patients on the stroke unit who required a nasogastric tube 
for feeding were eligible for enrolment in the MAPS trial. All patients who needed a 
nasogastric tube were reviewed by the researcher as possible recruits for the MAPS study. 
This included a complete physical examination and review of their case notes. Patients who 
had already been diagnosed as having a lower respiratory tract infection or pneumonia or 
who had other exclusion criteria were excluded from recruitment. As the unit provided a 
seven day acute stroke service and the researcher worked seven days a week during the trial 
period (apart from holidays), most of the acute stroke patients could be reviewed for the 
suitability for the MAPS study on the day of admission to the stroke unit. Patients with 
advanced malignancy or patients who were commenced on the Liverpool care pathway for 
dying on admission due to severe strokes with multiple co-morbidities were not recruited as 
they would not live long enough to the completion of the trial. In patients with a severe 
stroke (NIHSS >30), recruitment was not considered if the patient’s family had a strong 
opinion that the patient should only have symptomatic/palliative treatment due to either 
patient’s previous wishes or as a collective family decision. Such patients were not 
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considered to have active treatment such as nasogastric feeds or antibiotics. Recruitment of 
other brain pathologies such as brain tumours and brain abscesses which can mimic 
vascular strokes due to their focal neurological signs was averted as all patients were 
scanned on admission.  
 
During the period of research application process for the MAPS trial, metoclopramide was 
widely used in clinical practice as an antiemetic and a prokinetic agent in many disease 
conditions and there was no time limit on its usage. For the MAPS trial metoclopramide 
was used for these therapeutic effects over a period of three weeks. Therefore an 
authorisation was obtained from the Medicine and Healthcare products Regulatory Agency 
(MHRA) for the MAPS trial as a phase 4 clinical trial. The study was approved by the by 
the North Staffordshire Local Ethics Committee on 26th July 2007 and the North 
Staffordshire Research and Development Consortium granted permission for the research 
to be conducted on 10th August 2007 (REC reference number is 07/Q2604/41).  
  
3.2.3. Inclusion criteria  
All adult patients admitted to the Acute Stroke Unit were considered for enrolment into the 
study if they required placement of a nasogastric tube for enteral feeding and if they could 
be recruited either before or within 48 hours of insertion of the nasogastric tube, no longer 
than a week had passed since the stroke,  
 
3.2.4. Exclusion criteria 
• Patients who had a nasogastric tube in place for more than two days  
• More than seven days following the stroke 
• Patients with signs and symptoms of a chest infection before recruitment  
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• Patients with a known oesophageal stricture or a carcinoma which would interfere 
with the insertion of a nasogastric tube 
• Patients with terminal illnesses such as advanced malignancies  
• Patients on concurrent dopaminergic drugs  
• Patients with a history of neurodegenerative condition which should affect 
swallowing e.g. Parkinson’s disease and motor neurone disease 
• Patients who had presented as strokes, but later were diagnosed to have a non stroke 
pathology (e.g. brain tumour) were excluded retrospectively  
• Pregnancy  
• Patients recruited to another study 
• Patients where a decision not to treat actively had been made either due to poor 
chances of survival due to severity of the stroke or because of the patient’s prior 
expressed wishes 
• Known contraindications for the use of metoclopramide: Gastro-intestinal 
obstruction, perforation or haemorrhage; recent gastro-intestinal surgery; 
phaeochromocytoma; breast-feeding398 
 
3.2.5. Consent  
Patients and their next of kin were approached for the recruitment to the trial. Consent was 
sought from the patients if they were competent to give fully informed consent. For 
incompetent patients assent was sought from the next of kin. Consent was obtained at the 
earliest possible time if trial inclusion criteria were met. The principles of informed consent 
in the current edition of declaration of Helsinki were used as guidance489. Information was 
given about the aim, objectives intervention, possible side effects, planned observations 
and follow up procedures of the study. Information was provided verbally and in writing, 
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using clear and understandable language. Oral explanations were given if further 
information was needed. Adequate time and opportunity was given to read and ask 
questions before signing the consent form. In competent patients who had difficulties in 
signing due to right upper limb weakness a partial signature or some written sign on the 
consent paper was accepted. Such signatures were always witnessed by an independent 
member of staff. The consent form was dated and kept with the patient’s notes. A second 
copy was kept in the research file. After consent or assent was obtained patients were 
randomised to the trial and an entry was made in the patient’s case notes documenting 
recruitment to the trial. 
 
3.2.6. Randomisation  
Patients were given an identification recruitment number sequentially from one. Sixty 
patients were randomised by the lead of the research network who was independent from 
the study. This randomisation was done by numbered cards at a ratio of 1:1, 
metoclopramide: placebo. Sixty identical cards numbered 1 – 60 were placed in a 
cardboard box for the intended sixty patients. The stroke research network member who 
was independent from the study pulled out 30 cards out of the box. They were allocated to 
metoclopramide 10 mg and the remaining 30 cards were allocated to placebo. The 
randomisation was done in the presence of three independent witnesses and the researcher 
had no part in the randomisation process. Each card, with the randomisation number and 
the treatment option was placed in identically numbered, sealed opaque envelopes. In 
addition, the randomisation number and the treatment options were written in a confidential 
log, which was also sealed and was only was opened at the end of the trial when the trial 
was unblinded. All sixty envelopes were kept in a locked cabinet in a secure room to which 
the researcher had no access. After recruiting a patient the researcher informed the research 
office of the recruitment and the patient’s details. A member of staff in the office then 
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released the numbered opaque envelope with the patient’s recruitment number written 
outside and the treatment instruction (metoclopramide 10 mg TDS or placebo) inside. In 
addition the patient’s details and the recruitment number were recorded in a separate log in 
the research office.  
 
3.2.7. Blinding  
This study was conducted as a double blind trial. The trial treatment was prescribed on the 
patient’s prescription chart by the researcher, as “Metoclopramide trial drug 
(metoclopramide 10 mg or placebo) per nasogastric tube TDS as detailed in the trial 
envelope (trial number 07/Q2604/41). The sealed randomisation envelope was taken by the 
researcher from the research office following randomisation and handed to the nurse in 
charge on the acute stroke unit. The nurse in charge opened the envelope after confirming 
with another senior nurse or a doctor that it was sealed at the time of handing over. The 
envelopes with the treatment instruction were kept in the locked drug trolley. The drug 
trolley is always kept locked or when opened is observed by the nurse responsible for the 
drug round. The researcher had no access to the drug trolley or its keys. The nurse who 
does the drug round administered metoclopramide or placebo as instructed in the envelope, 
sign the prescription chart to confirm the drug administration and returned the envelope 
back to the drug trolley. Recruitment of a patient to the MAPS study was added on to the 
daily nurses hand-over sheet to ensure all nurses would be aware of the recruitment and the 
need to administer a trial drug according to the instructions in the sealed envelop in the 
drug trolley. Neither the patient nor the researcher knew which treatment was administered 
to the patient. Once the treatment period was complete the envelope was sealed and 
returned to the research office by a senior staff nurse of the unit. 
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The nurse administering the study drug was not blinded to the treatment options. However, 
the research team and the rest of the team who were involved in the patients’ care were 
blinded to the treatment options. Most of the nursed on the stroke unit are experienced 
nurses and are fully aware of the importance of blinding process of a double blinded 
randomised control trial. However, there was potential for inadvertent unmasking of 
treatment allocation, especially when requesting medication from the pharmacy and when 
the treatment chart monitoring was done by the ward pharmacist. Therefore to overcome 
this potential problem and possible bias, independent assessors were used for interpretation 
of chest radiographs and for the diagnosis of pneumonia. 
  
3.2.8. Intervention 
Patients were randomized to one of two groups: 
1) The intervention group: colourless metoclopramide syrup 10 mg tds (08:00, 15:00, and 
21:00) via the nasogastric tube for 3 weeks or until discontinuation of nasogastric 
feeding 
2) The control group: normal saline 10 ml via nasogastric tube tds (08:00, 15:00, and 
21:00) for 3 weeks or until discontinuation of nasogastric feeding 
 
The dose of metoclopramide used in this study is the standard recommended dose 
according to the British National Formulary398. Colourless metoclopramide syrup was 
supplied by the Hospital Pharmacy Department free of charge as a good will gesture to 
support this student project. Following randomisation a nasogastric tube was inserted by 
Acute Stroke Unit staff if the tube was not already present, according to Stroke Unit 
protocol. Insertion of a nasogastric tube and its maintenance was not part of the trial.  
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Other than the above mentioned treatment, a daily examination for pneumonia and the 
weekly observations done for three weeks which have been detailed later in the chapter, no 
other intervention was done as a part of the trial. All other management and care related to 
nasogastric tubes, type of nasogastric feeds, volume of feeds, safety issues regarding 
nasogastric tube placement and dietician review were done as routine patient care. All 
patients received standard stroke care according to Royal College of Physicians guidelines 
and local guidelines which included early mobilisation, daily physiotherapy and 
occupational therapy assessment, chest physiotherapy as required, regular attention to 
positioning and turning, and oropharyngeal suctioning, as required. None of the above 
mentioned care standards were altered for the purpose of the trial. Treatment of pneumonia 
or any other infection was according to the standard antibiotic policy of the hospital.  
 
3.2.9. Care of nasogastric feeding and post-stroke care received by MAPS participants 
At the University Hospital of North Staffordshire, bedside swallowing assessment (Level 1 
swallowing test) in post-stroke patients was performed similar to method described by 
Smithard (described in section 1.6.1.4), as it is safe, easily repeated and straightforward to 
perform109. Patients who are comatose or too drowsy to be assessed for the safety of their 
swallow and patients who are identified as being at high risk of aspiration by bedside 
swallowing tests were kept nil by mouth and a flexible polyurethane nasogastric tube, with 
an inner diameter of 10 mm unless otherwise indicated (Medicina NG tubes, Medicina, 
Bolton, United Kingdom) was inserted by a doctor or a senior staff nurse. The same type of 
nasogastric tube was used in all patients. After initial placement correct position of the tube 
was confirmed by a chest X-ray or by pH testing (pH testing strips, Medicina, Bolton, 
United Kingdom) as per the nasogastric feeding protocol. (appendix14) All patients were 
positioned in semi-reclined position throughout the nasogastric feeds and three hours after 
the feed. Being on nasogastric feeds did not preclude patients from being sat out or 
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receiving therapy input. Nasogastric feeds were not interrupted during therapy sessions. 
Nasogastric feeds which were continuous rather than bolus feeds, were commenced in the 
morning after the patients were washed to reduce the effect of changes of body posture on 
aspiration and as general patient’s care is easier in this position. Feeding overnight was not 
routinely carried out as patients cannot be observed for feed-related complications. The 
amount and type of nasogastric feeds was calculated by a dietician according to the 
patient’s nutritional requirements and other parameters such as serum electrolytes, presence 
of lactose intolerance, renal function and the severity of hypo-albuminaemia415. Patients 
who were fed via nasogastric tubes were managed closer to the nurses’ station so that they 
could be observed for complications such as vomiting and displacement of the nasogastric 
tube. When necessary, soft mittens were applied after consent from the next of kin to 
restless patients to prevent patients pulling at their nasogastric tubes. Reinsertion of a 
nasogastric tube when displaced, confirmation of the position before each feed and 
application of mittens to prevent a restless patient pulling out the tube were part of routine 
patient care on the ward (appendix 14). Patients’ other medications were continued as 
routine care.  
 
If a patient developed aspiration pneumonia antibiotics were commenced according to local 
guidelines. The initial choice was co-amoxiclav and clarithromycin if the pneumonia 
occurred within 48 hours of admission. This was changed to Tazocin 
(piperacillin/tazobactam) if there was no clinical improvement as determined by clinical 
examination and laboratory investigations. A pneumonia which occurred more than 48 
hours after admission was treated initially with Tazocin. Metronidazole was added to the 
antibiotic regime routinely to cover anaerobic bacteria. Patients who were allergic to 
penicillin were treated with clarithromycin as the first line antibiotic and aztreonam if there 
was a poor response. Sputum was sent for culture and sensitivities, and antibiotics were 
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changed according to sensitivities. Most sputum samples were obtained during chest 
physiotherapy or oropharyngeal suctioning. Regular chest physiotherapy and suctioning of 
the upper airways was done as required. Nasogastric feeds were continued uninterrupted 
during episodes of pneumonia, as long as the correct placement of the tube was confirmed.  
 
Use of other anti-emetics, ACE inhibitors and catheters 
If an antiemetic was needed for clinical reasons, only non-prokinetic agents were used in 
trial patients and were prescribed in the ‘as required’ section of the prescription chart. This 
is again part of routine patient care. Cyclizine 50 mg, three times a day was the alternative 
antiemetic used in these patients. If a patient required a prokinetic agent for clinical 
reasons, the trial code was to be broken, and treatment was to be given as clinically 
indicated. However, such need did not arise during the trial. The use of other antiemetics 
was recorded during the trial. ACE inhibitors were the preferred antihypertensive agent if 
there were no contraindications as they have shown to improve mortality in stroke patients. 
Erythromycin is an antibiotic which has prokinetic properties and the plan was to use an 
alternative antibiotic for infections needing a Gram positive cover. However, there was no 
indication for the use of erythromycin on the patients as hospital guidelines had 
recommended the use of clarithromycin in the treatment of pneumonia.  
 
The unit adhere a “minimal catheter” policy, and urinary incontinence was managed with 
incontinence pads rather than by indwelling catheters to reduce urinary tract infections. 
However, in the presence of signs and symptoms of an infection, possibilities of a non-
respiratory tract infection was always considered and investigated by careful inspection of 
the cannula sites, urine dipsticks and mid stream urine culture examinations. 
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3.2.10. Assessments  
Patients were assessed at baseline and then at weekly intervals for 3 weeks.  
Baseline assessment 
• Demographic details (e.g. age, gender) 
• Date of stroke 
• Date of admission  
• Date of recruitment 
• Date of commencement of nasogastric feeds 
• Body weight 
• Level of consciousness (Glasgow Coma Scale [GCS]) at recruitment 
• Presence of other medical conditions - atrial fibrillation, hypertension, diabetes 
mellitus, heart failure (by history, examination or on more than 20 mg frusemide or 
equivalent per day), ischaemic heart disease (history of angina or myocardial 
infarction or treatment with nitrates or nicorandil) 
• Previous lung disease – e.g. chronic obstructive pulmonary disease or asthma (by 
history or from list of drugs), other chronic lung problem (e.g. pulmonary fibrosis, 
thoracoplasty, pneumoconiosis) 
• Oxygen saturation on admission to the Acute Stroke Unit and at enrolment (Milolta 3i 
pulse oximeter, Minolta Radiometric Instruments Operations, Osaka, Japan) 
• Clinical stroke syndrome (Oxfordshire Community Stroke Project [OCSP] stroke 
classification categories: total anterior circulation stroke (TACS), partial anterior 
circulation stroke (PACS), lacunar stroke and posterior circulation stroke (POCS)37 
• Full neurological examination and assessment of stroke severity (National Institute of 
Health Stroke Scale [NIHSS])490 
• Results of the CT scan of the brain (infarct, haemorrhage, normal, non specific 
changes) 
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•  Medications on admission (see below) 
• Current use of antibiotics and the reasons for its usage. Use of antibiotics at the time of 
recruitment were recorded as it could have an impact on the patients’ susceptibility to 
pneumonia and possible side effects such as Clostridium difficile 
• Baseline inflammatory markers e.g. WBC, CRP, ESR 
 
Only medications which were thought to be of relevance to the trial were recorded. 
Cardiovascular medications recorded included diuretics, digoxin, antihypertensives and 
antianginals as they were indicative of cardiovascular co-morbidity. Angiotensin 
converting enzyme inhibitors (ACEI), angiotensin receptor blockers were listed separately 
as they have been shown to improve swallowing and reduce the incidence of pneumonia, 
and will be required in secondary analysis of results. Proton pump inhibitor intake was 
recorded as this affects the pH of gastric secretions and promotes bacterial colonisation of 
the stomach. In addition, the presence of medications which affect the respiratory system, 
such as bronchodilators, medications with anti-cholinergic actions [antidepressants, bladder 
stabilizing agents, tranquillizers, antihistamines] and sedatives [hypnotics, tranquillizers, 
antihistamines] was recorded. 
 
3.2.11. Follow-up  
The maximum period of patient followed up was 3 weeks.  All patients were examined 
daily for the presence of pneumonia until they were enteraly fed and were on the trial 
medication. In addition, detailed assessments were made at the end of week 1, 2 and 3. 
Permanent removal of the nasogastric tube for whatever reason (swallowing improvement 
or withdrawal of treatment), transfer out of the Acute Stroke Unit to another unit, or 
completion of the 3 weeks in the study were considered as the end of the trial as for trial 
medication administration and daily clinical examination. However, even if the nasogastric 
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feeds were discontinued before the end of third week, all patients had a weekly review for 
presence of pneumonia. This weekly review also included a case-note review to record any 
diagnosis of pneumonia made by the clinical team managing the patient. In addition all 
formal reports of chest radiographs and inflammatory marker levels were recorded of these 
patients. 
 
Week 1 and 2 assessment:  
• Five minute pulse oximetry in the morning at rest 
• Routine observation – pulse, blood pressure and temperature  
• Lowest oxygen saturation for the week 
• Highest temperature for the week 
• Number of antibiotics 
• Need for ACE inhibitors 
• Antiemetics used outside the trial 
• Neurological status- NIHSS 
 
Final (week 3) assessment: 
• As for week 1 and 2 oxygen saturation for 5 minutes, pulse and blood pressure  
• Date of the removal of nasogastric tube (if removed before the end of 21 days) 
• Reason for removal of the nasogastric tube (patient no longer requires nasogastric feeds 
as swallowing has improved, PEG tube insertion and treatment withdrawal) 
• Insertion of a non-standard nasogastric tube (yes/no, size if yes___) 
• Number of episodes of pneumonia over 3 weeks (as detailed in 3.2.1) 
• Number of episodes of witnessed aspirations over 3 weeks  
• Number of days oxygen was given 
• Number of days on NG feeds during the 3 weeks 
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• Number of days nasogastric feeds interrupted or without NG feeds during the 3 weeks 
• Number of nasogastric tubes reinserted during the trial period 
• Body weight 
• Lowest oxygen saturation during the 3 weeks 
• Number of different antibiotics given during the 3 weeks 
• Number of days of antibiotic treatment during the 3 weeks 
• Highest temperature during the 3 weeks 
• Highest WBC count during the 3 weeks 
• Highest CRP level during 3 weeks 
• Weekly NIHSS score 
• Number of days with an urinary catheter  
• Co-existing other infections e.g. UTI 
• Treatment with angiotensin converting enzyme inhibitors (yes/no) 
• Treatment with erythromycin (yes/no) 
• Use of non-trial antiemetics (yes/no) 
 
End of trial assessment:  
All the details as above and the documentation of the final outcome were made at end of 
the third week or when the nasogastric feeding was discontinued, which ever was earlier. 
Four end of trial outcomes were recorded: 
• nasogastric tube was removed as swallowing improved 
• referred for a PEG tube insertion 
• nasogastric tube removed due to withdrawal of treatment/palliation or 
commencement of the Liverpool care pathway for the dying 
• transferred out of the stroke unit 
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 Oxygen saturations were assessed for the MAPS trial by pulse oximetry. On weekly 
assessments the researcher monitored oxygen saturations over five minutes in the morning 
on room air using a pulse oximeter (Minolta 3i). While there are several other causes for 
the development of hypoxia than aspiration, it is assumed that these other causes 
(development of heart failure, pulmonary emboli, hypostatic pneumonia) will be equally 
distributed between the two groups, and the differences are therefore an indicator of 
treatment effect (e.g. prevention of aspiration), especially if they did not develop all the 
criteria for the diagnosis of pneumonia. Oxygen saturations are assessed every six hourly 
on the stroke unit on a daily basis for the first 72 hours and later according to clinical need. 
However, these results were difficult to interpret, as some of the readings were done in 
patients while being treated with oxygen. Longer (overnight) pulse oximetry was also 
considered, but was considered as technically not feasible and again would be affected by 
oxygen treatment in some patients. Weekly assessments over 5 minutes on air were 
therefore was the feasible option for the purposes of this study. 
 
3.2.12. Outcomes 
Primary outcomes 
• The number of diagnosed episodes of pneumonia (any) as detailed in section 3.2.1. 
Secondary outcomes 
• The number of episodes of witnessed aspiration  
• The number of antibiotic days 
• The number of different antibiotics prescribed 
• The highest CRP and WBC levels 
• End of trial outcomes 
• The lowest oxygen saturation 
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Figure 3-1 – MAPS Patient Flow Chart 
 
MAPS Study flow chart 
 
Acute stroke patient needing a nasogastric (NG) tube 
Patients eligible for the study 
 
• Age >18 years 
• Acute stroke within 7 days 
• No signs of chest infection 
• Recruited within 48 hours of 
nasogastric tube insertion 
 
 
Patients excluded from MAPS 
• Already has chest infection 
• Contraindication to 
metoclopramide 
• On dopaminergic 
medications 
• Terminal diagnosis 
• Oesophageal stricture / 
carcinoma 
Explained study obtain 
informed consent / assent 
Baseline assessment 
Insertion of nasogastric tube if 
not already present 
Allocation to the study 
Randomisation (n=60) 
Week 2 assessments 
Daily assessment of 
pneumonia 
Week 3 assessments and 
end of trail 
Week 1 Assessments 
Daily assessment of 
pneumonia 
 
 
 
 
 
At any 
stage 
removal 
of 
nasogast
ric tube 
– End of 
Trial 
Placebo 10 ml 
TDS (n=30) 
Metoclopramide 
10 mg TDS 
(n=30) 
Daily assessment for 
pneumonia 
End of trial 
assessment  
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3.2.13. Diagnosis of pneumonia for the MAPS Trial 
The diagnosis of pneumonia in this study was based on a combination of clinical findings, 
laboratory results and radiological features. The British Thoracic Society (BTS) 
recommendations for the diagnosing pneumonia with few additions were used for the 
diagnosis of pneumonia250. Quantification of tachypnoea as a respiratory rate above 25/min 
and hypoxia as oxygen saturation less than 90% on room air were added on to the 
symptoms and changes in the white blood cell count and elevated inflammatory markers 
were added on to the systemic features. These modifications were added following the 
recommendations made by the local ethics committee. The rest of the criteria remained 
unaltered. Therefore diagnosis of pneumonia for the MAPS trial was made following if the 
patient fulfilled at least one of each four criteria listed below. 
1) Symptoms of an acute lower respiratory tract illness (at least one of – cough, 
Respiratory rate over 25 per minute, sputum production or presence of hypoxia 
with oxygen saturation less than 90% on room air). 
2) New focal chest signs on examination (new inspiratory crackles, bronchial 
breathing or signs of consolidation). 
3) At least one systemic feature – fever over 38°C, shivers, rigors, leucocytosis 
(>11000 /ml) or leucopenia (<3000 /ml) or elevated inflammatory markers e.g. 
CRP  
4) Radiological shadowing which includes at least in one segment and was not known 
to be previously present. 
 
Each patient in the study was examined once a day, including weekends, by the researcher 
and this included a comprehensive examination of the respiratory system as detailed below.  
i) Baseline observations - pulse, blood pressure, oxygen saturation, temperature and 
respiratory rate 
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ii) Chest examination – percussion for dullness, auscultation for bronchial breathing 
and inspiratory crackles  
iii) Need for suctioning due to increased respiratory secretions and the presence of 
purulent sputum was noted  
 
A CRP level above a cut-off level of 30 mg/l was considered as elevated. Clinical suspicion 
of pneumonia was defined as either the presence of two or more signs such as hypoxia with 
an oxygen saturation of less than 90% or a drop in the saturation of more than 3%, a 
respiratory rate of more than 25 per minute, a rise in of temperature more than 38°C and 
new chest signs on auscultation. Productive cough with purulent sputum or the presence of 
purulent sputum during chest physiotherapy or during oropharyngeal suctioning was also 
considered as a sign of a chest infection. Changes in oxygenation were assessed by pulse 
oximetry. In addition, evidence supporting a diagnosis of pneumonia was taken from the 
medical notes if the diagnosis had already been made by another doctor. In all patients who 
were recruited to the trial, another doctor on the ward was asked to examine the patient to 
confirm chest signs if the researcher found any abnormal signs. This was usually a medical 
registrar attached to the Stroke Unit. A chest radiograph and a blood test for CRP and a full 
blood count were requested as part of routine clinical care in all patients with suspected 
pneumonia if they had localising chest signs on examination. Even without localising chest 
signs, if the clinical suspicion of pneumonia was high, these investigations were requested, 
which is the usual ward practice for the early diagnosis of pneumonia. If there was purulent 
sputum a sample was sent to the microbiology laboratory for culture and sensitivities. The 
final diagnosis of pneumonia was made by an independent senior doctor after reviewing the 
symptoms, physical signs, blood results and the chest radiograph. This was usually the 
stroke consultant responsible for the management of the patient. As for the trial purposes, 
the diagnosis of pneumonia was recorded only after consultant confirmation. Patients who 
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had clinical signs of pneumonia without new infiltrates in the chest radiograph were 
classified as having a probable pneumonia and patients who had a clinical diagnosis of 
pneumonia with new infiltrates in the chest radiograph were classified as having a definite 
pneumonia. For this study aspiration pneumonia was diagnosed if the patient developed 
pneumonia according to the modified BTS criteria following an observed or suspected 
episode of vomiting or aspiration. Aspiration was diagnosed either if aspiration was 
witnessed by ward staff or if nasogastric feed was noticed in the respiratory secretions on 
suctioning or during chest physiotherapy.  
 
The lowest oxygen saturations were documented on air prior to administration of oxygen. 
If the patient was already on oxygen, observation charts were used to obtain saturations on 
air prior to the commencement on oxygen therapy. This was mainly in patients who had 
low oxygen saturations at night and when oxygen treatment was commenced prior to the 
ward team review of the patient on the morning ward rounds. Such patients’ oxygen 
therapy was not discontinued to record of the lowest oxygen saturations for the purpose of 
the trial, as it was thought unethical and may cause undue distress or deterioration of the 
patient’s condition. The lowest oxygen saturation while on oxygen was not recorded as the 
concentration of oxygen treatment varied and all were adjusted to maintain saturations 
above 94%. However, if there were episodes where the patient was without oxygen due to 
being restless and accidently removing the oxygen therapy device, these opportunities were 
used as soon as possible to record the oxygen saturation on air. 
 
All episodes of pneumonia were treated with intravenous antibiotics according to the local 
guidelines. Initial treatment was intravenous co-amoxiclav 1.2 g three times a day and 
clarithromycin 500 mg twice a day if the pneumonia was within few days of hospital 
admission and did not fulfil the criteria for severe pneumonia. If the onset of pneumonia 
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was more than a few days after admission or the patient had signs of a severe pneumonia 
the choice of antibiotic was intravenous Tazocin, as this was the first line of antibiotic for 
severe hospital acquired pneumonia according to the hospital guidelines. As silent 
aspiration plays a significant role in most stroke associated pneumonias, metronidazole was 
commonly added to the antibiotic combination. If there was a poor response to the initial 
antibiotic combination, which was suggested by a poor clinical response and the absence of 
a fall or a continuing rise of the inflammatory markers, antibiotics were changed according 
to advice of a consultant microbiologist. Poor response to co-amoxiclav and clarithromycin 
was commonly encountered and the second line of antibiotics was either Tazocin or 
meropenem. Aztreonam or levofloxacin were used in patients who were allergic to 
penicillin. Patients were examined daily and the examination findings were recorded in the 
patient’s case notes. These measures were done as part of routine clinical practice. A C-
reactive protein reading over 30 mg/l was considered as significantly elevated for the 
MAPS trial. This figure was obtained by review of previous research papers 264;266. A white 
cell count (WBC) over 11 x 106/ml was considered as elevated. The response to the 
antibiotics was defined as normalisation of the WBC and a 50% or more reduction of the 
CRP value from its highest within five days of starting antibiotics, together with the 
normalisation of the body temperature, a reduction of chest signs, a reduction in the colour 
and volume of sputum and the ability to wean off the supplementary oxygen therapy, if 
used, to maintain oxygen saturations above 94% on air. This is again was standard clinical 
practice on the unit.  
 
As for the research, data were recorded in separate data sheets allocated to each patient, in 
addition to entries made in the case notes. Baseline observations, inflammatory markers (if 
available) and chest signs were recorded in data sheets for all patients on recruitment and 
on day 4, 7, day 14 and day 21. If the end of the trial was earlier than the day 21, these 
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observations were recorded on that day. If there were no positive chest signs it was noted as 
chest was clear in the trial log. If a diagnosis of pneumonia was made, all physical signs 
were recorded on the day of diagnosis and at the end of the course of antibiotics were 
recorded in the patients’ research data sheet. In addition the vital signs and chest signs on 
the day prior to the pneumonia were taken from the case notes and from the observation 
charts and were recorded in the research data sheets. All CRP and white cell counts done 
during the trial period irrespective of presence of pneumonia were recorded in the data 
sheets. 
 
3.2.14. Plans for drop-outs and missing data 
Patients who would withdraw consent / assent, intervention needed to be discontinued due 
to side-effects and patients who would be transferred out to another unit were the possible 
drop-outs. Non-compliance was not expected as the trial medication was administered 
regularly by the nursing staff. Data and outcome measures of patients who had to be 
withdrawn from the trial due to withdrawal of consent / assent or due to side-effects were 
to be included in the final analysis until the day of withdrawal from the trial. All relevant 
data and outcome measures of patients who were transferred out from the stroke unit were 
to be used in the analysis from the recruitment to the point of transfer. In addition, local 
hospitals were to be contacted on the 21st day from recruitment to assess whether the 
patients were alive and whether they still required enteral feeds. These details were to be 
included in the final analysis. However, details of further episodes of pneumonia, courses 
of antibiotics and their neurological status were not to be included in the final analysis as 
trial intervention and observations end at the point of transfer. Patients with no outcomes 
were not expected as the outcomes were assessed in a dichotomised yes/no response for the 
presence of pneumonia and aspiration. Every effort was made to minimise missing data. 
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However, if there were missing data, retrospective case note review was planned to obtain 
such data.     
 
3.2.15. Statistical methods 
Data entry and analyses were conducted in SPSS 21 (Armonk, NY: IBM Corporation) and 
Stata 13 (College Station, TX: StataCorp). The efficacy of metoclopramide in reducing 
post-stroke pneumonia was investigated using the intention-to-treat approach. Intention-to-
treat analysis was chosen as it provides an unbiased comparison of the two study 
populations and to avoid effects of drop-outs. Though poor compliance was not expected in 
the MAPS trial, using intention-to-treat analysis does not require observation of 
compliance status or incorporation of compliance into the analysis. Normally distributed 
interval data were described using means and standard deviations, non-normal data or 
ordinal data were described using medians and inter-quartile ranges, and nominal data were 
expressed as percentages.  
 
Initially the treatment group and the placebo groups were compared for baseline 
demographics, neurological scores, CT findings, previous illnesses and previous lung 
pathologies to assess for baseline imbalances between the two groups. Later the two groups 
were compared in relation to the outcome variables such as episodes of pneumonia, 
episodes of aspiration, highest WBC and CRP, the number of different antibiotics 
prescribed, number of days of antibiotic treatment, NIHSS scores at the end of the trial 
period and the lowest oxygen saturations. Three final outcome variables namely 
nasogastric tube removal as improvement of swallowing, referral for insertion of a PEG 
tube, and withdrawal of treatment as terminally ill, were compared between the two 
groups.  
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During statistical analysis outcomes were adjusted for age and baseline NIHSS score, as 
pre-specified covariates. Missing values were imputed through multiple imputation, on a 
‘missing at random’ assumption, using ten imputed datasets. The primary outcome – 
number of episodes of pneumonia – was compared between groups using a Poisson 
regression model, with estimates reported as rate ratios (RRs). A similar analysis was 
applied to the number of aspirations, but owing to zero-inflation a negative binomial 
regression model was applied to the number of days of antibiotic treatment. Mortality and 
final clinical outcome were analysed using binary and multinomial logistic regression, 
respectively, with estimates reported as odds ratios (ORs). Follow-up NIHSS scores and 
lowest oxygen saturation values were analysed using analysis of covariance and reported 
as mean differences. Highest WBC and highest CRP did not satisfy the distributional 
assumptions of analysis of covariance and therefore were first log-transformed; these 
estimates were expressed as fold changes.  
 
A sensitivity analysis was performed for all outcomes by calculating unadjusted estimates. 
Statistical significance was set at p ≤ 0.05 (two-tailed) and 95% confidence intervals were 
calculated for estimates of treatment effect.  
 
3.2.16. Sample size  
No previous study has been performed to assess the efficacy and safety of metoclopramide 
to prevent pneumonia in stroke patients fed via NGTs. The MAPS trial was done as a pilot 
study of testing metoclopramide for the prevention of aspiration and pneumonia in acute 
stroke patients who are fed using nasogastric tubes. The previous studies which used 
metoclopramide were conducted in patients managed on intensive care units and as 
described before they constitute a very different patient population than acute stroke 
patients who are managed on stroke units. Therefore the findings of these studies could not 
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have been taken for a formal sample size calculation for the MAPS study. Therefore the 
MAPS study was designed as a pilot study and was intended to assess the feasibility, 
safety, the potential efficacy of metoclopramide procedural issues and make basic estimates 
of effect size if findings indicate that it is worth while going onto a full study. If procedures 
were shown to be good and valid the findings of the pilot study will be used to inform and 
work up a full trial. Data of this study will be used to estimate the sample size for the major 
trial.  
 
As this was a pilot study no formal study size calculation was undertaken. The size of the 
study was determined by time constraints and feasibility. UHNS admits approximately 900 
patients to the stroke unit per year. About 10% of these patients need nasogastric feeding. 
Not all fit the inclusion criteria or would be willing to consent to be included into a clinical 
trial. Many were expected to be excluded because of pneumonia on admission or before 
insertion of a nasogastric tube. Also recruitment to other trials prevented some patients 
being recruited to the MAPS trial. Therefore, recruitment of 1-2 patients per month was 
thought to be feasible. The research project was expected to be carried out over two years 
and it was considered that enrolment of 60 subjects was a feasible target. This was set as 
the sample size. 
 
3.2.17. Ethical considerations 
The study was conducted according to the Medical Research Council guidelines for good 
clinical practice in clinical trials and the declaration of Helsinki489. The research was 
conducted in compliance with national and local regulations. The research was approved by 
the Local Research Ethics Committee and the North Staffordshire Research and 
Development Consortium. The scientific design and conduct of the study was guided by 
the Research Governance Framework for Health and Social Care.  
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3.2.18. Data protection 
Data collection for all patients was done by the researcher. The research supervisor and 
research staff within the stroke unit supported the researcher in the data entry and analysis. 
Data collection forms containing personally identifiable data were kept in a locked cabinet, 
which was located in the local research office which had a coded lock. For data entry on to 
computerized databases and analysis, personally identifiable data were converted to an 
alphanumerical code using a specific code number for each participant. The principal 
investigator, members of the stroke unit research staff, statisticians and supervisors at 
Keele University had access to the anonymised data.  
 
Data were stored on a password protected office computer and a password protected 
portable computer. One back up copy was made of all data which was kept in a locked 
cupboard on the acute stroke unit. Anonymised data may be made available to other 
researchers for meta-analysis and publication in media such as the Cochrane Database. 
Data records and files will be destroyed after 15 years of storage. 
 
3.3. MAPS trial Results 
3.3.1. Recruitment 
The MAPS trial was conducted over a period of three years, from October 2008 to 
September 2011. During this period 2932 acute stroke patients were admitted to the Acute 
Stroke Unit and recorded in the Stroke Register. Out of these admissions, 296 patients 
needed a nasogastric tube for a period of at least 24 hours. A significant number of these 
patients (n = 202) already had signs of lower respiratory tract infection or pneumonia and 
were not eligible for recruitment to the MAPS trial. Thirty-four patients were excluded due 
to other exclusion criteria, inability to obtain consent or due to recruitment to another 
clinical trial. A total of 60 patients were recruited to the MAPS trial and the data of all 60 
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patients were used in the analysis. Written informed consent was obtained in 14 patients, 
and assent from the next of kin in 46 patients. As the plan was to use intention-to-treat 
analysis, data of all participants were included in analysis. Of the 60 patients who were 
recruited, there were no patients who had to be withdrawn from the trial due to later 
withdrawal of consent or assent. Also there were no patients who needed to be withdrawn 
due to later identification of an exclusion criterion or due to a non-stroke diagnosis which 
was not apparent at recruitment. All participants had outcome measures and adhered to the 
study protocol. There were no participants who had to be withdrawn from the trial due to 
development of side-effects to the intervention. However, there were two patients who 
were transferred out of the stroke unit to a peripheral hospital during the trial period while 
they were on nasogastric feeds. The data of these patients until they were transferred out of 
our unit were utilised in the analysis. Both patients were transferred out during their third 
week of the trial (one each from the treatment group and the placebo group) and enquiries 
made from the hospitals they were transferred to confirmed that both patients were alive 
and had PEG tubes inserted in the fourth week after the stroke. Apart from the lowest 
oxygen saturations, there were no missing data in any of the primary or secondary outcome 
measurements. 
 
All patients were admitted on the same day of their stroke (table 3.1). Five patients were 
recruited to the MAPS trial on the day of their admission and four of them were in the 
placebo group. In both groups, 44 patients (73%) were recruited within 48 hours of 
admission. The majority of patients were recruited prior to the insertion of the nasogastric 
tube, which was usually within the first 48 hours of admission to the ward. The mean time 
duration from admission to randomisation to the MAPS trial for all patients was 2 days. All 
patients who were recruited were randomised to the treatment or to the placebo arm within 
30 minutes of recruitment.  
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3.3.2. Baseline characteristics 
 
Baseline characteristics of the groups are given in table 3.2. The mean age of the subjects 
was 78 years and subjects were predominantly female (63%). Though six patients (10%) 
did not have any significant co-morbidity, most patients had one to three comorbidities on 
admission. The common comorbidities were hypertension (66%), diabetes (30%) and atrial 
fibrillation (61%). Atrial fibrillation was known in 31 patients on admission and six more 
patients were diagnosed as having atrial fibrillation during the trial period. Twenty-one 
patients (35%) had a history of ischaemic heart disease and nine patients (15%) had 
congestive cardiac failure. There were ten patients (16%) with a history of previous lung 
disease, namely bronchial asthma (n=2), chronic obstructive pulmonary disease (n=7) and 
pulmonary fibrosis (n=1). Fifty-three patients (88%) had a normal baseline chest 
radiograph on admission, emphysematous lung fields in five patients and pulmonary 
congestion in two patients.  
Nine patients (15%) were not on any medication prior to admission. Common medications 
on admission were diuretics (48%), proton pump inhibitors (45%) and digoxin (30%). 
Eighteen patients (30%) were on an ACE inhibitor (Nine patients in each group), nine 
(15%) were on beta-blockers, 15 patients (25%) were on other antihypertensives, seven 
patients (12%) were on anti-anginal medication and five (9%) were taking regular 
salbutamol and ipratropium inhalers prior to admission. Five patients were on oral 
anticoagulants for atrial fibrillation. Apart from one patient who was on penicillin for 
suspected sub-acute bacterial endocarditis no other patient was on antibiotics at the time of 
recruitment. There was no difference in the medication on admission between the two 
groups. Acute stroke treatment was similar in both groups. Nine patients (15%) had 
therapeutic intravenous thrombolysis on admission, five (8%) in the placebo group and four 
(7%) in the treatment group.  
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The mean Glasgow coma scale of 12 was in both groups. Both groups had high mean 
NIHSS scores, 20 in the treatment group and 19 in the placebo group 19, which suggests 
that most had severe strokes with significant disability. The majority of patients had severe 
strokes with a total anterior circulation syndrome in 51 (83%) patients the majority of 
patients 56 (94%) had ischaemic strokes. Baseline CRP levels were available in 49 patients 
(81%), baseline WBC was available in all 60 patients (100%) and the baseline albumin was 
available in 45 patients (75%). As ESR is not a commonly done baseline investigation, it 
was available only in 20 patients (33%). The mean WBC of the treatment and placebo 
groups were within the normal range and the differences were statistically not significant.  
 
The mean time from admission to insertion of a nasogastric tube for all patients was two 
days. Most patients had their nasogastric tube inserted within 48 hours of admission, 26 
patients (86%) from the treatment group and 23 (76%) from the placebo group. Two 
patients from the placebo group had their nasogastric tube inserted within 24 hours of 
admission. In summary, there was no statistical difference in the baseline characteristics 
between the two groups and the two groups were well matched for baseline clinical 
characteristics. Also they did not have evidence of an early or ongoing pneumonia on 
admission. 
 
Follow-up period 
One patient had treatment withdrawal within the first week. All other 59 participants were 
enteraly fed during the first week and had daily clinical examinations according to the 
study protocol. During the second week nine more participants had their treatment 
withdrawal and by the end of 2 weeks 31 participants were still fed via nasogastric tubes 
(66% of the total number of participants). The 31 participants who were still enteraly fed 
by the end of two weeks continued to have daily clinical examinations. Each remaining 20 
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(34%) participants who were not fed enteraly and therefore not on the trial medication were 
reviewed at the end of two weeks for presence of pneumonia and a full case-note review 
for the diagnosis of pneumonia was performed. By the end of three weeks only 33% of 
participants were enteraly fed and they received full three weeks of daily clinical 
examination. All other participants who were alive (other than the two who were 
transferred out) had their three weekly reviews for the presence of pneumonia and a full 
case-note review. Telephone enquiries were made to the local hospitals for the possible 
diagnosis of pneumonia for the two patients who were transferred to peripheral hospitals. 
This ensured that all participants (n=60) were reviewed for the diagnosis of pneumonia 
(primary outcome) during the entire length of study period, which was three weeks. 
 
3.3.3. Main outcomes  
3.3.3.1. Episodes of pneumonia  
Thirty-four patients (57%) had at least one episode of pneumonia, 26 patients (76%) in the 
placebo group and 8 (24%) in the treatment group. The mean number of episodes of 
pneumonia was 1.33 in the control group and 0.27 in the metoclopramide group. From the 
Poisson regression, this represented an RR of 3.241 (p <0.001, 95% CI 1.76- 5.96) (table 
3.3). All 8 patients who had pneumonia in the treatment group and thirteen patients in the 
placebo group had only one episode of pneumonia. However, thirteen patients (40%) in the 
placebo group had two episodes of pneumonia. There were no patients who had more than 
two episodes of pneumonia during the trial period.  
 
In the MAPS study only 14 episodes of pneumonia (30% of all pneumonias) were 
confirmed by a positive sputum culture. Eleven of these microbiologically confirmed 
pneumonias were in the placebo group and three episodes were in the treatment group. The 
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organisms isolated were Staphylococcus aureus (n = 4) and Gram negative bacilli such as 
Klebsiella (n = 4), E. coli (n = 2), Proteus (n = 1), Citrobacter (n = 1) and Seratia (n = 1). 
 
3.3.3.2. Time to pneumonia 
The time from admission to the onset of pneumonia and the time from insertion of the 
nasogastric tube to the diagnosis of pneumonia were reviewed. The mean time from 
admission to the stroke unit to the diagnosis of pneumonia was 4 days for all patients, was 
4 days for the placebo group and 6 days for the treatment group. The onset of pneumonia 
was delayed by two days in the treatment group (p = 0.006). 
 
3.3.3.3. Witnessed aspirations 
There were 17 patients (28%) who had at least one episode of witnessed aspiration (Table 
3.3). Of forty-three patients who had no witnessed aspirations, 29 (67%) were in the 
treatment group and 14 (33%) were in the placebo group. The patients in the placebo group 
had a mean of 0.73 episodes of aspiration, compared to a mean of 0.03 in the 
metoclopramide group (RR = 20.54; p = 0.003). The mean time from nasogastric tube 
insertion to the first episode of aspiration was 5 days for all patients. The mean time for 
aspiration was 5 days in the placebo group and 9 days in the treatment group. 
 
Of 17 patients who aspirated, one was in the treatment group and had only one episode of 
aspiration. Of 16 in the placebo group, 5 (29%) had not more than one episode of witnessed 
aspiration and nine patients (53%) had not more than two episodes of aspiration. Two 
patients had multiple episodes of aspiration of which details of first three episodes were 
recorded. There were total of 30 episodes of witnessed aspirations. Thirteen episodes 
occurred while the patient was in the supine position, 15 episodes occurred when 
maintained at 30 degrees inclination and two episodes were associated with spontaneous 
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vomiting while the patients were sat out of bed (Table 3.4 and 3.5). Most aspirations 
occurred while on nasogastric feeds or within two hours of completion nasogastric feeds. 
Nine episodes of aspiration occurred when patients were being transferred to the radiology 
department and 13 episodes occurred when the patients were being turned. All patients 
received oro-pharyngeal suction and chest physiotherapy as soon as the aspiration was 
noted. Seven episodes resulted in aspiration pneumonia. During the other ten episodes 
patients were already on treatment for pneumonia. However, the aspirations caused further 
clinical deterioration in these patients and led to a change of the antibiotic regime to a 
stronger antibiotic and the addition of metronidazole. 
 
3.3.3.4. The number of antibiotic days and the number of antibiotics 
There were a total of 296 antibiotic days for all patients during the trial period (treatment 
group was 68 and the placebo group 228 days). Patients in the placebo group also had a 
higher mean number of days on antibiotic treatment (7.57) than those in the 
metoclopramide group (2.27); this represented an RR of 3.94 (p < 0.001). The average 
number of different antibiotics types used in the treatment group was 0.7 per patient 2.6 per 
patient in the placebo group (table 3.6). 
 
3.3.3.5. WBC and C-reactive protein 
All white cell counts and C-reactive protein results from recruitment to the end of the trial 
were reviewed to obtain the highest levels, rather than recording the CRP and white cell 
counts according to a specified date (table 3.6). The mean of the highest white cell count 
for the total group was 15.0 x 106/ml and the highest C-reactive protein for the total group 
was 79.4 mg/l. There was a statistically significant reduction in the two inflammatory 
parameters in the treatment group compared to the control group. The mean for the highest 
white cell count in the treatment group was 12.2 x 106/ml, lower than the placebo group 
Student No: 940137947014 194 
16.8 x 106/ml (p = 0.004). The treatment group had a lower mean CRP value at 61.1 mg/l 
than the placebo group at 97.7 mg/l (p = 0.045).  
 
3.3.3.6. Trial termination 
The mean time from the stroke to the end of the trial, which was either the removal of the 
nasogastric tube or completion of 21 days which ever was shorter (which constitute the end 
of trial drug administration), was 14 days for all sixty patients and from the insertion of 
nasogastric tube to the end of the trial was 12 days, though all patients who were alive 
(n=50) had their second and third week review for the presence of pneumonia. The mean 
time from the stroke to the end of the trial was 15 days for the placebo group and 13 days 
for the treatment group. Seventeen patients (28%) spent the full three weeks in the trial 
with nasogastric feeds and trial medication, while being cared by the Acute Stroke Unit. Of 
these 11 patients were in the placebo group and 6 were in the treatment group. Two patients 
who were transferred out of the unit in the 3rd week of the trial were referred to have a PEG 
tube inserted in the local hospitals they had been transferred to. This makes a total of 19 
patients (31%) who were on nasogastric feeds at the end of 21 days. 
 
Three defined end of trial outcomes were removal of nasogastric tube due to improvement 
of swallow, referral for PEG and treatment withdrawal. Thirty-one patients (52%) had their 
nasogastric tubes removed as their swallowing improved during the trial period of three 
weeks (table 3.6). Significantly more patients in the treatment group (66%) had their 
nasogastric tube removed than in the placebo group (53%) due to improvement of their 
swallow improved (p = 0.006, RR = 1.817, 95% CI 1.07-3.1). The type of diet they were 
commenced and the consistency of fluid when they were commenced on oral feeds were 
not recorded. Of patients who remained at UHNS, seventeen patients (28%) were referred 
to have a PEG tube inserted as there was no improvement of their swallow. Two patients, 
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one from each group were transferred to another hospital during their 3rd week of the study 
period. Both had nasogastric tubes as there was no swallow and both had been referred to 
have a PEG after transfer. Therefore nineteen patients (32%) were referred for PEG, 7 
(23%) from the treatment group and 12 (40%) from the placebo group. There were more 
patients who required PEG tubes in the placebo group, however, the difference was not 
statistically significant (p-value = 0.17). Patients who continued nasogastric feeds for more 
than the 3 weeks after the trial period were not assessed for further development of 
pneumonia or aspiration in accordance with the study protocol.  
 
Ten patients (17%), three (10%) from the treatment group and seven (23%) from the 
placebo group, had their nasogastric tube removed as they were considered for treatment 
withdrawal and palliation. Though there were more treatment withdrawals in the placebo 
group this was not statistically significant (p = 0.17) Poor response to treatment, 
neurological complications of the stroke such as malignant middle cerebral artery 
syndrome, extension of the stroke, and severe pneumonia with poor response to antibiotics 
were the most frequent reasons for treatment withdrawal. Consideration of poor quality of 
life even if there was a chance of survival was another reason for treatment withdrawal in 
patients with large strokes with multiple co-morbidities who were expected to require 
institutionalised care with PEG feeds. Such decisions were made after regular multi-
disciplinary meetings and discussions with next of kin and other close family members. 
The initial phase of the treatment withdrawal included removal of the nasogastric tube and 
agreement not to further escalate medical treatment or to prescribe further courses of 
antibiotics. Trial-related observations were terminated once the nasogastric tube was 
removed as per protocol. Patients at the end of their lives were referred to the hospital 
palliative care team for supportive treatment or for the commencement of the Liverpool 
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Care pathway for the dying. There were no unexpected deaths in patients who were on the 
MAPS study during the time of the clinical trial. 
 
3.3.3.7. Oxygen saturations 
Of all available oxygen saturation readings the lowest saturation on air during the trial 
period was recorded for analysis. However, the lowest oxygen saturations were not 
available in all 60 patients. The commonest reason for this missing data was that some 
patients had commenced oxygen therapy at the time of the assessment for the trial and the 
lowest oxygen saturations on air were not documented by the attending staff prior to the 
commencement of oxygen therapy. This was mainly seen in patients who had oxygen 
treatment commenced at night (n = 7). Misplacement of patients’ observation charts (n = 4) 
was another contributory factor. Retrospective case-notes review did not provide any 
further information on these missing lowest oxygen saturations. Out of 49 patients who had 
the lowest saturation recorded, the mean lowest oxygen saturation on air was 89.2% mm 
Hg. The mean of the lowest oxygen saturation on air was available in 27 patients (90%) in 
the placebo group and was 85.1% mm Hg (Table 3.6). There were 22 patients (73) in the 
treatment group who lowest oxygen saturation readings and they had a mean of 93.9%, 
which was significantly higher than in the placebo group (p <0.001). 
 
 3.3.3.8. Neurological scores  
In the treatment group, the mean NIHSS score improved from 20 to 16 at the end of the 
first week (Table 3.8). After this initial improvement the NIHSS score remained almost 
unchanged for patients in the treatment group. In the placebo group the initial mean NIHSS 
score of 19 remained almost unchanged for the first two weeks and deteriorated to 22 at the 
end of the third week. The differences of the NIHSS scores in the treatment group vs. the 
Student No: 940137947014 197 
placebo group were 4 at the end of week 1, 3 at the end of week 2 and 6 at the end of week 
3 (p = 0.008). 
 
3.3.3.9. Recovery of swallow 
All patients in the treatment group and 29 patients (96%) in the placebo group needed 
nasogastric feeds during the first week of the trial. From there onwards there were more 
patients leaving the trial in the treatment group due to improvement of their swallow. At 
the end of two weeks 13 patients (43%) of patients in the treatment group and 18 patients 
(60%) in the control group were on nasogastric feeds, and at the end of three weeks the 
remaining patients were 7 (23%) and 12 (40%) for treatment and placebo groups 
respectively.  
 
3.3.3.10. Other bacterial infections 
The commonest non-respiratory infection encountered during the trial period was urinary 
tract infection. There were six patients with culture positive urinary tract infections, four 
(13%) in the treatment group and two (7%) in the placebo group. Four urine infections 
were due to Escherichia coli, one due to a Klebsiella species and the other due to a Proteus 
species. All infections were treated according to sensitivities with either trimethoprim or 
co-amoxiclav for a total of five days. One patient in the treatment group had lower limb 
cellulitis and was treated with intravenous benzyl penicillin for 5 days. 
 
3.3.3.11. The use of ACE inhibitors and of other antiemetic agents 
Nine patients in each group were on ACE inhibitors on admission. One patient in the 
treatment group and seven patients in the placebo group were commenced on ACE 
inhibitors during the trial period. Therefore there were more patients on an ACE inhibitor 
in the placebo group. Ten patients (33%) in the placebo group and two patients (7%) in the 
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treatment group needed another anti-emetic at least once during the trial period. Cyclizine 
50 mg was the antiemetic used and majority of patients who had cyclizine were in the 
placebo group.  
 
3.3.3.12. Thirty Day Mortality 
Though formal trial observations ended at 21 days following recruitment, retrospective 
case-notes review was done to record thirty day mortality for all patients who were on the 
trial. Forty patients (66%) were alive at that point as ten more patients had died following 
the end of the trial. Though statistically not significant, there were more survivors in the 
treatment group (treatment group 22 patients and placebo group 18 patients p = 0.2). 
Pneumonia was recorded as either the immediate cause of death or a contributory cause of 
death in the death certificates in all ten patients who died following the end of the trial. 
 
3.3.4. Summary of results  
The two groups were well matched in the demographic data, stroke type and severity, co-
morbidities and previous lung pathologies. There was a significant reduction in the 
incidence of pneumonia in the patients who were treated with metoclopramide. Also in 
patients who developed pneumonia this occurred significant delayed in the treatment group 
than in the control group. In keeping with a reduction in the incidence of pneumonia, the 
treatment group also had a lower number of antibiotic days and significantly lower levels 
of inflammatory markers. There were also significantly fewer witnessed aspirations in the 
treatment group than in control group and oxygen saturations were higher. 
 
Patients who had metoclopramide also had significant neurological recovery at the end of 3 
weeks and had more patients not needing nasogastric feeds due to resuming oral feeds. 
There was a weak trend towards more survivors in the treatment group at the end of three 
Student No: 940137947014 199 
weeks and there were fewer patients who required a PEG tube insertion though both were 
not statistically significant. The reduction of the incidence of pneumonia in the treatment 
group was not influenced by the use of concomitant medication such as ACE inhibitors or 
antiemetic as they were more used in the placebo group.  
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Figure 3-2 - Flow of patients
Total number of patients who 
required NG feeding  
n=296 
 
Informed consent/assent 
 
Randomised  
n=60 
Active treatment (Metoclopramide) 
Allocated n=30 
Metoclopramide 10 ml /three times a day 
Continue for 21 d or until nasogastric tube no 
longer needed 
(Received n =30) 
 
Control treatment (Normal saline) 
Allocated n=30 
Placebo 10 ml / three times a day 
Continue for 21 d or until nasogastric tube no 
longer needed 
(Received n = 30) 
 
Follow-up day 7  
Clinical assessment; safety reporting (n=60) 
Follow-up day 14  
Primary outcome: diagnosis of pneumonia 
Clinical assessment; safety reporting (n=50)  
Treatment withdrawn (Died) n=10 
Follow-up d 21  
Primary outcome: diagnosis of pneumonia 
Clinical assessment; safety reporting (n=50)       
Excluded due to pneumonia  
n=202 
Excluded due to other reasons 
n=34 
 
Active treatment Group 
Analysed (n=30) 
Excluded (n=0) 
Placebo Group 
Analysed (n=30) 
Excluded (n=0) 
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Table 3-1- Time from Admission to NGT Placement and Recruitment 
 
    
Treatment Group 
n = 30 (%) 
Placebo Group 
n = 30 (%) 
Admission to fist 
nasogastric tube 
(days) 0 0/30 (0) 2/30 (7) 
  1 17/30 (57) 11/30 (36) 
  2 9/30 (30) 10/30 (33) 
  3 3/30 (10) 5/30(17)  
  4 0/30 (0) 2/30 (7) 
  5 1/30 (3) 0/30 (0) 
  
Mean 
(SD)  2.0 (1.0) 2.0 (1.0) 
 Range 1.0 to 5.0  0.0 to 4.0 
    
Admission to 
randomization (days) 0 1/30 (3) 4/30 (14) 
  1 12/30 (40) 8/30 (26) 
  2 9/30 (30) 10/30 (33) 
  3 5/30 (17) 5/30 (17) 
  4 2/30(7)  3/30 (10) 
  5 0/30 (0) 0/30 (0) 
  6 1/30 (3) 0/30 (0) 
  Mean (SD) 2.0 (1.0) 2.0 (1.0) 
 Range 0.0 to 6.0  0.0 to 4.0 
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Table 3-2 – Baseline characteristics  
    
Treatment 
Group n = 30 
(%) 
Placebo Group 
n = 30 (%) 
p-value1 
Age (years) Range 55 to 91 46 to 95 
  Mean (SD) 76.9 (± 6.3) 79.2 (± 10.8) 0.19 
Gender  Male 11/30 (37) 11/30 (37) 
  Female 19/30 (63) 19/30 (63) 1.00 
Number of 
comorbidities 0 3/30 (10) 3/30 (10) 
 
  1 5/30 (17) 4/30 (14)  
  2 7/30 (23) 12/30 (40)  
  3 11/30 (37) 6/30 (20)  
  =>4 4/30 (13) 5/30 (17)  
Diabetes  07 (23) 10 (33) 0.4 
Hypertension  18 (60) 22 (73) 0.3 
Atrial fibrillation   20 (66) 17 (57) 0.4 
Lung pathology 0 27/30 (90) 23/30 (77)  
  1 3/30(10)  6/30 (20)  
  2 0/30 (0) 1/30 (3)  
Baseline chest 
radiograph Normal 28/30 (93) 25/30 (87) 
0.3 
  Abnormal 2/30 (7) 5/30 (17)  
Number of 
different drugs 0 4/30 (14) 5/30 (17) 
 
  1 5/30(17)  10/30 (33)  
  2 7/30 (23) 5/30 (17)  
  3 8/30 (27) 6/30 (20)  
  =>4 6/30 (20) 4/30 (13)  
NIHSS Range 11.0 to 31.0 5.0 to 30.0 0.4 
  Mean 19.9 ± 6.0 18.6 ± 6.7  
GCS Range 8.0 to 15.0 6.0 to 15.0 0.4 
  Mean 12.1 ± 2.5 12.1 ± 2.8  
CT diagnosis Infarction 29/30 (97) 27/30 (90) 0.3 
  Haemorrhage 1/30 (3) 3/30 (10)  
Type of stroke TACS 27/30 (90) 24/30 (80) 0.3 
  PACS 2/30 (7) 3/30 (10)  
  POCS 1/30 (3) 3/30 (10)  
CRP (mg/l) Mean (SD) 13.6 (14.7) 11.2 (8.1) 0.5 
ESR (mm/h) Mean (SD) 15.4 (13.7) 19.3 (13.5) 0.5 
Albumin (mg/l) Mean (SD) 37.9 (4.3) 36.7 (4.0) 0.3 
WBC (103/l) Mean (SD) 9.5 (2.5) 9.9 (3.8) 0.6 
(1By Student’s t test two-tailed, NIHSS - National Institute of Health Stroke Scale, GCS - 
Glasgow Coma Scale, CT- Computerised Tomograghic, TACS – Total Anterior Circulation 
Syndrome, PACS – Partial Anterior Circulation Syndrome, LACS – Lacunar Syndrome, PoCS 
– Posterior Circulation Syndrome, CRP- C Reactive Protein, ESR - Erythrocyte Sedimentation 
rate, WBC- White Blood Cells) 
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Table 3-3 - Episodes of Pneumonia and Aspiration 
 
 
 
 
 
 
 
 
 
 
 
  
Number of 
Episodes 
n 
Treatment 
Group n = 30 
n (%) 
Placebo 
Group n = 30 
n (%) 
Total  
n = 60  
n (%) 
p-value1 
Pneumonia 1 or more 8 (27) 26 (87) 34 (57) 
  0 22 (73) 4 (13) 26 (43) 
Number of 
patients with 
pneumonia 0 22 (73) 4 (14) 26 (43)  
  1 8 (26) 13 (43) 21 (35) 
  2 0 (0) 13 (43) 13 (22) <0.001 
       
No of patients 
with aspiration 0 29 (97) 14 (47) 43 (72) 
  1 1 (3) 5 (17) 6 (10) 
  2 0 (0)  9 (30) 9 (15) 
  3 0 (0) 2 (7) 2 (4) <0.001 
 
(1By student’s t-test two-tailed, PEG – Percutaneous Endoscopic Gastrostomy) 
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Table 3-4 - Details of each Episodes of Witnessed Aspirations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Position  Number 
of 
Patients 
Supine 30 
Degrees 
Seated 
Presence of 
Nasogastric 
Tube 
Pneumonia  
 
Treatment Group 
1st episode 
 
1 1 0 0 1 0 
2nd episode 
 
0 0 0 0 0 0 
3rd episode 
 
0 0 0 0 0 0 
Total 
episodes 
 
1 1 0 0 1 0 
 
Placebo Group 
1st episode 16 6 10 0 15 
 
12 
2nd episode 11 4 5 2 11 
 
5 
3rd episode 
 
2 2 0 0 2 1 
Total 
episodes 29 12 15 2 28 18 
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Table 3-5 - Positions Associated with Aspiration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1st episode 2nd episode 3rd episode Total (%) 
Activity 
Turning 7 6 0 13 (43) 
Transfers 7 2 0 9 (30) 
None 3 3 2 8 (27) 
Position 
Supine 7 4 2 13 (43) 
30 degrees 10 5 0 15 (50) 
Seated 0 2 0 2 (7) 
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Table 3-6 - Highest Inflammatory Markers, Antibiotic Days during 3 Weeks of Study and End of Trial 
Outcomes 
 
 
 
 
    
Treatment Group 
n = 30 
Placebo 
Group 
n = 30 
Total n = 60 p-value1 
Range 3.2 to 23.5 4.1 to 41.0 3.2 to 41.0 Highest 
WBC 
(106/ml ) 
  Mean (SD) 12.2 (3.9) 16.8 (7.6) 15.0 (6.0) 0.004 
        
Range 0.4 to 258.0 3.5 to 307.0 0.4 to 307.0 Highest CRP 
(mg/l) Mean (SD) 60.1 (62.2) 97.7 (79.3) 78.9 (73.2) 0.045 
        
Number of 
patients n(%) 22 (73) 27 (90) 49 (82) 
Range 89.0% to 97.0% 
68.0% to 
94.0% 
68.0% to 
97.0% 
Lowest 
Oxygen 
Saturation 
Mean 93.8% (2.3) 85.2% (5.4) 89.0% (6.1) <0.001 
      
Antibiotic 
treatment 
(days) Range 0.0 to 12.0 0.0 to 16.0 0.0 to 16.0 
  Mean 2.3 7.7 5.0 <0.001 
      
Nasogastric 
tube removed 
-swallow 
improved 20 (67) 11 (36) 31(52) 
 
 
0.02 
 
Referred for 
PEG 
 7 (23) 12 (40) 19 (32) 
 
0.17 
End of trial 
outcomes 
Nasogastric 
tube removed 
treatment 
withdrawn 3 (10) 7 (23) 10 (17) 
 
 
0.17 
 
(1By student’s t-test two-tailed, CRP- C-Reactive Protein, WBC - White Blood Cells) 
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Table 3-7 - Time lag between the Admission and First Pneumonia / Aspiration 
 
 
  
Treatment 
Group n = 30 
Placebo 
Group n =30 
Whole Group 
n = 60 
p-value1 
Time from admission to 
first pneumonia (days) Number2 8 26 34 
  Mean (SD) 6.0 (4.0) 4.0 (2.0) 4.0 (3.0) 
  Range  3.0 to 14.0   2.0 to 9.0 2.0 to 14.0 0.05 
       
Time from Nasogastric 
tube insertion to 
pneumonia (days) Mean (SD) 4.0 (3.0) 2.0 (1.0) 3.0 (2.0) 
  Range 2.0 to 9.0 1.0 to 6.0 1.0 to 9.0 0.006 
         
Admission to first 
aspiration (days) Mean (SD) 11.0 7.0 (6.0) 7.0 (6.0) 
  Total 1 16 17  
           
Nasogastric tube to 
aspiration (days) Mean (SD) 6.0 5.0 (3.0) 5.0 (3.0)  
           
Recruitment to end of 
trial (days) Mean  13.0 15.0 14.0  
 Number of patients 
who completed 3 weeks 
of the trial   7.0 12.0 19.0  
 
(1By student’s t-test two-tailed, 2Number of patients with pneumonia (n)) 
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Table 3-8 Changes in Neurological Deficit (NIHSS) over the Trial Period 
 
 
 
 
 
 
 
 
 
 
 
 
 Admission Week 1 Week 2 Week 3 
 
number 
n (%) 
Mean 
(range) 
number Mean 
(range) 
number Mean 
(range) 
number Mean 
(range
) 
Total 
Group  
n = 60 59 (98) 
19.3  
(5.0 – 
31.0)  58 
16.8  
(2.0 – 
34.0) 31 
17.4 
(4.0 – 
32.0) 17 
19.6  
(4.0-
32.0) 
Treatment 
Group  
n = 30 
29 (97) 
20.0 
(11.0– 
31.0)  29 
15.7  
(6.0 – 
33.0) 13 
15.8  
(4.0 – 
25.0) 6 
15.7  
(8.0 
– 
24.0) 
Placebo 
Group  
n = 30 
30 
(100) 
18.6 
(5.0 – 
30.0)  29 
18.0 
(2.0 -
34.0) 18 
18.6 
(4.0 -
32.0) 11 
21.5  
(4.0 -
30.0) 
 
(NIHSS – National Institute of Health Stroke Scale) 
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Figure 3-3 Changes in NIHSS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(NIHSS – National Institute of Health Stroke Scale) 
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3.4. Discussion  
3.4.1. Effect of metoclopramide on pneumonia  
The MAPS study findings suggest that metoclopramide reduces the incidence of 
pneumonia in acute stroke patients who are fed via NGT. This is the first randomised 
controlled study of metoclopramide in patients with acute stroke fed via nasogastric tubes 
and was designed as a pilot study with no sample size calculation. While this outcome is 
statistically highly significant, the study size was relatively small (n=60) and a false 
positive result cannot be excluded. In keeping with the observed reduction in the incidence 
of pneumonia, the treatment group also required fewer days of antibiotics, had lower levels 
of inflammatory markers, and were less hypoxic. There were fewer deaths in the 
metoclopramide group than in the placebo group, but this effect was not statistically 
significant. The results of MAPS have also shown that recruitment in the sub-acute stage of 
stroke is feasible and that regular administration of metoclopramide for a maximum of 21 
days is safe in this patient group.   
 
3.4.2. Timing of Pneumonia  
MAPS study also demonstrated that most pneumonia occurred within the first week 
following stroke. Also of 296 patients who required a nasogastric tube, almost two thirds of 
patients were excluded as they already had signs and symptoms of pneumonia. This is in-
keeping with previous studies that have demonstrated that post-stroke pneumonia is an 
early complication and most occurred within the first week of following stroke178. Of 34 
episodes of initial pneumonias, almost all occurred within the first week following stroke 
and of all 47episodes of pneumonia seen during the trial, 76% occurred within the first 
week. Also pneumonia was seen as an early complication following nasogastric tube 
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insertion, with a mean duration of three days to pneumonia following nasogastric tube 
insertion. This emphasises the fact that these patients need maximising all protective 
measures against pneumonia at least during their first week following acute stroke.  
 
The maximum number of episodes of pneumonia was two over the study period. There 
were no patients who had three or more episodes of pneumonia, a problem which is not 
uncommon in day-to-day clinical practice. The trial period was three weeks and most 
episodes of pneumonia were treated with courses of antibiotics lasting for 7-10 days thus 
limiting the episodes of pneumonia to a maximum of two. However, the review of causes 
of 30 day mortality showed that all deaths between the end of the trial and day 30 were in 
patients who were still enteraly fed and was due to recurrence of hospital acquired 
pneumonia. Also during second and third weekly reviews of patients who were not on 
nasogastric feeds, none of them had any further episodes of pneumonia. This shows that 
pneumonia is not only an early complication of stroke but also continues to be a significant 
problem as long as the patients are fed via nasogastric tubes. There were equal numbers of 
patients from each group in the ten deaths which occurred between completion of the 
treatment period and 30 days. This demonstrates that the mortality in the treatment group 
increased when they stopped receiving metoclopramide. It is possible that the withdrawal 
of the protective effect of metoclopramide in patients who were in the treatment group was 
responsible for equalising this incidence of pneumonia and mortality between the two 
groups. 
3.4.3. Matching of the two groups 
The two groups of the study were well matched for demographic data and co-morbidities, 
especially vascular comorbidities such as hypertension and diabetes. Most of the 
participants had few comorbidities with 83% having less than three other diagnoses. 
Incidences of hypertension and diabetes in the MAPS study were very similar to the 
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incidences seen in previous studies of post-stroke pneumonia. A significant proportion of 
participants were in atrial fibrillation, making a cardiac source of the emboli a likely cause 
for the stroke. This would also explain the high incidence of total anterior circulation 
strokes observed in this patient group as cardiac emboli are larger than platelet emboli and 
result in large areas of cerebral ischaemia491. In addition, most of the patients with atrial 
fibrillation were not anticoagulated at the time of admission. This may be partly due to the 
fact that recruitment to the trial was done before the widespread education campaigns for 
the detection and treatment of atrial fibrillation was conducted locally. 
  
The two groups were well matched for previous lung pathologies and baseline chest 
radiograph findings in this study. Previous lung pathologies were reviewed as people with 
chronic respiratory disease are prone to recurrent respiratory tract infections. As Stoke-on-
Trent is a former industrial and mining area, it was expected a significant number of 
patients would have chronic lung disease. However, the majority (80%) of participants did 
not have previous respiratory disease, and the baseline chest radiograph was normal in 
most subjects. It is possible that patients with chronic lung disease also to have a higher 
incidence of smoking and other co-morbidities and may not have survived to an older age 
in which stroke is more common. 
 
The two groups were also similar in their neurological burden on admission as measured by 
GCS and NIHSS scores. The predominant CT diagnosis in both groups was cerebral 
infarction and there were only four patients (7%) with cerebral haemorrhage. The incidence 
of cerebral haemorrhage in the MAPS study is less than incidences demonstrated in some 
previous studies of post-stroke pneumonia5;67;377, though several other studies excluded 
patients with cerebral haemorrhages from their study28;180;378. The reasons for reduced 
incidence of haemorrhages were partly due to those patients with small cerebral 
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haemorrhages not requiring nasogastric feeds and the patients with large intra cerebral 
haemorrhages had aspiration pneumonia on admission, secondary to associated vomiting 
with an intra cranial bleed. Also many patients with large cerebral haemorrhages had been 
commenced on the Liverpool care pathway for dying or decision made for no further active 
treatment other than palliation prior to admission to the Stroke Unit. Such decisions were 
made after recognising such large intra cerebral haemorrhages were incompatible with 
survival.  
 
Most patients requiring nasogastric feeds usually have large strokes which involve a 
significant part of the cerebral hemisphere228. This was reflected in the MAPS study. The 
majority of participants (85%) had signs and symptoms of a total anterior circulation 
stroke, which was reflected in high NIHSS scores on admission. When compared to many 
previous studies MAPS study had more patients with total anterior circulation syndrome 
strokes5;29;161;377;378. None of the participants had lacunar strokes as such patients tend to 
have relatively minor non-disabling strokes, and low NIHSS scores and therefore rarely 
require nasogastric feeds226. Patients with low NIHSS scores (5 – 10) in the MAPS study 
were those with posterior circulation strokes. This group had significant impairment of 
their swallowing mechanism as lesions in the brain stem frequently involve the swallowing 
centre often sparing the more peripheral long tracts35. Therefore patients with posterior 
circulation strokes can have relatively mild weakness with severe swallowing problems. 
Also some neurological deficits in posterior circulation strokes, such as cranial nerve 
palsies, are not scored in the NIHSS scoring system resulting in a low NIHSS score in spite 
of significant signs and symptoms. 
 
Therefore participants of the MAPS study were well matched and were not very different 
from patients recruited to other stroke related clinical trials.  
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3.5. Effect of metoclopramide on other outcomes 
3.5.1. Aspiration 
There was a significant reduction (p <0.001) in the incidence of vomiting and aspiration in 
the treatment group. Out of 17 patients who had witnessed aspiration, 16 were in the 
placebo group. Most episodes of vomiting resulted in aspiration pneumonia and significant 
disruption to the feeding regime. As a potent antiemetic the reduction of episodes of 
vomiting in the treatment group can be explained, which was partly responsible for the 
reduction in the incidence of pneumonia in this patient group. Most episodes of vomiting 
and aspiration occurred when the patients were being washed or turned in bed. In addition, 
transfers of patients for various investigations were associated with vomiting and 
aspiration. It has been demonstrated that supine posture was more associated with 
aspiration in patients who are fed via nasogastric tubes than a semi-reclined posture. 
However, it is common practice to maintain patients in supine posture during washing and 
transfer, which might have contributed to this observed association of vomiting during 
patient transfer and personal care. These findings can be related to a study by Rowat et al 
on changes of oxygen saturations following acute stroke, in which patients had their lowest 
oxygen saturations in the CT scanner or during transfer between units408. These findings 
may also be secondary to either overt or silent aspiration during these procedures. 
Therefore it is advisable to complete washing and personal care of patients prior to 
connecting them to nasogastric feeds and to avoid transfer while being connected to or 
soon after nasogastric feeds. It is best to delay transfers if possible, two hours after 
completion of feeds, which will allow time for adequate gastric emptying.  
 
It was also interesting to observe that patients continued to vomit and aspirate even when 
they were maintained at a semi-reclined position of 300 during their nasogastric feeds. Few 
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previous studies have shown that semi-reclined position was still associated with reflux and 
aspiration in the presence of a nasogastric tube. These results suggest that stroke patients 
may require a higher inclination than used in previous studies, possibly 450 or more during 
nasogastric feeds. This is further confirmed as there were only two episodes of vomiting 
and aspiration when patients were sat out during their feeds.  
 
3.5.2. Treatment withdrawal 
There were ten patients who had their nasogastric feeds discontinued as all active treatment 
was withdrawn to be commenced on the Liverpool Care Pathway for dying. Decision to 
withdraw treatment was made due to a combination of extension of stroke, worsening 
neurology and poor response to optimal medical management. There were less number of 
patients who had their treatment withdrawn in the treatment group and at the end of the 
third week more patients were alive in the treatment group though it was not statistically 
significant.  
 
3.5.3. Resumption of oral feeds and neurological recovery 
There was statistically significant number of patients who had their swallow improved to 
resume oral feeds so that their nasogastric feeds could be discontinued in the treatment 
group. There was also a significant reduction in the number of patients who required a 
percutaneous endoscopic gastrostomy tube insertion in the treatment group though it was 
not statistically significant.  
 
As for the neurological recovery, both groups showed an improvement in their neurological 
scores during the first week. This is the neurological recovery which can be expected 
within the first week of an uncomplicated stroke, secondary to the reduction in cerebral 
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oedema and improvement of the penumbral circulation. However, the treatment group 
appeared to have a better neurological recovery which was apparent from the first week of 
the trial. In addition, the patients in the placebo group demonstrated a further deterioration 
of their neurological status during the third week, which was demonstrated by worsening of 
the NIHSS scores.  
 
Studies have shown that presence of a nasogastric tube for a longer time was associated 
with recurrent episodes of aspiration and pneumonia17;151. The effects of persistent 
activation of the inflammatory cascade secondary to pneumonia on the penumbral micro-
circulation may have contributed to this observed impaired neurological recovery of the 
patients in the placebo group223. In addition, pneumonia is a leading cause for post-stroke 
hypoxia and persistent hypoxia will delay the recovery of the ischaemic penumbra 
214;215;217
. Being relatively free of pneumonia made patients in the treatment group less 
hypoxic which was confirmed by the significant difference in the lowest recorded oxygen 
saturations in the two groups. It can be postulated that better oxygen saturations and 
reduced inflammatory activity contributed to the better neurological recovery including an 
early recovery of swallow in patients who were treated with metoclopramide.  
  
3.5.4. Other infections 
The MAPS study also demonstrated that there was a statistically significant difference in 
the white blood cell count and the CRP levels between the treatment and the placebo group. 
This confirms that some form of an infection or an inflammatory process was more 
prevalent in the placebo group following acute stroke. With the fulfilment of criteria for 
pneumonia during the periods of increased inflammatory response, it is safe to assume that 
these changes were due to the higher incidence of pneumonia in the placebo group. None 
of the participants had infected venflon sites. One patient in the treatment group had an 
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unrelated lower limb cellulitis. Urinary tract infection was diagnosed in six patients (10%) 
in the total group of which four were in the treatment group. The incidence of urinary tract 
infection following acute stroke varies between 6-27%, older studies and studies done in 
ITUs reporting higher incidences4;492-494. Many stroke patients were catheterised in the past 
and many ITU patients are still commonly are catheterised, which is responsible to this 
high incidence of urinary infections494. The low incidence of urinary tract infections 
observed in the MAPS trial compared to other trials reflect the catheter policy of the stroke 
unit which minimises the use of urinary catheters to promote continence following stroke. 
 
3.6. General discussion 
3.6.1. Metoclopramide 
Metoclopramide is a commonly used prokinetic agent, which acts on the dopamine D2 
receptors in the upper gastrointestinal tract30. Metoclopramide antagonises the inhibitory 
effects of dopamine on the gastric contractility and sensitise the upper gastrointestinal tract 
to the stimulatory effects of acetylcholine471. By these actions metoclopramide increases 
the lower oesophageal sphincter pressure, gastric tone and gastric antral contractility 
therefore, accelerates gastric emptying, increases lower oesophageal sphincter tone, and 
reduce gastric stasis and gastro-oesophageal reflux495.  
 
There are no other studies of the effect of metoclopramide in post-stroke patients fed via 
nasogastric tubes. The only trial that used metoclopramide three times daily in patients fed 
via nasogastric tubes failed to demonstrate a reduction of the incidence of pneumonia, 
mortality or length of stay with metoclopramide488. Nevertheless, the onset of pneumonia 
was delayed by nearly two days in the treatment group which was statistically significant 
and likely to be clinically relevant in acute care. The latter study had several major 
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differences to the MAPS study. The mean age of the study population was 36 years, 
younger than most stroke patients. It was conducted on an intensive care unit, and the 
patient population was not comparable including critically ill patients with head injuries, 
post-operative patients, and patients with a mixture of acute neurological conditions 
including acute stroke. The paper does not state the proportion of acute stroke patients who 
were included in the trial, but of 305 participants 71 (25%) were post-operative patients. In 
addition, 136 patients (45%) were intubated and mechanically ventilated and 58 patients 
(19%) needed a tracheostomy, all of which predisposes patients to aspiration by depressing 
pharyngeal reflexes and compromising protective laryngeal reflexes163. Raised intra-gastric 
pressure during ventilation increases gastro-oesophageal reflux and patients receiving 
mechanical ventilation have shown to have a high incidence of nosocomial pneumonia, 
especially if they are fed via nasogastric tubes177. In addition, critically ill patients managed 
in an intensive care unit are exposed to other factors that affect gastro-intestinal motility 
and absorptive function129. These include opioids, dopamine and catecholamines. 
Furthermore autonomic effects of pain, stress and trauma further impairs gastro-intestinal 
function. Hypotension and the vasoconstrictor effects of stress hormones can lead to gastric 
hypoperfusion129. All these additional factors in critically ill patients might have affected 
the desired effects of metoclopramide in reducing reflux and pneumonia. This has been 
further confirmed by a study using another prokinetic agent cisapride on gastric emptying 
in critically ill patients fed via nasogastric tubes. The study demonstrated that there was 
significant day to day variation in gastric motility despite therapeutic plasma levels of the 
drug and the effect on gastric emptying was not consistent secondary to mechanical 
ventilation and the use of other medication such as narcotics and inotrops496.  
 
When compared to the study by Yavagal et al, the patient population of the MAPS trial 
were much older (average age of 77 years) and only had an acute stroke as their critical 
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illness488. None of them had endotracheal intubation or tracheostomy and no patient 
received mechanical ventilation. Similarly none of the MAPS participants were post 
operative and none received any opioids, dopamine or catecholamine infusions which 
could affect peristalsis. Thus the patient population of the MAPS study was very much 
different from Yavagal’s study and the difference in the two patient populations may 
explain the difference in the results of the two trials. Also our patients represent many 
patients who are usually managed on an acute stroke unit. However, though Yavagal et al 
failed to demonstrate any reduction in pneumonia in patients who were treated with 
metoclopramide, their study demonstrated that metoclopramide significantly delayed the 
onset of pneumonia by 1.5 days488. Similarly the MAPS study also demonstrated that there 
was a 2 day delay in the development of pneumonia in the patients who received 
metoclopramide which was also statistically significant. As pneumonia is an early 
complication following acute stroke and there were significant number of patients who 
only required nasogastric feeds for the first week following stroke, these few extra days of 
protection may be all what these patients need to be free of pneumonia. Therefore it was 
justified to test the effect of metoclopramide on acute stroke patients who were fed via 
nasogastric tubes. 
 
3.6.2. Rationale for duration of treatment, treatment regime and type of pneumonia 
Metoclopramide was given for a period of three weeks. Practicalities of following up 
patients for a longer period than this were the main reason to limit the duration of the study 
for three weeks. Also, dysphagia would have resolved in a significant proportion of patients 
by the end of the second week following acute stroke, and that patients with persistent 
dysphagia would have had a percutaneous endoscopic gastrostomy by this time, therefore 
significantly reducing the number of patients likely to benefit at this stage497. Furthermore, 
studies have shown that there is a reduction of efficacy of metoclopramide after four weeks 
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when administered regularly473. Most importantly, the maximum incidence of pneumonia is 
seen within the first two weeks following acute stroke and it was thought that was the time 
these patients need interventions to prevent episodes of regurgitation, aspiration and 
pneumonia117;177;184. Also by limiting the use of metoclopramide to three weeks would 
prevent more serious and potentially irreversible extra-pyramidal side-effects such as 
tardive dyskinesia, which are associated with long-term usage of metoclopramide. 
 
It has been demonstrated that higher doses of prokinetic agents can achieve optimal effect 
in critically ill patients496. These doses may overcome the gastro-intestinal dysfunction 
caused by drugs, decreased gastric perfusion and the autonomic effects of stress and pain, 
commonly seen in the critically ill496. However, higher doses of prokinetic agents may not 
be safe in critically ill patients as doses of metoclopramide 40 mg per day or higher can 
produce drowsiness, extra-pyramidal reactions and restlessness due to central nervous 
system toxicity481. These side effects may occur at a lower dose in patients with impaired 
renal function, which is not uncommon in critically ill patients498. Therefore the 
recommended regular dose according to the BNF, which is 10 mg/tds was used in the 
MAPS trial398;498.  
 
3.6.3. Choice of outcome assessment 
There were several reasons for having any pneumonia rather than aspiration pneumonia as 
the primary outcome. The diagnosis of aspiration pneumonia has always been based on a 
combination of clinical suspicion or observed aspirations, new physical signs and new 
infiltrates in chest radiograph of dependant lung region following such aspiration139. The 
medical literature does not give any better way of clinical diagnosis of aspiration 
pneumonia. Many clinical studies reported using various combinations of criteria for the 
diagnosis of pneumonia but none clearly defined a set of criteria for the diagnosis of 
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aspiration pneumonia. In addition up to 50% of aspiration in stroke patients can be silent, 
and therefore confirmed pneumonia without overt signs of aspiration may still be caused by 
aspiration88. Also, patients who have the most depressed cough reflex are those most at risk 
of silent aspiration and these are the patients who would be kept nil by mouth and fed via 
nasogastric tubes17. Therefore, it can be assumed that stroke associated pneumonia in a 
significant number of patients with large strokes started as aspiration pneumonia. Patients 
in this study were not observed constantly for aspiration and the trial did not include 
interventions such as tracheal pH monitoring or other measurements to diagnose aspiration. 
Therefore aspiration pneumonia was not chosen as the primary outcome, because the high 
prevalence of silent aspiration may have lead to under diagnosis, making this an unreliable 
indicator of the efficacy of trial intervention. Thus, number of episodes of any pneumonia 
was chosen as the primary outcome and number of episode of aspiration pneumonia was 
chosen as a secondary outcome. It was assumed that patients with other causes of hypoxia 
and lung shadowing will be equally distributed between the intervention and control group. 
Therefore any difference in additional chest signs, radiological changes and hypoxia should 
be due to the intervention.  
 
3.6.4. Dopamine and swallow 
Dopamine agonists increase substance P levels and both dopamine D1 and D2 antagonists 
decrease substance P levels499. The basal ganglia are involved in dopamine metabolism in 
the brain and patients with basal ganglia infarcts have an impaired dopamine 
metabolism500. It has been suggested that reduced dopamine levels secondary to basal 
ganglia involvement lead to a reduction in substance P levels in the glossopharyngeal and 
vagus nerves resulting in an impairment of swallow and cough reflexes, with an increased 
the risk of aspiration and pneumonia. It has been demonstrated that patients with basal 
ganglion infarctions have a higher incidence of pneumonia than patients with hemispheric 
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strokes or strokes in other locations and this is thought to be due to reduced dopamine 
metabolism, therefore reduced the substance P levels in the glossopharyngeal and vagal 
sensory nerves366. In addition, bilateral basal ganglion strokes are associated with delayed 
triggering of the swallowing reflex, multiple episodes of pneumonia and increased 
mortality500. Replacement of dopamine corrects these abnormalities and it has been 
demonstrated that intravenous infusion of levodopa in patients who had basal ganglia 
infarcts improved of their swallowing reflex501;502.  
 
It is interesting to see how a dopamine antagonist could reduce the incidence of pneumonia 
in post-stroke patients who are fed via nasogastric tubes as a dopamine antagonist may be 
expected to delay the recovery of swallow and worsen aspiration. Conversely, recent 
studies done in patients with Parkinson’s disease have shown that treating Parkinson’s with 
dopaminergic medication did not achieve the improvement in swallowing as anticipated 
though there was a constant improvement in the rest of the motor function503. The 
swallowing abnormalities persisted after administration of drugs, either with or without 
dopaminergic activity504. These new findings cast a doubt on the importance of dopamine 
in the recovery of swallow. In acute strokes the facilitation of cerebral plasticity to take 
over the swallowing function by the non-dominant swallowing centre may be more 
important in the recovery of dysphagia. Having less inflammatory activity and better 
oxygen levels would have helped the recovery of the penumbra, improved of cortical 
plasticity and take over the swallow by the non-dominant swallow centres in the 
undamaged hemisphere.  
 
In addition, the peripheral action of dopamine on the gastrointestinal tract is predominantly 
inhibitory, leading to poor lower oesophageal sphincter tone and gastroparesis505. It is very 
likely that this peripheral action of dopamine on the gastrointestinal tract was responsible 
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for the reduction of pneumonia in the patient group who were treated with metoclopramide. 
In addition, the action of metoclopramide on the chemoreceptor trigger zone and the 
vomiting centre did reduce the episodes of vomiting and aspiration which was partly 
responsible for the reduction in aspiration and pneumonia.  
 
3.6.5. Other factors might have affected the results 
Another possible reason for the metoclopramide in the reduction of pneumonia in our 
patient group is that the possibility of these patients might have had pre-existing gastro-
oesophageal dysfunction. Most stroke patients are older and it has been shown that older 
people have a higher incidence of gastro-oesophageal reflux diseases including hiatus 
hernia. Nearly half of our patients were on a proton pump inhibitor or an antacid at the time 
of recruitment, which further indicate the possibility of peptic ulcer disease or reflux. 
Metoclopramide as a commonly used anti-reflux medication reduced the reflux the patients 
in the treatment group if they already had hiatus hernia or gastro-oesophageal reflux 
disease. A nasogastric tube would have caused further disruption of the gastro-oesophageal 
sphincter dysfunction in patients who already had gastro-oesophageal reflux disease, which 
may explain the very high incidence of pneumonia in the placebo group. However, none of 
our patients had a diagnosis of gastroesophageal reflux disease at randomisation nor were 
investigated for such disease prior to admission. None of the patients were investigated for 
gastro-oesophageal reflux disease following randomisation as it was not in the study 
protocol.  
 
It is possible that D2 receptor blockade of metoclopramide might have had an immuno-
modulating effect which may have contributed towards the reduction in the incidence of 
pneumonia. Significant percentage of normal healthy subjects aspirate during sleep with no 
adverse effects127;506. It has been demonstrated that stroke patients have a higher incidence 
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of pneumonia than age matched patients on an elderly care ward507. This is partly 
secondary to stroke-induced immunosuppression making them more susceptible to 
infections, in which stress hormones play a significant role. Beta blockers have been 
demonstrated to reduce the impact of stroke-induced immunosuppression260. Further 
research is needed to assess the peripheral action of dopamine, which is a stress hormone, 
as a mediator of stroke-induced immunosuppression.  
 
3.6.6. Adverse Effects 
The well known side-effects of metoclopramide are extra pyramidal dysfunctions including 
dystonic reactions, occulogyric crisis and tardive dyskinesia398. There have been recent 
concerns of these central nervous system side-effects in the long term use of 
metoclopramide and drug safety authorities such as Medicines and Healthcare products 
Regulatory Agency (MHRA) have issued restrictions on long term regular use of 
metoclopramide508. Participants of the MAPS study were observed regularly for the 
development of extrapyramidal side-effects. However, none of the patients participated in 
the MAPS study manifested any major side-effects of metoclopramide during their 
treatment period. In addition, the previously mentioned Yavagal et al’s study on 
metoclopramide also did not report on any serious side-effects of metoclopramide488. 
Literature states that these side-effects are more likely to be associated with high doses, 
intravenous administration and prolonged usage. Dystonic reactions including occulogyric 
crises, are most likely to occur within a few days of treatment, and are more common in 
young patients, though they have also been reported in older females398;481. In addition, 
dystonic reactions are easily recognised and completely reversed on discontinuation of 
metoclopramide with no long lasting damage. Drug-induced Parkinsonism and tardive 
dyskinesia are associated with long-tem drug usage, usually more than three months. 
Tardive dyskinesia is most common in older females and may not be reversible with 
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withdrawal of metoclopramide482. Other side-effects such as confusion, diarrhoea, cardiac 
arrhythmias and hyperprolactinaemia are fully reversible with discontinuation of 
metoclopramide. As only 30 patients were exposed to active treatment with 
metoclopramide in the MAPS study, we cannot exclude that such effects could occur in 
larger cohorts. It is possible that limiting the maximum dose to 10mg three times a day was 
safe and did not produce toxic drug levels that would have produced early dystonic 
reactions and limiting the usage of metoclopramide for a maximum of 3 weeks prevented 
manifestation of side-effects associated with its long-term use. In addition, longer courses 
of metoclopramide may not be needed in stroke patients who are fed via nasogastric tubes 
as they need maximum protection during the first two weeks when the incidence of 
pneumonia is at its peak. Also most patients will regain their swallow by the end of two 
weeks. The participants of the MAPS study represent the average patient population of a 
stroke unit. Our findings suggest that metoclopramide in the doses and duration used in the 
MAPS trial appears to be safely used in this patient population. A much larger study is 
needed to exclude rare side effects. When balancing the potential fatal complication of 
pneumonia against potentially reversible side-effects in short-term usage, time-limited use 
of metoclopramide under close clinical supervision on the stroke unit is a reasonable 
option.  
 
The MAPS study has also shown that testing the effects of metoclopramide in this patient 
population was feasible, as it was possible to obtain consent, randomize, and to complete 
observations, investigations, and follow-up of participants without major impediment, and 
as there was a good adherence to the allocated treatment. However, 80% of patients who 
had NGTs were not eligible for recruitment, mainly because they already has signs of 
pneumonia. Early recruitment within few hours of admission in patients who are likely to 
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need NGT feeding (severe stokes, reduced level of consciousness) would allow a higher 
proportion of potentially eligible patients to be recruited.  
 
Our study has limitations. No formal sample size calculation was performed. While the 
reduction in pneumonia was highly significant statistically the sample is not large enough 
to exclude a false positive result (type 1 error) with confidence. The study was not fully 
blinded, as the nurse dispensing the treatment was aware of the allocation. This could have 
introduced bias, but as the nurses were not involved in recruitment or assessment of 
patients this risk is considered low. Also to counter-act this possible source of bias, 
independent assessors were used to interpret chest radiographs and for the diagnosis 
pneumonia. A larger randomized controlled fully blinded study is needed to confirm the 
reduction of pneumonia and to determine whether metoclopramide affects mortality and 
long-term handicap. These have been discussed in detail in chapter 5. 
 
3.7. Conclusion 
In conclusion, metoclopramide in the doses of 10 mg administered every eight hours 
appear to reduce the incidence of pneumonia in acute stroke patients who are fed via 
nasogastric tubes. In patients who had pneumonia, metoclopramide delayed the onset of 
pneumonia by two days. The MAPS study has also shown that testing the effects of 
metoclopramide in this patient population was feasible and metoclopramide was well 
tolerated. In addition to the observed reduction in pneumonia, patients were less hypoxic, 
needed fewer types of antibiotics and had fewer antibiotic days. They also had less 
episodes of witnessed aspiration. At the end of the third week though statistically not 
significant, fewer patients required a PEG tube insertion and there were more survivors in 
Student No: 940137947014 227 
patients who received metoclopramide. A trial with larger patient number and full blinding 
is needed to confirm the findings of the MAPS study. 
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Chapter 4  Diagnosis of pneumonia 
 
Abstract - Diagnosis of pneumonia in acute stroke patients 
Introduction: The diagnosis of pneumonia following stroke is difficult as patients do not 
manifest well recognised signs and symptoms of a respiratory illness.  
 
Method: Signs and symptoms of 47 radiologically confirmed episodes of pneumonia in 
patients with severe acute stroke (mean age 77, mean NIHSS 17) were reviewed to 
establish the most consistent signs of post-stroke pneumonia. In addition, baseline and all 
available CRP and WBC values of the first pneumonia (n = 34) were reviewed to compare 
the performance of white cell count (WBC) and C-reactive protein (CRP) as diagnostic 
markers of post-stroke pneumonia 
 
Results: 70% of pneumonias occurred within the first week following stroke. The most 
common symptoms were tachypnoea 45/47 (95%) and a drop in oxygen saturation <90% 
on air 44/47 (93%). Cough, purulent sputum, and temperature >38°C were observed in 28 
(59%), 25(53%) and 15(32%) episodes respectively. The highest mean temperature with 
pneumonia was 37.7°C. The commonest physical sign was new onset unilateral coarse 
crackles (97%). Signs of consolidation and bronchial breathing were elicited in 25 (53%) 
and in 3 (6%) episodes respectively. 14 (30%) pneumonias had positive sputum cultures.  
 
The highest CRP levels (mean±SD) were 35.5±32.4 mg/l for patients with no pneumonia 
and 120.3±89.6 mg/l for patients with pneumonia (p <0.001). The highest WBC 
(mean±SD) was 11.1±3.1/ml for the no pneumonia group and 15.7±5.7/ml for the 
pneumonia group (p <0.001). The highest CRP levels were observed within 24 hours of 
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pneumonia. CRP alone had a predictive power (R2) of 0.50; adding WBC only improved 
this by 4% (predictive power of CRP and WBC combination 0.54, WBC alone 0.25). On 
ROC analysis, the area under the curve was 0.86 for CRP and 0.77 for WBC. A CRP cut-
off of 40 mg/l had sensitivity 0.69, specificity 0.84; a cut-off value of 65 mg/l had 
sensitivity 0.61, specificity 0.96 for diagnosing post-stroke pneumonia. For every 1 mg/l 
increment of CRP, the risk of pneumonia increased by 0.5% (OR = 1.05). 
 
Conclusion: Pneumonia is an early complication following acute stroke but is not usually 
associated with well recognised signs and symptoms of pneumonia. A drop in oxygen 
saturation, tachypnoea, and coarse inspiratory crackles were the most consistent clinical 
signs and though nonspecific should alert the attending physicians of impending 
pneumonia. A positive sputum culture is not common. CRP appears to have a better 
predictive power than a raised WBC for early diagnosis of post-stroke pneumonia. A cut-
off value of CRP 40 mg/l had the best combination of sensitivity and specificity. 
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4.1. Introduction 
The diagnosis of pneumonia is based on clinical, biochemical and microbiological 
parameters258. In addition a chest radiograph is recommended by many guidelines258;275. 
However, diagnosis of pneumonia in stroke patients, especially in those with a severe 
stroke can be difficult as the recognised signs and symptoms of infections such as pyrexia, 
rigors and leucocytosis are not always manifested in this patient group259. In addition a 
reduced level of consciousness, impaired voluntary inspiration on the affected side, reduced 
pharyngeal sensation and an impaired cough reflex can make signs and symptoms of a 
chest infection difficult to detect213;261. The systemic inflammatory response may be muted 
and interpretation of chest radiographs can be difficult due to a multitude of reasons such as 
older age, hemiparesis, co-existing other illness and stroke-induced immunosuppression242. 
However, early diagnosis of pneumonia is important to allow initiation of treatment and to 
prevent complications and associated mortality. In this chapter, secondary analysis of all 
available data on clinical signs, symptoms and inflammatory markers for the diagnosis of 
pneumonia will be performed to identify predictors for an early diagnosis of on-going post-
stroke pneumonia, which will help in early decision making and therapeutic intervention. 
  
4.2. Aim of the study 
The aim of the study is to find out early predictors of post-stroke pneumonia by secondary 
analysis of data collected in the MAPS trial. 
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4.3. Hypotheses to test 
• Increased respiratory rate and a drop in oxygen saturation are good predictors of 
pneumonia in acute stroke patients  
• A raised CRP level can be used as a biochemical marker for early prediction of 
pneumonia in acute stroke patients  
 
4.4. Methodology 
A brief outline on diagnosis of pneumonia is given here as this has been discussed in detail 
in the methodology section in chapter 4. As a part of routine clinical practice all patients 
were examined daily for signs and symptoms of pneumonia as detailed below. 
iv) Baseline observations pulse, blood pressure, oxygen saturations, temperature and 
respiratory rate. 
v) Chest examination – percussion for dullness, auscultation for type of breath sounds 
including bronchial breathing and additional sounds such as inspiratory 
crackles.  
vi) Need for suctioning due to cough or increased respiratory secretions and the 
presence of purulent sputum was noted.  
 
If clinical symptoms and signs were suggestive of pneumonia a chest radiograph was 
requested and blood was taken for inflammatory markers. If there was purulent sputum a 
sample was sent to the microbiology laboratory for culture and sensitivities. Daily 
examination findings were recorded in patient’s case notes. These measures are done as 
part of routine clinical practice. 
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As for the research, data were collected on separate data sheets allocated to each patient. 
Baseline observations, inflammatory markers (if available) and chest signs were recorded 
in all patients on recruitment and on day 7, day 14 and day 21. If the end of the trial was 
earlier than day 21, these observations were recorded on that day. If there were no positive 
chest signs it was noted as ‘chest was clear’ in the trial log. If a diagnosis of pneumonia 
was made, all physical signs were recorded on the day of diagnosis and at the end of the 
course of antibiotics in the patients’ research data sheet. In addition the vital signs and 
chest signs on the day prior to the pneumonia were reviewed from the case notes and the 
observation charts and were recorded in the research data sheets. All available CRP and 
WBC counts performed during the trial period irrespective of presence of pneumonia were 
recorded in the data sheets.  
 
Early indicators of stroke associated pneumonia 
Data on the day of the diagnosis of pneumonia were analysed to identify early signs and 
symptoms of post-stroke pneumonia. Further statistical analysis of increased respiratory 
rate, a drop in the oxygen saturations and the highest values of CRP and WBC were carried 
out to see their predictive power, sensitivity and specificity for the diagnosis of pneumonia. 
Also further analysis of CRP levels was done to determine a cut-off level that would be 
sensitive and specific for the diagnosis of post-stroke pneumonia. All patients had C-
reactive protein and white cell counts measured on arrival to the Acute Stroke Unit or at 
least within 48 hours of admission and if there was a suspicion of pneumonia. Also a 
patient with a diagnosis of pneumonia had several measurements of inflammatory markers 
to see the response to antibiotics or the need to change antibiotics. Thus patients with 
pneumonia had several C-reactive protein and white cell count measurements during the 
trial period, and all of the readings taken on these variables were used in the analysis. 
Erythrocyte sedimentation rate (ESR) was not regularly measured, as samples were often 
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rejected by the laboratory for unknown reasons or not being processed due to undisclosed 
reasons. Therefore available ESR readings were not used in the initial analysis. 
 
Measurement of CRP and WBC was mainly performed in patients with a clinical suspicion 
of pneumonia. Therefore patients who did not have pneumonia did not have many data on 
inflammatory markers. However, there were more data on inflammatory markers during the 
first week following stroke, even in patients who did not have pneumonia. As most of the 
pneumonia episodes occurred within the first week following stroke and as there were more 
data in both groups, only the first episodes of pneumonia were chosen for the analysis. The 
data were grouped as event (pneumonia) / no event. The values of the day of the diagnosis 
of pneumonia, or the closest, were considered for analysis for the participants who had 
pneumonia. The mean of the available measurements of relevant values during the first 
week were included in the analysis in patients who did not have pneumonia. Only the CRP 
and WBC of first 34 episodes of pneumonia were chosen for the analysis as most of these 
episodes occurred within the first week of the stroke where there were more data in patients 
who did not have pneumonia. Also the parameters for the diagnosis of second pneumonia 
would have been affected by the longer hospital stay of these patients, such as possibility of 
appearance of other medical complications, previous course of antibiotics and the 
possibility of the general condition of the patient could have deteriorated following a longer 
hospital stay. Though clinically and biochemically highly suggestive of a new episode of 
pneumonia, there was no way to prove that the initial pneumonia had fully resolved by the 
time of the onset of new symptoms related to the second episode of pneumonia. 
 
In the first stage of analysis, diagnostic markers of pneumonia were identified by entering 
candidate predictors in a multivariable logistic regression model. The variables included as 
predictors in the model were: crepitus, O2 saturation, temperature, respiratory rate, C-
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reactive protein (CRP), white blood count (WBC).  The diagnostic markers were identified 
in terms of their significance as predictors in the logistic regression model, but also 
evaluated in terms of their predictive strength; this was indicated by their contribution to 
the goodness-of-fit of the model, as expressed by the Nagelkerke pseudo-R2 statistic. 
 
The second stage of analysis focused on any diagnostic markers identified in the first stage 
that were numeric variables. Receiving operating characteristics (ROC) methods were used 
to identify appropriate diagnostic thresholds on these variables in terms of sensitivity and 
specificity. The area under the ROC curve (AUC) indicates the accuracy with which the 
scale can be used to classify or diagnose. An AUC statistic of one indicates that the scale 
has the greatest possible sensitivity and specificity whilst zero denotes the worst possible 
sensitivity and specificity. An intermediate value of 0.5 indicates that the scale 
classification is no more accurate than guessing. The Youden index was also calculated for 
each observed point on the scale. This statistic expresses, on a 0–1 scale, the maximum 
difference between sensitivity and 1–specificity (i.e. between the true positive rate and the 
false positive rate) for a given cut-off score, and can thereby identify the cut-off that 
simultaneously maximizes both sensitivity and specificity. 
 
4.5. Results of diagnosis of pneumonia 
4.5.1. Signs and symptoms of pneumonia 
During the MAPS study there were 47 episodes of radiologically confirmed pneumonia 
(table 4.1). Thirty-four patients had only one episode of pneumonia and 13 patients had two 
episodes of pneumonia during the trial period. Most patients (97%) had the first pneumonia 
during the first week following commencement of nasogastric feeds. Details of signs and 
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symptoms of pneumonia are shown in table 4.1. All these signs and symptoms of 
pneumonia were the signs that were present on the first day of the diagnosis. The most 
commonly encountered symptom was tachypnoea, which was observed in 45 episodes 
(95%) of pneumonia. A drop in oxygen saturation less than 90% on air was seen in 44 
episodes (93%). Cough and purulent sputum were seen in 28 episodes (59%) and 25 
episodes (53%) of pneumonia respectively. An increased temperature more than 38°C was 
seen only in 15 episodes (32%) and chills and rigors were only observed in one occasion. 
The mean of the highest temperature associated with pneumonia was 37.7°C. The 
commonest physical sign on chest examination was new-onset crackles and 46 episodes 
(97%) of pneumonia had coarse inspiratory crackles. The crackles which were recognised 
as a sign of infection were of new onset, coarse and unilateral or asymmetrically distributed 
on the lower lung fields. Signs of consolidation such as dullness to percussion, reduced air 
entry and aegophony were seen only on 25 episodes (53%). Bronchial breathing was 
detected only on three occasions. Positive sputum cultures were only found in 14 episodes 
of pneumonia (30% of all pneumonias). The commonest organisms identified were 
Staphylococcus aureus (n = 4) and Gram negative bacilli such as Klebsiella (n = 4), E. coli 
(n=2), Proteus (n = 1), Citrobacter (n = 1) and Serratia (n = 1). 
  
In the MAPS study all 47 episodes of pneumonia were confirmed by new radiological 
changes on the chest radiograph. Most of the patients had several chest radiographs during 
the first week after nasogastric tube insertion to confirm the position of the nasogastric 
tube, a procedure done routinely if no aspirate can be obtained or if the pH of the aspirate is 
not acidic. This gave the researcher the opportunity to review and compare several chest 
radiographs in making the diagnosis of pneumonia. The most consistent inflammatory 
marker for the diagnosis of pneumonia was an increase in C-reactive protein levels over 30 
mg/l, which was seen in 41 episodes of pneumonia (87%). Also the elevation of CRP level 
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was an early indicator of pneumonia as in most episodes of pneumonia the elevation 
occurred within the first 24 hours of the diagnosis of pneumonia. An elevated white cell 
count was observed in 38 episodes of pneumonia (80%). A rise of the white cell count was 
also seen within the first 24 hours and resolved after successful treatment of pneumonia.  
 
4.5.2. Early indicators of stroke associated pneumonia 
In the first stage of data analysis, many of the clinical variables (crepitus, O2 saturation, 
respiratory rate) exhibited ‘complete separation’ with no overlap in values of the predictor 
variable between the two outcome categories (‘pneumonia’ and ‘no pneumonia’). This was 
because there were no patients in the non-pneumonia group documented tachypnoea, 
hypoxia or new onset unilateral chest signs. This precluded these variables from being 
tested statistically in the logistic regression model, but also confirmed their association 
with the diagnosis of pneumonia. CRP and WBC were, however, testable. The odds ratios 
for CRP and WBC were 1.046 (95% CI 1.019, 1.073; p = .001) and 1.247 (95% CI 1.060, 
1.468; p = .008), respectively. Thus, an increase of one mg/l CRP or one unit WBC 
increases the likelihood of pneumonia by approximately 0.5% and 25%, respectively (the 
magnitude of the odds ratios cannot be compared, as there a different numbers of points on 
the two scales). If each predictor is analysed separately, the Nagelkerke R2 value for CRP 
is .506, compared to .232 for WBC, suggesting that CRP is a stronger predictor of 
pneumonia. If analysed together, the addition of WBC to CRP increases the R2 only 
modestly – from .501 to .546, suggesting that information on WBC adds little additional 
diagnostic information to that derived from CRP. 
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4.5.2.1. Cut-off values 
 
CRP and WBC were taken forward to the second stage of data analysis. A cut-off value for 
CRP was reviewed using receiver operating characteristic (ROC) analysis. The area under 
the ROC curve (AUC) indicates the accuracy with which the scale can be used to classify 
or diagnose. An AUC statistic of one indicates that the scale has the greatest sensitivity and 
specificity whilst zero denotes the worst possible sensitivity and specificity. An 
intermediate value of 0.5 indicates that the scale classification is no more accurate than 
guessing and the closer the value is to 1, the more accurately it can predict sensitivity and 
specificity. From the ROC analysis, the AUC for CRP was 0.86 (95% CI 0.79, 0.95) and 
the AUC for WBC 0.77 (95% CI 0.64, 0.90) which demonstrates that CRP is a more 
accurate diagnostic marker than WBC (figure 5.1). Table 4 shows the sensitivity, 
specificity and the Youden index for observed values of CRP. The highest Youden index 
observed for CRP was 0.57, which corresponded to three cut-offs: ≥25.6 mg/l (sensitivity, 
0.85; specificity 0.72), ≥36.5 mg/l (sensitivity, 0.73; specificity, 0.84), ≥64.7 mg/l 
(sensitivity, 0.61; specificity, 0.96). The choice of the optimum diagnostic cut-off for CRP 
will therefore depend on the relative weight given to sensitivity and specificity; if 
sensitivity is prioritized, ≥25.6 is the optimum cut-off. Table 5 shows values of sensitivity, 
specificity and the Youden index for WBC. The highest Youden index observed for WBC 
was 0.65, which corresponded to a cut-off of ≥11.53 (sensitivity, 0.73; specificity 0.92). 
Cut-off values for specific CRP values are given below. 
 
Cutoff Sensitivity Specificity 
36.5 mg/l 0.727 0.840 
45.0 mg/l 0.697 0.840 
50.0 mg/l 0.667 0.840 
59.4 mg/l 0.606 0.920 
 
 
 
Cut-off values for specific WBC values were calculated and are given below. 
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Cutoff Sensitivity Specificity 
10.0 .788 .720 
11.0 .727 .840 
12.0 .667 .920 
13.0 .485 .960 
14.0 .364 .960 
15.0 .333 1.000 
 
 
4.5.3. Summary of results 
 The most commonly encountered symptoms were tachypnoea and a drop in oxygen 
saturation, which were seen in almost all pneumonias. Cough and purulent sputum were 
only observed in half and an increased temperature more than 38°C was only seen in one-
third of pneumonias. The commonest physical sign was new onset crackles and was present 
in almost all pneumonias.  
Results also suggest that if one had the choice of using CRP or WBC, CRP would be the 
best to use. If both were available both parameters can be used. However, the improvement 
of predictive power was quite small (about 5%), and also it would be much more complex 
to produce a clinical rule of thumb using the two variables rather than just one.  
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Table 4-1 Signs and Symptoms of Pneumonia (episode and frequencies) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(CRP-C Reactive Protein, ESR–Erythrocyte Sedimentation Rate, WBC-White Blood Cells) 
 
First episode  
n = 34 (%) 
Second episode  
n = 13 (%) 
Total  
n = 47 (%) 
Signs and symptoms 
Respiratory rate >25/m 32 (94) 13 (100) 45 (96) 
Oxygen saturations <90% 31 (91) 13 (100) 44 (94) 
Cough 22 (65) 6 (46) 28 (60) 
Purulent sputum 19 (56) 6 (46) 25 (53) 
Temperature >38°C 12 (35) 3 (23) 15 (32) 
Chill and rigors 1 (3) 0 (0) 1 (2) 
     
Chest examination 
Inspiratory crackles 33 (97) 13 (100) 46 (98) 
Sign of consolidation 18 (54) 7 (54) 25 (53) 
Bronchial breathing 3 (9) 0 (0) 3 (6) 
     
Investigations 
CRP > 30 mg/l 30 (88) 11 (85) 41 (87) 
WBC >11 29 (85) 9 (69) 38 (81) 
ESR > 20 mm/hour 5 (15) 1 (8) 6 (13) 
WBC <3 1 (3) 0 (0) 1 (2) 
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Figure 4-1 Receiver operating characteristic (ROC) curves of CRP and WBC 
 
 
 
  CRP – C reactive proteine, WBC – White blood cells 
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4.6. Discussion 
4.6.1. Clinical signs and Symptoms for diagnosis of pneumonia 
The diagnosis of post-stroke pneumonia can be difficult as stroke patients do not manifest 
well known signs and symptoms of respiratory illness76;177. However, early diagnosis is 
important to enable timely initiation of antibiotic treatment and to prevent complications 
and associated mortality. According to our findings increased respiratory rate and a fall in 
oxygen saturation were the most common symptoms of stroke-associated pneumonia. The 
most consistent physical sign on examination of the chest was inspiratory crackles. 
However, these signs are very nonspecific and can be present in many respiratory diseases 
such as lung collapse, pulmonary embolism or bronchospasm. Tachypnoea and drop in 
oxygen saturation to less than 90% on air with new onset inspiratory crackles should alert 
the attending physician of possible pneumonia, which would warrant careful examination 
for further signs of consolidation and initiation of investigations such as inflammatory 
markers and a chest radiograph. This is especially true as our results demonstrated that 
other well-known symptoms such as high temperature, cough, and purulent sputum were 
less often observed in post-stroke pneumonia. Also other known signs of pneumonia were 
less commonly encountered in the study population. Poor patient compliance, difficulty in 
maintaining an optimal positioning to auscultate all over the lung bases and poor 
inspiratory efforts of the patient may have contributed to this reduced level of identification 
of consolidation and bronchial breathing.  
 
Older people do not commonly manifest high temperatures with acute infection, and this is 
also well documented following acute stroke266. These findings are reflected in our study as 
only fifteen episodes of confirmed pneumonia had a temperature of above 38°C. Our stroke 
patients were older, average age was 78 years and as previous studies have shown, did not 
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manifest temperature above 38°C. It is also possible that stroke-induced 
immunosuppression could have played a role in the muted temperature response. However, 
the majority of patients had a temperature above 37.5°C with pneumonia. Thus it is 
important to be vigilant of an impending infection with a rise of temperature of 37.5°C or 
more rather than expecting higher temperature spikes. However, if patients mount an 
immune response with a rise in temperature, it is a significant sign of acute infection as it 
has been demonstrated that in an older person, for every single degree of rise in 
temperature (in Celsius), the risk of infection was increased by almost four-fold266. 
 
It has been demonstrated that large strokes are associated with an initial rise of temperature, 
which was a poor prognostic sign267. Patients in our trial had large strokes reflected by an 
average NIHSS score of 18. However, an initial rise in the temperature was not observed in 
participants. This may be because after the initial record of temperature on admission it was 
not recorded for the following 6 to 24 hours, the time for the organisation of investigations 
and transfer of patients from the Emergency Department to the Acute Stroke Unit. Even in 
the Acute Stroke Unit, unless required, frequent temperature recording more than three 
times a day is not carried out as standard practice. Therefore this initial rise in temperature 
could have been missed. It is also possible that patients who had a high temperature 
weren’t approached to participate in the study as the temperature rise was considered as a 
sign of possible early infection. 
 
4.6.2. Laboratory Tests 
 In this study only 14 episodes (30%) of pneumonia had a positive microbiological 
diagnosis, all from the first episode of pneumonia. Bacteria isolated from these sputum 
cultures were similar to those in other studies performed in patients with acute stroke. 
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Sputum cultures from the second episodes of pneumonia did not produce any significant 
bacterial growth, possibly because all these patients had already had a long course of 
antibiotics for their first pneumonia, which may have selected out a strain that is not 
commonly tested in laboratories including anaerobes, or simply because the presence of 
antibiotics hindered any bacterial growth in cultures213. Though an elevated WBC count 
with neutrophilia is commonly observed in bacterial infections, a similar response was not 
expected in our patient group as the leukocyte response is not always present in an older 
person and would have been affected by stroke induce immunosuppression. However, most 
of our patients in the MAPS study did have an adequate WBC response to pneumonia, 
which settled with the resolution of pneumonia.  
 
4.6.3. Predictors of Pneumonia 
Diagnosis of post-stroke pneumonia cannot be delayed, as commencement of antibiotics as 
soon as possible is necessary for a better recovery and to avoid complications. As described 
before, well recognised signs and symptoms are frequently absent in stroke patients and, as 
demonstrated in the study, commonly observed signs and symptoms such as an increased 
respiratory rate and hypoxia can occur in other respiratory illnesses. Departmental chest 
radiographs can be difficult to organise, are commonly done as portable, and may be of 
poor quality. Many portable chest radiographs are done towards the end of the day due to 
organisational difficulties and may not be reviewed by experienced physicians until next 
the day which will further delay the commencement of appropriate antibiotics. However, in 
clinically suspected post-stroke pneumonia, having most recent CRP and WBC will 
provide adequate justification for early initiation antibiotics without relying on chest 
radiographs. 
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The study demonstrated that CRP and WBC values were highly predictive of pneumonia. 
CRP appears to have a better predictive power and adding WBC did not significantly 
improve the predictive power of the model. Also it appears that CRP of 36.5 mg/l has the 
best cut-off value for sensitivity and specificity for the diagnosis of stroke associated 
pneumonia. As a practically workable, easy to remember cut-off value, CRP of 40 mg/l 
can be recommended to be used for the diagnosis of post-stroke pneumonia.  This is less 
than cut-off values observed in some studies performed on older people with pneumonia 
and some studies have suggested cut-off values high as 60 – 80 mg/l264;266;509. Stroke-
induced immunosuppression may have played a role in this lower cut-off value observed in 
stroke patients. Therefore a modest rise of CRP should alert attending physicians of 
impending pneumonia in acute stroke patients. 
 
 As CRP is as good as or a better predictor of pneumonia and adding the WBC gives no 
significant improvement to its predictability, the diagnosis of post-stroke pneumonia can be 
achieved by fewer blood samples. This is especially important in patients with difficult or 
limited venous access due to long hospital stay, multiple venepunctures, venous sclerosis 
and hypoalbuminaemic oedema. The commonest set of investigations on an enterally fed 
patient is urea and electrolytes, done as a single biochemical sample, which is required for 
the adjustment of feeds and the intravenous fluids. CRP being a biochemical investigation 
can be assessed from the same sample unlike WBC, which is analysed as a haematological 
sample, therefore needing an extra blood sample. Therefore having CRP as the predictor 
will reduce patient discomfort, limit the required blood samples and reduce cost. 
 
It can be argued that WBC and CRP are nonspecific indicators of any infection and the 
findings of the study may not reflect true changes which may occur with pneumonia. 
However, as described in chapter 4, the incidence of other infections was low in this patient 
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group. Also the data on all available CRP and WBC measurements were incorporated in 
the analysis, including data on patients who had other infections. Therefore it can be argued 
that the findings of the analysis are a true reflection of changes seen in post-stroke 
pneumonia. These findings need to be validated in a separate sample of stroke patients, 
which will be done along with the second stage of the MAPS study. 
 
4.6.4. Incidence and the timing of pneumonia 
In the MAPS study the overall incidence of pneumonia was 56%. However, compared to 
the intervention group, the incidence of pneumonia was much higher at 87% in the non-
intervention group. This is a higher incidence of pneumonia than quoted in older studies, 
though recent studies that have reviewed patients fed via nasogastric tubes reported around 
70% incidence of pneumonia180;181. The incidence varied according to the type of patients 
included, criteria for diagnosis and the place of the study. Most of these studies included all 
stroke patients admitted during a defined time period irrespective of the severity of the 
neurological deficits and dysphagia. Many studies included mild strokes that are less likely 
to be at risk of developing aspiration and pneumonia. Some older studies excluded stroke 
patients who were semiconscious or unconscious, the subgroup of patients who have the 
highest risk of aspiration and pneumonia. Our patient population had severe strokes with an 
average NIHSS of 19 and had no swallow reflex, thus needed nasogastric feeds to sustain 
life. This is the type of post-stroke patient who would have the maximum risk of 
developing pneumonia. A recent study demonstrated that 88 to 91% of enterally fed stroke 
patients developed aspiration pneumonia in the presence of a nasogastric tube13. Sub-
analysis of the turn-mob study demonstrated that nearly 70% of patients who were fed via 
nasogastric tubes had pneumonia. Therefore more detailed studies to look into the 
incidence of pneumonia in stroke patients who are fed via nasogastric tubes are required. In 
the MAPS study the patients who did not have metoclopramide to improve gastric reflux 
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and motility had a similar incidence, which was significantly corrected by administration of 
metoclopramide three times a day. 
  
This study showed that the average time from the acute stroke to the onset of pneumonia 
was 4 days and the average time from insertion of a nasogastric tube to the onset of 
pneumonia was 3 days. This is in keeping with many studies done before which 
demonstrated that pneumonia is an early complication of a post-stroke patient89;177. Of 56% 
of all patients with pneumonia, the majority (64%) had only one episode of pneumonia. In 
addition non-resolving or recurrent pneumonia contributed significantly to the mortality of 
the stroke patients who were fed via nasogastric tubes. 
 
4.7. Summary 
In summary, an increase in the respiratory rate more than 25 breaths per minute, a fall in 
oxygen saturations less than 90% on air and new onset inspiratory crackles were the most 
commonly observed signs and were highly predictive of the onset of pneumonia. Well 
recognised symptoms of a chest infection such as cough, purulent sputum, and pyrexia 
were less commonly observed. Isolation of an organism from sputum samples was not 
common. As for the investigations, elevation of CRP and WBC were highly predictive of 
pneumonia and CRP had the highest predictive value. A CRP level of 40 mg/l can be taken 
as the cut-off level for the diagnosis of pneumonia. This is particularly important in stroke 
patients as stroke itself can increase the serum CRP levels. 
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Chapter 5 General conclusion, limitations and scope for future 
trials 
5.1. General summary 
The focus of this study was to identify methods to prevent aspiration and pneumonia in 
stroke patients who are fed via nasogastric tubes. The literature review identified that 
pneumonia is common after acute stroke and it contributes significantly to the post-stroke 
mortality and morbidity5;6. In addition, it is evident that pneumonia is directly related to 
dysphagia and aspiration that follows stroke and severely dysphagic patients have to rely 
on nasogastric feeds for their survival. Similarly, evidence suggest that nasogastric tubes 
are associated with a high incidence of pneumonia, due to continued aspiration of infected 
oropharyngeal secretions and to gastro-oesophageal dysfunction that follows stroke13;17. 
These include gastro-oesophageal sphincter dysfunction, gastric stasis and reflux, which 
are made worse by the presence of a nasogastric tube12;13;17. The mechanisms of how 
nasogastric feeds cause this refluxed gastric contents to be infected was reviewed. In 
addition it was argued how a prokinetic agent would counter-act these mechanisms and 
reduce reflux, therefore aspiration and pneumonia in stroke patients who are fed via 
nasogastric tubes.  
 
The systematic review of available literature undertaken for this study has demonstrated 
that there is a paucity of research into prevention of pneumonia in acute stroke patients and 
that there were no studies that specifically addressed prevention of pneumonia in stroke 
patients fed via nasogastric tubes. The MAPS study has demonstrated that metoclopramide 
at a dose of 10 mg administered every eight hours significantly reduced the incidence of 
pneumonia in acute stroke patients who are fed via nasogastric tubes. In addition, this study 
has provided evidence that stroke patients do not regularly manifest several well known 
diagnostic criteria for the diagnosis of pneumonia but that an increase in the respiratory rate 
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<25 breaths per minute, a fall in the oxygen saturation <90% on air and new onset of 
inspiratory crackles were the most commonly observed signs and were highly predictive of 
pneumonia. 
 
 
5.1.2. MAPS study 
The specific objective of the MAPS study was to test the effect of prokinetic agent 
metoclopramide on the incidence of pneumonia in acute stroke patients who are fed via 
nasogastric tubes. Metoclopramide was specifically chosen as it is a commonly used 
prokinetic agent and has a dual action, namely a central action to reduce vomiting and a 
peripheral prokinetic action on the upper gastrointestinal tract472. It has fewer serious side- 
effects than other prokinetic agents especially in short-term use, side-effects are easily 
recognised, and most are easily reversed by discontinuing the medication481. 
 
This is the first randomized controlled study of metoclopramide in patients with acute 
stroke fed via nasogastric tubes. Conducted as a pilot study, results of MAPS have shown 
that recruitment in the sub-acute stage of stroke is feasible and that regular administration 
of metoclopramide for a maximum of 21 days is safe in this patient group. Study findings 
suggest that metoclopramide reduces the incidence of pneumonia in acute stroke patients 
who are fed via NGT. Being a potent prokinetic, metoclopramide very likely reduced the 
contribution of infected gastric reflux and aspiration towards the development of 
pneumonia following stroke. Also as an antiemetic, metoclopramide reduced vomiting and 
aspiration in this patient group. In keeping with the observed reduction in pneumonia, the 
treatment group had less number of antibiotics and antibiotics days, had lower 
inflammatory marker levels and were less hypoxic. In addition to the reduction in the 
incidence of pneumonia, the onset of pneumonia was delayed by two days which was in 
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keeping with previous research488. There were more survivors in the metoclopramide group 
at 30 days though it was not statistically significant.  
 
Patients who were treated with metoclopramide appear to have a better neurological 
recovery at the end of 3 weeks and more patients could discontinue nasogastric tubes as 
they resumed oral feeds. Neurological recovery following stroke depends on recovery of 
ischaemic and injured tissue in the penumbra and taking over of various functions by non-
dominant cortical centres55;510. Inflammatory activity and hypoxia worsen the penumbral 
ischaemia and delay its recovery secondary to activation of tumour necrosis factor and 
macrophages and the resultant changes in the micro-vasculature511. Having less 
inflammatory activity and better oxygen levels due less pneumonia might have helped the 
recovery of the penumbra, facilitated cortical plasticity to take over the swallow by the 
non-dominant swallow centre in the undamaged hemisphere. This may explain the 
observed better neurological recovery and early recovery of swallow in patients who were 
treated with metoclopramide. 
 
There have been recent concerns of the central nervous system side effects of 
metoclopramide with long-term treatment508. Extra-pyramidal movements including 
dystonia reactions, well known side effects of metoclopramide, were not encountered 
during the MAPS study. Dystonic reactions are more commonly seen in younger patients, 
higher doses and others such as drug-induced Parkinsonism and Tardive dyskinesia on 
prolong treatment481. Patients in the MAPS study were much older, doses were according 
to the recommendations of British National formulary and the maximum treatment duration 
was 3 weeks which was not long enough for side-effects such as Tardive dyskinesia to 
manifest. Pneumonia is an early complication following acute stroke and many patients 
would have had recovered their swallow within first two weeks following stroke112. This 
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makes the need for metoclopramide mainly during the first few weeks following stroke, 
which is not long enough for more permanent adverse effects to occur. Also acute dystonic 
reactions, the anticipated side-effects during early days of treatment are easily identified, 
and are completely reversed on discontinuation of metoclopramide481. Therefore when 
comparing with the risk of pneumonia, a potentially fatal complication following acute 
stroke to the risk of developing a potentially reversible set of extrapyramidal side effects, 
the use of metoclopramide under adequate supervision during the first few weeks following 
stroke can be justified, if these patients have to rely on nasogastric tubes for their feeds and 
medication. 
 
5.1.3. Diagnosis of pneumonia 
Review of the literature showed that the diagnosis of pneumonia in post-stroke patients is 
difficult as they do not manifest well recognised signs and symptoms of a respiratory 
illness213;262. The objective of the secondary analysis of the data collected for the diagnosis 
of pneumonia was to find reliable criteria for the early diagnosis of post-stroke pneumonia. 
Three types of parameters are commonly used for the diagnosis of pneumonia, which are 
clinical, laboratorial, and radiological parameters250. Though various combinations of 
clinical signs, inflammatory markers, and microbiological data have been used for the 
diagnosis of pneumonia, new infiltrates in the chest radiograph is an essential criterion for 
the diagnosis of pneumonia according to most standard guidelines81;322. However, relying 
on a chest radiograph to diagnose pneumonia in a bed bound stroke patient can be 
difficult274. This may delay the diagnosis of pneumonia and the initiation of antibiotics, 
which in turn will delay recovery and increase pneumonia related complications250. 
Therefore early diagnosis of pneumonia is paramount in the management of pneumonia.  
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In my clinical practice, I have observed that an increased respiratory rate and a fall in the 
oxygen saturations were common and preceded the development of chest signs and 
radiological changes of pneumonia in post-stroke patients. Also I have identified CRP as a 
reliable parameter for the diagnosis and monitoring the progress of pneumonia. Therefore I 
hypothesised that an increased respiratory rate and a fall in the oxygen saturations were 
reliable early predictors and CRP is a good biochemical marker for the diagnosis of post-
stroke pneumonia. As a part of the MAPS study, data on the signs and symptoms of the 
radiologically confirmed episodes of pneumonia were recorded in detail. In view of the 
difficulties in the early diagnosis of post-stroke pneumonia, the signs, symptoms and 
results of inflammatory markers of all episodes of pneumonia were analysed to identify 
reliable criteria for the early diagnosis of pneumonia in stroke patients and they were tested 
for the reliability and the predictability.  
 
The thesis demonstrated that pneumonia is an early complication following stroke and an 
increase in the respiratory rate more than 25 breaths per minute, a fall in oxygen saturations 
less than 90% on air and new onset inspiratory crackles were the most commonly observed 
signs and were highly predictive of pneumonia. Well recognised symptoms of a respiratory 
infection such as cough and purulent sputum were not observed in one third of patients and 
pyrexia was not observed in two thirds of patients. A positive microbiological culture was 
not common and was observed in 25% of pneumonias. As for biochemical investigations, 
elevation of CRP and WBC were highly predictive of pneumonia and CRP had the highest 
predictive value. A CRP level of 40 mg/l has been shown to be the cut-off level for the 
diagnosis of pneumonia. 
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5.2. Limitations  
5.2.1. The MAPS trial 
A total of 60 patients make the MAPS trial a relatively small research project. Also a 
sample size power calculation was not performed as this was done as a pilot project as 
there were no previous publications on the use of metoclopramide in acute stroke patients. 
While the reduction in pneumonia was highly significant statistically the sample is not 
large enough to exclude a false positive result with confidence. In addition, the trial was 
conducted only on one stroke unit. Therefore it is possible that local practice of this unit 
might have had an effect on the results, which may have been different if conducted on a 
unit that had different treatment criteria for treating acute stroke patients fed via nasogastric 
tubes. Management of post-stroke patients and management of nasogastric feeds on our 
unit are based on National Institute of Clinical Excellence guidelines and Royal College of 
Physicians guidelines and are carried out by a well trained multi-disciplinary team. 
However, some practices of acute stroke care may differ in other stroke units, depending on 
resources and facilities available. As for an example, principles of early mobilisation and 
having physiotherapy and occupational therapy services on the ward throughout the day 
until 9pm, seven days a week which is available in our stroke unit may not be available on 
other units. Having less urinary catheterisations made the incidence of urinary tract 
infections low in the MAPS study participants. However, urinary tract infections will be 
more common in units where patients are frequently catheterised and will have an effect on 
criteria for the diagnosis of pneumonia. 
 
Effects of local population on the trial results should be considered. Other than few (n = 3) 
Asian patients, most of the participants were local people from Stoke-on-Trent who were 
white Caucasian in their ethnicity. There were no Afro-Caribbean or Oriental patients in 
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the trial. Effects of ethnicity on the metabolism of ACE inhibitors and its effect on reducing 
pneumonia have been discussed before. Though unlikely, it cannot be excluded that people 
who live in Stoke-on-Trent have a higher incidence of gastro-oesophageal reflux, which 
makes the effect of metoclopramide in reducing reflux, aspiration and pneumonia very 
significant. However, lack of a good ethnic mix is not uncommon in many previous 
studies5;29;161;377;378. 
 
5.2.1.1. Researcher bias 
The trial was designed to minimise researcher bias. Allocation of the treatment options for 
the intended 60 participants was done prior to the commencement of the trial and these 
codes were kept in a locked safe in the research facility. This process was performed by an 
independent team working for the West Midlands research network and the researcher had 
no part in this. Following randomisation of a patient and production of the consent or the 
assent from, the sealed envelope of the treatment option for that randomisation number was 
released from the office. All details of randomisation numbers and patient’s details were 
kept in another register in the same office to which the researcher had no access. 
 
The study was not fully blinded, as the nurse dispensing the treatment was aware of the 
allocation. This could have introduced bias, as a doctor working on the same stroke unit, 
one can argue that the principle researcher had the opportunity to know the treatment 
options of the participants. Also there was potential for inadvertent unmasking of treatment 
allocation especially when requesting medication from the pharmacy and treatment chart 
monitoring was done by the ward pharmacist. This could have biased the diagnosis of 
pneumonia. This bias would have been prevented by having similar looking 
metoclopramide and placebo rather than using 10 ml of saline as the placebo. Various steps 
were undertaken to ensure blinding of the study. Allocation bias was minimised by 
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randomisation of all intended treatment options prior to the commencement of the study 
and sealed envelopes containing the treatment options being retained in an independent 
research office until their release after recruitment of a participant. After release, envelopes 
containing the treatment options were always kept in the locked drug cabinet which was 
handled only by qualified nurses. Treatment was prescribed as MAPS trial drug 
metoclopramide 10 ml or normal saline 10 ml on the drug chart thus doctors handling the 
drug chart could not know which arm of the trial the patient was recruited into. The 
confirmation of chest signs was made by at least two other independent assessors, either 
consultants or registrars, who would examine the patient prior to making a clinical 
diagnosis of a lower respiratory infection or pneumonia. The final diagnosis of pneumonia 
was made by the consultant who was responsible for the patients’ overall care. Most of the 
time there were several entries of physical signs and diagnosis of pneumonia in case notes 
by on-call doctors who were even not aware of the study. The key feature for the diagnosis 
of definite pneumonia, the chest radiograph, was reported by independent doctors in the 
radiology department as a part of routine clinical practice. Inflammatory markers were 
handled by the University Hospital of North Staffordshire pathology laboratory as part of 
ward practice, and the lab personnel were not aware of this research project. 
 
All of these ensured that there was minimal bias when the clinical findings, chest 
radiograph findings and laboratory test results were considered for the diagnosis of 
pneumonia. During the period of the MAPS trial there were more than 10 other on-going 
clinical trials on the stroke unit. All patients received standard medical and stroke care 
according to local guidelines and NICE guidelines in management of stroke patients. This 
ensured the uniformity of treatment of patients on clinical trials and all received the 
standard stroke care irrespective of being recruited to a trial and whether the patient were 
on a trial drug or on a placebo. 
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5.2.1.2. Exclusion risks 
Almost two-thirds of patients who required nasogastric feeds were excluded from the 
MAPS study due to the presence of pneumonia. This is partly due to the presence of 
pneumonia on admission or development of pneumonia while a decision was being made 
for nasogastric feeds, which was two days in MAPS trial. These patients would have been 
the most vulnerable for the development of pneumonia, in whom the effect of 
metoclopramide was not tested.  
 
5.2.1.3. Follow-up period and functional out-comes 
A longer follow-up period on neurological recovery and functional recovery would have 
added strength to the findings of the trial. Longer follow up was not planed due to practical 
difficulties in follow-up of these patients. However, the neurological recovery of the 
patients who were treated with metoclopramide at the end of three weeks was suggestive of 
a good clinical outcome. Details of functional recovery, using modified Rankin score or 
Barthel score would have added strength to the findings of the trial.  
 
Procedures such as measurements of gastric residual volume at regular intervals to 
demonstrate gastroparesis or oesophageal manometry or pH measurements to demonstrate 
gastro-oesophageal dysfunction in two groups would have added strength to the findings of 
the trial and would have been useful in making further recommendations. These were not 
planned due to lack of resources, funding and time.  
5.2.2. Diagnosis of pneumonia 
The main limitation was that this was performed as a retrospective analysis of data which 
were collected for the MAPS trial. Therefore the data collection was done according to a 
protocol intended for the MAPS trial rather than for a trial that was intended to identify 
criteria for the diagnosis of post-stroke pneumonia. This resulted in laboratory 
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investigations being performed only with the clinical suspicion of pneumonia and not 
performed according to a specific protocol at regular intervals. As the patients with no 
pneumonia did not require regular laboratory tests, there were less data on inflammatory 
markers in this patient group, though all had baseline and day 7 inflammatory marker 
levels. Availability of inflammatory marker levels at regular intervals would have provided 
a better comparison between the two groups. Even in patients with pneumonia, 
inflammatory markers were not done at regular intervals after the diagnosis of pneumonia. 
This prevented detailed analysis of these markers to assess their response to antibiotic 
treatment. Lack of laboratory data was also evident in the second episodes of pneumonia, 
therefore had to be excluded from the analysis. A well-defined prospective study will 
overcome this short-coming. 
 
The predictors for the diagnosis of post-stroke pneumonia have not been validated in 
another post-stroke population. Also the predictors were tested only on a specific cohort of 
stroke patients (patients with severe strokes who were fed via nasogastric tubes), therefore 
the findings may not be applicable to the whole stroke population. However severe strokes, 
especially patients who are fed via nasogastric tubes have the highest incidence of 
pneumonia and it is in this cohort of patients the diagnosis of pneumonia is particularly 
difficult due lack of well known signs and symptoms of pneumonia. At any given time on a 
stroke unit, there are several patients who depend on enteral feeds and the predictors 
demonstrated in this thesis will help a clinician in the early diagnosis of pneumonia in this 
patient cohort. However, a prospective study on unselected stroke patients with non-stroke 
controls will provide predictors which can be generalised to all stroke patients according to 
the stroke severity.  
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5.3. Possible further trials for the future 
5.3.1. MAPS study as a larger, multi-centre study 
Planning the MAPS study as a multi-centre study with a larger number of participants will 
strengthen the findings of the study. Also having identical looking trial drug and the 
placebo in similar looking vials would strengthen the blindness of the study. Nearly two-
thirds of patients who required nasogastric tubes could not be recruited to the MAPS study 
as these patients developed pneumonia within 24 hours of admission to the hospital. 
Having different inclusion criteria to recruit patients within few hours of admission, with 
the assumption of that these patients will need nasogastric feeds will allow more 
participants to be recruited, especially the most vulnerable for the development of 
pneumonia. This decision can be either based on clinical assessment of severity of stroke 
(e.g. NIHSS >10) or size of the infarct on the CT scan, as patients with large strokes 
frequently require nasogastric feeds. If such a patient with a large stroke, would fail the 
water swallow test or remain too drowsy to be assessed can be reviewed as a potential 
participant to the MAPS trial, if they could be recruited within 12 hours of admission to the 
hospital. With such early recruitment many of the participants will not have a nasogastric 
tube at the time of recruitment and metoclopramide can be administered intravenously until 
insertion of a nasogastric tube is performed. In view of MHRA concerns of extra-pyramidal 
side effects of long-term metoclopramide treatment, the duration of intervention can be 
limited to two weeks as this is the time period where post-stroke pneumonia is prevalent. In 
addition, dysphagia in the majority of patients would have resolved by the end of this 
period. Exclusion criteria can remain as in the MAPS pilot study and British Thoracic 
Guidelines for the diagnosis of pneumonia can be used in the larger study. 
 
The diagnosis of any post-stroke infection may be affected by clinical practices and 
policies of other stroke units. The use of urinary catheters and venflon care may vary 
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between units, which will affect the incidences of urinary tract infections and venflon 
related infections. A low threshold to diagnose urinary tract infections and the use of 
antibiotics for such infections potentially can affect the clinical manifestations and the 
diagnosis of pneumonia. Therefore having another primary outcome such as mortality or 
length of stay, in addition to the episodes of pneumonia will strengthen the findings of the 
study. Secondary outcomes and the weekly follow-up plans can remain as in the pilot 
study. A longer follow-up which includes mortality, neurological and functional recovery 
(mRS) will also strengthen the findings of the study. 
 
The findings of the MAPS pilot study can be used to calculate the sample size for the 
intended larger study. The incidence of pneumonia was 27% and 87% in the treatment 
group and the placebo groups respectively. The incidence of pneumonia in the placebo 
group is higher than other post-stroke pneumonia studies and the possible reasons have 
been discussed before. Other studies have shown an incidence of 44% for post-stoke 
pneumonia in acute stroke patients who are fed via nasogastric tubes. Therefore for the 
proposed multi-centre study 44% is preferred as the expected rate of pneumonia in the 
control group rather than the 87% seen in the pilot study. The expected incidence of 
pneumonia in the intervention group can be taken from the MAPS pilot study (27%), which 
will be a 40% reduction in the incidence of pneumonia by the use of the intervention. As 
patients are recruited within the first 12 hours, some patients will not require longer-term 
tube feeding as some patients may have rapid improvement of dysphagia within 24 -48 
hours of admission. To account for this, the study size has to be increased by 20% and a 
further 10% to be added to account for loss of follow up and withdrawals. To achieve 80% 
power with a significance level (alpha) of <0.05 and 1:1 randomization, a study size of 298 
participants are required for the planned multi-centre study. 
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5.3.2. Other possible future studies 
Oral decontamination has been shown to reduce the incidence of pneumonia in stroke 
patients as significant amount of bacteria are transmitted from the infected oropharynx. A 
combination of anti-reflux medication and oral decontamination may prove to be even 
more effective than using each intervention separately. Though had shown promising 
results in animal studies, evidence for regular use of prophylactic antibiotics in acute stroke 
in humans is still lacking. It may be due to the many causative factors for pneumonia such 
as oropharyngeal colonisation, gastro-oesophageal dysfunction and reflux, and silent 
aspiration still continues despite the treatment with systemic antibiotics. A new randomised 
control trial with varying combinations of oral decontaminants, metoclopramide and 
intravenous antibiotics can be piloted and may prove very successful in the reduction of 
post-stroke pneumonia. 
 
Bolus feeds have been investigated by few researchers to reduce the incidence of 
pneumonia in patients who are fed via nasogastric tubes. Some physicians prefer bolus 
feeds as they are more physiological than continuous feeds and patients can be better 
observed during the feeds are in progress. Main problems of bolus feeds were increased 
residual gastric volume, discomfort and possible worsening regurgitation. However, a study 
can be designed to assess the efficacy of bolus feeds used along with metoclopramide, 
which would increase forward peristalsis of the stomach and reduce the residual volume 
and regurgitation, therefore be more effective than used alone.  
 
Not many studies have been performed to understand the reasons that lead to poor 
nutritional status in post-stroke patients who are fed via nasogastric tubes. Effect of a stroke 
on the small intestine has been less researched, when compared to research performed to 
assess the effects of stroke on the upper gastro-intestinal tract. Possibilities of poor 
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digestion, pancreatic failure and poor absorption are possibilities. Any of the research 
planned to assess the incidence of pneumonia in stroke patients fed via nasogastric tubes 
can be combined with a sub-project that will review the adequacy of a formally calculated 
nasogastric feeds on patients’ nutritional state. In addition, a randomised control trial on 
regular supplementation of pancreatic enzyme preparation Creon can be combined to one 
of the future research projects designed in stroke patients fed via nasogastric tubes to assess 
possible pancreatic dysfunction following acute stroke. 
 
5.4. Conclusion 
The MAPS study suggests that time-limited prophylactic use of metoclopramide in patients 
fed via NGT is well tolerated and has the potential to reduce the rate of pneumonia and 
improve other clinical outcomes in acute stroke patients fed via NGTs. These findings need 
to be confirmed in larger, multicentre, randomized and blinded trials. If confirmed the 
findings could lead to a new approach to the prevention of pneumonia in stroke patients 
fed via NGTs.  
 
In addition, the work done for the thesis also demonstrated that stroke patients do not 
regularly manifest several well known clinical signs and symptoms of a chest infection. An 
increase in the respiratory rate, a fall in the oxygen saturation and new onset inspiratory 
crackles were the most commonly observed signs and were highly predictive of 
pneumonia. As for investigations, elevation of both CRP and WBC were highly predictive 
of pneumonia but CRP appears to have the highest predictive value. For every single point 
in increase in the CRP levels there was a 0.5% rise in the predictability of pneumonia. A 
CRP level of 40 mg/l had the best sensitivity and specificity as the cut-off level for the 
diagnosis of post-stroke pneumonia. 
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Appendices  
Appendix 1: Stroke syndromes 
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Appendix 2: Methodology checklist: randomised controlled trials 
A.2 Methodology checklist: randomised controlled trials  
  
Study identification 
Include author, title, reference, year of 
publication  
 
Guideline topic:  Key question no:  
Checklist completed by:  
SECTION 1: INTERNAL VALIDITY  
In a well-conducted RCT study:  In this study this criterion is: 
(Circle one option for each 
question)  
1.1  The study addresses an appropriate and 
clearly focused question.  
Well covered  
Adequately 
addressed  
Poorly addressed  
Not addressed  
Not reported  
Not applicable  
1.2  The assignment of subjects to 
intervention groups is randomised.  
Well covered  
Adequately 
addressed  
Poorly addressed  
Not addressed  
Not reported  
Not applicable  
1.3  An adequate concealment method is 
used.  
Well covered  
Adequately 
addressed  
Poorly addressed  
Not addressed  
Not reported  
Not applicable  
1.4  Subjects and investigators are kept 
‘blind’ about intervention allocation.  
Well covered  
Adequately 
addressed  
Poorly addressed  
Not addressed  
Not reported  
Not applicable  
1.5  The intervention and control groups are 
similar at the start of the trial.  
Well covered  
Adequately 
addressed  
Poorly addressed  
Not addressed  
Not reported  
Not applicable  
1.6  The only difference between groups is 
the intervention under investigation.  
Well covered  
Adequately 
addressed  
Not addressed  
Not reported  
Not applicable  
1.7  All relevant outcomes are measured in a 
standard, valid and reliable way.  
Well covered  
Adequately 
addressed  
Poorly addressed  
Not addressed  
Not reported  
Not applicable  
1.8  What percentage of the individuals or 
clusters recruited into each intervention 
arm of the study dropped out before the 
study was completed?  
 
1.9  All the subjects are analysed in the 
groups to which they were randomly 
allocated (often referred to as intention-
to-treat analysis).  
Well covered  
Adequately 
addressed  
Poorly addressed  
Not addressed  
Not reported  
Not applicable  
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1.10  Where the study is carried out at more 
than one site, results are comparable for 
all sites.  
Well 
covered  
Adequately 
addressed  
Poorly 
addressed  
Not addressed  
Not reported  
Not applicable  
SECTION 2: OVERALL ASSESSMENT OF THE STUDY  
2.1  How well was the study done to 
minimise bias? Code ++, + or –  
 
2.2  If coded as + or – what is the likely 
direction in which bias might affect 
the study results?  
 
2.3  Taking into account clinical 
considerations, your evaluation of 
the methodology used, and the 
statistical power of the study, are 
you certain that the overall effect is 
due to the study intervention?  
 
2.4  Are the results of this study directly 
applicable to the patient group 
targeted by this guideline?  
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Appendix 3: Type and quality of evidence for studies on the efficacy of 
interventions  
 
 
Adapted from the Scottish Intercollegiate Guidelines Network (2001); for further 
information, see further reading. 
 
Type and quality of evidence 
1
++
 
High quality meta-analyses, systematic reviews of RCTs, or RCTs 
(including cluster RCTs) with a very low risk of bias  
1
+
 
Well conducted meta-analyses, systematic reviews of RCTs, or RCTs 
(including cluster RCTs) with a low risk of bias  
1
–
 
Meta-analyses, systematic reviews of RCTs, or RCTs (including cluster 
RCTs) with a high risk of bias  
2
++
 
High quality systematic reviews of these types of studies, or individual, 
non-RCTs, case-control studies, cohort studies, CBA studies, ITS, and 
correlation studies with a very low risk of confounding, bias or chance 
and a high probability that the relationship is causal  
2
+
 
Well conducted non-RCTs, case-control studies, cohort studies, CBA 
studies, ITS and correlation studies with a low risk of confounding, bias 
or chance and a moderate probability that the relationship is causal  
2
–
 
Non-RCTs, case-control studies, cohort studies, CBA studies, ITS and 
correlation studies with a high risk – or chance – of confounding bias, 
and a significant risk that the relationship is not causal  
3  Non-analytic studies (for example, case reports, case series)  
4  Expert opinion, formal consensus  
NB: for policy interventions, then CBA can be awarded level 1 evidence.  
 
PHIAC or the PDG is responsible for endorsing the final levels ascribed to the body of 
evidence. 
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Appendix 4: Data Extraction form 
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Appendix 5: GCS Score 
 
 
GLASGOW     Patient Name: 
___________________________ 
COMA      Rater Name: 
____________________________ 
SCALE      Date: 
__________________________________ 
 
 
 
Activity Score 
 
EYE OPENING 
None     1 = Even to supra-orbital pressure 
To pain    2 = Pain from sternum/limb/supra-orbital pressure 
To speech    3 = Non-specific response, not necessarily to command 
Spontaneous    4 = Eyes open, not necessarily aware    
_______ 
 
MOTOR RESPONSE 
None     1 = to any pain; limbs remain flaccid 
Extension  2 = Shoulder adducted and shoulder and forearm internally 
rotated 
Flexor response   3 = Withdrawal response or assumption of hemiplegic 
posture 
Withdrawal    4 = Arm withdraws to pain, shoulder abducts 
Localizes pain    5 = Arm attempts to remove supra-orbital/chest pressure 
Obeys commands   6 = Follows simple commands     
_______ 
 
VERBAL RESPONSE 
None     1 = No verbalization of any type 
Incomprehensible   2 = Moans/groans, no speech 
Inappropri ate    3 = Intelligible, no sustained sentences 
Confused    4 = Converses but confused, disoriented 
Oriented    5 = Converses and oriented     
_______ 
 
 
TOTAL (3–15): 
_______ 
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Appendix 6: NIHSS score 
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Appendix 7: Research and Development approval letter 
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Appendix 8: Ethic Committee approval letter  
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Appendix 9: Patient Information Sheet 
Patient information sheet 
The metoclopramide aspiration study 
 
A randomised controlled study of the effect of metoclopramide in reducing aspiration, 
pneumonia and hypoxia of patients who are fed by nasogastric tubes after an acute 
stroke (pilot study) 
 
I am doctor attached to the Acute Stroke Unit, intending to do the above research project as 
a part of my MSc in Geriatric Medicine. This research is to assess whether the drug called 
metoclopramide will reduce the incidence of aspiration and pneumonia in stroke patients 
who are receiving nasogastric feeds. 
 
I you are interested in helping us with our research, it is important to that you understand 
not only why the research is being done, but also what it would involve. Therefore could 
you please take time to read this information sheet carefully, and if you wish discuss it with 
others, before deciding whether or not you would like to participate in this study. If any 
information is unclear or if you would like more information please contact Dr. A 
Warusevitane or Dr. C Roffe (contact details can be found at the end of this form). Do take 
time to decide whether you wish to take part. If you do not want to take part in this study, 
we would like to assure you that your current medical care will not be compromised in 
anyway and we would like to thank you for giving us a bit of your time.  
 
Introduction to the study 
Patients who have had a stroke often lose the ability to swallow. If this happens feeding by 
mouth is not safe because of the risk of choking on food and drinks. Artificial nutrition via 
a feeding tube often has to be given for a period of time to prevent starvation. Pneumonia is 
a common complication of tube feeding. One of the major causes of pneumonia in this 
patient group is the entry of stomach contents in to the lungs (aspiration). This happens 
when food in the stomach is pushed back (regurgitated) in to the oesophagus (gullet). This 
is due to a combination of delayed emptying of stomach contents into the small bowel and 
malfunction of the valve which prevents stomach contents entering into the gullet.  
 
Metoclopramide is a drug which is commonly used in clinical practice to prevent and treat 
sickness and vomiting. It accelerates the passage of stomach contents into the gut and 
improves function of the lower oesophageal sphincter, the valve which prevents leakage of 
stomach contents into the gullet. Because of this it might be useful in preventing 
pneumonia in stroke patients with feeding tubes. Some doctors use metoclopramide for this 
purpose, but there is no evidence form clinical studies in stroke patients to show that it is 
effective. The purpose of this study is to examine whether metoclopramide prevents 
pneumonia due to regurgitation of stomach contents in stroke patients fed via feeding 
tubes. 
 
What are the side effects of the drug? 
Metoclopramide is commonly used by doctors in routine clinical practice to prevent 
vomiting. Side effects of this drug are rare. Rarely this drug can cause involuntary 
movements mainly affecting the muscles of the head and neck (dystonic reactions). These 
usually occur within the first few days after starting metoclopramide, are easily recognised, 
and usually settle within 24 hours of stopping the drug. If the movements are distressing 
they can also be aborted by an injection of procyclidine. There is no long term harm done 
to the patient by these dystonic reactions or the medication which is given to reverse it. 
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Other, less frequent side effects of metoclopramide listed in the British National Formulary 
are: drowsiness, diarrhoea, depression, itching, rashes and swelling of the feet. 
Hyperprolactinaemia (increased blood levels of a hormone called prolactin) and tardive 
dyskinesia (involuntary movements of the mouth and tongue) can occur after prolonged use 
(several months). These are only very rarely encountered in routine clinical practice. Each 
patient is will be observed for adverse effects, and the drug will be discontinued if such 
adverse effects develop. If you or your relatives become in any way concerned do not 
hesitate to contact the ward doctor. (tel.01782 552257) 
 
Why are we telling you this now? 
We are inviting you to join this study to find out whether metoclopramide prevent 
pneumonia in tube fed stroke patients. You have been chosen because you have had a 
stroke affecting your swallowing and therefore need to be fed via a tube.  
 
Do I have to take part? 
Participation in this clinical trial is entirely voluntary and you are not obliged to support 
this clinical trial. If you do decide to take part you will be given this information sheet to 
keep and will be requested to sign a consent form. Even if you decide to take part you are 
still free to withdraw at any time without giving any reason. This will not affect the 
standard of care you would receive. 
 
What will happen if I take part? 
If agree to take part in the study you will be asked to sign a consent form. The researcher 
will then asks you questions about your health, examine you and record baseline 
information about you and your stroke. You will then be given metoclopramide 10 mg 
three times a day via the feeding tube or a matching dummy treatment (placebo) for three 
weeks or until the feeding tube is removed. Whether you are given metoclopramide or 
placebo will be chosen randomly by using a pack of sealed envelopes, prepared before the 
commencement of the trial. The treatment allocation is determined by chance (random) and 
neither you nor the researcher will know which of the two treatments you are given. This 
type of a trial is called a randomised controlled trial. This is done to reduce the bias of 
interpretation of your progress by the researcher.  
 
You will be examined five times a week for the next 3 weeks to check for signs of 
pneumonia and recovery from the stroke. If you develop symptoms of a chest infection 
(such as cough or a high temperature) this will be reported to the doctor looking after you 
who will arrange further investigations and treatment. If clinically indicated a blood sample 
will be taken to confirm the diagnosis of a new infection. You may also have a chest x-ray 
to see whether you have developed radiological evidence of a chest infection. All this is 
routine clinical practice for any patient in this situation but for this trial the results of your 
tests will also be recorded in the research file. Treatment of any chest infection will be 
according to the hospital guidelines. 
 
The trial ends 3 weeks after the insertion of the feeding tube. On the last day of the trial 
your health, the level of you recovery, and test results from your clinical notes will be 
reviewed and recorded in the trial file.  
 
What are the possible advantages and disadvantages of taking part in this research? 
You will not directly benefit from this study yourself, however your participation may help 
others who, in the future find themselves in the same position as you are in now. As 
mentioned above, acute dystonic reactions could be a rare side effect. This is reversible and 
there will be no long term or permanent problems or side effects. 
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What happens if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
agreements. If you are harmed due to someone’s negligence, then you may have grounds 
for legal action, but you have to pay for it. Regardless of this if you wish to complain about 
any aspect of the way you have been approached or treated during the course of the study, 
the normal National Health Service Complaints Mechanism may help you. 
 
Will my taking part in this study be confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will not have 
your name, date of birth or address, so that you cannot be identified from that information. 
If you agree your GP will be notified of your participation in the trial.  
 
What happens to the results of the research study? 
The results of the study will be presented at scientific meetings and published in medical or 
scientific journals as well as in literature relevant to stroke patients and their carers. The 
findings may affect the way future stroke patients would be treated and may be included in 
clinical guidelines for stroke management. You will not be identified in any of these reports 
or publications. You can obtain a copy of the results by contacting me or my supervisor 
directly (the addresses are given at the end of this page). 
 
And finally…. 
We would now like to thank you having taken the time to enquire about our study. If you 
have any further questions please contact us and we will be happy to answer all your 
questions. Further information on research studies can also be obtained from the Patient 
Advocacy Liaison Services (PALS), tel: 01782 552814, 01782 552317. If we have 
answered all your questions and you want to support this study you will now need to sign 
the consent from. If however, you have decided not to participate, we would like to thank 
you for taking the time to find out about this study.  
 
Thank you.  
Contact for further information 
 
Dr. Anushka Warusevitane. 
 Ward 84, City General Hospital 
 Newcastle Road 
 Stoke on Trent ST4 6QG. 
 Tel: 01782 552257 
Dr. Christine Roffe 
 Springfield Unit, 
 City General Hospital. 
 Stoke on Trent ST4 6QG. 
 Tel: 01782 552313. 
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Appendix 10: Consent form  
 
Version 04 
20/06/2007 
 
 CONSENT FORM 
 
 
Title of the project: Does Metoclopramide reduce the incidence of aspiration, 
pneumonia and hypoxia in acute stroke patients who are fed by nasogastric 
tubes (pilot study). 
 
 Name of the researches: Dr. Anushka Warusevitane, Dr. C. Roffe 
          Please initial box 
 
1. I confirm that I have read and understood the information sheet for the above  
study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my medical care or legal  
rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by  
responsible members of the research team or by members of the data  
monitoring committee. I give permission for these individuals to have access  
to my records. 
 
4. I agree to take part in the above study. 
 
 
___________________  _________________  ________________________ 
Name of the patient   Date    Signature 
 
 
 
___________________  _________________  ________________________ 
Name of person taking consent  Date    Signature  
(If different from researcher) 
 
 
 
___________________  _________________  ________________________ 
Researcher    Date    Signature  
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Appendix 11: Assent Form  
 
  Version 04 
  20/06/2007 
 
ASSENT FORM 
 
 
 Title of the project: Does Metoclopramide reduce the incidence of aspiration, 
 pneumonia and hypoxia in acute stroke patients who are fed by nasogastric 
 tubes (pilot study). 
 
 Name of the researches: Dr. Anushka Warusevitane, Dr. C. Roffe 
 
         Please initial box 
 
1. I confirm that I have read and understood the information sheet for the above  
study and have had the opportunity to ask questions. 
 
2. I understand that my relative’s participation is voluntary and that he/she is  
free to withdraw at any time, without giving any reason, without his/her  
medical care or legal rights being affected. 
 
3. I understand that sections of any of my relative’s medical notes may be  
looked at by responsible members of the research team or by members of the  
data monitoring committee. I give permission for these individuals to have  
access to my relative’s records. 
 
4. I agree my relative ………………………………………., to take part in the  
above study. 
 
 
______________________  _________________  __________________ 
Name of the relative    Date    Signature 
 
 
______________________  _________________  __________________ 
Name of person taking consent  Date    Signature  
(If different from researcher) 
 
 
 
_____________________  _________________  __________________ 
Researcher     Date    Signature  
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 Appendix 12: MAPS trial data collection form 
 
Metoclopramide 
preventing Aspiration 
and Pneumonia in acute 
Stroke (MAPS) trial  
Data collection Form  
 
 
Eligibility for trial inclusion 
Admitted to the Stoke Unit Yes
 
No
 
<7 days from admission  Yes
 
No
 
 Please proceed if both answered as Yes 
 
Pre existing pneumonia Yes
 
No
 
Patient with a terminal illness Yes
 
No
 
Brain tumour or metastases presenting as stroke Yes
 
No
 
Known oesophageal stricture or carcinoma  Yes
 
No
 
>24 hours form the nasogastric tube insertion  Yes
 
No
 
 Please proceed to the next section if all answered as No  
 
Baseline criteria 
 Date of stroke         DD MM YYYY 
 Date of admission:         
 GCS on admission:               At randomisation:  
 Date of first NG insertion: 
 Type of Stroke:   
  
LACS TACS PACS POCS Unclassifiable 
 
 CT diagnosis  
  
Cerebral infarct
 
Intracerebral h'age Small V disease
 
SHD
 
  
SAH
  
Not done
 
Other
 
 
 Past medical history 
  
DM Htn AF
 
IHD CCF
 
  
E         V        M E      V      M  
Hospital ID Sticker or 
 
Name: 
Sex: Male/Female 
DOB:            DD MM YYYY 
Unit No/Hiss NO:   
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 Previous lung disease 
  
Athsma
  
COPD
 
Pulmonary Fibrosis 
   
  
Pneumoconiosis 
 
Other
 
 
 Medication:   
  
Diuretics ACEI
 
Inhalers Nebs Digoxin
 
  
PPI Other antiHtn
 
antianginal
 
 
 Baseline CXR 
  
Normal Lung Congesion Emphysematous Fibrosis
 
  
Effusion Consolidation
 
Other
 
 
 Baseline inflammatory markers 
  CRP  ESR  WBC  Albumin  
 Already on antibiotics  
  
Yes No
 
 If yes  Antibiotic: 
  Reason:   
 
 
 Randomisation 
 Randomisation No: 
    
Consent
  
Assent
 
 Date & time of randomisation:           DD MM YYYY 
                HH:MM 
 
 Trial Medication group: 
   
Medicine A Medicine B
 
 Date Time O2 sat RR HR BP Temp Weight 
Admission        
Randomisation        
 
1st week 
assessment  
        
2nd week 
assessment  
        
3rd week 
assessment  
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 Weekly assessment:  
 
 First week 
assessment  
Second week 
assessment 
Third week 
assessment 
O2 saturation at 10 am     
On oxygen  Yes / No 
….……% 
Yes / No 
…….....% 
Yes / No 
………% 
If on oxygen – Sats on room 
air 
 
  
Lowest BP    
Highest BP    
Highest temperature    
No of days with NG feed    
No of doses of trial drug    
Days NG interrupted     
  Problems with 
confirming  
   
 No NG tube    
 Etc.    
Course of antibiotics Yes  /   No Yes   /   No Yes   /   No 
 Type    
 Days up to now    
 Presumed diagnosis     
New medications    
 ACEI    
 Other antiemetics    
 Erythromycin     
GCS E    M V E M V E M V 
NIHSS score    
Inflammatory markers     
 CRP    
 ESR    
 WBC    
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Witnessed aspiration  
 
 
Diagnosis of Pneumonia 
 
Presence of at least one criterion from each category will establish the diagnosis of pneumonia. Presence of at least one criterion 
from three categories will make a diagnosis of possible pneumonia.    
 
  
 1st episode 2nd episode  3rd episode  
Date    
Time    
Body posture     
Presence of NG feeds    
Intervention     
 Suction only    
 Suction and antibiotics     
 Stop feeding    
Outcome     
 No change    
 Pneumonia    
 Feed discontinued for >24h    
 Death    
 1st episode  2nd episode 3rd episode 
Date    
Symptoms of acute LRTI    
 Cough    
 Purulent Sputum    
 RR >25/m    
 O2 Sats <90%    
New focal chest signs    
 Inspiratory crackles     
 Bronchial breathing    
 Signs of consolidation     
Systemic features of inflammation     
 Fever >38° C    
 Chills and/or rigors     
 WBC >11    
 WBC <3    
 CRP    
 ESR    
Radiological evidence (at least one 
segment not known to be previously present) 
   
Diagnosis     
 Definite pneumonia    
 Probable pneumonia    
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% 
Kg 
CXR in episode one  
  
No change Incresed lung markings 
 
Inflammatory shadowings
  
  
Effusion Other
 
 
 
 
 CXR in episode two  
  
No change Incresed lung markings 
 
Inflammatory shadowings
  
  
Effusion Other
 
 
 
 
 CXR in episode three  
  
No change Incresed lung markings 
 
Inflammatory shadowings
  
  
Effusion Other
 
 
 
 
 
 
 Outcome                 Date 
 
NG removed as swallowing improved
  
 
Referred for PEG 
 
 
RIP
 
 No of episode of pneumonia (any) 
No of episode of aspiration  
No of antibiotic days 
No of different antibiotics 
Highest WCC/ CRP at any time 
Lowest oxygen saturation at any time 
  Change in body weight from baseline to Week 3  
 
Consolidation
 
 Side 
 Lobe 
 Segment 
Consolidation
 
 Side 
 Lobe 
 Segment 
Consolidation
 
 Side 
 Lobe 
 Segment 
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Appendix 13: SPSS calculations of predictability of CRP and WBC 
 
C-Reactive Protein as a Predictor 
Variables in the Equation 
95% C.I. for odds ratio 
 
B S.E. Wald df p-value Odds ratio 
Lower Upper 
CRP .045 .013 11.659 1 .001 1.046 1.019 1.073
Constant -1.717 .562 9.316 1 .002 .180  
Nagelkerke pseudo-R2  = .506, CRP-C-Reactive Protein 
 
 
 
 
 
White Blood Cells as a Predictor 
Variables in the Equation 
95% C.I. for odds ratio 
 
B S.E. Wald df p-value Odds ratio 
Lower Upper 
WBC .221 .083 7.061 1 .008 1.247 1.060 1.468
Constant -2.267 .953 5.656 1 .017 .104  
Nagelkerke pseudo-R2  = .232, C.I -Confidence Interval, WBC- White Cell Count  
 
 
 
 
 Predictability of the Combination 
Variables in the Equation 
95% C.I. for odds ratio 
 
B S.E. Wald df p-value Odds ratio 
Lower Upper 
WBC .178 .114 2.439 1 .118 1.194 .956 1.493
CRP .037 .013 8.327 1 .004 1.038 1.012 1.065
Constant 
-3.401 1.278 7.077 1 .008 .033
  
Nagelkerke pseudo-R2  = .546, C.I Confidence Interval CRP- C-Reactive Protein, WBC- White Cell Count 
 
 
 
 
CRP Cut-off Values 
 
  
 
 
 
 
 CRP cut-off value Youden Index Sensitivity Specificity 
25.6 0.568 0.85 0.72 
36.5 0.567 0.73 0.84 
64.7 0.566 0.61 0.96 
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Appendix 14: Standard Operating policy on nasogastric feeding of the 
Stroke Unit  
The policy on the stroke unit was to perform a swallowing assessment in all stroke patients 
within the first 24 hours of admission. Patients are kept nil by mouth until a safe swallow is 
established. Assessment of swallowing was done by a nurse trained in the level 2 swallowing 
assessment as a part of routine patient care within 24 hours of admission. If swallowing 
problems were identified patients were reviewed by a speech and language therapist within the 
next 24 to 48 hours. If swallowing problems persisted and an adequate oral nutritional intake 
was not achievable, a nasogastric tube was considered within 24 to 48 hours of admission. 
When the need for a nasogastric tube was agreed by clinicians, patients or their next of kin 
were informed about the need of a nasogastric tube. 
 
The swallowing assessment can only be performed in patients who are alert and cooperative, 
able to sit up for feeding and who maintain awareness during the time period of assessment, 
which is about twenty minutes. The test consists of administration of 5 ml of water on a spoon 
and observation of the patient’s ability to clear this from the mouth and pharynx promptly. 
This can be done by watching the patient’s swallow and feeling for laryngeal elevation during 
swallowing with fingers placed over the patient’s larynx. The patients are observed for delayed 
or impaired swallowing and are watched for further 2 minutes for choking, respiratory distress, 
cough or change of voice. This procedure is repeated twice. If 5 ml of water is swallowed 
without difficulty, 50 ml of water in a beaker is given with the same observations before 
proceeding to a soft diet. 
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A level two swallowing assessment can only be done by a nurse who is trained to do such 
assessment or by a qualified speech and language therapist. In a patient who is unable to 
swallow water safely, fluid and foods of varying consistencies were tried to see what form of 
modified diet and thickened fluid can be given safely and in what quantities. During the testing 
oral transition, oral retention, initiation of swallow, possible delays, laryngeal excursion, voice 
change after the bolus and cough were assessed. Depending on the severity of the dysphagia 
and the risk of aspiration patients were placed on modified fluids ranging from syrup to custard 
thickness and modified diet ranging from pureed to fork mashed consistency. Also the 
quantities provided varied from a few teaspoons at a time with supervision and progress to 
normal portions. Various feeding strategies such as reducing the bolus size, keeping the chin 
tilted and the head turned while eating and the practice of double swallowing were carried out 
in addition. 
 
Patients who are comatose or too drowsy to be assessed for the safety of their swallow and 
patients who are identified as being at high risk of aspiration by bedside swallowing tests or 
who continued to show signs of aspiration with pureed food and custard thick fluids were kept 
nil by mouth until it is considered safe to be commenced oral feeds. This was determined by 
swallowing assessments which were done at regular intervals depending on the clinical state of 
the patient. A nasogastric tube was inserted in all patients who were kept nil by mouth. 
Similarly, patients who were only on oral trials with limited oral input also had a nasogastric 
tube placed to supplement their oral intake (top up feeds). A flexible polyurethane nasogastric 
tube, with an inner diameter of 10 mm unless otherwise indicated (Medicina NG tubes, 
Medicina, Bolton, United Kingdom) was inserted by a doctor or a senior staff nurse. The same 
type of nasogastric tube was used in all patients. After initial placement correct position of the 
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tube was confirmed by a chest X-ray or by pH testing (pH testing strips, Medicina, Bolton, 
United Kingdom) as per the nasogastric feeding protocol. All patients were positioned in semi-
reclined position throughout the nasogastric feeds and three hours after the feed. Being on 
nasogastric feeds did not preclude patients from being sat out or receiving therapy input. 
Nasogastric feeds were not interrupted during therapy sessions. Nasogastric feeds were 
commenced in the morning after the patients were washed to reduce the effect of changes of 
body posture on aspiration and as general patient’s care is easier in this position. Feeding 
overnight was not routinely carried out as patients cannot be observed for feed-related 
complications. 
 
Feeding regimes and the type of the feed was determined by the dietician based on the calorie 
and other nutritional requirements of the patient. The nasogastric feeds were started at a lower 
rate of 25 ml/hour, which was gradually increased daily by 25 ml/hour and kept to a maximum 
of 125 ml/hour. Before each feed the position of the tube was confirmed by assessing the pH 
of the nasogastric aspirate using the pH testing strips (Medicina, Bolton, United Kingdom). An 
acidic pH confirms that distal end of the tube is within the stomach. If the nasogastric tube was 
accidentally displaced or pulled out by the patient, a new tube was reinserted as soon as 
possible. If there was a problem confirming the accurate position of the nasogastric tube by pH 
assessment, the position was confirmed by a chest radiograph. Feeds were given by continuous 
flow over ten to twelve hours, rather than bolus feeds. Patients who were fed via nasogastric 
tubes were managed closer to the nurses’ station so that they could be observed for 
complications such as vomiting and displacement of the nasogastric tube. When necessary, 
soft mittens were applied after consent from the next of kin to restless patients to prevent 
patients pulling at their nasogastric tubes. Reinsertion of a nasogastric tube when displaced, 
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confirmation of the position before each feed and application of mittens to prevent a restless 
patient pulling out the tube were part of routine patient care on the ward. Patients’ other 
medications were continued as routine care.  
 
Patients fed via nasogastric tubes were assessed regularly by the SALT team attached to the 
unit and oral feeds were commenced as soon as swallowing had recovered. The nasogastric 
tube was only removed once the team was confident that the patient was able to take adequate 
amounts of oral feeds. This was done by nutritional assessment of the oral intake balancing 
with their caloric needs. If the patient’s swallowing had not recovered by the second week, 
insertion of a percutaneous endoscopic gastrostomy (PEG) tube was considered and 
appropriate referrals were done to the gastroenterological and nutritional teams.  
 
 
